nct_id,start_date,primary_completion__date,study_type,brief_title,overall_status,phase,sponsor,why_stopped,ctg_links,Abstract,Registry,Total_pubs,vaccine_trial_flag,Number_of_updates,US_site_flag,country,Has_Results,mapped_intervention,ArticleType
NCT04326790,2020-04-03,2020-04-27,Interventional,The GReek Study in the Effects of Colchicine in Covid-19 cOmplications Prevention,Terminated,Phase 2,National and Kapodistrian University of Athens,Slow enrollment as a result of the rapid flattening of the curve of COVID-19 cases in Greece,https://clinicaltrials.gov/ct2/show/NCT04326790,2,0,2,0,5,0,Greece,0,colchicine|standard care,Clinical Trial Protocol|Journal Article/Journal Article|Randomized Controlled Trial
NCT04315948,2020-03-22,2023-03-31,Interventional,Trial of Treatments for COVID-19 in Hospitalized Adults,"Active, not recruiting",Phase 3,"Institut National de la SantÃ© Et de la Recherche MÃ©dicale, France",NA,https://clinicaltrials.gov/ct2/show/NCT04315948,3,1,4,0,9,0,Austria|Belgium|France|Luxembourg|Portugal,0,remdesivir|lopinavir/ritonavir|interferon|hydroxychloroquine|standard care|azd7442|placebo|lopinavir|ritonavir,"Journal Article/Adaptive Clinical Trial|Clinical Trial Protocol|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04323527,2020-03-23,2020-05-07,Interventional,Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicaltrials.gov/ct2/show/NCT04323527,1,0,1,0,3,0,Brazil,0,chloroquine,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04355936,2020-05-19,2020-11-02,Interventional,Telmisartan for Treatment of COVID-19 Patients,Completed,Phase 4,Laboratorio Elea Phoenix S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04355936,1,0,1,0,8,0,Argentina,0,telmisartan|standard care,Journal Article
NCT04308668,2020-03-17,2020-05-20,Interventional,Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2,Completed,Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04308668,4,1,5,0,12,1,United States|Canada,0,hydroxychloroquine|placebo,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Systematic Review/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04321278,2020-03-28,2020-06-14,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-CoV2 Virus (Coalition Covid-19 Brasil II),Completed,Phase 3,Hospital Israelita Albert Einstein,NA,https://clinicaltrials.gov/ct2/show/NCT04321278,2,0,2,0,6,0,Brazil,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,"Editorial/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04261517,2020-02-06,2020-02-25,Interventional,Efficacy and Safety of Hydroxychloroquine for Treatment of COVID-19,Completed,Phase 3,Shanghai Public Health Clinical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04261517,1,0,1,0,3,0,China,0,hydroxychloroquine,Journal Article|Randomized Controlled Trial
NCT04276688,2020-02-10,2020-03-30,Interventional,"Lopinavir/ Ritonavir, Ribavirin and IFN-beta Combination for nCoV Treatment",Completed,Phase 2,The University of Hong Kong,NA,https://clinicaltrials.gov/ct2/show/NCT04276688,2,0,2,0,2,0,Hong Kong,0,lopinavir/ritonavir|ribavirin|interferon|lopinavir|ritonavir,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04366960,2020-05-14,2021-08-31,Interventional,Comparison of Two Doses of Enoxaparin for Thromboprophylaxis in Hospitalized COVID-19 Patients,Recruiting,Phase 3,Niguarda Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04366960,2,0,2,0,3,0,Italy,0,enoxaparin,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04372589,2020-05-20,2021-05-31,Interventional,Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC),"Active, not recruiting",Phase 2/Phase 3,University of Manitoba,NA,https://clinicaltrials.gov/ct2/show/NCT04372589,3,0,3,1,5,1,United States|Brazil|Canada|Mexico,0,heparin,"Journal Article/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04367831,2020-05-02,2020-11-30,Interventional,Intermediate or Prophylactic-Dose Anticoagulation for Venous or Arterial Thromboembolism in Severe COVID-19,Recruiting,Phase 4,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04367831,2,0,2,0,2,1,United States,0,enoxaparin|heparin|enoxaparin/lovenox|lovenox,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04345848,2020-04-28,2021-03-31,Interventional,Preventing COVID-19 Complications With Low- and High-dose Anticoagulation,Recruiting,Phase 3,"University Hospital, Geneva",NA,https://clinicaltrials.gov/ct2/show/NCT04345848,2,0,2,0,3,0,Switzerland,0,enoxaparin,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04257656,2020-02-06,2020-03-30,Interventional,A Trial of Remdesivir in Adults With Severe COVID-19,Terminated,Phase 3,Capital Medical University,"The epidemic of COVID-19 has been controlled well in China, no eligible patients can be
    enrolled at present.",https://clinicaltrials.gov/ct2/show/NCT04257656,2,0,2,0,3,0,China,0,remdesivir|placebo,Journal Article|Multicenter Study|Randomized Controlled Trial/Clinical Trial Protocol|Journal Article
NCT04329832,2020-03-30,2020-12-18,Interventional,Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,"Intermountain Health Care, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04329832,2,0,2,0,3,1,United States,0,hydroxychloroquine|azithromycin,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article"
NCT04280705,2020-02-21,2020-05-21,Interventional,Adaptive COVID-19 Treatment Trial (ACTT),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04280705,3,0,3,0,24,1,"United States|Denmark|Germany|Greece|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Introductory Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04313127,2020-03-16,2020-12-30,Interventional,Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults,"Active, not recruiting",Phase 1,CanSino Biologics Inc.,NA,https://clinicaltrials.gov/ct2/show/NCT04313127,1,0,1,1,4,0,China,0,adenovirus type 5 vector,"Clinical Trial, Phase I|Journal Article"
NCT04292899,2020-03-06,2020-04-09,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Severe Coronavirus Disease (COVID-19),Completed,Phase 3,Gilead Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04292899,1,0,1,0,20,1,"United States|China|France|Germany|Hong Kong|Italy|Japan|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard care,"Clinical Trial, Phase III|Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04321421,2020-03-17,2020-04-28,Interventional,Hyperimmune Plasma for Critical Patients With COVID-19,Completed,N/A,Foundation IRCCS San Matteo Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04321421,3,0,3,0,2,0,Italy,0,convalescent plasma,"Clinical Trial Protocol|Journal Article|Multicenter Study/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04332991,2020-04-02,2020-06-19,Interventional,Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease,Completed,Phase 3,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04332991,2,0,2,0,9,1,United States,1,hydroxychloroquine|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04330638,2020-04-03,2020-12-18,Interventional,Treatment of COVID-19 Patients With Anti-interleukin Drugs,"Active, not recruiting",Phase 3,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04330638,1,0,1,0,7,0,Belgium,0,standard care|anakinra|siltuximab|tocilizumab,Clinical Trial Protocol|Letter
NCT04343768,2020-04-09,2020-04-27,Interventional,"An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial",Completed,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04343768,2,0,2,0,3,0,"Iran, Islamic Republic of",0,hydroxychloroquine|lopinavir/ritonavir|interferon|lopinavir|ritonavir,Clinical Trial Protocol|Letter/Journal Article|Randomized Controlled Trial
NCT04328961,2020-03-31,2020-09-24,Interventional,Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP),Completed,Phase 2/Phase 3,University of Washington,NA,https://clinicaltrials.gov/ct2/show/NCT04328961,2,0,2,0,5,1,United States,0,hydroxychloroquine|vitamin c,"Clinical Trial Protocol|Letter/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04328441,2020-03-25,2021-03-31,Interventional,Reducing Health Care Workers Absenteeism in Covid-19 Pandemic Through BCG Vaccine,"Active, not recruiting",Phase 3,UMC Utrecht,NA,https://clinicaltrials.gov/ct2/show/NCT04328441,1,0,1,1,3,0,Netherlands,0,bcg|placebo,Clinical Trial Protocol|Letter
NCT04360980,2020-03-20,2021-09-01,Interventional,The Effects of Standard Protocol With or Without Colchicine in Covid-19 Infection,Recruiting,Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04360980,1,0,1,0,3,0,"Iran, Islamic Republic of",0,colchicine,Clinical Trial Protocol|Letter
NCT04333589,2020-04-01,2020-06-01,Interventional,Corona Virus Disease 2019 Patients Whose Nucleic Acids Changed From Negative to Positive,Recruiting,N/A,Peking University First Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04333589,1,0,1,0,2,0,China,0,favipiravir,Clinical Trial Protocol|Letter
NCT04316377,2020-03-25,2020-05-25,Interventional,Norwegian Coronavirus Disease 2019 Study,"Active, not recruiting",Phase 4,"University Hospital, Akershus",NA,https://clinicaltrials.gov/ct2/show/NCT04316377,2,0,2,0,3,0,Norway,0,hydroxychloroquine,"Clinical Trial Protocol|Letter/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04326920,2020-03-24,2020-09-28,Interventional,Sargramostim in Patients With Acute Hypoxic Respiratory Failure Due to COVID-19 (SARPAC),Completed,Phase 4,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04326920,2,0,2,0,5,0,Belgium,0,sargramostim|control,"Clinical Trial Protocol|Letter/Journal Article|Research Support, Non-U.S. Gov't|Review"
NCT04306393,2020-03-21,2021-03-21,Interventional,Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19,Recruiting,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04306393,2,0,2,0,7,1,United States,0,nitric oxide,Preprint/Journal Article
NCT04335786,2020-04-17,2020-12-31,Interventional,Valsartan for Prevention of Acute Respiratory Distress Syndrome in Hospitalized Patients With SARS-COV-2 (COVID-19) Infection Disease,Recruiting,Phase 4,Radboud University,NA,https://clinicaltrials.gov/ct2/show/NCT04335786,1,0,1,0,6,0,Netherlands,0,diovan|placebo,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04341493,2020-04-06,2020-08-30,Interventional,Hydroxychloroquine vs Nitazoxanide in Patients With COVID-19,Terminated,Phase 4,Materno-Perinatal Hospital of the State of Mexico,Concerns about safety of Hydroxychloroquine,https://clinicaltrials.gov/ct2/show/NCT04341493,1,0,1,0,3,0,Mexico,0,nitazoxanide|hydroxychloroquine,Clinical Trial Protocol|Letter
NCT04334265,2020-04-01,2020-06-01,Interventional,Efficacy and Safety of Anluohuaxian in the Treatment of Rehabilitation Patients With Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04334265,1,0,1,0,1,0,China,0,anluohuaxian,Clinical Trial Protocol|Letter
NCT04359810,2020-04-21,2020-12-31,Interventional,Plasma Therapy of COVID-19 in Severely Ill Patients,Recruiting,Phase 2,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04359810,1,0,1,0,3,1,United States|Brazil,0,convalescent plasma|plasma,Clinical Trial Protocol|Letter
NCT04338958,2020-04-22,2021-07-31,Interventional,Ruxolitinib in Covid-19 Patients With Defined Hyperinflammation,Recruiting,Phase 2,University of Jena,NA,https://clinicaltrials.gov/ct2/show/NCT04338958,1,0,1,0,4,0,Germany,0,ruxolitinib,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04322396,2020-04-06,2021-02-02,Interventional,Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19,Completed,Phase 2,"Chronic Obstructive Pulmonary Disease Trial Network, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04322396,2,0,2,0,4,0,Denmark,0,azithromycin|hydroxychloroquine|placebo,Clinical Trial Protocol|Letter/Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04336254,2020-05-06,2021-11-30,Interventional,Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients,Recruiting,Phase 1/Phase 2,Renmin Hospital of Wuhan University,NA,https://clinicaltrials.gov/ct2/show/NCT04336254,1,0,1,0,1,0,China,0,mesenchymal stem cells|placebo|utooth btc),"Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter"
NCT04369469,2020-05-11,2021-05-31,Interventional,Efficacy and Safety Study of IV Ravulizumab in Patients With COVID-19 Severe Pneumonia,"Active, not recruiting",Phase 3,Alexion Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04369469,3,0,3,0,9,1,United States|France|Japan|Spain|United Kingdom,0,ravulizumab|best supportive care,"Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't|Review/Clinical Trial Protocol|Letter/Journal Article"
NCT04354259,2020-05-13,2020-08-01,Interventional,Interferon Lambda for Immediate Antiviral Therapy at Diagnosis in COVID-19,Recruiting,Phase 2,"University Health Network, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04354259,3,0,3,0,1,0,Canada,0,peginterferon|placebo,"Journal Article|Review/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04355364,2020-04-21,2021-12-21,Interventional,Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE),Recruiting,Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicaltrials.gov/ct2/show/NCT04355364,1,0,1,0,8,0,France,0,pulmozyme|standard care,Clinical Trial Protocol|Letter|Multicenter Study
NCT04368156,2020-04-20,2021-02-23,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,"Active, not recruiting",N/A,Hospital ClÃ­nico Universitario de Valencia,NA,https://clinicaltrials.gov/ct2/show/NCT04368156,1,0,1,0,1,0,Spain,0,gammacoreâ® (vagus nerve stimulation)|gammacoreâ® (vagus nerve stimulation),Clinical Trial Protocol|Letter
NCT04348513,2020-05-29,2021-05-02,Interventional,Triiodothyronine for the Treatment of Critically Ill Patients With COVID-19 Infection,Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04348513,1,0,1,0,1,0,Greece,0,t3 solution|placebo,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter|Multicenter Study"
NCT04380818,2020-06-05,2021-05-04,Interventional,Low Dose Anti-inflammatory Radiotherapy for the Treatment of Pneumonia by COVID-19,Recruiting,N/A,Grupo de InvestigaciÃ³n ClÃ­nica en OncologÃ­a Radioterapia,NA,https://clinicaltrials.gov/ct2/show/NCT04380818,1,0,1,0,2,0,Spain,0,radiotherapy|hydroxychloroquine|lopinavir/ritonavir|tocilizumab|azithromycin|corticosteroid|heparin|oxygen|ritonavir|lopinavir,Journal Article
NCT04410562,2020-05-13,2021-05-13,Interventional,Hydroxychloroquine Efficacy and Safety in Preventing SARS-CoV-2 Infection and COVID-19 Disease Severity During Pregnancy and Postpartum,Recruiting,Phase 3,Barcelona Institute for Global Health,NA,https://clinicaltrials.gov/ct2/show/NCT04410562,1,0,1,0,1,0,Spain,0,hydroxychloroquine|placebo,Clinical Trial Protocol|Letter
NCT04307693,2020-03-11,2020-04-30,Interventional,Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19),Terminated,Phase 2,Asan Medical Center,Terminated early because no patients were further enrolled since mid-Apr 2020.,https://clinicaltrials.gov/ct2/show/NCT04307693,1,0,1,0,2,0,"Korea, Republic of",0,lopinavir/ritonavir|hydroxychloroquine|lopinavir|ritonavir,Journal Article|Comment
NCT04368676,2020-06-25,2022-06-30,Interventional,Breath Regulation and Yogic Exercise An Online Therapy for Calm and Happiness During the COVID-19 Pandemic,"Active, not recruiting",Early Phase 1,Lawson Health Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04368676,2,0,2,0,3,0,Canada,0,sudarshan kriya yoga (sky)|health enhancement program,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Clinical Trial, Phase I|Clinical Trial, Phase II|Letter"
NCT04390464,2020-05-08,2021-05-07,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Repurposed Drugs (TACTIC-R),Recruiting,Phase 4,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04390464,1,0,1,0,1,0,United Kingdom,0,ravulizumab|baricitinib|standard care,"Clinical Trial Protocol|Clinical Trial, Phase IV|Letter"
NCT04339816,2020-05-13,2020-11-04,Interventional,Azithromycin Added to Hydrochloroquine in Patients Admitted to Intensive Care With COVID-19: Randomised Controlled Trial,Terminated,Phase 3,"Charles University, Czech Republic",Steering Committee decision in accordance with stopping rule 1: Emergence of new data,https://clinicaltrials.gov/ct2/show/NCT04339816,1,0,1,0,3,0,Czechia,0,azithromycin|hydroxychloroquine|placebo,Clinical Trial Protocol|Journal Article|Multicenter Study
NCT04264533,2020-02-14,2020-03-02,Interventional,Vitamin C Infusion for the Treatment of Severe 2019-nCoV Infected Pneumonia,Terminated,Phase 2,Zhongnan Hospital,"the study was started in the second half of the outbreak, and the number of qualifying COVID-19
    patients decreased with the control of the epidemic so that we had to stop our trial before
    reaching the predefined sample size.",https://clinicaltrials.gov/ct2/show/NCT04264533,1,0,1,0,2,0,China,0,vitamin c|water,"Clinical Trial Protocol|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04312009,2020-04-13,2021-02-01,Interventional,Losartan for Patients With COVID-19 Requiring Hospitalization,Completed,Phase 2,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04312009,1,0,1,0,14,1,United States,0,losartan|placebo,Journal Article
NCT04335123,2020-04-04,2020-06-21,Interventional,Study of Open Label Losartan in COVID-19,Completed,Phase 1,University of Kansas Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04335123,1,0,1,0,3,1,United States,0,losartan,Journal Article
NCT04311177,2020-04-09,2021-02-01,Interventional,Losartan for Patients With COVID-19 Not Requiring Hospitalization,Completed,Phase 2,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04311177,1,0,1,0,10,1,United States,0,losartan|placebo,Journal Article
NCT04283461,2020-03-16,2022-11-22,Interventional,Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04283461,2,0,2,1,24,1,United States,0,mrna-1273,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04252274,2020-01-30,2020-08-31,Interventional,Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19,Recruiting,Phase 3,Shanghai Public Health Clinical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04252274,1,0,1,0,2,0,China,0,darunavir/cobicistat|darunavir|cobicistat,Journal Article
NCT04251871,2020-01-22,2021-01-22,Interventional,Treatment and Prevention of Traditional Chinese Medicines (TCMs) on COVID-19 Infection,Recruiting,N/A,Beijing 302 Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04251871,2,0,2,0,1,0,China,0,"conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,|lopinavir|ritonavir|traditional chinese medicine",Journal Article|Randomized Controlled Trial/Journal Article|Systematic Review
NCT04381936,2020-03-19,2021-12-31,Interventional,Randomised Evaluation of COVID-19 Therapy,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04381936,3,2,5,0,9,0,Indonesia|Nepal|United Kingdom,0,lopinavir/ritonavir|corticosteroid|hydroxychloroquine|azithromycin|convalescent plasma|tocilizumab|immunoglobulin|synthetic neutralising antibodies|aspirin|colchicine|baricitinib|anakinra|dimethyl fumarate|infliximab|high dose corticosteroid,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04361474,2020-05-18,2020-11-24,Interventional,Trial Evaluating the Efficacy of Local Budesonide Therapy in the Management of Hyposmia in COVID-19 Patients Without Signs of Severity,"Active, not recruiting",Phase 3,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicaltrials.gov/ct2/show/NCT04361474,1,0,1,0,4,0,France,0,budesonide|serum,Clinical Trial Protocol|Letter|Multicenter Study
NCT04324606,2020-04-23,2021-10-31,Interventional,A Study of a Candidate COVID-19 Vaccine (COV001),"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04324606,4,0,4,1,14,0,United Kingdom,0,chadox1|menacwy|paracetamol|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine (lv)|chadox1 ncov-19 0.5ml (3.5-6.5x10^10vp) late vaccine two (lvt),"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't"
NCT04341389,2020-04-12,2021-01-31,Interventional,A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector),"Active, not recruiting",Phase 2,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://clinicaltrials.gov/ct2/show/NCT04341389,1,0,1,1,3,0,China,0,adenovirus type 5 vector|placebo,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04322123,2020-04-01,2020-08-30,Interventional,Safety and Efficacy of Hydroxychloroquine Associated With Azithromycin in SARS-Cov-2 Virus (COVID-19),"Active, not recruiting",Phase 3,Hospital do Coracao,NA,https://clinicaltrials.gov/ct2/show/NCT04322123,1,0,1,0,7,0,Brazil,0,hydroxychloroquine|hydroxychloroquine / azithromycin|azithromycin,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04331834,2020-04-03,2020-06-25,Interventional,Pre-Exposure Prophylaxis With Hydroxychloroquine for High-Risk Healthcare Workers During the COVID-19 Pandemic,Completed,Phase 3,Barcelona Institute for Global Health,NA,https://clinicaltrials.gov/ct2/show/NCT04331834,1,0,1,0,3,0,Spain,0,hydroxychloroquine|placebo,Clinical Trial Protocol|Letter|Multicenter Study
NCT04393246,2020-07-03,2022-02-15,Interventional,mulTi-Arm Therapeutic Study in Pre-ICu Patients Admitted With Covid-19 - Experimental Drugs and Mechanisms,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04393246,1,0,1,0,3,0,United Kingdom,0,edp1815|dapagliflozin|ambrisentan|standard care,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Letter"
NCT04363827,2020-05-14,2021-06-30,Interventional,Protect: Study With Hydroxychloroquine for Prevention and Early Phase Treatment of Coronavirus Disease (COVID-19),"Active, not recruiting",Phase 2,Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,NA,https://clinicaltrials.gov/ct2/show/NCT04363827,1,0,1,0,3,0,Italy,0,hydroxychloroquine,Clinical Trial Protocol|Comparative Study|Journal Article|Observational Study
NCT04433910,2020-08-30,2021-01-21,Interventional,A Clinical Trial of Convalescent Plasma Compared to Best Supportive Care for Treatment of Patients With Severe COVID-19,Completed,Phase 2,Deutsches Rotes Kreuz DRK-Blutspendedienst Baden-Wurttemberg-Hessen,NA,https://clinicaltrials.gov/ct2/show/NCT04433910,1,0,1,0,4,0,Germany,0,convalescent plasma,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04416399,2020-07-16,2021-01-12,Interventional,STerOids in COVID-19 Study,Terminated,Phase 2,University of Oxford,Independent statistical review advice,https://clinicaltrials.gov/ct2/show/NCT04416399,2,0,2,0,4,0,United Kingdom,0,budesonide,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04331470,2020-04-04,2020-04-20,Interventional,Evaluation of Efficacy of Levamisole and Formoterol+Budesonide in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Fasa University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04331470,1,0,1,0,2,0,"Iran, Islamic Republic of",0,levamisole / budesonide/formoterol|lopinavir/ritonavir / hydoxychloroquine|levamisole|budesonide|formoterol|lopinavir|ritonavir|hydroxychloroquine,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04330586,2020-04-01,2021-03-31,Interventional,A Trial of Ciclesonide in Adults With Mild-to-moderate COVID-19,Recruiting,Phase 2,Korea University Guro Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04330586,1,0,1,0,2,0,"Korea, Republic of",0,ciclesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04355637,2020-04-21,2021-08-31,Interventional,Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia,Recruiting,Phase 4,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicaltrials.gov/ct2/show/NCT04355637,1,0,1,0,4,0,Argentina|Spain,0,budesonide,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04377711,2020-06-08,2021-01-05,Interventional,A Study of the Safety and Efficacy of Ciclesonide in the Treatment of Non-hospitalized COVID-19 Patients,Completed,Phase 3,Covis Pharma S.Ã .r.l.,NA,https://clinicaltrials.gov/ct2/show/NCT04377711,1,0,1,0,4,1,United States,0,ciclesonide|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04296643,2020-04-01,2021-02-01,Interventional,Medical Masks vs N95 Respirators for COVID-19,Recruiting,N/A,McMaster University,NA,https://clinicaltrials.gov/ct2/show/NCT04296643,1,0,1,0,2,0,Canada|Israel,0,medical mask|n95 respirator,Journal Article
NCT04338698,2020-04-22,2020-09-01,Interventional,"Hydroxychloroquine, Oseltamivir and Azithromycin for the Treatment of COVID-19 Infection: An RCT",Recruiting,Phase 3,University of Health Sciences Lahore,NA,https://clinicaltrials.gov/ct2/show/NCT04338698,1,0,1,0,2,0,Pakistan,0,hydroxychloroquine|oseltamivir|azithromycin,Clinical Trial Protocol|Letter|Multicenter Study|Observational Study|Randomized Controlled Trial
NCT04401202,2020-05-21,2020-12-31,Interventional,Nigella Sativa in COVID-19,Completed,Phase 2,King Abdulaziz University,NA,https://clinicaltrials.gov/ct2/show/NCT04401202,1,0,1,0,1,0,Saudi Arabia,0,nigella sativa oil,"Clinical Trial Protocol|Clinical Trial, Phase II|Letter"
NCT04434131,2020-04-28,2021-04-28,Interventional,Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19,Recruiting,Phase 2,University of New Mexico,NA,https://clinicaltrials.gov/ct2/show/NCT04434131,2,0,2,0,2,1,United States,0,convalescent plasma,"Clinical Trial|Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04368728,2020-04-29,2021-10-29,Interventional,"Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals",Recruiting,Phase 2/Phase 3,BioNTech SE,NA,https://clinicaltrials.gov/ct2/show/NCT04368728,4,0,4,1,28,1,United States|Argentina|Brazil|Germany|South Africa|Turkey,0,bnt162b1|bnt162b2|placebo|bnt162b2sa,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial/Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article"
NCT04343729,2020-04-18,2020-06-16,Interventional,Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicaltrials.gov/ct2/show/NCT04343729,1,0,1,0,7,0,Brazil,0,methylprednisolone|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04344600,2020-05-29,2021-06-30,Interventional,Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicaltrials.gov/ct2/show/NCT04344600,1,0,1,0,3,1,United States,0,peginterferon|saline,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04385095,2020-03-16,2021-02-17,Interventional,Trial of Inhaled Anti-viral (SNG001) for SARS-CoV-2 (COVID-19) Infection,"Active, not recruiting",Phase 2,Synairgen Research Ltd.,NA,https://clinicaltrials.gov/ct2/show/NCT04385095,2,0,2,0,3,0,United Kingdom,0,sng001|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04343976,2020-06-22,2021-09-01,Interventional,Pegylated Interferon Lambda Treatment for COVID-19,Enrolling by invitation,Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04343976,1,0,1,0,4,1,United States,0,peginterferon,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04345614,2020-04-08,2021-07-31,Interventional,A Study of Auxora in Patients With Severe COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04345614,1,0,1,0,18,1,United States|Puerto Rico,0,auxora|placebo,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04325061,2020-04-03,2020-06-19,Interventional,Efficacy of Dexamethasone Treatment for Patients With ARDS Caused by COVID-19,Terminated,Phase 4,Dr. Negrin University Hospital,Lack of enrollment,https://clinicaltrials.gov/ct2/show/NCT04325061,1,2,3,0,8,0,Spain,0,dexamethasone,"Clinical Trial Protocol|Journal Article|Multicenter Study/Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04381962,2020-06-03,2021-01-29,Interventional,A Multicentre Open-label Two-arm Randomised Superiority Clinical Trial of Azithromycin Versus Usual Care In Ambulatory COVID19 (ATOMIC2),Completed,Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04381962,1,0,1,0,2,0,United Kingdom,0,azithromycin,"Clinical Trial Protocol|Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study"
NCT04412057,2020-06-09,2020-12-02,Interventional,Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury,Completed,Phase 2,Cerecor Inc,NA,https://clinicaltrials.gov/ct2/show/NCT04412057,1,0,1,0,6,1,United States,0,cerc-002|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04292730,2020-03-15,2020-04-29,Interventional,Study to Evaluate the Safety and Antiviral Activity of Remdesivir (GS-5734â„¢) in Participants With Moderate Coronavirus Disease (COVID-19) Compared to Standard of Care Treatment,Completed,Phase 3,Gilead Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04292730,1,1,2,0,20,1,"Japan|United States|China|France|Germany|Hong Kong|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|Taiwan|United Kingdom",1,remdesivir|standard care,"Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04370288,2020-04-19,2020-09-20,Interventional,Clinical Application of Methylene Blue for Treatment of Covid-19 Patients,Recruiting,Phase 1,Mashhad University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04370288,1,0,1,0,1,0,"Iran, Islamic Republic of",0,methylene blue/ vitamin c/n-acetyl cysteine,Case Reports|Journal Article
NCT04337541,2020-04-02,2020-06-02,Interventional,Reduction in COVID-19 Infection Using Surgical Facial Masks Outside the Healthcare System,Completed,N/A,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04337541,2,0,2,0,1,0,Denmark,0,surgical facial mask,"Journal Article|Randomized Controlled Trial/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04357730,2020-05-14,2021-03-22,Interventional,Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection,"Active, not recruiting",Phase 2,Denver Health and Hospital Authority,NA,https://clinicaltrials.gov/ct2/show/NCT04357730,1,0,1,0,9,1,United States,0,activase,Journal Article
NCT04252885,2020-01-28,2020-04-30,Interventional,The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus Infection,Completed,Phase 4,Guangzhou 8th People's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04252885,1,0,1,0,1,0,China,0,lopinavir/ritonavir|arbidol|lopinavir|ritonavir,Journal Article
NCT04395105,2020-05-21,2020-12-31,Interventional,"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial",Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicaltrials.gov/ct2/show/NCT04395105,1,0,1,0,3,0,Argentina,0,dexamethasone,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial
NCT04420741,2020-06-15,2021-02-23,Interventional,Infusion of Prostacyclin (Iloprost) vs Placebo for 72-hours in COVID-19 Patients With Respiratory Failure,"Active, not recruiting",Phase 2,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04420741,1,0,1,0,6,0,Denmark,0,iloprost|saline,Clinical Trial Protocol|Letter|Multicenter Study|Randomized Controlled Trial
NCT04327401,2020-04-13,2020-07-22,Interventional,COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III,Terminated,Phase 3,Hospital Sirio-Libanes,"The Data Monitoring Committee recommended to stop the trial based on the Recovery Trial
    results, which was accepted by the CoDEX Steering Committee.",https://clinicaltrials.gov/ct2/show/NCT04327401,1,0,1,0,5,0,Brazil,0,dexamethasone,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04368988,2020-05-25,2020-12-01,Interventional,Evaluation of the Safety and Immunogenicity of a SARS-CoV-2 rS Nanoparticle Vaccine With/Without Matrix-M Adjuvant,"Active, not recruiting",Phase 1/Phase 2,Novavax,NA,https://clinicaltrials.gov/ct2/show/NCT04368988,3,0,3,1,5,1,United States|Australia,0,sars-cov-2 rs|sars-cov-2 rs/matrix-m1 adjuvant|placebo|adjuvant|21 - phase 2,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04338841,2020-04-09,2020-06-17,Interventional,HOME-CoV: Hospitalization or Outpatient ManagEment of Patients With a SARS-CoV-2 Infection,Completed,N/A,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04338841,1,0,1,0,2,0,Belgium|France|Monaco,0,home-cov rule implementation,Journal Article
NCT04445935,2020-06-28,2020-09-28,Interventional,Anticoagulation in Patients Suffering From COVID-19 Disease The ANTI-CO Trial,Recruiting,Phase 4,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04445935,1,0,1,0,0,0,Qatar,0,bivalirudin|standard care,Clinical Trial Protocol|Equivalence Trial|Letter
NCT04436471,2020-06-17,2020-08-03,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of the Drug ""Gam-COVID-Vac"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04436471,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04437875,2020-06-17,2020-08-03,Interventional,"An Open Study of the Safety, Tolerability and Immunogenicity of ""Gam-COVID-Vac Lyo"" Vaccine Against COVID-19",Completed,Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04437875,1,0,1,1,3,0,Russian Federation,0,gam-covid-vac lyo,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04347681,2020-04-18,2020-12-31,Interventional,Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19,Recruiting,Phase 2,King Fahad Specialist Hospital Dammam,NA,https://clinicaltrials.gov/ct2/show/NCT04347681,2,0,2,0,3,0,Saudi Arabia,0,convalescent plasma,Journal Article/Journal Article
NCT04400799,2020-06-15,2022-03-14,Interventional,Enoxaparin for Primary Thromboprophylaxis in Ambulatory Patients With COVID-19,Recruiting,Phase 3,University of Zurich,NA,https://clinicaltrials.gov/ct2/show/NCT04400799,1,0,1,0,2,0,Switzerland,0,enoxaparin|0.4ml inj syringe 0.4ml,Clinical Trial Protocol|Letter
NCT04357808,2020-04-13,2020-11-30,Interventional,Efficacy of Subcutaneous Sarilumab in Hospitalised Patients With Moderate-severe COVID-19 Infection (SARCOVID),Completed,Phase 2,FundaciÃ³n de InvestigaciÃ³n BiomÃ©dica - Hospital Universitario de La Princesa,NA,https://clinicaltrials.gov/ct2/show/NCT04357808,1,0,1,0,3,0,Spain,0,sarilumab|standard care,Clinical Trial Protocol|Letter
NCT04399317,2020-05-28,2020-07-31,Interventional,Flow Controlled Ventilation in ARDS Associated With COVID-19,Recruiting,N/A,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04399317,1,0,1,0,1,0,Qatar,0,flow controlled ventilation (evone-ventilator),Clinical Trial Protocol|Letter
NCT04327206,2020-03-30,2021-06-30,Interventional,BCG Vaccination to Protect Healthcare Workers Against COVID-19,"Active, not recruiting",Phase 3,Murdoch Childrens Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04327206,1,0,1,1,11,0,Australia|Brazil|Netherlands|Spain|United Kingdom,0,bcg|saline,"Journal Article|Research Support, Non-U.S. Gov't|Review"
NCT04352959,2020-04-27,2020-12-11,Interventional,COVID-19: Nasal and Salivary Detection of the SARS-CoV-2 Virus After Antiviral Mouthrinses,Completed,N/A,Claude Bernard University,NA,https://clinicaltrials.gov/ct2/show/NCT04352959,2,0,2,0,4,0,France,0,mouthrinse with bãªta-cyclodextrin/citrox|mouthrinse without bãªta-cyclodextrin/citrox|mouthrinse with bãªta-cyclodextrin|citrox|mouthrinse without bãªta-cyclodextrin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Letter"
NCT04364802,2020-04-29,2021-05-31,Interventional,COVID-19: Povidone-Iodine Intranasal Prophylaxis in Front-line Healthcare Personnel and Inpatients,Recruiting,Phase 2,University of Kentucky,NA,https://clinicaltrials.gov/ct2/show/NCT04364802,1,0,1,0,2,1,United States,0,povidone/iodine|gargle,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04373291,2020-05-18,2021-07-31,Interventional,Using BCG Vaccine to Protect Health Care Workers in the COVID-19 Pandemic,"Active, not recruiting",Phase 3,Bandim Health Project,NA,https://clinicaltrials.gov/ct2/show/NCT04373291,1,0,1,1,4,0,Denmark,0,bcg-denmark|saline,Clinical Trial Protocol|Letter
NCT04343261,2020-04-10,2020-07-23,Interventional,Convalescent Plasma in the Treatment of COVID 19,Completed,Phase 2,Saint Francis Care,NA,https://clinicaltrials.gov/ct2/show/NCT04343261,3,2,5,0,9,1,United States,1,convalescent plasma,"Journal Article/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial, Phase II|Journal Article/Journal Article"
NCT04321928,2020-04-01,2021-04-21,Interventional,Personalized Health Education Against the Health Damage of Novel Coronavirus (COVID-19) Outbreak in Hungary,Recruiting,N/A,University of Pecs,NA,https://clinicaltrials.gov/ct2/show/NCT04321928,1,0,1,0,2,0,Hungary,0,personalized health education|general health education,Clinical Trial Protocol|Journal Article
NCT04394416,2020-06-02,2022-06-01,Interventional,Trial of Imatinib for Hospitalized Adults With COVID-19,Recruiting,Phase 3,"University of Maryland, Baltimore",NA,https://clinicaltrials.gov/ct2/show/NCT04394416,2,0,2,0,1,1,United States,0,imatinib|placebo,"Letter|Research Support, N.I.H., Extramural/Clinical Trial Protocol|Letter"
NCT04329923,2020-04-09,2020-11-11,Interventional,The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine),Terminated,Phase 2,University of Pennsylvania,"Cohort 1: slow accrual Cohort 2: Other studies showed no benefit Cohort 3: Study met
    pre-specificied futility analysis at planned second interim analysis",https://clinicaltrials.gov/ct2/show/NCT04329923,1,1,2,0,7,1,United States,1,hydroxychloroquine|placebo,Journal Article|Multicenter Study|Randomized Controlled Trial/Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04333420,2020-03-31,2021-05-31,Interventional,"Randomized, Controlled Study of IFX-1 in Patients With Severe COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,InflaRx GmbH,NA,https://clinicaltrials.gov/ct2/show/NCT04333420,1,0,1,0,8,0,Belgium|Brazil|France|Germany|Mexico|Netherlands|Peru|Russian Federation,0,soc / ifx-1|soc / placebo|standard care|ifx-1|placebo,Journal Article
NCT04317092,2020-03-19,2021-12-19,Interventional,Tocilizumab in COVID-19 Pneumonia (TOCIVID-19),"Active, not recruiting",Phase 2,"National Cancer Institute, Naples",NA,https://clinicaltrials.gov/ct2/show/NCT04317092,3,0,3,0,4,0,Italy,0,tocilizumab,"Clinical Trial Protocol|Journal Article/Journal Article/Clinical Trial, Phase II|Journal Article|Multicenter Study"
NCT04342182,2020-04-08,2021-07-01,Interventional,Convalescent Plasma as Therapy for Covid-19 Severe SARS-CoV-2 Disease (CONCOVID Study),"Active, not recruiting",Phase 2/Phase 3,Erasmus Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04342182,1,0,1,0,11,0,Netherlands,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04340050,2020-04-10,2020-12-23,Interventional,COVID-19 Convalescent Plasma,Completed,Early Phase 1,University of Chicago,NA,https://clinicaltrials.gov/ct2/show/NCT04340050,1,0,1,0,4,1,United States,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04357106,2020-04-13,2020-07-31,Interventional,COPLA Study: Treatment of Severe Forms of COronavirus Infection With Convalescent PLAsma,Recruiting,Phase 2,Centro de HematologÃ­a y Medicina Interna,NA,https://clinicaltrials.gov/ct2/show/NCT04357106,1,0,1,0,0,0,Mexico,0,convalescent plasma,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04441424,2020-04-03,2020-06-01,Interventional,Convalescent Plasma Therapy on Critically-ill Novel Coronavirus (COVID-19) Patients,Completed,N/A,Alkarkh Health Directorate-Baghdad,NA,https://clinicaltrials.gov/ct2/show/NCT04441424,1,0,1,0,1,0,Iraq,0,convalescent plasma|hydroxychloroquine / azithromycin,"Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04555096,2020-09-09,2021-11-30,Interventional,A Trial of GC4419 in Patients With Critical Illness Due to COVID-19,Recruiting,Phase 2,"Galera Therapeutics, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04555096,1,0,1,0,4,1,United States,0,gc4419|placebo,Journal Article
NCT04356495,2020-07-29,2021-08-15,Interventional,Trial of COVID-19 Outpatient Treatment in Individuals With Risk Factors for Aggravation,Recruiting,Phase 2/Phase 3,"University Hospital, Bordeaux",NA,https://clinicaltrials.gov/ct2/show/NCT04356495,1,0,1,0,6,0,France,0,vitamins|telmisartan|ciclesonide|interferon î²-1b|interferon î²-1b,"Clinical Trial, Phase III|Letter|Randomized Controlled Trial"
NCT04445467,2020-08-01,2020-11-30,Interventional,An Adaptive Clinical Trial of Antivirals for COVID-19 Infection,Recruiting,Phase 2,Bayside Health,NA,https://clinicaltrials.gov/ct2/show/NCT04445467,1,0,1,0,1,0,Australia,0,favipiravir,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04343963,2020-04-04,2020-09-30,Interventional,Pyridostigmine in Severe SARS-CoV-2 Infection,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04343963,1,0,1,0,2,0,Mexico,0,pyridostigmine bromide|placebo,Clinical Trial Protocol|Journal Article
NCT04346355,2020-03-31,2020-06-06,Interventional,Efficacy of Early Administration of Tocilizumab in COVID-19 Patients,Terminated,Phase 2,Azienda UnitÃ  Sanitaria Locale Reggio Emilia,Based on interim analysis for futility and given an enrolment rate almost nil,https://clinicaltrials.gov/ct2/show/NCT04346355,1,0,1,0,2,0,Italy,0,tocilizumab,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04331808,2020-03-30,2021-03-31,Interventional,CORIMUNO-19 - Tocilizumab Trial - TOCI (CORIMUNO-TOCI),"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicaltrials.gov/ct2/show/NCT04331808,1,0,1,0,2,0,France,0,tocilizumab,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04436276,2020-07-15,2021-12-03,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Janssen Vaccines & Prevention B.V.,NA,https://clinicaltrials.gov/ct2/show/NCT04436276,3,0,3,0,10,1,United States|Belgium,0,ad26.cov2.s|placebo,"Journal Article/Journal Article/Clinical Trial, Phase I|Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04356937,2020-04-20,2020-07-13,Interventional,Efficacy of Tocilizumab on Patients With COVID-19,Completed,Phase 3,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04356937,1,0,1,0,4,1,United States,0,tocilizumab|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04374526,2020-05-27,2021-04-30,Interventional,Early transfusIon of Convalescent Plasma in Elderly COVID-19 Patients. to Prevent Disease Progression.,Recruiting,Phase 2/Phase 3,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicaltrials.gov/ct2/show/NCT04374526,1,0,1,0,2,0,Italy,0,convalescent plasma,"Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Letter|Randomized Controlled Trial"
NCT04403477,2020-05-20,2020-07-20,Interventional,Convalescent Plasma Therapy in Severe COVID-19 Infection,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://clinicaltrials.gov/ct2/show/NCT04403477,1,0,1,0,0,0,Bangladesh,0,convalescent plasma,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04389840,2020-06-03,2021-02-28,Interventional,Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure,Recruiting,Phase 2/Phase 3,Chimerix,NA,https://clinicaltrials.gov/ct2/show/NCT04389840,1,0,1,0,11,1,United States,0,dociparstat sodium|placebo,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial"
NCT04328493,2020-04-07,2021-04-01,Interventional,The Vietnam Chloroquine Treatment on COVID-19,Recruiting,Phase 2,"Oxford University Clinical Research Unit, Vietnam",NA,https://clinicaltrials.gov/ct2/show/NCT04328493,1,0,1,0,3,0,Vietnam,0,chloroquine,Journal Article
NCT04427501,2020-06-17,2020-09-20,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2/Phase 3,Eli Lilly and Company,NA,https://clinicaltrials.gov/ct2/show/NCT04427501,2,0,2,0,36,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Clinical Trial, Phase III|Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04392973,2020-05-21,2021-11-30,Interventional,FAvipiravir and HydroxyChloroquine Combination Therapy,Recruiting,N/A,King Abdullah International Medical Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04392973,1,0,1,0,2,0,Saudi Arabia,0,favipiravir/hydroxychloroquine|favipiravir|hydroxychloroquine,Clinical Trial Protocol|Letter
NCT04521309,2020-06-19,2021-01-26,Interventional,SARS-CoV-2 Antibodies Based IVIG Therapy for COVID-19 Patients,Completed,Phase 1/Phase 2,Dow University of Health Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04521309,2,0,2,0,4,0,Pakistan,0,sars-cov-2 antibody based ivig therapy,"Clinical Trial Protocol|Letter/Journal Article|Research Support, Non-U.S. Gov't"
NCT04401579,2020-05-08,2020-07-31,Interventional,Adaptive COVID-19 Treatment Trial 2 (ACTT-2),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04401579,2,0,2,0,16,1,"United States|Denmark|Japan|Korea, Republic of|Mexico|Singapore|Spain|United Kingdom",1,placebo|remdesivir|baricitinib,"Journal Article|Review/Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04492475,2020-08-05,2020-12-21,Interventional,Adaptive COVID-19 Treatment Trial 3 (ACTT-3),Completed,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04492475,1,0,1,0,29,1,"United States|Japan|Korea, Republic of|Mexico|Singapore",0,interferon|placebo|remdesivir,Journal Article|Review
NCT04557605,2020-09-14,2020-10-15,Interventional,Effects of a Face Mask on Oxygenation During Exercise,Completed,N/A,University of Saskatchewan,NA,https://clinicaltrials.gov/ct2/show/NCT04557605,1,0,1,0,1,0,Canada,0,progressive cycling exercise test to exhaustion,Journal Article|Randomized Controlled Trial
NCT04351152,2020-05-05,2021-03-31,Interventional,Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19,"Active, not recruiting",Phase 3,"Humanigen, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04351152,2,0,2,0,11,1,United States|Brazil,0,lenzilumab|standard care,"Journal Article|Multicenter Study|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Letter|Comment"
NCT04428099,2020-01-13,2022-01-12,Interventional,Healthy Lifestyle Promotion as Adjunctive Teletherapy for Treatment-resistant Major Depression,Recruiting,N/A,University of the Balearic Islands,NA,https://clinicaltrials.gov/ct2/show/NCT04428099,1,0,1,0,0,0,Spain,0,lifestyle change promotion program|mindfulness|information,Clinical Trial Protocol|Journal Article
NCT04412538,2020-05-15,2020-09-30,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19,Recruiting,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04412538,2,0,2,1,1,0,China,0,inactivated sars-cov-2 vaccine|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-/14-day schedule|placebo|28-day schedule|14-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-,"Journal Article/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04557241,2020-01-14,2021-01-14,Interventional,Brief Informational Intervention for COVID-19 Misinformation Prophylaxis,Completed,N/A,Indiana University,NA,https://clinicaltrials.gov/ct2/show/NCT04557241,1,0,1,0,1,1,United States,0,brief informational infographic|placebo control (non-behavioral infographic),Journal Article
NCT04366882,2020-04-14,2020-12-31,Interventional,Minimal Invasive Autopsies to Investigate Changes in Deceased COVID-19 Patients,Recruiting,N/A,Jessa Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04366882,1,0,1,0,0,0,Belgium,0,ct-scan,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04487990,2020-06-29,2020-12-31,Interventional,CoV-Hep Study: Regional Anticoagulation Modalities in Continuous Venous Venous Hemodialysis in Patients With COVID-19,Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04487990,1,0,1,0,0,0,Brazil,0,heparin,Clinical Trial Protocol|Letter
NCT04347941,2020-07-11,2021-06-11,Interventional,Awake Prone Positioning to Reduce Invasive VEntilation in COVID-19 Induced Acute Respiratory failurE,Recruiting,N/A,University College Hospital Galway,NA,https://clinicaltrials.gov/ct2/show/NCT04347941,1,0,1,0,1,0,Ireland,0,prone positioning|standard care,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04391140,2020-05-13,2020-12-31,Interventional,Prone Positioning and High-flow Nasal Cannula in COVID-19 Induced ARDS,Recruiting,N/A,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04391140,1,0,1,0,2,0,Spain,0,prone positioning,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04358939,2020-04-27,2021-02-21,Interventional,Prone Position in Patients on High-flow Nasal Oxygen Therapy for COVID-19 (HIGH-PRONE-COVID-19),Completed,N/A,"University Hospital, Tours",NA,https://clinicaltrials.gov/ct2/show/NCT04358939,1,0,1,0,8,0,France,0,prone positioning,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04395144,2020-05-15,2021-03-15,Interventional,COVid-19: Awake Proning and High-flow Nasal Cannula in respiratorY DistrEss,Completed,N/A,HÃ´pital de Verdun,NA,https://clinicaltrials.gov/ct2/show/NCT04395144,1,0,1,0,3,0,Canada,0,prone positioning|standard care,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04342663,2020-04-10,2020-08-20,Interventional,"A Double-blind, Placebo-controlled Clinical Trial of Fluvoxamine for Symptomatic Individuals With COVID-19 Infection",Completed,Phase 2,Washington University School of Medicine,NA,https://clinicaltrials.gov/ct2/show/NCT04342663,2,0,2,0,5,1,United States,0,fluvoxamine|placebo,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04364022,2020-04-23,2021-03-24,Interventional,Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in Switzerland,Completed,Phase 3,"University Hospital, Geneva",NA,https://clinicaltrials.gov/ct2/show/NCT04364022,1,0,1,0,2,0,Brazil|Switzerland,0,lopinavir/ritonavir|lopinavir|ritonavir,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04459247,2020-06-15,2021-08-30,Interventional,"Short Term, High Dose Vitamin D Supplementation for COVID-19","Active, not recruiting",N/A,Postgraduate Institute of Medical Education and Research,NA,https://clinicaltrials.gov/ct2/show/NCT04459247,1,0,1,0,2,0,India,0,vitamin d,Journal Article
NCT04435184,2020-07-09,2020-11-28,Interventional,Crizanlizumab for Treating COVID-19 Vasculopathy,Completed,Phase 2,Johns Hopkins University,NA,https://clinicaltrials.gov/ct2/show/NCT04435184,1,0,1,0,5,1,United States,0,crizanlizumab|saline,"Comparative Study|Journal Article|Research Support, N.I.H., Extramural"
NCT04374149,2020-04-30,2020-09-30,Interventional,Therapeutic Plasma Exchange Alone or in Combination With Ruxolitinib in COVID-19 Associated CRS,Completed,Phase 2,Prisma Health-Upstate,NA,https://clinicaltrials.gov/ct2/show/NCT04374149,1,0,1,0,2,1,United States,0,therapeutic plasma exchange (tpe)|ruxolitinib,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04487964,2020-01-01,2020-12-01,Interventional,Complementary Intervention for COVID-19,Recruiting,N/A,Egyptian Biomedical Research Network,NA,https://clinicaltrials.gov/ct2/show/NCT04487964,1,0,1,0,1,0,Egypt,0,licorice extract,Journal Article
NCT04468893,2020-05-20,2021-07-31,Interventional,Online Positive Psychology Intervention for Depression and Anxiety Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,https://clinicaltrials.gov/ct2/show/NCT04468893,1,5,6,0,2,0,Mexico,0,online intervention mental health covid-19,Journal Article/Journal Article
NCT04455360,2020-10-01,2021-03-31,Interventional,Early EMDR Following Covid-19 Critical Illness: A Feasibility Trial,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04455360,1,0,1,0,1,0,United Kingdom,0,eye movement desensitisation/reprocessing recent traumatic event protocol|eye movement desensitisation|reprocessing recent traumatic event protocol,Clinical Trial Protocol|Letter
NCT04328467,2020-04-06,2020-08-31,Interventional,Pre-exposure Prophylaxis for SARS-Coronavirus-2,"Active, not recruiting",Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04328467,1,0,1,0,5,1,United States,0,hydroxychloroquine|placebo,Journal Article
NCT04341922,2020-05-09,2020-08-20,Interventional,A Online-delivered Cognitive-behavioral Intervention for Dysfunctional Worry Related to the Covid-19 Pandemic,"Active, not recruiting",N/A,Karolinska Institutet,NA,https://clinicaltrials.gov/ct2/show/NCT04341922,1,0,1,0,5,0,Sweden,0,internet-delivered cognitive behavior therapy (icbt) for dysfunctional worry related to the covid-19 pandemic,Journal Article|Randomized Controlled Trial
NCT04382755,2020-05-22,2020-12-29,Interventional,ZilucoplanÂ® in Improving Oxygenation and Short- and Long-term Outcome of COVID-19 Patients With Acute Hypoxic Respiratory Failure,"Active, not recruiting",Phase 2,"University Hospital, Ghent",NA,https://clinicaltrials.gov/ct2/show/NCT04382755,1,0,1,0,3,0,Belgium,0,zilucoplanâ®|placebo|zilucoplanâ®,"Clinical Trial, Phase II|Letter|Multicenter Study|Randomized Controlled Trial"
NCT04352608,2020-04-16,2020-07-10,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prophylaxis of SARS CoV-2 Infection (COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicaltrials.gov/ct2/show/NCT04352608,1,0,1,1,3,0,China,0,placebo|inactivated sars-cov-2 vaccine,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04400838,2020-05-28,2021-09-30,Interventional,Investigating a Vaccine Against COVID-19,Recruiting,Phase 2/Phase 3,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04400838,5,0,5,1,10,0,United Kingdom,0,chadox1|menacwy|menacwy vaccine|two dose menacwy vaccine min. 4 weeks apart|two dose chadox1 ncov-19/covishield 0.5ml|two dose chadox1 ncov-19/covishield 0.25ml/0.5ml|2.2x10^10vp (qpcr) boost|boost|two dose chadox1 ncov-19|covishield 0.5ml|covishield 0.25ml|0.5ml,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't/Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04449380,2020-11-02,2021-03-30,Interventional,Clinical Study for the Treatment With Interferon-ÃŸ-1a (IFNÃŸ-1a) of COVID-19 Patients,Terminated,Phase 2,IRCCS San Raffaele,Futility,https://clinicaltrials.gov/ct2/show/NCT04449380,1,0,1,0,5,0,Italy,0,interferon-ãÿ-1a|standard care|interferon-ãÿ-1a,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial"
NCT04495816,2020-07-15,2021-08-31,Interventional,COVID-19 Anosmia Study,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,NA,https://clinicaltrials.gov/ct2/show/NCT04495816,1,0,1,0,3,1,United States,0,omega-3|placebo/control|placebo|control,Letter|Randomized Controlled Trial
NCT04477655,2020-05-03,2021-01-26,Interventional,Prone Positioning in Non-intubated Patients With COVID-19 Associated Acute Respiratory Failure,Completed,N/A,Hospital Civil de Guadalajara,NA,https://clinicaltrials.gov/ct2/show/NCT04477655,1,0,1,0,3,0,Mexico,0,prone positioning|oxygen,Letter|Randomized Controlled Trial
NCT04438070,2020-04-10,2020-06-30,Interventional,COVID Screening Strategies in Homeless Shelters,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicaltrials.gov/ct2/show/NCT04438070,1,0,1,0,0,0,Canada,0,covid-19 swab,Comparative Study|Letter|Randomized Controlled Trial
NCT04383535,2020-05-15,2020-09-27,Interventional,Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia,Completed,N/A,Hospital Italiano de Buenos Aires,NA,https://clinicaltrials.gov/ct2/show/NCT04383535,1,1,2,0,4,0,Argentina,0,convalescent plasma|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04529525,2020-08-19,2021-02-28,Interventional,Ivermectin to Prevent Hospitalizations in COVID-19,Recruiting,Phase 2/Phase 3,Instituto de CardiologÃ­a de Corrientes,NA,https://clinicaltrials.gov/ct2/show/NCT04529525,1,11,12,0,5,0,Argentina,0,ivermectin|placebo,Letter|Randomized Controlled Trial
NCT04341142,2020-04-09,2023-04-09,Interventional,Assessment of Serological Techniques for Screening Patients Regarding COVID-19-COVID-SER,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicaltrials.gov/ct2/show/NCT04341142,1,0,1,0,5,0,France,0,serology test,Clinical Study|Journal Article|Multicenter Study
NCT04430608,2020-05-25,2021-04-25,Interventional,Remote Continues Glucose Monitoring During the COVID-19 Pandemic in Quarantined Hospitalized Patients,Recruiting,N/A,Nordsjaellands Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04430608,1,0,1,0,0,0,Denmark,0,dexcom,Letter|Randomized Controlled Trial
NCT04244591,2020-01-26,2020-04-13,Interventional,Glucocorticoid Therapy for COVID-19 Critically Ill Patients With Severe Acute Respiratory Failure,Completed,Phase 2/Phase 3,Peking Union Medical College Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04244591,1,0,1,0,6,0,China,0,methylprednisolone|standard care,Journal Article|Review
NCT04321174,2020-04-17,2021-03-31,Interventional,COVID-19 Ring-based Prevention Trial With Lopinavir/Ritonavir,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04321174,3,0,3,0,1,0,Canada,0,lopinavir/ritonavir|lopinavir|ritonavir,Journal Article|Review/Journal Article|Systematic Review/Clinical Trial Protocol|Journal Article
NCT04304313,2020-02-09,2020-03-01,Interventional,A Pilot Study of Sildenafil in COVID-19,Recruiting,Phase 3,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04304313,1,0,1,0,1,0,China,0,sildenafil citrate,Journal Article|Review
NCT04348695,2020-04-12,2020-05-13,Interventional,Study of Ruxolitinib Plus Simvastatin in the Prevention and Treatment of Respiratory Failure of COVID-19.,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,https://clinicaltrials.gov/ct2/show/NCT04348695,1,0,1,0,1,0,Spain,0,ruxolitinib|standard care|simvastatin,Journal Article|Review
NCT04359329,2020-04-20,2020-11-15,Interventional,Estrogen Patch for COVID-19 Symptoms,Recruiting,Phase 2,Stony Brook University,NA,https://clinicaltrials.gov/ct2/show/NCT04359329,1,0,1,0,0,1,United States,0,estradiol,Journal Article|Review
NCT04429854,2020-05-02,2021-04-30,Interventional,Donated Antibodies Working Against nCoV,"Active, not recruiting",Phase 2,Universitaire Ziekenhuizen Leuven,NA,https://clinicaltrials.gov/ct2/show/NCT04429854,1,0,1,0,3,0,Belgium,0,convalescent plasma|standard care,"Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial"
NCT04447534,2020-06-23,2030-10-01,Interventional,Zinc With Chloroquine/Hydroxychloroquine in Treatment of COVID-19,Recruiting,Phase 3,Tanta University,NA,https://clinicaltrials.gov/ct2/show/NCT04447534,1,0,1,0,3,0,Egypt,0,chloroquine|zinc,Journal Article
NCT04349592,2020-04-14,2020-08-14,Interventional,Hydroxychloroquine With or Without Azithromycin for Virologic Cure of COVID-19,Completed,N/A,Hamad Medical Corporation,NA,https://clinicaltrials.gov/ct2/show/NCT04349592,1,0,1,0,2,0,Qatar,0,hydroxychloroquine|azithromycin|placebo,Journal Article
NCT04445324,2020-08-25,2020-08-25,Interventional,Effects of Online and Recovery-oriented Peer Support Groups Facilitated by Peer Support Workers in Times of COVID-19,"Active, not recruiting",N/A,Centre de Recherche de l'Institut Universitaire en santÃ© Mentale de MontrÃ©al,NA,https://clinicaltrials.gov/ct2/show/NCT04445324,1,0,1,0,4,0,Canada,0,"online support group|control|or psychotherapy, n=10)",Journal Article
NCT04343053,2020-04-08,2020-06-09,Interventional,Pro-thrombotic Status in Patients With SARS-Cov-2 Infection,"Active, not recruiting",N/A,University Hospital of Ferrara,NA,https://clinicaltrials.gov/ct2/show/NCT04343053,3,0,3,0,2,0,Italy,0,sars-cov-2 infection,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04395807,2020-06-03,2021-04-12,Interventional,Helmet CPAP Versus HFNC in COVID-19,Terminated,N/A,Lund University,"1. Few eligible patients at study start

      2. Patients received HFNC prior to intermediate care ward admission

      3. NIV was locally considered a step-up therapy to HFNC

      4. Full-face masks replaced the Helmet interface as local NIV standard",https://clinicaltrials.gov/ct2/show/NCT04395807,1,0,1,0,2,0,Sweden,0,cpap|oxygen,Comparative Study|Journal Article|Randomized Controlled Trial
NCT04405739,2020-06-16,2021-05-28,Interventional,The Safety of Molnupiravir (EIDD-2801) and Its Effect on Viral Shedding of SARS-CoV-2 (END-COVID),Recruiting,Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://clinicaltrials.gov/ct2/show/NCT04405739,1,0,1,0,15,1,United States,0,eidd-2801|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04405570,2020-06-16,2021-02-21,Interventional,"A Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19",Completed,Phase 2,"Ridgeback Biotherapeutics, LP",NA,https://clinicaltrials.gov/ct2/show/NCT04405570,1,0,1,0,18,1,United States,0,eidd-2801|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04558476,2020-09-01,2022-09-01,Interventional,Efficacy of CONvalescent Plasma in Patients With COVID-19 Treated With Mechanical Ventilation,Recruiting,Phase 2,University of Liege,NA,https://clinicaltrials.gov/ct2/show/NCT04558476,1,0,1,0,0,0,Belgium,0,convalescent plasma|standard care,Clinical Trial Protocol|Journal Article
NCT04304053,2020-03-18,2020-06-15,Interventional,Treatment of COVID-19 Cases and Chemoprophylaxis of Contacts as Prevention,Completed,Phase 3,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicaltrials.gov/ct2/show/NCT04304053,2,0,2,0,9,0,Spain,0,treatment/prophylaxis|standard care|treatment|prophylaxis,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Systematic Review"
NCT04476667,2020-06-15,2021-05-31,Interventional,"Online Delivery of Psychotherapy, Tailored to Patients' Suffering From Mental Health Problems Due to COVID-19",Recruiting,N/A,Queen's University,NA,https://clinicaltrials.gov/ct2/show/NCT04476667,1,0,1,0,1,0,Canada,0,psychotherapy,Journal Article
NCT04369378,2020-08-19,2021-02-28,Interventional,Effectiveness of Using a Meditation App in Reducing Anxiety and Improving Well-being During the Covid-19 Pandemic,Recruiting,N/A,Lake Erie College of Osteopathic Medicine,NA,https://clinicaltrials.gov/ct2/show/NCT04369378,1,0,1,0,2,1,United States,0,meditation app usage,Letter|Randomized Controlled Trial
NCT04362059,2020-06-18,2021-07-27,Interventional,A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicaltrials.gov/ct2/show/NCT04362059,1,14,15,0,3,0,United Kingdom,0,covsurf drug delivery system|standard care,Letter|Randomized Controlled Trial
NCT04348929,2020-04-16,2021-08-16,Interventional,Birth Experience During COVID-19 Confinement,Recruiting,N/A,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04348929,1,0,1,0,3,0,France,0,questionnaire,Comparative Study|Journal Article|Multicenter Study
NCT04351906,2020-05-03,2021-06-01,Interventional,Low-flow Extracorporeal Carbon Dioxide Removal in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,N/A,University of Giessen,NA,https://clinicaltrials.gov/ct2/show/NCT04351906,1,1,2,0,5,0,Germany,0,ecco2r,Journal Article
NCT04444674,2020-06-24,2020-12-31,Interventional,COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection,"Active, not recruiting",Phase 1/Phase 2,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04444674,3,0,3,1,4,0,South Africa,0,chadox1|saline,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't/Journal Article"
NCT04315480,2020-03-12,2020-04-09,Interventional,Tocilizumab for SARS-CoV2 (COVID-19) Severe Pneumonitis,"Active, not recruiting",Phase 2,UniversitÃ  Politecnica delle Marche,NA,https://clinicaltrials.gov/ct2/show/NCT04315480,1,0,1,0,2,0,Italy,0,tocilizumab,"Clinical Trial, Phase II|Journal Article|Multicenter Study"
NCT04555005,2020-03-10,2020-04-26,Interventional,Mindfulness-based Crisis Intervention for COVID-19 Frontline Healthcare Workers During COVID-19,Completed,N/A,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicaltrials.gov/ct2/show/NCT04555005,1,0,1,0,0,0,Spain,0,mindfulness,Journal Article
NCT04425629,2020-06-16,2021-04-10,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",Recruiting,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04425629,1,0,1,0,18,1,United States|Chile|Mexico|Romania,0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,"Clinical Trial, Phase I|Clinical Trial, Phase II|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04372186,2020-05-14,2020-08-18,Interventional,A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia,Recruiting,Phase 3,"Genentech, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04372186,1,0,1,0,8,1,United States|Brazil|Kenya|Mexico|Peru|South Africa,0,placebo|tocilizumab,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04371419,2020-05-13,2020-05-24,Interventional,COVID-19 Health Messaging to Underserved Communities,Completed,N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04371419,1,0,1,0,2,1,United States,0,messaging,"Comparative Study|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Video-Audio Media"
NCT04501978,2020-08-04,2022-07-31,Interventional,ACTIV-3: Therapeutics for Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicaltrials.gov/ct2/show/NCT04501978,1,0,1,0,33,1,United States|Denmark|India|Poland|Singapore|Spain|Switzerland|United Kingdom,0,vir-7831|ly3819253|placebo|remdesivir|brii-196/brii-198|azd7442|brii-196|brii-198,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04579393,2020-10-08,2021-03-30,Interventional,Fostamatinib for Hospitalized Adults With COVID-19,"Active, not recruiting",Phase 2,National Institutes of Health Clinical Center (CC),NA,https://clinicaltrials.gov/ct2/show/NCT04579393,1,0,1,0,19,1,United States,0,placebo|fostamatinib,Journal Article
NCT04344041,2020-04-15,2021-01-14,Interventional,COvid-19 and Vitamin D Supplementation: a Multicenter Randomized Controlled Trial of High Dose Versus Standard Dose Vitamin D3 in High-risk COVID-19 Patients (CoVitTrial),Completed,Phase 3,"University Hospital, Angers",NA,https://clinicaltrials.gov/ct2/show/NCT04344041,1,0,1,0,5,0,France,0,cholecalciferol,Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04635241,2020-06-01,2021-04-01,Interventional,Inhaled Heparin for Hospitalised COVID-19 Patients,Recruiting,Phase 2/Phase 3,Australian National University,NA,https://clinicaltrials.gov/ct2/show/NCT04635241,1,0,1,0,1,0,Argentina|Egypt,0,heparin,Journal Article
NCT04470427,2020-07-27,2022-10-27,Interventional,"A Study to Evaluate Efficacy, Safety, and Immunogenicity of mRNA-1273 Vaccine in Adults Aged 18 Years and Older to Prevent COVID-19","Active, not recruiting",Phase 3,"ModernaTX, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04470427,1,0,1,1,15,1,United States,0,mrna-1273|placebo,"Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04336410,2020-04-03,2022-01-31,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy Volunteers","Active, not recruiting",Phase 1,Inovio Pharmaceuticals,NA,https://clinicaltrials.gov/ct2/show/NCT04336410,1,0,1,1,9,1,United States,0,ino-4800|cellectraâ® 2000|cellectraâ® 2000,Journal Article
NCT04549376,2020-07-01,2020-10-20,Interventional,Virucidal Effect of Povidone Iodine on COVID-19 In-Vivo,Recruiting,Phase 2,"Pi Research Consultancy Center, Bangladesh",NA,https://clinicaltrials.gov/ct2/show/NCT04549376,1,0,1,0,0,0,Bangladesh,0,povidone-iodine|placebo,Clinical Trial Protocol|Letter
NCT04414631,2020-08-06,2021-06-30,Interventional,Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,"University Hospital, Basel, Switzerland",NA,https://clinicaltrials.gov/ct2/show/NCT04414631,1,0,1,0,5,0,Brazil|Mexico|Switzerland,0,conestat alfa,Clinical Trial Protocol|Letter
NCT04459286,2020-10-09,2021-03-31,Interventional,The Nitazoxanide Plus Atazanavir for COVID-19 Study,Recruiting,Phase 2,Obafemi Awolowo University,NA,https://clinicaltrials.gov/ct2/show/NCT04459286,1,0,1,0,3,0,Nigeria,0,nitazoxanide/atazanavir/ritonavir|standard care|nitazoxanide|atazanavir|ritonavir,Clinical Trial Protocol|Comparative Study|Letter
NCT04479163,2020-06-04,2020-10-25,Interventional,Prevention of Severe Covid-19 in Infected Elderly by Early Administration of Convalescent Plasma With High-titers of Antibody Against SARS-CoV2,Completed,N/A,Fundacion Infant,NA,https://clinicaltrials.gov/ct2/show/NCT04479163,1,0,1,0,3,0,Argentina,0,convalescent plasma|placebo,"Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04615429,2020-09-15,2021-01-04,Interventional,Clinical Trial to Assess the Efficacy of MSC in Patients With ARDS Due to COVID-19,"Active, not recruiting",Phase 2,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04615429,1,0,1,0,2,0,Spain,0,mesenchymal stem cells|placebo,Clinical Trial Protocol|Letter
NCT04338009,2020-03-31,2020-08-20,Interventional,Elimination or Prolongation of ACE Inhibitors and ARB in Coronavirus Disease 2019,Completed,N/A,University of Pennsylvania,NA,https://clinicaltrials.gov/ct2/show/NCT04338009,1,0,1,0,3,1,United States,1,discontinuation of arb|continuation of arb|ace inhibitor,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04484493,2020-08-08,2020-10-25,Interventional,Corticosteroid Nasal Spray in COVID-19 Anosmia,Completed,Phase 3,Benha University,NA,https://clinicaltrials.gov/ct2/show/NCT04484493,1,0,1,0,5,0,Egypt,0,mometasone furoate nasal spray,Journal Article|Randomized Controlled Trial
NCT04438980,2020-05-15,2020-12-31,Interventional,Glucocorticoids in COVID-19 (CORTIVID),Recruiting,Phase 3,Fundacion Miguel Servet,NA,https://clinicaltrials.gov/ct2/show/NCT04438980,1,0,1,0,1,0,Spain,0,methylprednisolone|placebo,Clinical Trial Protocol|Letter
NCT04472728,2020-06-16,2021-07-31,Interventional,Testing the Efficacy and Safety of BIO101 for the Prevention of Respiratory Deterioration in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Biophytis,NA,https://clinicaltrials.gov/ct2/show/NCT04472728,1,0,1,0,6,1,United States|Belgium|Brazil|France|Puerto Rico,0,bio101|placebo,Clinical Trial Protocol|Letter
NCT04364893,2020-04-09,2020-10-01,Interventional,Angiotensin Receptor Blockers and Angiotensin-converting Enzyme Inhibitors and Adverse Outcomes in Patients With COVID19,Recruiting,N/A,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04364893,1,0,1,0,2,0,Brazil,0,suspension/maintenance of angiotensin receptor blockers/angiotensin-converting enzyme inhibitors|suspension|maintenance|ace inhibitor,Journal Article|Multicenter Study|Pragmatic Clinical Trial|Randomized Controlled Trial
NCT04345523,2020-04-03,2021-02-28,Interventional,Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients,Recruiting,Phase 2,Puerta de Hierro University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04345523,1,0,1,0,2,0,Spain,0,blood/derivatives|standard care|blood|derivatives.,Clinical Trial Protocol|Journal Article
NCT04403685,2020-05-08,2020-07-08,Interventional,Safety and Efficacy of Tocilizumab in Moderate to Severe COVID-19 With Inflammatory Markers,Terminated,Phase 3,BeneficÃªncia Portuguesa de SÃ£o Paulo,Safety,https://clinicaltrials.gov/ct2/show/NCT04403685,1,0,1,0,3,0,Brazil,0,tocilizumab,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04319731,2020-03-20,2021-03-20,Interventional,A Pilot Study of Human Amniotic Fluid for COVID19 Associated Respiratory Failure,Recruiting,Early Phase 1,University of Utah,NA,https://clinicaltrials.gov/ct2/show/NCT04319731,1,0,1,0,1,1,United States,0,human amniotic fluid,Clinical Trial|Journal Article
NCT04471519,2020-07-15,2020-07-31,Interventional,Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers,"Active, not recruiting",Phase 1/Phase 2,Bharat Biotech International Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04471519,3,0,3,1,3,0,India,0,bbv152a - phase i|bbv152b - phase i|bbv152c - phase i|placebo - phase i|bbv152a - phase ii|bbv152b - phase ii,"Clinical Trial, Phase I|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04273321,2020-02-14,2020-04-15,Interventional,Efficacy and Safety of Corticosteroids in COVID-19,Completed,N/A,Beijing Chao Yang Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04273321,1,0,1,0,4,0,China,0,methylprednisolone,Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04351295,2020-04-20,2020-12-01,Interventional,Efficacy of Faviprevir in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicaltrials.gov/ct2/show/NCT04351295,1,0,1,0,2,0,Egypt,0,favipiravir|placebo,"Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial"
NCT04341038,2020-04-01,2020-06-01,Interventional,Clinical Trial to Evaluate Methylprednisolone Pulses and Tacrolimus in Patients With COVID-19 Lung Injury,Recruiting,Phase 3,Hospital Universitari de Bellvitge,NA,https://clinicaltrials.gov/ct2/show/NCT04341038,1,0,1,0,0,0,Spain,0,tacrolimus|methylprednisolone,Journal Article|Review
NCT04390022,2020-07-31,2020-09-17,Interventional,Sars-CoV-2/COVID-19 Ivermectin Navarra-ISGlobal Trial,Completed,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicaltrials.gov/ct2/show/NCT04390022,1,0,1,0,6,0,Spain,1,ivermectin|placebo,Journal Article
NCT04451174,2020-06-23,2020-11-30,Interventional,Early Use of Corticosteroids in Non-critical Patients With COVID-19 Pneumonia,Recruiting,Phase 3,University of Chile,NA,https://clinicaltrials.gov/ct2/show/NCT04451174,1,0,1,0,3,0,Chile,0,prednisone,Letter
NCT04394182,2020-04-21,2020-12-31,Interventional,Ultra Low Doses of Therapy With Radiation Applicated to COVID-19,Recruiting,N/A,Fundacion GenesisCare,NA,https://clinicaltrials.gov/ct2/show/NCT04394182,1,10,11,0,0,0,Spain,0,radiotherapy|oxygen|lopinavir/ritonavir|hydroxychloroquine|azithromycin|piperacillin/tazobactam|heparin|corticosteroid|tocilizumab|lopinavir|ritonavir|piperacillin|tazobactam,Case Reports|Clinical Trial|Journal Article/Journal Article/Journal Article|Review/Editorial|Comment/Journal Article
NCT04373707,2020-05-13,2021-11-30,Interventional,Weight-Adjusted vs Fixed Low Doses of Low Molecular Weight Heparin For Venous Thromboembolism Prevention in COVID-19,Recruiting,Phase 4,"Central Hospital, Nancy, France",NA,https://clinicaltrials.gov/ct2/show/NCT04373707,1,0,1,0,5,0,France,0,enoxaparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04368377,2020-04-06,2020-04-23,Interventional,Enhanced Platelet Inhibition in Critically Ill Patients With COVID-19,Completed,Phase 2,University of Milan,NA,https://clinicaltrials.gov/ct2/show/NCT04368377,1,0,1,0,0,0,Italy,0,tirofiban|clopidogrel|acetylsalicylic acid|fondaparinux,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04416048,2020-11-30,2021-04-30,Interventional,Effect of Anticoagulation Therapy on Clinical Outcomes in COVID-19,Recruiting,Phase 3,"Charite University, Berlin, Germany",NA,https://clinicaltrials.gov/ct2/show/NCT04416048,1,0,1,0,3,0,Germany,0,rivaroxaban|standard care,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04362085,2020-05-11,2022-03-31,Interventional,Coagulopathy of COVID-19: A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care,Recruiting,Phase 3,"St. Michael's Hospital, Toronto",NA,https://clinicaltrials.gov/ct2/show/NCT04362085,2,0,2,0,3,0,Canada,0,anticoagulation,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Clinical Trial Protocol|Letter"
NCT04360824,2020-05-06,2021-04-16,Interventional,Covid-19 Associated Coagulopathy,Recruiting,Phase 4,University of Iowa,NA,https://clinicaltrials.gov/ct2/show/NCT04360824,1,0,1,0,4,1,United States,0,thromboprophylaxis|standard of care thromboprophylaxis,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04359277,2020-04-21,2020-09-20,Interventional,A Randomized Trial of Anticoagulation Strategies in COVID-19,Terminated,Phase 3,NYU Langone Health,the PROTECT study is being transitioned to ACTIV4 ACUTE anticoagulation inpatient study,https://clinicaltrials.gov/ct2/show/NCT04359277,1,0,1,0,3,1,United States,0,enoxaparin|anticoagulation,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04354155,2020-06-02,2022-09-30,Interventional,COVID-19 Anticoagulation in Children - Thromboprophlaxis (COVAC-TP) Trial,Recruiting,Phase 2,Johns Hopkins All Children's Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04354155,1,0,1,0,2,1,United States,0,enoxaparin,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04397510,2020-06-01,2021-12-31,Interventional,Nebulized Heparin for the Treatment of COVID-19 Induced Lung Injury,Enrolling by invitation,Phase 4,Frederick Health,NA,https://clinicaltrials.gov/ct2/show/NCT04397510,1,0,1,0,7,1,United States,0,heparin|saline,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04394377,2020-06-21,2021-03-31,Interventional,Full Anticoagulation Versus Prophylaxis in COVID-19: COALIZAO ACTION Trial,"Active, not recruiting",Phase 4,Brazilian Clinical Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04394377,2,0,2,0,8,0,Brazil,0,group 1: rivaroxaban 20mg/d followed by enoxaparin/unfractionated heparin when needed|enoxaparin|rivaroxaban|d followed by enoxaparin|heparin|d,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article"
NCT04401293,2020-04-26,2021-04-26,Interventional,Full Dose Heparin Vs. Prophylactic Or Intermediate Dose Heparin in High Risk COVID-19 Patients,Recruiting,Phase 3,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04401293,2,0,2,0,2,1,United States,0,enoxaparin|prophylactic,"Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Multicenter Study"
NCT04647604,2020-06-23,2021-04-30,Interventional,Resolving Inflammatory Storm in COVID-19 Patients by Omega-3 Polyunsaturated Fatty Acids -,Recruiting,Phase 2,Karolinska University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04647604,1,0,1,0,0,0,Sweden,0,omegavenâ®|sodium chloride|omegavenâ®,Journal Article|Review
NCT04411446,2020-08-11,2021-05-15,Interventional,Cholecalciferol to Improve the Outcomes of COVID-19 Patients,Recruiting,Phase 4,Vitamin D Study Group,NA,https://clinicaltrials.gov/ct2/show/NCT04411446,1,1,2,0,4,0,Argentina,0,vitamin d|placebo,Clinical Trial Protocol|Letter
NCT04405908,2020-06-19,2020-10-16,Interventional,SCB-2019 as COVID-19 Vaccine,"Active, not recruiting",Phase 1,Clover Biopharmaceuticals AUS Pty Ltd,NA,https://clinicaltrials.gov/ct2/show/NCT04405908,1,0,1,1,4,0,Australia,0,scb-2019|scb-2019 with as03 adjuvant|scb-2019 with cpg 1018 adjuvant/alum adjuvant|scb-2019 with cpg 1018 adjuvant|alum adjuvant,"Clinical Trial, Phase I|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04505722,2020-09-07,2021-01-22,Interventional,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants,"Active, not recruiting",Phase 3,Janssen Vaccines & Prevention B.V.,NA,https://clinicaltrials.gov/ct2/show/NCT04505722,2,0,2,0,13,1,South Africa|United States|Argentina|Brazil|Chile|Colombia|Mexico|Peru,0,ad26.cov2.s|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04380701,2020-04-23,2023-04-30,Interventional,A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy and Immunocompromised Adults,Recruiting,Phase 1/Phase 2,BioNTech SE,NA,https://clinicaltrials.gov/ct2/show/NCT04380701,1,0,1,1,5,0,Germany,0,bnt162a1|bnt162b1|bnt162b2|bnt162c2,Journal Article
NCT04371965,2020-09-01,2020-10-23,Interventional,"Povidone Iodine Mouthwash, Gargle, and Nasal Spray to Reduce Naso- Pharyngeal Viral Load in Patients With COVID-19",Completed,Phase 2,Poitiers University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04371965,1,0,1,0,3,0,France,0,povidone/iodine,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04530396,2020-09-07,2021-05-01,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicaltrials.gov/ct2/show/NCT04530396,1,0,1,1,8,0,Russian Federation,0,gam-covid-vac|placebo,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04275414,2020-02-15,2020-04-05,Interventional,Bevacizumab in Severe or Critical Patients With COVID-19 Pneumonia,Completed,Phase 2,Qilu Hospital of Shandong University,NA,https://clinicaltrials.gov/ct2/show/NCT04275414,1,0,1,0,2,0,China|Italy,0,bevacizumab,"Clinical Trial|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04383574,2020-05-22,2020-08-28,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of SARS-CoV-2 Infection(COVID-19),"Active, not recruiting",Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicaltrials.gov/ct2/show/NCT04383574,1,0,1,1,2,0,China,0,"two doses of low dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of medium dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of high dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|placebo",Journal Article
NCT04350723,2020-06-10,2021-07-30,Interventional,Awake Prone Position in Hypoxemic Patients With Coronavirus Disease 19 (COVI-PRONE): A Randomized Clinical Trial,Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicaltrials.gov/ct2/show/NCT04350723,1,0,1,0,1,0,Canada|Saudi Arabia,0,prone positioning,"Journal Article|Research Support, U.S. Gov't, Non-P.H.S."
NCT04568525,2020-07-01,2020-07-25,Interventional,Passive Microwave Radiometry (MWR) and AI for COVID-19 Complications Early Diagnostics of Lungs,Completed,N/A,Kyrgyz State Medical Academy,NA,https://clinicaltrials.gov/ct2/show/NCT04568525,1,0,1,0,0,0,Kyrgyzstan,0,passive microwave radiometry,Journal Article
NCT04473261,2020-07-14,2021-07-15,Interventional,Efficacy of Iodine Complex Against COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04473261,1,0,1,0,1,0,Pakistan,0,iodine|placebo|idoine complex,Clinical Trial Protocol|Letter
NCT04288102,2020-03-05,2020-05-12,Interventional,Treatment With Human Umbilical Cord-derived Mesenchymal Stem Cells for Severe Corona Virus Disease 2019 (COVID-19),Completed,Phase 2,Beijing 302 Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04288102,1,0,1,0,5,0,China,0,mesenchymal stem cells|saline containing 1% human serum albuminï¼ˆsolution without uc-mscsï¼‰|saline containing 1% human serum albuminï¼ˆsolution without uc-mscsï¼‰,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04303507,2020-04-29,2021-04-30,Interventional,Chloroquine/ Hydroxychloroquine Prevention of Coronavirus Disease (COVID-19) in the Healthcare Setting,Recruiting,N/A,University of Oxford,NA,https://clinicaltrials.gov/ct2/show/NCT04303507,1,0,1,0,7,0,Indonesia|Italy|Lao People's Democratic Republic|Pakistan|Thailand|United Kingdom,0,chloroquine/hydroxychloroquine|placebo|chloroquine|hydroxychloroquine,Journal Article|Systematic Review
NCT04312243,2020-04-07,2021-04-07,Interventional,NO Prevention of COVID-19 for Healthcare Providers,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04312243,1,0,1,0,3,1,United States,0,nitric oxide,Journal Article|Systematic Review
NCT04318444,2020-03-29,2021-03-31,Interventional,Hydroxychloroquine Post Exposure Prophylaxis for Coronavirus Disease (COVID-19),Recruiting,Phase 2/Phase 3,Columbia University,NA,https://clinicaltrials.gov/ct2/show/NCT04318444,1,0,1,0,2,1,United States,0,hydroxychloroquine|placebo,Journal Article|Systematic Review
NCT04413968,2020-06-02,2020-07-02,Interventional,"COVID-19 Infection and Transmission in Exposed, Confined and Community-based Infants",Completed,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicaltrials.gov/ct2/show/NCT04413968,1,0,1,0,3,0,France,0,rapid test|nasopharyngeal swab|stool collection,"Clinical Trial|Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't"
NCT04609865,2020-11-04,2021-12-31,Interventional,Impact of Intravenous Lidocaine on Clinical Outcomes of Patients With ARDS During COVID-19 Pandemia,Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,https://clinicaltrials.gov/ct2/show/NCT04609865,1,0,1,0,2,0,France,0,lidocaine 2%|control,Clinical Trial Protocol|Letter
NCT04497389,2020-10-28,2021-09-15,Interventional,Safety and Feasibility of Amniotic Fluid as a Treatment for COVID-19 Patients,Recruiting,Phase 1/Phase 2,University of Utah,NA,https://clinicaltrials.gov/ct2/show/NCT04497389,1,0,1,0,2,1,United States,0,human amniotic fluid,"Clinical Trial Protocol|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04342728,2020-04-08,2020-12-30,Interventional,Coronavirus 2019 (COVID-19)- Using Ascorbic Acid and Zinc Supplementation,Completed,N/A,The Cleveland Clinic,NA,https://clinicaltrials.gov/ct2/show/NCT04342728,1,0,1,0,6,1,United States,0,vitamin c|zinc|ascorbic acid/zinc gluconate|standard care,Comparative Study|Journal Article|Multicenter Study|Randomized Controlled Trial
NCT04509973,2020-08-27,2021-09-17,Interventional,Higher vs. Lower Doses of Dexamethasone for COVID-19 and Severe Hypoxia,Recruiting,Phase 3,Scandinavian Critical Care Trials Group,NA,https://clinicaltrials.gov/ct2/show/NCT04509973,1,0,1,0,1,0,Denmark|India|Sweden|Switzerland,0,dexamethasone,Clinical Trial Protocol|Comparative Study|Journal Article
NCT04730323,2020-05-12,2020-06-12,Interventional,TOCILIZUMAB - An Option for Patients With COVID-19 Associated Cytokine Release Syndrome; A Single Center Experience,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,https://clinicaltrials.gov/ct2/show/NCT04730323,1,0,1,0,0,0,Pakistan,0,tocilizumab,Journal Article
NCT04569188,2020-05-15,2020-08-15,Interventional,Convalescent Plasma in COVID-19 Elderly Patients,Completed,Phase 2,Azienda Socio Sanitaria Territoriale di Mantova,NA,https://clinicaltrials.gov/ct2/show/NCT04569188,1,0,1,0,1,0,Italy,0,convalescent plasma,Journal Article
NCT04449718,2020-06-01,2020-10-07,Interventional,Vitamin D Supplementation in Patients With COVID-19,Completed,N/A,University of Sao Paulo,NA,https://clinicaltrials.gov/ct2/show/NCT04449718,1,0,1,0,1,0,Brazil,0,vitamin d|placebo,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04365127,2020-04-27,2020-08-20,Interventional,Progesterone for the Treatment of COVID-19 in Hospitalized Men,Completed,Phase 1,Cedars-Sinai Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04365127,1,0,1,0,2,1,United States,0,progesterone,Journal Article
NCT04557046,2020-06-26,2021-11-30,Interventional,Performance Evaluation of LumiraDx COVID-19 (SARS-CoV-2) Ag Test,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicaltrials.gov/ct2/show/NCT04557046,1,0,1,0,3,1,United States,0,nasal|nasopharyngeal swab|throat swab|fingerstick|saliva,Journal Article
NCT04320615,2020-04-03,2020-06-24,Interventional,A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia,Completed,Phase 3,Hoffmann-La Roche,NA,https://clinicaltrials.gov/ct2/show/NCT04320615,1,0,1,0,10,1,United States|Canada|Denmark|France|Germany|Italy|Netherlands|Spain|United Kingdom,0,tocilizumab|placebo,"Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04366050,2020-05-11,2021-05-31,Interventional,Ramipril for the Treatment of COVID-19,Recruiting,Phase 2,"University of California, San Diego",NA,https://clinicaltrials.gov/ct2/show/NCT04366050,1,0,1,0,2,1,United States,0,ramipril|placebo,"Journal Article|Research Support, N.I.H., Extramural"
NCT04719234,2020-06-15,2020-12-01,Interventional,Lung Ultrasonography in COVID-19 Pneumonia,Completed,N/A,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04719234,1,0,1,0,0,0,Turkey,0,lung ultrasonography,Journal Article
NCT04344587,2020-04-23,2021-05-31,Interventional,Awake Prone Position for Early Hypoxemia in COVID-19,"Active, not recruiting",N/A,Boston University,NA,https://clinicaltrials.gov/ct2/show/NCT04344587,1,0,1,0,12,1,United States|Spain,0,prone positioning|standard care,Journal Article
NCT04380909,2020-05-06,2021-07-31,Interventional,ROCO - Self-help for People With Psychological Distress Due to the Covid-19 Situation,"Active, not recruiting",N/A,University of Bern,NA,https://clinicaltrials.gov/ct2/show/NCT04380909,1,0,1,0,2,0,Switzerland,0,internet-based self-help|internet-based self-help after 3 weeks,Clinical Trial Protocol|Journal Article
NCT04350580,2020-04-11,2021-04-30,Interventional,Polyvalent Immunoglobulin in COVID-19 Related ARds,Recruiting,Phase 3,Centre Hospitalier St Anne,NA,https://clinicaltrials.gov/ct2/show/NCT04350580,1,0,1,0,2,0,France,0,immunoglobulin|placebo,Clinical Trial Protocol|Journal Article
NCT04663555,2021-02-02,2022-03-31,Interventional,Effect of Two Different Doses of Dexamethasone in Patients With ARDS and COVID-19,Recruiting,Phase 4,Brno University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04663555,1,0,1,0,3,0,Czechia,0,dexamethasone,Clinical Trial Protocol|Letter
NCT04375098,2020-05-04,2020-08-17,Interventional,Efficacy and Safety of Early COVID-19 Convalescent Plasma in Patients Admitted for COVID-19 Infection,Completed,Phase 2,Pontificia Universidad Catolica de Chile,NA,https://clinicaltrials.gov/ct2/show/NCT04375098,1,0,1,0,3,0,Chile,0,convalescent plasma,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04405843,2020-07-14,2020-12-21,Interventional,Efficacy of Ivermectin in Adult Patients With Early Stages of COVID-19 (EPIC Trial),Completed,Phase 2/Phase 3,Centro de Estudios en InfectogÃ­a Pediatrica,NA,https://clinicaltrials.gov/ct2/show/NCT04405843,1,0,1,0,8,0,Colombia,0,ivermectin|placebo,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04318431,2020-04-14,2020-05-12,Interventional,Prevalence of SARS -Cov2 Carriage in Asymptomatic and Mildly-symptomatic Children,Completed,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicaltrials.gov/ct2/show/NCT04318431,1,0,1,0,7,0,France,0,data collection/rhinopharyngeal swab|data collection|rhinopharyngeal,Journal Article
NCT04393818,2020-05-05,2020-08-24,Interventional,Mobile Phone Based Intervention to Protect Mental Health in Healthcare Workers at Frontline Against COVID19,Completed,Phase 3,FundaciÃ³ d'investigaciÃ³ SanitÃ ria de les Illes Balears,NA,https://clinicaltrials.gov/ct2/show/NCT04393818,2,0,2,0,4,0,Spain,0,intervention app,Journal Article/Journal Article
NCT04327388,2020-03-28,2020-07-30,Interventional,Sarilumab COVID-19,Completed,Phase 3,Sanofi,NA,https://clinicaltrials.gov/ct2/show/NCT04327388,1,0,1,0,18,0,Argentina|Brazil|Canada|Chile|France|Germany|Israel|Italy|Japan|Russian Federation|Spain,0,sarilumab|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04354428,2020-04-16,2020-12-31,Interventional,Treatment for COVID-19 in High-Risk Adult Outpatients,"Active, not recruiting",Phase 2/Phase 3,University of Washington,NA,https://clinicaltrials.gov/ct2/show/NCT04354428,1,0,1,0,6,1,United States,0,vitamin c|hydroxychloroquine|azithromycin|folic acid|lopinavir 200 mg / ritonavir 50 mg [kaletra]|lopinavir 200 mg|ritonavir 50 mg [kaletra],Journal Article
NCT04357366,2020-04-15,2022-04-15,Interventional,suPAR-guided Anakinra Treatment for Validation of the Risk and Management of Respiratory Failure by COVID-19 (SAVE),Recruiting,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicaltrials.gov/ct2/show/NCT04357366,1,0,1,0,6,0,Greece,0,anakinra,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't"
NCT04385017,2020-05-11,2021-06-12,Interventional,Role of Inflammasomes in COVID-19 Disease,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicaltrials.gov/ct2/show/NCT04385017,1,0,1,0,0,0,France,0,covid-19 patients,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04499677,2020-09-24,2021-11-30,Interventional,FLARE: Favipiravir +/- Lopinavir: A RCT of Early Antivirals,Recruiting,Phase 2,"University College, London",NA,https://clinicaltrials.gov/ct2/show/NCT04499677,1,0,1,0,3,0,United Kingdom,0,favipiravir|lopinavir/ ritonavir|placebo|lopinavir|ritonavir,Clinical Trial Protocol|Letter
NCT04362176,2020-04-24,2021-05-31,Interventional,Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults,Recruiting,Phase 3,Vanderbilt University Medical Center,NA,https://clinicaltrials.gov/ct2/show/NCT04362176,2,0,2,0,6,1,United States,0,convalescent plasma|placebo,Preprint/Clinical Trial Protocol|Journal Article
NCT04405076,2020-05-29,2021-11-01,Interventional,"Dose-Confirmation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1273 COVID-19 Vaccine in Adults Aged 18 Years and Older","Active, not recruiting",Phase 2,"ModernaTX, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04405076,1,0,1,1,6,1,United States,0,biological: mrna-1273|placebo|mrna-1273.351,"Clinical Trial, Phase II|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04420806,2020-03-14,2020-07-30,Interventional,Effects of COVID-19 Lockdown in Exercising Early Postmenopausal Women,Completed,N/A,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicaltrials.gov/ct2/show/NCT04420806,1,0,1,0,3,0,Germany,0,exercise|placebo,Journal Article
NCT04546581,2020-10-08,2021-07-31,Interventional,Inpatient Treatment With Anti-Coronavirus Immunoglobulin (ITAC),"Active, not recruiting",Phase 3,University of Minnesota,NA,https://clinicaltrials.gov/ct2/show/NCT04546581,1,0,1,0,4,1,United States|Denmark|Greece|Japan|Nigeria|Spain|United Kingdom,0,hyperimmune immunoglobulin to sars-cov-2 (hivig)|placebo|remdesivir,Journal Article
NCT04537858,2020-06-18,2020-08-20,Interventional,Virtual Reality Therapy Influence on Heart Rate Variability of Inpatients With COVID-19,"Active, not recruiting",N/A,University of Sao Paulo,NA,https://clinicaltrials.gov/ct2/show/NCT04537858,1,0,1,0,0,0,Brazil,0,virtual reality therapy first|conventional therapy first,Journal Article
NCT04431466,2020-07-01,2020-12-01,Interventional,A Study to Compare the Efficacy and Safety of Different Doses of Ivermectin for COVID-19,Recruiting,Phase 2,Universidade Federal de Sao Carlos,NA,https://clinicaltrials.gov/ct2/show/NCT04431466,1,0,1,0,1,0,Brazil,0,ivermectin|standard care,Journal Article
NCT04475601,2020-07-15,2021-07-08,Interventional,Enzalutamide Treatment in COVID-19,Recruiting,Phase 2,VÃ¤sterbotten County Council,NA,https://clinicaltrials.gov/ct2/show/NCT04475601,1,0,1,0,0,0,Sweden,0,enzalutamide,Clinical Trial Protocol|Letter
NCT04486508,2020-07-30,2021-04-04,Interventional,Intermediate-dose vs Standard Prophylactic Anticoagulation and Statin vs Placebo in ICU Patients With COVID-19,"Active, not recruiting",Phase 3,Rajaie Cardiovascular Medical and Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04486508,1,1,2,0,8,0,"Iran, Islamic Republic of",0,intermediate dose enoxaparin/ unfractionated heparin|standard prophylactic dose enoxaparin/ unfractionated heparin|atorvastatin|placebo|enoxaparin|heparin|standard prophylactic dose enoxaparin,"Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Clinical Trial Protocol|Journal Article"
NCT04453384,2020-09-01,2020-12-31,Interventional,Study to Evaluate the Safety and Efficacy of XAV-19 in Patients With COVID-19 Induced Moderate Pneumonia,Recruiting,Phase 2,Nantes University Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04453384,1,0,1,0,2,0,France,0,xav-19|placebo,Clinical Trial Protocol|Journal Article
NCT04492514,2020-05-20,2021-05-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflation,Recruiting,Phase 2,University of Cincinnati,NA,https://clinicaltrials.gov/ct2/show/NCT04492514,1,0,1,0,0,1,United States,0,mavrilimumab|placebo,Journal Article
NCT04399980,2020-05-20,2021-05-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Phase 2,The Cleveland Clinic,NA,https://clinicaltrials.gov/ct2/show/NCT04399980,1,0,1,0,3,1,United States,0,mavrilimumab|placebo,Journal Article
NCT04463004,2020-09-02,2021-08-31,Interventional,Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation,"Active, not recruiting",Phase 2,Virginia Commonwealth University,NA,https://clinicaltrials.gov/ct2/show/NCT04463004,1,0,1,0,4,1,United States,0,mavrilimumab|placebo,Journal Article
NCT04466085,2020-07-12,2020-10-22,Interventional,Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 2,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicaltrials.gov/ct2/show/NCT04466085,1,0,1,1,2,0,China,0,recombinant new coronavirus vaccine (cho cell) low-dose group|recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,Journal Article
NCT04445194,2020-06-22,2020-10-22,Interventional,Phase I Clinical Study of Recombinant Novel Coronavirus Vaccine,"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicaltrials.gov/ct2/show/NCT04445194,1,0,1,1,3,0,China,0,recombinant new coronavirus vaccine (cho cell) low-dose group|recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,Journal Article
NCT04331899,2020-04-25,2020-08-14,Interventional,Single-Blind Study of a Single Dose of Peginterferon Lambda-1a Compared With Placebo in Outpatients With Mild COVID-19,"Active, not recruiting",Phase 2,Stanford University,NA,https://clinicaltrials.gov/ct2/show/NCT04331899,1,1,2,0,6,1,United States,1,peginterferon|placebo,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04486482,2021-01-12,2021-03-31,Interventional,A Clinical Study to Assess the Physiologic Effects of KB109 in Patients With COVID-19 on Gut Microbiota Structure and Function,Recruiting,N/A,Kaleido Biosciences,NA,https://clinicaltrials.gov/ct2/show/NCT04486482,1,0,1,0,1,1,United States,0,kb109 / self supportive care (ssc)|self supportive care (ssc) alone|kb109|self supportive care (ssc),Clinical Trial Protocol|Letter
NCT04578210,2020-09-04,2021-01-31,Interventional,Safety Infusion of NatuRal KillEr celLs or MEmory T Cells as Adoptive Therapy in COVID-19 pnEumonia or Lymphopenia,Recruiting,Phase 1/Phase 2,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicaltrials.gov/ct2/show/NCT04578210,1,0,1,0,1,0,Spain,0,t memory cells/nk cells|t memory cells|nk cells,Congress
NCT04368923,2020-03-15,2020-06-21,Interventional,Management of Covid-19 Patients During Home Isolation,"Active, not recruiting",N/A,Cairo University,NA,https://clinicaltrials.gov/ct2/show/NCT04368923,1,0,1,0,1,0,Egypt,0,oxygen|physical therapy,Journal Article
NCT04678843,2021-02-09,2021-10-31,Interventional,Adapting and Adopting Highly Specialized Pediatric Eating Disorder Treatment to Virtual Care: Implementation Research for the COVID-19 Context and Beyond,Enrolling by invitation,Early Phase 1,McMaster University,NA,https://clinicaltrials.gov/ct2/show/NCT04678843,1,0,1,0,1,0,Canada,0,virtual family-based treatment,Journal Article
NCT04715607,2021-01-22,2021-05-05,Interventional,"COVID-19: SARS-CoV-2 Detection in Saliva, Oropharyngeal and Nasopharyngeal Specimens",Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicaltrials.gov/ct2/show/NCT04715607,1,0,1,0,3,0,Denmark,0,sequence of testing.,Clinical Trial Protocol|Comparative Study|Journal Article
NCT04379453,2020-04-27,2020-04-27,Interventional,Robot Assisted Percutaneous Cardiovascular Intervention as a Strategy to Reduce or Risk of Intra-Procedure Contamination by COVID-19 and Other Respiratory Viruses,Recruiting,N/A,Hospital Israelita Albert Einstein,NA,https://clinicaltrials.gov/ct2/show/NCT04379453,1,0,1,0,1,0,Brazil,0,robot assisted percutaneous cardiovascular intervention,Journal Article
NCT04482647,2020-06-17,2021-07-01,Interventional,Breathing Techniques and Meditation for Health Care Workers During COVID-19 Pandemic,Recruiting,Phase 1,M.D. Anderson Cancer Center,NA,https://clinicaltrials.gov/ct2/show/NCT04482647,1,0,1,0,4,1,United States,0,media intervention|meditation therapy|quality-of-life assessment|questionnaire|yoga,Journal Article
NCT04635943,2020-08-29,2021-04-30,Interventional,Randomized Phase IIA Clinical Trial to Evaluate the Efficacy of Ivermectin to Obtain Negative PCR Results in Patients With Early Phase COVID-19,Recruiting,Phase 2,Universidad Peruana Cayetano Heredia,NA,https://clinicaltrials.gov/ct2/show/NCT04635943,1,0,1,0,1,0,Peru,0,ivermectin|placebo,Letter
NCT04569825,2020-08-01,2020-09-30,Interventional,Effect of Nasal Steroid in the Treatment of Anosmia Due to COVID-19 Disease,Recruiting,Early Phase 1,University Of Anbar,NA,https://clinicaltrials.gov/ct2/show/NCT04569825,1,0,1,0,0,0,Iraq,0,ophtamesone,Journal Article
NCT04581954,2020-10-02,2021-06-30,Interventional,Inflammatory Signal Inhibitors for COVID-19 (MATIS),Recruiting,Phase 1/Phase 2,Imperial College London,NA,https://clinicaltrials.gov/ct2/show/NCT04581954,1,0,1,0,1,0,United Kingdom,0,ruxolitinib|fostamatinib|standard care,Letter
NCT04582344,2020-09-14,2021-02-15,Interventional,Clinical Trial For SARS-CoV-2 Vaccine (COVID-19),Recruiting,Phase 3,Health Institutes of Turkey,NA,https://clinicaltrials.gov/ct2/show/NCT04582344,1,0,1,1,2,0,Turkey,0,coronavac|placebo,Letter
NCT04464408,2020-07-23,2021-12-31,Interventional,Favipiravir Therapy in Adults With Mild COVID-19,Recruiting,Phase 2/Phase 3,King Abdullah International Medical Research Center,NA,https://clinicaltrials.gov/ct2/show/NCT04464408,1,0,1,0,4,0,Saudi Arabia,0,favipiravir|placebo,"Clinical Trial Protocol|Journal Article|Research Support, Non-U.S. Gov't"
NCT04494984,2020-07-27,2020-11-23,Interventional,"A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19.",Completed,Phase 2/Phase 3,Inmunova S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04494984,1,0,1,0,4,0,Argentina,0,inm005|placebo,Journal Article
NCT04742738,2021-01-20,2021-08-31,Interventional,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19),Recruiting,Phase 1/Phase 2,"SK Chemicals Co., Ltd.",NA,https://clinicaltrials.gov/ct2/show/NCT04742738,1,0,1,1,0,0,"Korea, Republic of",0,gbp510 adjuvanted with alum (rbd 10î¼g/dose) - stage 1|normal saline (0.9% sodium chloride solution) - stage 1|gbp510 adjuvanted with alum (rbd 25î¼g/dose) - stage 1|gbp510 adjuvanted with alum (rbd 10î¼g/dose) - stage 2|gbp510 adjuvanted with alum (rbd 25î¼g/dose)- stage 2|normal saline (0.9% sodium chloride solution)- stage 2|gbp510 adjuvanted with alum (rbd 10î¼g|dose) - stage 1|gbp510 adjuvanted with alum (rbd 25î¼g|dose) - stage 2|dose)- stage 2,Journal Article
NCT04750343,2021-02-03,2021-07-31,Interventional,Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19),Recruiting,Phase 1/Phase 2,"SK Chemicals Co., Ltd.",NA,https://clinicaltrials.gov/ct2/show/NCT04750343,1,0,1,1,0,0,"Korea, Republic of",0,gbp510 adjuvanted with as03 (rbd 10î¼g/dose) - stage 1|gbp510 (rbd 10î¼g/dose) - stage 1|normal saline (0.9% sodium chloride solution) - stage 1|gbp510 adjuvanted with as03 (rbd 25î¼g/dose) - stage 1|gbp510 (rbd 25î¼g/dose) - stage 1|gbp510 adjuvanted with as03 (rbd 10î¼g/dose) - stage 2|gbp510 adjuvanted with as03 (rbd 25î¼g/dose)- stage 2|gbp510 (rbd 25î¼g/dose)- stage 2|normal saline (0.9% sodium chloride solution)- stage 2|gbp510 adjuvanted with as03 (rbd 10î¼g|dose) - stage 1|gbp510 (rbd 10î¼g|gbp510 adjuvanted with as03 (rbd 25î¼g|gbp510 (rbd 25î¼g|dose) - stage 2|dose)- stage 2,Journal Article
NCT04403100,2020-06-03,2021-02-01,Interventional,"Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: ""The Hope Coalition - 1""",Recruiting,Phase 3,Cardresearch,NA,https://clinicaltrials.gov/ct2/show/NCT04403100,1,0,1,0,2,0,Brazil,0,hydroxychloroquine|lopinavir/ritonavir|hydroxychloroquine/lopinavir/ritonavir|placebo|lopinavir|ritonavir,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't"
NCT04495933,2020-07-13,2020-10-09,Interventional,"A Study on the Safety, Tolerability and Immune Response of SARS-CoV-2 Sclamp (COVID-19) Vaccine in Healthy Adults",Recruiting,Phase 1,The University of Queensland,NA,https://clinicaltrials.gov/ct2/show/NCT04495933,1,0,1,1,2,0,Australia,0,mf59 adjuvanted sars-cov-2 sclamp vaccine|placebo,Journal Article
NCT04537208,2020-09-03,2021-11-30,Interventional,Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older,"Active, not recruiting",Phase 1/Phase 2,Sanofi,NA,https://clinicaltrials.gov/ct2/show/NCT04537208,1,0,1,1,5,1,United States,0,placebo|sars-cov-2 vaccine formulation 2 without adjuvant|sars-cov-2 vaccine formulation 1 with adjuvant 1|sars-cov-2 vaccine formulation 1 with adjuvant 2|sars-cov-2 vaccine formulation 2 with adjuvant 1|sars-cov-2 vaccine formulation 2 with adjuvant 2,Journal Article
NCT04528641,2020-08-10,2021-07-31,Interventional,GRAd-COV2 Vaccine Against COVID-19,"Active, not recruiting",Phase 1,ReiThera Srl,NA,https://clinicaltrials.gov/ct2/show/NCT04528641,1,0,1,1,2,0,Italy,0,grad-cov2,Journal Article
NCT04335279,2020-04-09,2020-06-03,Interventional,Evaluation of the Scleroderma Patient-centered Intervention Network COVID-19 Home-isolation Activities Together Program,Completed,N/A,Lady Davis Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04335279,1,0,1,0,7,0,Canada,0,spin-chat program,Journal Article
NCT04321096,2020-04-04,2022-01-31,Interventional,The Impact of Camostat Mesilate on COVID-19 Infection,Recruiting,Phase 1/Phase 2,University of Aarhus,NA,https://clinicaltrials.gov/ct2/show/NCT04321096,1,0,1,0,5,0,Denmark|Sweden,0,camostat mesilate|placebo,Journal Article
NCT04420247,2020-04-16,2020-08-20,Interventional,Efficacy of Chloroquine or Hydroxychloroquine in Treating Pneumonia Caused by SARS-Cov-2 - COVID-19,Completed,Phase 3,Centro de Estudos e Pesquisa em Emergencias Medicas e Terapia Intensiva,NA,https://clinicaltrials.gov/ct2/show/NCT04420247,1,0,1,0,2,0,Brazil,0,chloroquine|hydroxychloroquine|standard care,Journal Article
NCT04403646,2020-06-12,2020-10-20,Interventional,Tannin Specific Natural Extract for COVID-19 Infection,Terminated,N/A,Hospital de Clinicas JosÃ© de San MartÃ­n,low rate of covid patients,https://clinicaltrials.gov/ct2/show/NCT04403646,1,0,1,0,1,0,Argentina,0,arbox|placebo,Letter
NCT04408209,2020-04-23,2021-08-30,Interventional,Convalescent Plasma for the Treatment of Patients With Severe COVID-19 Infection,Recruiting,N/A,National and Kapodistrian University of Athens,NA,https://clinicaltrials.gov/ct2/show/NCT04408209,1,0,1,0,4,0,Greece,0,convalescent plasma,Journal Article
NCT04348656,2020-05-14,2021-03-31,Interventional,CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness (CONCOR-1),"Active, not recruiting",Phase 3,McMaster University,NA,https://clinicaltrials.gov/ct2/show/NCT04348656,1,0,1,0,11,1,United States|Brazil|Canada,0,convalescent plasma,Journal Article
NCT04533399,2020-08-17,2021-11-30,Interventional,A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults,Recruiting,Phase 2,Novavax,NA,https://clinicaltrials.gov/ct2/show/NCT04533399,1,0,1,1,3,0,South Africa,0,sars-cov-2 rs/matrix-m1 adjuvant|placebo|sars-cov-2 rs|adjuvant,Journal Article
NCT04399252,2020-06-24,2022-05-25,Interventional,Effect of Lactobacillus on the Microbiome of Household Contacts Exposed to COVID-19,Recruiting,N/A,Duke University,NA,https://clinicaltrials.gov/ct2/show/NCT04399252,1,0,1,0,2,1,United States,0,lactobaciltus rhamnosus gg|placebo,Journal Article
NCT04329533,2020-04-13,2020-11-01,Interventional,Effects of Using Mobile App on Perceived Stress During COVID-19 Pandemic,Completed,N/A,University of Arizona,NA,https://clinicaltrials.gov/ct2/show/NCT04329533,1,0,1,0,8,1,United States,0,"""calm"" is a mindfulness meditation mobile app",Journal Article
NCT04466670,2020-07-08,2020-12-30,Interventional,Hemostasis in COVID-19: an Adaptive Clinical Trial,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04466670,0,36,36,0,0,0,Brazil,0,heparin|acetylsalicylic acid|enoxaparin,"Journal Article|Review/Journal Article/Letter|Comment/Journal Article|Multicenter Study/Journal Article|Review/Comparative Study|Journal Article/Letter/Comparative Study|Journal Article|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't/Journal Article/Clinical Trial, Phase II|Controlled Clinical Trial|Journal Article/Journal Article|Observational Study/Letter"
NCT04333550,2020-04-30,2020-09-30,Interventional,Application of Desferal to Treat COVID-19,Recruiting,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04333550,0,17,17,0,2,0,"Iran, Islamic Republic of",0,deferoxamine,Journal Article
NCT04382768,2020-05-01,2021-01-31,Interventional,Inhaled Ibuprofen to Treat COVID-19,Recruiting,N/A,QuÃ­mica Luar SRL,NA,https://clinicaltrials.gov/ct2/show/NCT04382768,0,3,3,0,3,0,Argentina,0,ibuprofen,Journal Article/Journal Article
NCT04424953,2020-06-01,2020-09-25,Interventional,To Compare Videolaryngoscope Against Direct Laryngoscope for Intubation When Powered Air Purifying Respirator is Worn,Completed,N/A,Singapore General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04424953,0,17,17,0,3,0,Singapore,0,mcgrath videolaryngoscope|laryngoscope,"Journal Article/Journal Article/Comparative Study|Letter/Journal Article|Research Support, Non-U.S. Gov't"
NCT04482634,2020-09-01,2022-08-31,Interventional,Tele-rehabilitation Versus Home Exercise Program in COVID-19,Recruiting,N/A,KoÃ§ University,NA,https://clinicaltrials.gov/ct2/show/NCT04482634,0,10,10,0,1,0,Turkey,0,remote controlled exercise|home exercise,Journal Article|Review
NCT04359095,2020-08-18,2021-03-20,Interventional,Effectiveness and Safety of Medical Treatment for SARS-CoV-2 (COVID-19) in Colombia,Recruiting,Phase 2/Phase 3,Universidad Nacional de Colombia,NA,https://clinicaltrials.gov/ct2/show/NCT04359095,0,21,21,0,3,0,Colombia,0,emtricitabine/tenofovir|colchicine pill|rosuvastatin|standard care|emtricitabine|tenofovir,Journal Article
NCT04410328,2020-10-21,2021-03-15,Interventional,Aggrenox To Treat Acute Covid-19,Recruiting,Phase 3,"Rutgers, The State University of New Jersey",NA,https://clinicaltrials.gov/ct2/show/NCT04410328,0,5,5,0,4,1,United States,0,dipyridamole er 200mg/ aspirin 25mg orally/enterally/standard of care|standard care|dipyridamole er 200mg|aspirin 25mg orally|enterally,"Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural"
NCT04338568,2020-04-16,2020-11-30,Interventional,Screening COVID-19 by Point-of-care Lung Ultrasound: a Validation Study,Recruiting,N/A,Hasselt University,NA,https://clinicaltrials.gov/ct2/show/NCT04338568,0,2,2,0,3,0,Belgium,0,lung ultrasound,Journal Article/Evaluation Study|Journal Article
NCT04642326,2020-06-26,2020-07-01,Interventional,Study Investigating the Effects of UVC Beam and Laser Beam Therapy According to Standard Therapy in Patients With Covid-19 Diagnosis,"Active, not recruiting",N/A,RD Global AraÅŸtirma GeliÅŸtirme SaÄŸlik IlaÃ§ InÅŸaat Yatirimlari A.Åž.,NA,https://clinicaltrials.gov/ct2/show/NCT04642326,0,7,7,0,0,0,Turkey,0,test group: experimental - uvc therapy applied,"Clinical Trial|Journal Article|Research Support, Non-U.S. Gov't/Journal Article"
NCT04374786,2020-05-15,2020-09-01,Interventional,Effects of Mobile App in House Staff Health and Well-being During COVID-19 Pandemic,Enrolling by invitation,N/A,University of Arizona,NA,https://clinicaltrials.gov/ct2/show/NCT04374786,0,4,4,0,2,1,United States,0,meditation,Journal Article/Journal Article
NCT04282902,2020-02-04,2020-04-30,Interventional,A Study to Evaluate the Efficacy and Safety of Pirfenidone With Novel Coronavirus Infection,Recruiting,Phase 3,Tongji Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04282902,0,4,4,0,0,0,China,0,pirfenidone,Journal Article
NCT04673214,2020-12-16,2021-02-02,Interventional,Evaluation of Prognostic Modification in COVID-19 Patients in Early Intervention Treatment,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicaltrials.gov/ct2/show/NCT04673214,0,6,6,0,3,0,Mexico,0,azithromycin / ivermectin / ribaroxaban / paracetamol|azithromycin / ribaroxaban / paracetamol|azithromycin|ivermectin|ribaroxaban|paracetamol,"Journal Article|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Review"
NCT04501965,2020-06-01,2020-08-30,Interventional,Phytomedicines Versus Hydroxychloroquine as an Add on Therapy to Azythromycin in Asymptomatic Covid-19 Patients,Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,https://clinicaltrials.gov/ct2/show/NCT04501965,0,19,19,0,1,0,Guinea,0,hydroxychloroquine / azithromycin|quinquina-stevia/azythromycin|4plants/azythromycin|hydroxychloroquine|azithromycin|quinquina-stevia|4plants,Journal Article|Review/Journal Article|Published Erratum
NCT04407689,2020-06-08,2021-07-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort,Recruiting,Phase 2,Revimmune,NA,https://clinicaltrials.gov/ct2/show/NCT04407689,0,2,2,0,2,0,France,0,interleukin|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04442178,2020-09-15,2021-10-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ),Recruiting,Phase 2,Revimmune,NA,https://clinicaltrials.gov/ct2/show/NCT04442178,0,4,4,0,2,1,United States,0,cyt107|placebo,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04517162,2020-08-19,2021-02-19,Interventional,Intramuscular Effect of Polymerized Type I Collagen on the Cytokine Storm in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04517162,0,31,31,0,3,0,Mexico,0,collagen-polyvinylpyrrolidone,"Journal Article|Meta-Analysis|Systematic Review/Journal Article|Multicenter Study|Research Support, Non-U.S. Gov't/Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Validation Study"
NCT04366232,2020-08-19,2020-10-02,Interventional,Efficacy of Intravenous Anakinra and Ruxolitinib During COVID-19 Inflammation,Terminated,Phase 2,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,investigator decision,https://clinicaltrials.gov/ct2/show/NCT04366232,0,3,3,0,5,0,France,0,anakinra|anakinra/ruxolitinib|standard care|3)|ruxolitinib,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04353674,2020-04-28,2021-12-31,Interventional,Modulation of Hyperinflammation in COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicaltrials.gov/ct2/show/NCT04353674,0,17,17,0,6,0,Canada,0,control|sledd with a l-mod,"Journal Article|Research Support, Non-U.S. Gov't/Letter/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Journal Article/Journal Article"
NCT04627467,2020-03-28,2020-07-09,Interventional,Prevention With Chloroquine in Health Personnel Exposed to Infection With Coronavirus Disease 2019 (COVID-19) (TS-COVID),"Active, not recruiting",Phase 2,Fundacion Clinica Valle del Lili,NA,https://clinicaltrials.gov/ct2/show/NCT04627467,0,20,20,0,1,0,Colombia,0,chloroquine,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Meta-Analysis|Systematic Review/Journal Article/Journal Article/Letter|Comment/Clinical Trial|Journal Article/Historical Article|Journal Article|Review"
NCT04344951,2020-04-06,2021-04-01,Interventional,"Chloroquine Phosphate Against Infection by the Novel Coronavirus SARS-CoV-2 (COVID-19): The HOPE Open-Label, Non Randomized Clinical Trial",Recruiting,Phase 2,Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.,NA,https://clinicaltrials.gov/ct2/show/NCT04344951,0,3,3,0,1,0,Greece,0,chloroquine,Journal Article/Journal Article/Clinical Trial|Journal Article
NCT04385043,2020-05-01,2020-10-15,Interventional,Hyperimmune Plasma in Patients With COVID-19 Severe Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,https://clinicaltrials.gov/ct2/show/NCT04385043,0,3,3,0,0,0,Italy,0,convalescent plasma|standard care,"Clinical Trial, Phase I|Journal Article|Research Support, N.I.H., Extramural"
NCT04494724,2020-07-13,2020-12-31,Interventional,Clazakizumab vs. Placebo - COVID-19 Infection,Recruiting,Phase 2,The Methodist Hospital System,NA,https://clinicaltrials.gov/ct2/show/NCT04494724,0,8,8,0,0,1,United States,0,clazakizumab|placebo,"Journal Article|Research Support, Non-U.S. Gov't/Journal Article|Published Erratum"
NCT04479202,2020-02-08,2020-04-18,Interventional,The Effect of Berberine on Intestinal Function and Inflammatory Mediators in Severe Patients With Covid-19,Completed,Phase 4,Chinese Medical Association,NA,https://clinicaltrials.gov/ct2/show/NCT04479202,0,3,3,0,0,0,China,0,berberine|montmorrillonite,"Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Letter"
NCT04384380,2020-04-01,2020-05-31,Interventional,Efficacy and Tolerability of Hydroxychloroquine in Adult Patients With COVID-19,Completed,N/A,Taoyuan General Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04384380,0,5,5,0,1,0,Taiwan,0,hydroxychloroquine,Journal Article|Systematic Review/Clinical Trial|Journal Article
NCT04516811,2020-09-21,2021-12-30,Interventional,Therapeutic Use of Convalescent Plasma in the Treatment of Patients With Moderate to Severe COVID-19,Recruiting,Phase 3,South African National Blood Service,NA,https://clinicaltrials.gov/ct2/show/NCT04516811,0,1,1,0,2,0,South Africa,0,convalescent plasma/standard care|standard care/placebo|convalescent plasma|standard care|placebo,Journal Article
NCT04392323,2020-05-13,2020-07-01,Interventional,Incidence of COVID-19 Test Conversion in Post-surgical Patients,Recruiting,N/A,Northwell Health,NA,https://clinicaltrials.gov/ct2/show/NCT04392323,0,12,12,0,0,1,United States,0,pcr/serology|pcr|serology test,"Journal Article/Journal Article|Observational Study|Research Support, Non-U.S. Gov't/Journal Article/Case Reports|Journal Article/Journal Article/Journal Article/Journal Article"
NCT04356482,2020-05-20,2020-11-30,Interventional,CONVALESCENT PLASMA FOR ILL PATIENTS BY COVID-19,Recruiting,Phase 1/Phase 2,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,https://clinicaltrials.gov/ct2/show/NCT04356482,0,6,6,0,3,0,Mexico,0,convalescent plasma,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04393727,2020-05-01,2020-09-30,Interventional,Transfusion of Convalescent Plasma for the Early Treatment of Patients With COVID-19,Terminated,Phase 2,"Azienda Ospedaliero, Universitaria Pisana","Study was stopped because the Promoter was changed and a new study on convalescent plasma
    promoted by AIFA was started in Italy.",https://clinicaltrials.gov/ct2/show/NCT04393727,0,1,1,0,2,0,Italy,0,convalescent plasma,"Case Reports|Journal Article|Research Support, Non-U.S. Gov't"
NCT04798677,2020-10-29,2021-04-30,Interventional,Efficacy and Tolerability of ABBC1 in Volunteers Receiving the Influenza or Covid-19 Vaccine,Recruiting,N/A,AB Biotek,NA,https://clinicaltrials.gov/ct2/show/NCT04798677,0,19,19,1,1,0,Spain,0,abbc1 immunoessential|placebo,"Journal Article|Review|Research Support, Non-U.S. Gov't/Letter/Journal Article/Clinical Trial, Phase II|Clinical Trial, Phase III|Journal Article|Multicenter Study|Randomized Controlled Trial|Research Support, Non-U.S. Gov't/Journal Article|Research Support, Non-U.S. Gov't"
NCT04366089,2020-03-26,2020-10-30,Interventional,Oxygen-Ozone as Adjuvant Treatment in Early Control of COVID-19 Progression and Modulation of the Gut Microbial Flora,Recruiting,Phase 2,Azienda Policlinico Umberto I,NA,https://clinicaltrials.gov/ct2/show/NCT04366089,0,3,3,0,0,0,Italy,0,oxygen-ozone|sivomixx|azithromycin|hydroxychloroquine|standard care,Editorial/Journal Article
NCT04378738,2020-05-01,2020-05-07,Interventional,Social Media and Covid19 Pandemic,Enrolling by invitation,N/A,Acibadem University,NA,https://clinicaltrials.gov/ct2/show/NCT04378738,0,1,1,0,0,0,Turkey,0,questionnaire,"Journal Article|Research Support, N.I.H., Extramural"
NCT04360837,2020-05-06,2021-06-01,Interventional,PEEP Incremental and Decremental Alveolar Recruitment of Critically Ill Corona Virus Disease-19 (COVID-19) Patients,Recruiting,N/A,Szeged University,NA,https://clinicaltrials.gov/ct2/show/NCT04360837,0,1,1,0,2,0,Hungary,0,alveolar,"Journal Article|Research Support, Non-U.S. Gov't"
NCT04361942,2020-05-01,2021-11-30,Interventional,Treatment of Severe COVID-19 Pneumonia With Allogeneic Mesenchymal Stromal Cells (COVID_MSV),Recruiting,Phase 2,Red de Terapia Celular,NA,https://clinicaltrials.gov/ct2/show/NCT04361942,0,4,4,0,3,0,Spain,0,mesenchymal stem cells|placebo,Journal Article
NCT04480593,2020-06-02,2020-08-30,Interventional,The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19.,Completed,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,https://clinicaltrials.gov/ct2/show/NCT04480593,0,8,8,0,1,0,Brazil,0,brazilian green propolis extract (epp-af)|standard care,Journal Article|Review/Journal Article|Review/Journal Article|Review
NCT04392713,2020-04-15,2020-07-31,Interventional,Efficacy of Ivermectin in COVID-19,Recruiting,N/A,"Combined Military Hospital, Pakistan",NA,https://clinicaltrials.gov/ct2/show/NCT04392713,0,1,1,0,0,0,Pakistan,0,ivermectin,Journal Article|Review
NCT04530617,2020-10-05,2021-04-30,Interventional,Camostat and Artemisia Annua vs Placebo in COVID-19 Outpatients,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicaltrials.gov/ct2/show/NCT04530617,0,28,28,0,4,0,Mexico,0,camostat mesilate|artemisia annua leaf,Published Erratum
NCT04568356,2020-04-24,2020-06-12,Interventional,A Clinical Evaluation of COVID-19 Rapid Point of Care Antigen Tests,Completed,N/A,"E25Bio, Inc.",NA,https://clinicaltrials.gov/ct2/show/NCT04568356,0,17,17,0,1,1,United States,0,direct antigen tests for covid-19,"Comparative Study|Journal Article/Journal Article/Evaluation Study|Letter/Journal Article|Research Support, N.I.H., Extramural|Research Support, N.I.H., Intramural|Review/Journal Article/Evaluation Study|Journal Article/Journal Article|Comment/Journal Article|Research Support, Non-U.S. Gov't|Review/Preprint/Evaluation Study|Journal Article/Journal Article|Research Support, Non-U.S. Gov't/Journal Article/Comparative Study|Journal Article|Validation Study/Journal Article/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article|Meta-Analysis|Research Support, Non-U.S. Gov't|Systematic Review"
NCT04488484,2020-07-01,2021-12-31,Interventional,Medical and Serological Follow-up of the Staff of the Paris Saint-Joseph Hospital Group Infected With Severe Acute Respiratory Syndrome Coronavirus 2.,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicaltrials.gov/ct2/show/NCT04488484,0,5,5,0,1,0,France,0,serology test follow-up,"Journal Article|Systematic Review/Journal Article|Research Support, Non-U.S. Gov't"
NCT04522492,2020-08-11,2021-03-31,Interventional,Impact of COVID-19 on Mental Health of Patients With Skin Picking,"Active, not recruiting",N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicaltrials.gov/ct2/show/NCT04522492,0,2,2,0,1,0,Brazil,0,internet-based cognitive behavioral therapy|quality of life promotion,Journal Article|Randomized Controlled Trial
NCT04841681,2020-06-07,2020-08-25,Interventional,Video-based Psychotherapy for COVID-19 Patients in Isolation Ward in Jakarta,Completed,N/A,Indonesia University,NA,https://clinicaltrials.gov/ct2/show/NCT04841681,0,7,7,0,0,0,Indonesia,0,video-based psychotherapy,Journal Article/Journal Article|Comment/Journal Article/Journal Article
NCT04647695,2020-11-20,2021-07-31,Interventional,IFN-beta 1b and Remdesivir for COVID19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicaltrials.gov/ct2/show/NCT04647695,0,2,2,0,2,0,Hong Kong,0,interferon|remdesivir,"Clinical Trial, Phase III|Journal Article|Randomized Controlled Trial|Research Support, N.I.H., Extramural|Research Support, Non-U.S. Gov't"
NCT04454606,2020-05-01,2020-05-15,Interventional,The New Silicone N99 Half-Piece Respirator,Completed,N/A,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,https://clinicaltrials.gov/ct2/show/NCT04454606,0,1,1,0,0,0,Thailand,0,fit test|filtration test,Journal Article|Published Erratum
NCT04517422,2020-08-19,2021-02-02,Interventional,Efficacy of L. Plantarum and P. Acidilactici in Adults With SARS-CoV-2 and COVID-19,Completed,N/A,"AB Biotics, SA",NA,https://clinicaltrials.gov/ct2/show/NCT04517422,0,7,7,0,7,0,Mexico,0,probiotics|placebo,Journal Article/Journal Article/Journal Article|Review/Journal Article/Journal Article/Journal Article/Journal Article|Review
NCT04685512,2020-11-18,2021-04-01,Interventional,Effect of Tenofovir/Emtricitabine in Patients Recently Infected With SARS-COV2 (Covid-19) Discharged Home,Recruiting,Phase 2/Phase 3,"University Hospital, Caen",NA,https://clinicaltrials.gov/ct2/show/NCT04685512,0,5,5,0,0,0,France,0,tenofovir disoproxil/emtricitabine|tenofovir disoproxil|emtricitabine,"Journal Article|Research Support, N.I.H., Extramural"
NCT04514705,2020-08-11,2021-12-31,Interventional,Characteristics in Post Covid-19 Patients,Recruiting,N/A,Universidade Metodista de Piracicaba,NA,https://clinicaltrials.gov/ct2/show/NCT04514705,0,6,6,0,0,0,Brazil,0,exercise,"Editorial/Case Reports|Journal Article/Journal Article|Research Support, Non-U.S. Gov't|Systematic Review/Journal Article/Journal Article"
NCT04578158,2020-09-29,2021-03-28,Interventional,Trial to Study the Adjuvant Benefits of Quercetin Phytosome in Patients With COVID-19,Completed,Phase 3,Liaquat University of Medical & Health Sciences,NA,https://clinicaltrials.gov/ct2/show/NCT04578158,0,3,3,0,9,0,Pakistan,0,standard covid-19 care|quercetin phytosome,Journal Article/Journal Article
NCT04753476,2020-06-08,2021-06-08,Interventional,Treatment of Severe COVID-19 Patients Using Secretome of Hypoxia-Mesenchymal Stem Cells in Indonesia,Recruiting,Phase 2,Stem Cell and Cancer Research Indonesia,NA,https://clinicaltrials.gov/ct2/show/NCT04753476,0,2,2,0,1,0,Indonesia,0,injection of secretome-mscs|standard treatment of covid-19,Journal Article|Review/Journal Article|Review
NCT04331795,2020-04-04,2020-06-05,Interventional,"Tocilizumab to Prevent Clinical Decompensation in Hospitalized, Non-critically Ill Patients With COVID-19 Pneumonitis",Completed,Phase 2,University of Chicago,NA,https://clinicaltrials.gov/ct2/show/NCT04331795,0,1,1,0,8,1,United States,0,tocilizumab,"Clinical Trial, Phase II|Journal Article|Research Support, Non-U.S. Gov't"
NCT04721457,2021-01-03,2021-02-28,Interventional,The Efficacy of Pre-procedural Mouth Rinses on COVID-19 Saliva Viral Load,Recruiting,Phase 4,King Abdulaziz University,NA,https://clinicaltrials.gov/ct2/show/NCT04721457,0,17,17,0,1,0,Saudi Arabia,0,distilled water|1% povidone iodine (pvp-i)|1.5% hydrogen peroxide (h2o2)|0.075% cetylpyridinium chloride (cpc)|0.1% sodium hypochlorite,Journal Article
NCT04705753,2020-04-01,2020-10-15,Interventional,"Assessment of the Clinical Effectiveness of a Herbal Extract (Cretan IAMA) in Patients With Viral Respiratory Infections, Including COVID-19, in Primary Healthcare Settings, and Co-assessment of Its Prophylactic Effect in People Cohabiting With These Patients",Completed,Phase 2/Phase 3,University of Crete,NA,https://clinicaltrials.gov/ct2/show/NCT04705753,0,4,4,0,0,0,Greece,0,cretan iama,Journal Article|Review
NCT04340349,2021-02-01,2021-05-30,Interventional,Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals,Enrolling by invitation,Early Phase 1,Instituto Nacional de Rehabilitacion,NA,https://clinicaltrials.gov/ct2/show/NCT04340349,0,19,19,0,3,0,Mexico,0,hydroxychloroquine|bromhexine hydrochloride,Journal Article/Journal Article
NCT04598581,2020-11-02,2021-04-09,Interventional,"Low Dose Radiation Therapy for Severe-Acute-Respiratory-Syndrome-Coronavirus-2 (SARS-CoV-2), COVID-19",Completed,N/A,"University Hospital, Basel, Switzerland",NA,https://clinicaltrials.gov/ct2/show/NCT04598581,0,1,1,0,4,0,Switzerland,0,radiotherapy|placebo,Journal Article
NCT04726111,2020-12-30,2021-07-30,Interventional,COVID-19 and Pregnancy: Placental and Immunological Impacts,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04726111,0,0,0,0,0,0,France,0,specimens specific for the study,NA
NCT04726098,2021-01-15,2021-06-30,Interventional,Low or High Dose of Dexamethasone in Patients With Respiratory Failure by COVID-19,Recruiting,Phase 4,Hospital Clinico Universitario de Santiago,NA,https://clinicalzeros.gov/ct2/show/NCT04726098,0,0,0,0,0,0,Spain,0,dexamethasone high dose|dexamethasone low dose,NA
NCT04320953,2020-03-16,2020-03-26,Interventional,Non-contact Endoscopy at Covid-19 Outbreak,Completed,N/A,Changhai Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04320953,0,0,0,0,1,0,China,0,non-contact mce system,NA
NCT04726371,2021-01-08,2022-10-31,Interventional,Best Practices to Prevent COVID-19 Illness in Staff and People With Serious Mental Illness and Developmental Disabilities in Congregate Living Settings,Recruiting,N/A,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04726371,0,0,0,0,0,1,United States,0,generic best practices|tailored best practices,NA
NCT04724681,2021-02-01,2021-12-31,Interventional,Continuous Wireless Monitoring of Vital Signs and Automated Alerts of Patient Deterioration in Patients Admitted With COVID-19 Infection,Recruiting,N/A,University Hospital Bispebjerg and Frederiksberg,NA,https://clinicalzeros.gov/ct2/show/NCT04724681,0,0,0,0,0,0,Denmark,0,ward css,NA
NCT04724629,2021-01-05,2021-03-31,Interventional,Survival TRial Using CytoKines in COVID-19 (STRUCK Trial),Recruiting,Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04724629,0,0,0,0,0,0,Brazil,0,ixekizumab|aldesleukin|colchicine|standard care,NA
NCT04724616,2021-01-06,2021-06-30,Interventional,CARTOON: CoronAviRus (COVID-19) educaTional prOgram fOr childreN,Recruiting,N/A,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04724616,0,0,0,0,0,0,Austria,0,educational program (cartoon),NA
NCT04724538,2020-10-15,2021-02-10,Interventional,Inhalation Low Dose Radionuclide Therapy in Treatment COVID-19,Recruiting,Phase 1/Phase 2,National Medical Research Radiological Centre of the Ministry of Health of Russia,NA,https://clinicalzeros.gov/ct2/show/NCT04724538,0,0,0,0,0,0,Russian Federation,0,99mtc-pertechnetate|99mtc-pertechnetate aerosol,NA
NCT04723576,2020-12-03,2022-02-28,Interventional,Mental and Physical Well-Being of Frontline Health Care Workers During Coronavirus Disease 2019 (COVID-19),Recruiting,N/A,RAND,NA,https://clinicalzeros.gov/ct2/show/NCT04723576,0,0,0,0,0,1,United States,0,stress first aid,NA
NCT04723550,2021-01-05,2021-11-05,Interventional,COVID-19 Lockdown Related Telemedicine for Type 2 Diabetes,Recruiting,N/A,Xuzhou No.1 Peoples Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04723550,0,0,0,0,1,0,China,0,hospital telemedicine management system|standard care,NA
NCT04720794,2020-09-25,2020-10-20,Interventional,A Study To Evaluate The Performance of the Lucira Health All-In-One COVID-19 Test Kit vs Hologic Panther Fusion,Completed,N/A,Lucira Health Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04720794,0,0,0,0,1,1,United States,0,lucira covid-19 all-in-one test kit,NA
NCT04721236,2020-11-19,2021-11-19,Interventional,Early Use of Hyperimmune Plasma in COVID-19,Recruiting,N/A,IRCCS Policlinico S. Matteo,NA,https://clinicalzeros.gov/ct2/show/NCT04721236,0,0,0,0,0,0,Italy,0,convalescent plasma,NA
NCT04718506,2021-01-12,2021-06-12,Interventional,Rehabilitation for Post-COVID-19 Syndrome Through a Supervised Exercise Intervention,Recruiting,N/A,Universidad de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04718506,0,0,0,0,0,0,Spain,0,exercise|controls,NA
NCT04720404,2020-06-23,2022-02-28,Interventional,Mindful Prevention of Psychopathology in Healthcare Workers During the COVID-19 Crisis (COVID-19 MindPreP),Recruiting,N/A,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04720404,0,0,0,0,0,0,Netherlands,0,mindfulness-based stress reduction|self-help mindfulness/compassion exercises|support as usual|self-help mindfulness|compassion exercises,NA
NCT04719208,2020-10-06,2021-05-31,Interventional,[COVID-19] Reduction of Sars-CoV-2 Oral Viral Load With Prophylactic Mouth Rinse,Recruiting,N/A,Augusta University,NA,https://clinicalzeros.gov/ct2/show/NCT04719208,0,0,0,0,0,1,United States,0,water (e) mouth rinse with the solution provided|chlorhexidine gluconate (a) mouth rinse with the solution provided|hydrogen peroxide (b) mouth rinse with the solution provided|betadine (c) mouth rinse with the solution provided|alcohol mouthwash (listerine) (d) mouth rinse with the solution provided,NA
NCT04718480,2020-11-27,2021-08-31,Interventional,Fluvoxamine Administration in Moderate SARS-CoV-2 (COVID-19) Infected Patients,Recruiting,Phase 2,SigmaDrugs Research Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04718480,0,0,0,0,0,0,Hungary,0,placebo|fluvoxamine,NA
NCT04716998,2021-01-31,2022-01-31,Interventional,Safety and the Efficacy of MesenCure for the Treatment of Pulmonary Manifestations of COVID-19,Recruiting,Phase 1/Phase 2,BonusBio Group Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04716998,0,0,0,0,1,0,Israel,0,mesencure,NA
NCT04716985,2021-01-22,2021-07-22,Interventional,Evaluation of the Daily Intake of 0.5 L of Water Saturated With Molecular Hydrogen for 21 Days in COVID-19 Patients Treated in Ambulatory Care,Recruiting,N/A,AGIR Ã  Dom,NA,https://clinicalzeros.gov/ct2/show/NCT04716985,0,0,0,0,2,0,France,0,molecular hydrogen|placebo magnesium,NA
NCT04716179,2021-01-18,2021-05-18,Interventional,Prospective Two-arm Study of Fertility in Men With COVID-19,Recruiting,N/A,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04716179,0,0,0,0,0,0,Russian Federation,0,"sperm test|hormone levels (testosterone, fsh, lh, prolactin)|sars-cov-2 ig g levels|testis pathology samples",NA
NCT04716647,2020-10-09,2020-12-12,Interventional,Feasibility of Ayurveda in Patients With Mild-to-Moderate COVID-19: A Community-Based Participatory Research,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04716647,0,0,0,0,0,0,United Kingdom,0,ayurveda,NA
NCT04715997,2020-12-30,2021-05-30,Interventional,"Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults",Recruiting,Phase 1/Phase 2,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04715997,0,0,0,1,0,0,"Korea, Republic of",0,gx-19n,NA
NCT04715295,2020-10-05,2021-05-30,Interventional,Safety and Efficacy of Doxycycline and Rivaroxaban in COVID-19,Recruiting,Phase 4,Yaounde Central Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04715295,0,0,0,0,0,0,Cameroon,0,doxycycline tablets|rivaroxaban 15mg tab|hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,NA
NCT04715243,2021-01-31,2021-04-30,Interventional,"Comparison of High Flow Nasal Cannula (HFNC), Face-mask Non-Invasive Ventilation (NIV) & Helmet NIV in COVID-19 ARDS Patients",Recruiting,N/A,Sultan Qaboos University,NA,https://clinicalzeros.gov/ct2/show/NCT04715243,0,0,0,0,1,0,Oman,0,high flow nasal cannula (hfnc)|helmet niv|face-mask niv,NA
NCT04715360,2020-12-29,2021-11-29,Interventional,Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy,Recruiting,Phase 1/Phase 2,Hayandra Peduli Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04715360,0,0,0,0,0,0,Indonesia,0,autologous activated platelet-rich plasma|avigan,NA
NCT04713878,2020-05-08,2020-06-30,Interventional,Mesenchymal Stem Cells Therapy in Patients With COVID-19 Pneumonia,Completed,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04713878,0,0,0,0,1,0,Turkey,0,mesenchymal stem cells,NA
NCT04712357,2020-11-09,2022-01-31,Interventional,Clinical Experimentation With Tenofovir Disoproxyl Fumarate and Emtricitabine for COVID-19,Recruiting,N/A,Universidade Federal do Ceara,NA,https://clinicalzeros.gov/ct2/show/NCT04712357,0,0,0,0,0,0,Brazil,0,vitamin c 500 mg oral tablet|tenofovir disoproxyl fumarate 300 mg oral tablet|tenofovir disoproxyl fumarate 300 mg/emtricitabine 200 mg oral tablet|tenofovir disoproxyl fumarate 300 mg|emtricitabine 200 mg oral tablet,NA
NCT04712344,2021-01-18,2021-09-30,Interventional,Assessment of Efficacy and Safety of Therapy With COVID-19 Convalescent Plasma in Subjects With Severe COVID-19 (IPCO),Recruiting,Phase 2,University of Erlangen-NÃ¼rnberg Medical School,NA,https://clinicalzeros.gov/ct2/show/NCT04712344,0,0,0,0,2,0,Germany,0,convalescent plasma,NA
NCT04712045,2020-08-01,2020-12-12,Interventional,Rational Use of Personal Protective Equipment During COVID-19 Pandemic,Completed,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04712045,0,0,0,0,0,0,United Kingdom,0,new ppe|old ppe,NA
NCT04709172,2021-01-05,2021-04-05,Interventional,Pilot Study of Cefditoren Pivoxil in COVID-19 Patients With Mild to Moderate Pneumonia,Recruiting,Phase 4,Meiji Pharma Spain S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04709172,0,0,0,0,1,0,Spain,0,cefditoren pivoxil 400mg,NA
NCT04705831,2020-12-30,2022-01-31,Interventional,Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 Infection,Recruiting,Phase 4,IMMUNOe Research Centers,NA,https://clinicalzeros.gov/ct2/show/NCT04705831,0,0,0,0,0,1,United States,0,ruconest,NA
NCT04707833,2020-11-26,2023-12-01,Interventional,Evaluation of Serological Techniques for Screening for COVID-19 Infection at the University Hospital of Rouen,Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04707833,0,0,0,0,0,0,France,0,serological testing for covid-19 infection,NA
NCT04707820,2020-04-16,2021-06-10,Interventional,Antiviral T Lymphocyte Immunity During Acute COVID-19 Infection,Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04707820,0,0,0,0,0,0,France,0,elispot,NA
NCT04707742,2020-06-15,2020-11-18,Interventional,Antiseptic Mouth Rinses to Reduce Salivary Viral Load in COVID-19 Patients,Completed,N/A,FundaciÃ³n para el Fomento de la InvestigaciÃ³n Sanitaria y BiomÃ©dica de la Comunitat Valenciana,NA,https://clinicalzeros.gov/ct2/show/NCT04707742,0,0,0,0,0,0,Spain,0,betadineâ© bucal 100 mg/ml|oximenâ® 3%|clorhexidine dental phbâ©|vitis xtra forteâ©|distilled water|betadineâ© bucal 100 mg|methylprednisolone|oximenâ® 3%|clorhexidine dental phbâ©|vitis xtra forteâ©,NA
NCT04706416,2020-11-14,2021-01-15,Interventional,N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19),"Active, not recruiting",Phase 1,Quantinosis.ai LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04706416,0,0,0,0,0,1,United States,0,n-acetyl glucosamine (nag),NA
NCT04703907,2020-12-03,2021-08-31,Interventional,Auricular Stimulation for Relief of Stress and Anxiety,Recruiting,N/A,University Medicine Greifswald,NA,https://clinicalzeros.gov/ct2/show/NCT04703907,0,0,0,0,0,0,Germany,0,auricular stimulation,NA
NCT04701528,2020-11-15,2022-03-25,Interventional,Anti-Viral Effects of Voclosporin in COVID-19 Positive Kidney Transplant Recipients,Recruiting,Phase 2,Leiden University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04701528,0,0,0,0,0,0,Netherlands,0,voclosporin|tacrolimus,NA
NCT04699851,2020-11-18,2021-04-18,Interventional,Optimization of the Management of COVID-19 Through Tailored Recommendations to the Citizens,Recruiting,N/A,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04699851,0,0,0,0,1,0,Canada,0,tailored recommendations|general recommendation,NA
NCT04699227,2020-04-23,2021-04-30,Interventional,Can RIC Prevent Deterioration to Critical Care in Covid19,Recruiting,N/A,University College London Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04699227,0,0,0,0,0,0,United Kingdom,0,cuff application with inflation|sham inflation,NA
NCT04695743,2020-09-01,2022-06-01,Interventional,Group CST Using Zoom: A Proof of Concept Study,Recruiting,N/A,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04695743,0,0,0,0,0,0,United Kingdom,0,online cognitive stimulation therapy,NA
NCT04694638,2020-05-21,2021-05-31,Interventional,"Use of Combined Prone Positioning and High-Flow Nasal Cannula, and Non-invasive Positive Pressure Ventilation to Prevent Intubation in COVID-19 Infection",Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04694638,0,0,0,0,0,1,United States,0,body position change,NA
NCT04694612,2021-01-01,2021-03-31,Interventional,Efficacy of Favipiravir in Treatment of Mild & Moderate COVID-19 Infection in Nepal,Recruiting,Phase 3,Nepal Health Research Council,NA,https://clinicalzeros.gov/ct2/show/NCT04694612,0,0,0,0,0,0,Nepal,0,favipiravir|placebo|remdesivir,NA
NCT04691947,2020-11-05,2021-03-01,Interventional,Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC,Recruiting,Phase 1,Health Institutes of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04691947,0,0,0,1,1,0,Turkey,0,erucov-vac|placebo,NA
NCT04690920,2020-07-23,2020-12-10,Interventional,Theranostic Implication of Complementary Medicines Against Interleukin Receptors and Gp-130 Proteins,Completed,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04690920,0,0,0,0,0,0,Pakistan,0,tocilizumab,NA
NCT04693026,2020-09-10,2021-02-15,Interventional,Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients,Recruiting,Phase 3,M Abdur Rahim Medical College and Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04693026,0,0,0,0,0,0,Bangladesh,0,remdesivir|baricitinib|tocilizumab,NA
NCT04687488,2020-07-23,2020-11-09,Interventional,Aerosol and Droplet Dispersion During Gastrointestinal Motility Investigations,Completed,N/A,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04687488,0,0,0,0,0,0,Belgium,0,fluorescein|particle measurement,NA
NCT04686760,2020-11-15,2021-01-15,Interventional,Efficacy of Inhaled Nitroglycerin in Moderate to Critically Ill COVID-19 Patients,Recruiting,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04686760,0,0,0,0,0,0,Pakistan,0,nitroglycerin,NA
NCT04685603,2020-12-07,2021-01-31,Interventional,Dendritic Cell Vaccine to Prevent COVID-19,Recruiting,Phase 1,Indonesia-MoH,NA,https://clinicalzeros.gov/ct2/show/NCT04685603,0,0,0,1,1,0,Indonesia,0,av-covid-19,NA
NCT04682873,2020-05-15,2021-06-01,Interventional,A Clinical Study to Assess the Efficacy and Safety of AmizonÂ® Max in the Treatment of Moderate Covid-19,Recruiting,Phase 3,"Joint Stock Company ""Farmak""",NA,https://clinicalzeros.gov/ct2/show/NCT04682873,0,0,0,0,0,0,Ukraine,0,enisamium iodide|placebo,NA
NCT04682574,2020-11-02,2020-12-30,Interventional,Role of Mega Dose of Vitamin C in Critical COVID-19 Patients,Recruiting,N/A,University of Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04682574,0,0,0,0,1,0,Pakistan,0,vitamin c,NA
NCT04681001,2020-12-20,2021-05-30,Interventional,"Prophylactic Treatment With Carragelose Nasal Spary to Prevent SARS-CoV-2, COVID-19, Infections in Health Care Workers",Recruiting,N/A,Marinomed Biotech AG,NA,https://clinicalzeros.gov/ct2/show/NCT04681001,0,0,0,0,1,0,Austria,0,nasal rinse,NA
NCT04680858,2020-07-01,2021-01-31,Interventional,Impact of Digital Communication Assist Tools in Endoscopic Team Communication During COVID-19,Enrolling by invitation,N/A,University of Ulm,NA,https://clinicalzeros.gov/ct2/show/NCT04680858,0,0,0,0,1,0,Germany,0,dect,NA
NCT04337996,2020-07-13,2021-01-13,Interventional,Dynamic Evaluation of COVID-19 Diagnostic Tests,Completed,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04337996,0,0,0,0,3,0,France,0,covid-19 diagnostic test,NA
NCT04677270,2020-08-31,2020-11-30,Interventional,Evaluation of Two Versions of a Digital Problem Solving Tool for the General Public Specific for the COVID-19 Pandemic,Completed,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04677270,0,0,0,0,0,0,Sweden,0,digital problem solving tool,NA
NCT04676971,2020-12-11,2021-07-07,Interventional,Efficacy and Safety of hzVSF-v13 in Patients With COVID-19 Pneumonia,Recruiting,Phase 2,"ImmuneMed, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04676971,0,0,0,0,2,0,Italy|Russian Federation,0,hzvsf-v13|placebo (normal saline solution),NA
NCT04674189,2020-12-23,2021-06-30,Interventional,A Study to Evaluate the Safety and Immunogenicity of Vaccine CVnCoV in Healthy Adults in Germany for COVID-19,Recruiting,Phase 3,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04674189,0,0,0,1,1,0,Germany,0,cvncov vaccine|placebo,NA
NCT04673149,2020-12-23,2022-07-31,Interventional,GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19),Recruiting,Phase 1/Phase 2,"GeneOne Life Science, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04673149,0,0,0,1,2,0,"Korea, Republic of",0,gls-5310|placebo,NA
NCT04668469,2020-06-08,2020-09-15,Interventional,Efficacy and Safety of Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic,Completed,N/A,Benha University,NA,https://clinicalzeros.gov/ct2/show/NCT04668469,0,0,0,0,0,0,Egypt,0,ivermectin|hydroxychloroquine|personal protective measures,NA
NCT04666558,2020-11-30,2021-12-17,Interventional,Heal-Me Personalized Online Nutrition and Exercise Routines,Recruiting,N/A,University of Alberta,NA,https://clinicalzeros.gov/ct2/show/NCT04666558,0,0,0,0,0,0,Canada,0,exercise/nutrition|exercise|nutrition,NA
NCT04666493,2020-12-04,2021-11-30,Interventional,Adapting Anxiety Intervention for Youth With Autism for Rapid Response to COVID-19,Recruiting,N/A,"Anagnostou, Evdokia, M.D.",NA,https://clinicalzeros.gov/ct2/show/NCT04666493,0,0,0,0,0,0,Canada,0,"cognitive behavior therapy (cbt), specifically using the facing your fears (fyf) curriculum",NA
NCT04666116,2020-04-01,2020-12-31,Interventional,Changes in Viral Load in COVID-19 After Probiotics,Recruiting,N/A,Hospital de Sagunto,NA,https://clinicalzeros.gov/ct2/show/NCT04666116,0,0,0,0,1,0,Spain,0,dietary supplementation in patients with covid disease admitted to hospital,NA
NCT04662684,2020-10-16,2021-04-30,Interventional,Medically Ill Hospitalized Patients for COVID-19 THrombosis Extended ProphyLaxis With Rivaroxaban ThErapy: The MICHELLE Trial,Recruiting,Phase 3,Science Valley Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04662684,0,0,0,0,0,0,Brazil,0,rivaroxaban 10 mg,NA
NCT04662021,2020-12-10,2021-02-10,Interventional,Aerobic Training Versus Cognitive Behavioral Therapy in Management of Anxiety,Enrolling by invitation,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04662021,0,0,0,0,1,0,Egypt,0,aerobic exercises,NA
NCT04661930,2020-12-13,2021-04-01,Interventional,Fenofibrate for Patients With COVID-19 Requiring Hospitalization,Recruiting,Phase 3,Hebrew University of Jerusalem,NA,https://clinicalzeros.gov/ct2/show/NCT04661930,0,0,0,0,0,0,Israel,0,tricorâ® 145mg tablets|standard care|placebo|tricorâ® 145mg tablets,NA
NCT04661527,2020-04-22,2020-12-30,Interventional,Sarilumab Treatment In cytoKinE Storm Caused by Infection With COVID-19,Recruiting,Phase 2,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicalzeros.gov/ct2/show/NCT04661527,0,0,0,0,1,0,Spain,0,sarilumab,NA
NCT04659746,2020-12-09,2021-02-28,Interventional,MejoraCare-Paraguay: mHealth Solution for Chronic Patients During the COVID-19 Outbreak in Paraguay,Recruiting,N/A,Universidad AutÃ³noma de EncarnaciÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04659746,0,0,0,0,2,0,Paraguay,0,mejoracare,NA
NCT04658433,2020-12-05,2021-02-15,Interventional,The Effect of Omega -3 Supplements on the Serum Levels of ACE/ACE2 Ratio as a Potential Key in Cardiovascular Disease and COVID-19; A Randomized Clinical Trial in the Covid-19 Uninfected Jordanian People,Recruiting,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04658433,0,0,0,0,0,0,Jordan,0,300 mg of omega3-fa,NA
NCT04649515,2020-12-04,2021-08-31,Interventional,"Efficacy and Safety of TY027, a Treatment for COVID-19, in Humans",Recruiting,Phase 3,Tychan Pte Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04649515,0,0,0,0,1,0,Singapore,0,ty027|saline,NA
NCT04648800,2020-07-07,2020-12-31,Interventional,Clinical Trial Evaluating the Effect of BCG Vaccination on the Incidence and Severity of SARS-CoV-2 Infections Among Healthcare Professionals During the COVID-19 Pandemic in Poland,Recruiting,Phase 3,University of Rzeszow,NA,https://clinicalzeros.gov/ct2/show/NCT04648800,0,0,0,1,0,0,Poland,0,bcg-10 vaccine|saline,NA
NCT04646655,2020-07-27,2021-05-31,Interventional,Enoxaparin at Prophylactic or Therapeutic Doses in COVID-19,Recruiting,Phase 3,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04646655,0,0,0,0,0,0,Italy,0,enoxaparin,NA
NCT04645407,2020-02-01,2020-04-15,Interventional,Effects of Fuzheng Huayu Tablets on COVID-19,Completed,Phase 4,ShuGuang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04645407,0,0,0,0,0,0,China,0,fuzheng huayu,NA
NCT04644172,2020-11-01,2023-11-30,Interventional,Improving Thinking in Everyday Life After Covid-19,Recruiting,Phase 1/Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04644172,0,0,0,0,0,1,United States,0,speed of processing training|instrumental activities of daily living shaping|transfer package from ci therapy|standard care,NA
NCT04643964,2020-11-30,2020-11-30,Interventional,Brief Video Interventions for Depression,Recruiting,N/A,Ohio State University,NA,https://clinicalzeros.gov/ct2/show/NCT04643964,0,0,0,0,0,1,United States,0,entrã©e: cognitive skills|entrã©e: behavioral skills|entrã©e: interpersonal skills|sampler skills|entrã©e: cognitive skills|entrã©e: behavioral skills|entrã©e: interpersonal skills,NA
NCT04643691,2020-09-11,2022-09-30,Interventional,Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS,Recruiting,Phase 2,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04643691,0,0,0,0,0,0,France,0,losartan 50 mg/spironolactone 25 mg pillules oral use|losartan 50 mg|spironolactone 25 mg pillules oral use,NA
NCT04643561,2020-11-01,2020-12-31,Interventional,Using Travelan to Boost Immune Response in Vitro to COVID-19,"Active, not recruiting",Phase 1/Phase 2,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04643561,0,0,0,0,1,0,Israel,0,travelan otc,NA
NCT04642040,2020-06-30,2021-01-31,Interventional,Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia,Recruiting,N/A,Sisli Hamidiye Etfal Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04642040,0,0,0,0,0,0,Turkey,0,pulmonary rehabilitation,NA
NCT04641858,2020-12-03,2022-02-28,Interventional,BCG to Reduce Absenteeism Among Health Care Workers During the COVID-19 Pandemic,Recruiting,Phase 4,University of Southern Denmark,NA,https://clinicalzeros.gov/ct2/show/NCT04641858,0,0,0,1,1,0,Cape Verde|Guinea-Bissau|Mozambique,0,bcg-denmark|saline,NA
NCT04640038,2020-12-18,2022-12-31,Interventional,Contrast Enhanced Ultrasound in COVID-19,Recruiting,Phase 3,Children's Hospital of Philadelphia,NA,https://clinicalzeros.gov/ct2/show/NCT04640038,0,0,0,0,2,1,United States,0,sulfur hexafluoride lipid-type a microspheres,NA
NCT04639466,2020-12-11,2022-11-10,Interventional,"A Synthetic MVA-based SARS-CoV-2 Vaccine, COH04S1, for the Prevention of COVID-19",Recruiting,Phase 1,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04639466,0,0,0,1,4,1,United States,0,placebo|vaccine therapy,NA
NCT04639349,2020-11-19,2021-03-01,Interventional,Effect of Home Exercise Activity on Cortisol and Depression in COPD During the Pandemic COVID,Recruiting,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04639349,0,0,0,0,0,0,Egypt,0,exercise|control,NA
NCT04638842,2020-12-24,2021-06-01,Interventional,Online Multi-component Psychological Intervention for Prevention of Grief Disorder Due to COVID-19,Recruiting,N/A,Universidad Internacional de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04638842,0,0,0,0,2,0,Mexico,0,online intervention grief covid-19,NA
NCT04638673,2020-11-19,2021-06-30,Interventional,NeuroCovid Rehab and Recovery Related to COVID-19 Diagnosis,Recruiting,Phase 2,Medical University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04638673,0,0,0,0,1,1,United States,0,soterix tavns model 0125-lte stimulator - active-active group|soterix tavns model 0125-lte stimulator - sham-active group,NA
NCT04637828,2020-11-18,2021-07-30,Interventional,A Study to Compare the Efficacy of GNS561 Versus Standard of Care in Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Genoscience Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04637828,0,0,0,0,0,0,France,0,gns561,NA
NCT04636034,2021-01-12,2021-08-31,Interventional,The Effect of Ganglion Sphenopalatine Block Versus Placebo on Persistent Headache Following COVID-19 Infection,Recruiting,Phase 3,University Hospital Bispebjerg and Frederiksberg,NA,https://clinicalzeros.gov/ct2/show/NCT04636034,0,0,0,0,3,0,Denmark,0,"sphenopalatine ganglion block with local anesthetic|sphenopalatine ganglion block with placebo (isotone nacl)|""sham""-block with placebo (isotone nacl)",NA
NCT04679415,2020-12-17,2021-04-30,Interventional,Efficacy and Safety of hzVSF-v13 in Moderate to Severe Patients With COVID-19 Pneumonia,Recruiting,Phase 2,"ImmuneMed, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04679415,0,0,0,0,1,0,Indonesia,0,hzvsf-v13|placebo (normal saline solution),NA
NCT04667780,2020-12-10,2021-05-09,Interventional,Study to Investigate the Treatment Effect of Colchicine in Patients With COVID-19,Recruiting,Phase 3,Ayub Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04667780,0,0,0,0,0,0,Pakistan,0,colchicine|standard covid-19 care,NA
NCT04664010,2020-02-06,2021-01-14,Interventional,Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19),"Active, not recruiting",N/A,Xi'an International Medical Center Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04664010,0,0,0,0,0,0,China,0,"alpha-interferon alpha, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste, fumigation/inhalation of vitamin c|alpha-interferon, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste/5% glucose|alpha-interferon, abidol, ribavirin, buzhong yiqi plus/minus formula, huhuang detoxicity paste, baimu qingre jiedu paste/high-dose vitamin c treatment|alpha-interferon alpha, abidol, ribavirin, buzhong yiqi plus|minus formula, huhuang detoxicity paste, baimu qingre jiedu paste, fumigation|inhalation of vitamin c|alpha-interferon, abidol, ribavirin, buzhong yiqi plus|minus formula, huhuang detoxicity paste, baimu qingre jiedu paste|5% glucose|high-dose vitamin c treatment",NA
NCT04663594,2020-12-04,2021-03-31,Interventional,Online Culture for Mental Health in People Aged 16-24,Recruiting,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04663594,0,0,0,0,1,0,United Kingdom,0,wofb|ashmolean website,NA
NCT04661410,2020-12-01,2021-12-01,Interventional,Reward Re-Training: A New Treatment to Address Reward Imbalance During the COVID-19 Pandemic,Recruiting,N/A,Drexel University,NA,https://clinicalzeros.gov/ct2/show/NCT04661410,0,0,0,0,1,1,United States,0,reward re-training|supportive therapy,NA
NCT04659941,2020-10-01,2021-10-01,Interventional,Use of BCG Vaccine as a Preventive Measure for COVID-19 in Health Care Workers,Recruiting,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04659941,0,0,0,1,0,0,Brazil,0,bcg,NA
NCT04659486,2020-09-24,2021-04-30,Interventional,Adolescents With COVID-19/MIS-C at HCFMUSP,Enrolling by invitation,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04659486,0,0,0,0,0,0,Brazil,0,home-based exercise training,NA
NCT04658979,2020-12-31,2021-03-31,Interventional,Pulmonary TELE-REHABilitation Program : Feasibility and Safety Study,Recruiting,N/A,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,NA,https://clinicalzeros.gov/ct2/show/NCT04658979,0,0,0,0,1,0,Canada,0,pulmonary tele-rehabilitation,NA
NCT04656626,2020-07-07,2020-07-21,Interventional,Brief Mindfulness Based Intervention to Improve Psychological Wellbeing,Completed,N/A,Imam Abdulrahman Bin Faisal University,NA,https://clinicalzeros.gov/ct2/show/NCT04656626,0,0,0,0,2,0,Saudi Arabia,0,brief mindfulness based intervention|progressive muscle relaxation,NA
NCT04654481,2020-12-31,2021-02-28,Interventional,Study of AffloVest in At-Risk Respiratory Patients During COVID-19 Pandemic,Recruiting,N/A,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04654481,0,0,0,0,0,1,United States,0,hcfwo|standard care/monitoring|standard care|monitoring,NA
NCT04653831,2020-11-08,2021-11-30,Interventional,Treatment With Pirfenidone for COVID-19 Related Severe ARDS,Recruiting,N/A,Soroka University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04653831,0,0,0,0,0,0,Israel,0,pirfenidone|standard care,NA
NCT04559035,2020-09-24,2020-12-31,Interventional,Nasal Irrigation to Reduce COVID-19 Morbidity,Enrolling by invitation,N/A,Augusta University,NA,https://clinicalzeros.gov/ct2/show/NCT04559035,0,0,0,0,0,1,United States,0,nasal lavage,NA
NCT04652648,2020-05-27,2020-10-31,Interventional,Rapid Development and Implementation of a Remote ECG-monitored Prospective Randomized Clinical Trial During a Pandemic: Hydroxychloroquine Prophylaxis in COVID-19 Household Contacts,Completed,Phase 4,Bryn Mawr Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04652648,0,0,0,0,0,1,United States,0,hydroxychloroquine,NA
NCT04649736,2020-10-26,2021-03-30,Interventional,Home-based Respiratory Physiotherapy and Telephone-Based Psychological Support in Severe COVID-19 Patients,Recruiting,N/A,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04649736,0,0,0,0,0,0,Peru,0,respiratory/psychological rehabilitation|respiratory|psychological rehabilitation,NA
NCT04646109,2020-05-11,2020-09-02,Interventional,Ivermectin for Severe COVID-19 Management,Completed,Phase 3,Afyonkarahisar Health Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04646109,0,0,0,0,1,0,Turkey,1,ivermectin,NA
NCT04644705,2020-11-02,2021-05-31,Interventional,Safety and Pharmacokinetics of a Novel Niclosamide Solution in Combination With Camostat,Recruiting,Phase 1,CharitÃ© Research Organisation GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04644705,0,0,0,0,0,0,Germany,0,niclosamide|placebo,NA
NCT04637867,2020-11-23,2021-11-01,Interventional,COVID-19 - Multicentre Study on Nosocomial Transmission of SARS-CoV-2 Virus: an Ancillary Study (NOSO-COR IMMUNO),Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04637867,0,0,0,0,1,0,France,0,"collection of blood, salivary/nasopharyngeal samples.|collection of blood, salivary|nasopharyngeal samples.",NA
NCT04636333,2020-10-30,2021-04-07,Interventional,Phase I Trial of a Recombinant COVID-19 Vaccine (CHO Cell),Recruiting,Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04636333,0,0,0,1,2,0,China,0,"two doses of middle-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14|three doses of middle-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14, 28|two doses of high-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14|three doses of high-dose recombinant sars-cov-2 vaccine (cho cell) at the schedule of day 0, 14, 28|two doses of placebo at the schedule of day 0, 14 #middle-dose group#|three doses of placebo at the schedule of day 0, 14, 28 #middle-dose group#|two doses of placebo at the schedule of day 0, 14 #high-dose group#|three doses of placebo at the schedule of day 0, 14, 28 #high-dose group#",NA
NCT04636320,2020-06-13,2021-01-13,Interventional,Prevalence of Myocardial Scars on CMR After COVID-19 Infection,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04636320,0,0,0,0,0,0,France,0,contrast-enhanced cmr|exercise test ecg|blood sample|resting 12 lead ecg|24 hour holter ecg,NA
NCT04635618,2020-11-05,2021-07-13,Interventional,Psychotherapy Strategies for the Treatment of Professionals and Students From Essential Services With High Levels of Emotional Distress in the Context of COVID-19,Enrolling by invitation,N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04635618,0,0,0,0,0,0,Brazil,0,cognitive behavioral brief-telepsychotherapy|brief interpersonal telepsychotherapy|telepsychoeducation,NA
NCT04634903,2020-11-19,2021-05-01,Interventional,"Testing Scalable, Single-Session Interventions for Adolescent Depression in the Context of COVID-19","Active, not recruiting",N/A,Stony Brook University,NA,https://clinicalzeros.gov/ct2/show/NCT04634903,0,0,0,0,2,1,United States,0,supportive therapy ssi|behavioral activation ssi|growth mindset ssi,NA
NCT04634799,2021-01-08,2021-11-30,Interventional,Study To antagOnize Plasminogen Activator Inhibitor-1 in Severe COVID-19,Recruiting,Phase 1/Phase 2,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04634799,0,0,0,0,2,1,United States,0,tm5614|placebo,NA
NCT04634422,2020-11-16,2021-06-30,Interventional,Plasma Exchange (PLEX) and Convalescent Plasma (CCP) in COVID-19 Patients With Multiorgan Failure,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04634422,0,0,0,0,1,0,Denmark,0,plasma exchange/convalescent plasma|plasma|convalescent plasma,NA
NCT04634318,2020-12-10,2021-12-31,Interventional,Organization of Pulmonary Rehabilitation of Post-COVID-19 Patient With Sequelae (REHABCOVID),Recruiting,N/A,Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer,NA,https://clinicalzeros.gov/ct2/show/NCT04634318,0,0,0,0,4,0,France,0,respiratory rehabilitation program (rr).|respiratory tele-rehabilitation program (trr).,NA
NCT04633772,2020-08-05,2021-02-01,Interventional,Use of Angiotensin-(1-7) in COVID-19,Recruiting,Phase 1/Phase 2,Erasme University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04633772,0,0,0,0,1,0,Brazil,0,angiotensin-(1-7)|placebo,NA
NCT04632719,2020-11-08,2020-12-29,Interventional,The MentalPlusÂ® for Assessment and Rehabilitation of Cognitive Function After Remission of the Symptoms of COVID-19,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04632719,0,0,0,0,0,0,Brazil,0,the use of the mentalplusâ® digital game for assessment/rehabilitation of cognitive function after remission of the symptoms of covid-19|the use of the mentalplusâ® digital game for assessment|rehabilitation of cognitive function after remission of the symptoms of covid-19,NA
NCT04632706,2020-09-22,2021-02-28,Interventional,Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19,Recruiting,Early Phase 1,MedinCell S.A,NA,https://clinicalzeros.gov/ct2/show/NCT04632706,0,0,0,0,0,0,United Kingdom,0,ivermectin|placebo,NA
NCT04632602,2020-04-04,2020-12-31,Interventional,Awake Prone Position to Reduce Ventilation Inhomogeneity in COVID-19 Acute Respiratory Failure,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04632602,0,0,0,0,0,0,France,0,physiological effects of awake prone position in covid 19 patients,NA
NCT04632368,2020-11-20,2021-04-30,Interventional,Targeting the Health Care Provider (HCP) Burnout Crisis During the COVID-19 Pandemic,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04632368,0,0,0,0,1,1,United States,0,transcendental meditation,NA
NCT04632082,2020-11-05,2021-07-13,Interventional,Telepsychoeducation for the Prevention of Emotional Distress in Professionals and Students From Essential Services in the Context of COVID-19,Enrolling by invitation,N/A,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04632082,0,0,0,0,1,0,Brazil,0,telepsychoeducation with personalized videos|telepsychoeducation without personalized videos,NA
NCT04631380,2020-08-01,2021-01-31,Interventional,Prayer in Commbate to Corona Virus - Covid -19,Recruiting,N/A,Hospital do Coracao,NA,https://clinicalzeros.gov/ct2/show/NCT04631380,0,0,0,0,0,0,Brazil,0,prayer,NA
NCT04630054,2020-11-15,2021-02-15,Interventional,Face Masks to Reduce COVID-19 in Bangladesh,Recruiting,N/A,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04630054,0,0,0,0,1,0,Bangladesh,0,face mask|face mask awareness,NA
NCT04629157,2020-11-05,2020-11-19,Interventional,The LAVA (Lateral Flow Antigen Validation and Applicability) Study for COVID-19,Recruiting,N/A,Alder Hey Children's NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04629157,0,0,0,0,0,0,United Kingdom,0,innova lateral flow device,NA
NCT04629105,2020-07-24,2021-08-31,Interventional,Regenerative Medicine for COVID-19 and Flu-Elicited ARDS Using Longeveron Mesenchymal Stem Cells (LMSCs) (RECOVER),Recruiting,Phase 1,Longeveron LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04629105,0,0,0,0,0,1,United States,0,longeveron mesenchymal stem cells (lmscs)|placebo,NA
NCT04625114,2020-11-04,2022-10-01,Interventional,The Potential of Oral Camostat in Early COVID-19 Disease in an Ambulatory Setting to Reduce Viral Load and Disease Burden,Recruiting,Phase 2,"University Hospital, Ghent",NA,https://clinicalzeros.gov/ct2/show/NCT04625114,0,0,0,0,0,0,Belgium,0,camostat|placebo,NA
NCT04623255,2020-10-16,2021-10-15,Interventional,Randomised Study of Plasma Exchange in Severe COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04623255,0,0,0,0,0,0,United Kingdom,0,octaplas,NA
NCT04622891,2020-04-01,2020-07-30,Interventional,Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04622891,0,0,0,0,0,0,Egypt,0,clarithromycin 500mg|azithromycin|placebo,NA
NCT04622865,2020-06-01,2021-06-30,Interventional,Masitinib Combined With Isoquercetin and Best Supportive Care in Hospitalized Patients With Moderate and Severe COVID-19,Recruiting,Phase 2,AB Science,NA,https://clinicalzeros.gov/ct2/show/NCT04622865,0,0,0,0,0,0,France,0,masitinib|isoquercetin|best supportive care,NA
NCT04622826,2020-05-15,2020-12-31,Interventional,plasmApuane CoV-2 : Efficacy and Safety of Immune Covid-19 Plasma in Covid-19 Pneumonia in Non ITU Patients,Recruiting,Phase 2,Azienda USL Toscana Nord Ovest,NA,https://clinicalzeros.gov/ct2/show/NCT04622826,0,0,0,0,0,0,Italy,0,immune plasma,NA
NCT04621903,2020-10-08,2020-10-27,Interventional,A Pilot Study on Efficacy and Safety of Ayurveda Combination in Patients With Mild-to-Moderate COVID-19,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04621903,0,0,0,0,1,0,United Kingdom,0,shanshamani vati plus,NA
NCT04621058,2020-11-09,2021-11-30,Interventional,Efficacy of Vitamin D Treatment in Mortality Reduction Due to COVID-19.,Recruiting,Phase 3,Bioaraba Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04621058,0,0,0,0,2,0,Spain,0,vitamin d|placebo,NA
NCT04621149,2020-11-15,2021-03-31,Interventional,An Outpatient Study Investigating Non-prescription Treatments for COVID-19,Recruiting,Phase 2,"Profact, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04621149,0,0,0,0,3,1,United States,0,"chlorine dioxide|zinc acetate|famotidine|placebo|lactoferrin, green tea extract",NA
NCT04620798,2020-09-14,2020-12-31,Interventional,Longitudinal COVID-19 Antibody Testing in Indiana University Undergraduate Students,"Active, not recruiting",N/A,Indiana University,NA,https://clinicalzeros.gov/ct2/show/NCT04620798,0,0,0,0,0,1,United States,0,immediate vs. delayed provision of antibody test results,NA
NCT04619290,2020-10-12,2020-11-30,Interventional,Outpatient Treatment With CoVid-19 With Prexablu,Recruiting,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,https://clinicalzeros.gov/ct2/show/NCT04619290,0,0,0,0,1,0,Mexico,0,sublingual methylene blue|control patients,NA
NCT04618042,2020-11-13,2021-07-31,Interventional,FX06 to Rescue Acute Respiratory Distress Syndrome During Covid-19 Pneumonia,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04618042,0,0,0,0,1,0,France,0,fx06|placebo of fx06,NA
NCT04617483,2020-10-31,2020-11-28,Interventional,"Study of the Commercial Scale SARS-CoV-2 Vaccine Against the Pilot Scale Among Adults, and Bridging Study of the Immunogenicity in Elderly Against That in Adults",Recruiting,Phase 3,"Sinovac Biotech Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04617483,0,0,0,1,0,0,China,0,"two doses of commercial scale inactivated sars-cov-2 vaccine at the schedule of day 0,14|two doses of pilot scale inactivated sars-cov-2 vaccine at the schedule of day 0,14|two doses of pilot scale inactivated sars-cov-2 vaccine at the schedule of day 0,14 in elderly",NA
NCT04616846,2020-08-04,2021-09-15,Interventional,Thromboembolic Risk Screening in Patients With Cancer and COVID-19,Recruiting,N/A,Centre Antoine Lacassagne,NA,https://clinicalzeros.gov/ct2/show/NCT04616846,0,0,0,0,0,0,France|Monaco,0,peripheral venous ultrasound,NA
NCT04615975,2020-11-01,2021-07-30,Interventional,Ketogenic Diet as Protective Factor During COVID-19,Recruiting,N/A,University of Padova,NA,https://clinicalzeros.gov/ct2/show/NCT04615975,0,0,0,0,0,0,Italy,0,ketogenic diet with phytoextracts,NA
NCT04615936,2020-07-10,2021-05-31,Interventional,Nasal Photodisinfection COVID Proof of Concept Study,Recruiting,N/A,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04615936,0,0,0,0,0,0,Canada,0,methylene-blue photodisinfection,NA
NCT04615416,2020-05-01,2021-01-31,Interventional,Emotion Regulation Training Via Telehealth During the COVID-19 Pandemic,Recruiting,N/A,"Teachers College, Columbia University",NA,https://clinicalzeros.gov/ct2/show/NCT04615416,0,0,0,0,0,1,United States,0,emotion regulation training via telehealth,NA
NCT04615052,2020-09-26,2021-10-31,Interventional,Home-based Exercise in COVID-19 Survivors,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04615052,0,0,0,0,1,0,Brazil,0,exercise training,NA
NCT04614883,2020-10-21,2021-10-31,Interventional,Analysis of Volatile Organic Compounds in Exhaled Air and in Sweat in the Context of Suspicion of COVID-19 Infection,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04614883,0,0,0,0,0,0,France,0,volatile organic compounds analysis|canine odor detection of volatile organic compounds,NA
NCT04614025,2020-11-30,2021-05-31,Interventional,Open-label Multicenter Study to Evaluate the Efficacy of PLX-PAD for the Treatment of COVID-19,Recruiting,Phase 2,Pluristem Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04614025,0,0,0,0,0,0,Germany|Israel,0,plx-pad,NA
NCT04614012,2020-07-02,2022-07-02,Interventional,Hyperimmune Plasma for Patients With COVID-19,Recruiting,N/A,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04614012,0,0,0,0,0,0,Italy,0,treated with hyperimmune plasma,NA
NCT04613310,2020-09-25,2020-12-31,Interventional,PCR and Rapid Diagnostic Test on Saliva and Nasopharyngeal Swabs for the Detection of SARS-CoV-2 (COVID-19),Recruiting,N/A,"Center for Primary Care and Public Health (Unisante), University of Lausanne, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04613310,0,0,0,0,1,0,Switzerland,0,rapid diagnostic test vs pcr,NA
NCT04613297,2020-10-19,2021-10-31,Interventional,HLA-G Immuno-Inhibitor Checkpoint Study in Patients With COVID-19 Infection: Molecular and Cellular Assessment,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04613297,0,0,0,0,0,0,France,0,baseline/during hospitalization blood samples|baseline blood sample|baseline|during hospitalization blood samples,NA
NCT04475575,2020-04-06,2020-06-30,Interventional,Can the Electronic Nose Smell COVID-19 Antibodies?,Completed,N/A,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04475575,0,0,0,0,0,0,Netherlands,0,aeonose,NA
NCT04611256,2020-08-01,2020-11-30,Interventional,Mesenchymal Stem Cells in Patients Diagnosed With COVID-19,Recruiting,Phase 1,Hospital Reg. Lic. Adolfo Lopez Mateos,NA,https://clinicalzeros.gov/ct2/show/NCT04611256,0,0,0,0,1,0,Mexico,0,msc|control,NA
NCT04610801,2020-08-08,2021-08-08,Interventional,Evaluation of the Efficacy of Xylitol Nasal Spray Against SARS-CoV-2,Recruiting,Phase 3,Larkin Community Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04610801,0,0,0,0,1,1,United States,0,nasal rinse,NA
NCT04609969,2020-10-13,2020-10-17,Interventional,Diagnostic Performance Evaluation of a Novel SARS-CoV-2 (COVID-19) Antigen Detection Test,Completed,N/A,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04609969,0,0,0,0,3,0,France,0,rt-qpcr test|covid-viroâ® test|covid-viroâ® test,NA
NCT04609722,2020-07-01,2021-02-01,Interventional,Effect of Solution-Focused Support Program on Anxiety Levels of Parents During the COVID-19 Pandemic,Recruiting,N/A,Adiyaman University Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04609722,0,0,0,0,2,0,Turkey,0,solution-focused support program,NA
NCT04609423,2020-11-10,2021-05-31,Interventional,Cod Liver Oil for Covid-19 Prevention Study,Recruiting,Phase 4,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04609423,0,0,0,0,3,0,Norway,0,cod liver oil|corn oil (placebo),NA
NCT04609371,2020-10-21,2021-03-01,Interventional,PanDirect: Self-care Tools and Telephone Coaching for Depression and Anxiety During Pandemics,Enrolling by invitation,N/A,"St. Mary's Research Center, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04609371,0,0,0,0,1,0,Canada,0,self-care tools|lay telephone coaching,NA
NCT04613050,2020-07-02,2021-12-24,Interventional,Effect of Respiratory Versus Aerobic Training on Respiratory and Immunity Efficiency in Recovered COVID- 19 Patients,Recruiting,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04613050,0,0,0,0,1,0,Egypt,0,respiratory training|aerobic training,NA
NCT04610567,2020-10-27,2021-03-15,Interventional,Treatment of Patients With Mild Coronavirus-19 (COVID-19) Disease With Methotrexate Associated to LDL Like Nanoparticles (Nano-COVID19),Recruiting,Phase 1/Phase 2,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04610567,0,0,0,0,2,0,Brazil,0,methotrexate-lde phase 1|methotrexate-lde phase 2|placebo-lde phase 2,NA
NCT04610541,2020-10-12,2021-10-30,Interventional,REMdesivir-HU Clinical Study and Severe Covid-19 Patients,"Active, not recruiting",Phase 3,University of Pecs,NA,https://clinicalzeros.gov/ct2/show/NCT04610541,0,0,0,0,1,0,Hungary,0,remdesivir-hu,NA
NCT04608201,2020-12-09,2021-12-31,Interventional,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Hospitalized Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04608201,0,0,0,0,2,0,France,0,nicotine 7 mg/ 24h transdermal patch - 24 hour|placebo of nicotine transdermal patch|nicotine 7 mg|24h transdermal patch - 24 hour,NA
NCT04607928,2020-08-01,2021-08-01,Interventional,Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19,Recruiting,Phase 2,Institut d'InvestigaciÃ³ BiomÃ¨dica de Bellvitge,NA,https://clinicalzeros.gov/ct2/show/NCT04607928,0,0,0,0,2,0,Spain,0,pirfenidone|placebo,NA
NCT04606563,2020-10-09,2021-06-30,Interventional,Host Response Mediators in Coronavirus (COVID-19) Infection - Is There a Protective Effect of Losartan on Outcomes of Coronavirus Infection?,Recruiting,Phase 3,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04606563,0,0,0,0,0,1,United States|Belgium|Canada|France|Japan|Spain,0,losartan,NA
NCT04605887,2021-01-18,2023-11-30,Interventional,Angiotensin 1-7 as a Therapy in the Treatment of COVID-19,Recruiting,Phase 2,Rambam Health Care Campus,NA,https://clinicalzeros.gov/ct2/show/NCT04605887,0,0,0,0,2,0,Israel,0,angiotensin,NA
NCT04475562,2020-04-06,2020-05-06,Interventional,Can the Electronic Nose Smell COVID-19?,Completed,N/A,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04475562,0,0,0,0,0,0,Netherlands,0,aeonose,NA
NCT04605588,2020-12-02,2021-04-30,Interventional,A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19,Recruiting,Phase 2,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04605588,0,0,0,0,3,1,United States,0,nitazoxanide|placebo nitazoxanide|ribavirin|placebo ribavirin|hydroxychloroquine|placebo hydroxychloroquine,NA
NCT04604327,2020-10-26,2021-05-31,Interventional,Comparison of Two Different Doses of Bemiparin in COVID-19,Recruiting,Phase 3,"Clinica Universidad de Navarra, Universidad de Navarra",NA,https://clinicalzeros.gov/ct2/show/NCT04604327,0,0,0,0,0,0,Spain,0,bemiparin sodium,NA
NCT04604977,2020-09-15,2021-10-31,Interventional,Feasibility and Effectiveness of Home-behavioral Program for Adolescents With Migraine,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04604977,0,0,0,0,0,0,Italy,0,mindfulness,NA
NCT04603794,2020-10-01,2020-11-30,Interventional,Efficacy of Mouthwash in Reducing Salivary Carriage of COVID-19,Recruiting,Phase 4,Ohio State University,NA,https://clinicalzeros.gov/ct2/show/NCT04603794,0,0,0,0,0,1,United States,0,0.12% chlorhexidine gluconate mouth rinse|0.5% povidone iodine|1% hydrogen peroxide|0.9% normal saline,NA
NCT04603729,2020-05-30,2020-06-30,Interventional,Comparison of Efficacy of Dexamethasone and Methylprednisolone in Moderate to Severe Covid 19 Disease,Completed,Phase 3,Fatima Memorial Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04603729,0,0,0,0,0,0,Pakistan,0,dexamethasone 2 mg/ml|methylprednisolone injection|dexamethasone 2 mg|methylprednisolone,NA
NCT04602507,2020-12-07,2021-03-31,Interventional,Ivermectin in Adults With Severe COVID-19.,Recruiting,Phase 2,CES University,NA,https://clinicalzeros.gov/ct2/show/NCT04602507,0,0,0,0,1,0,Colombia,0,ivermectin|placebo,NA
NCT04602442,2020-10-01,2021-08-01,Interventional,Safety and Efficiency of Method of Exosome Inhalation in COVID-19 Associated Pneumonia,Enrolling by invitation,Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,https://clinicalzeros.gov/ct2/show/NCT04602442,0,0,0,0,0,0,Russian Federation,0,exo 1 inhalation|exo 2 inhalation|placebo,NA
NCT04603963,2020-06-01,2020-10-10,Interventional,Inspiratory Muscle Training in Patients With COVID-19,Terminated,N/A,Hospital Israelita Albert Einstein,There was a change in the institutional flow reducing the cases of covid 19,https://clinicalzeros.gov/ct2/show/NCT04603963,0,0,0,0,1,0,Brazil,0,power breathe,NA
NCT04602832,2020-10-14,2020-12-31,Interventional,Enduring Happiness and Continued Self-Enhancement (ENHANCE) for COVID-19,Enrolling by invitation,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04602832,0,0,0,0,1,0,Canada,0,enduring happiness/continued self-enhancement (enhance) for covid-19|enduring happiness|continued self-enhancement (enhance) for covid-19,NA
NCT04602000,2020-09-25,2020-12-31,Interventional,To Evaluate the Safety and Efficacy of CT-P59 in Patients With Mild to Moderate Syptoms of Severe Acute Respiratory Syndrome COVID-19,Recruiting,Phase 2/Phase 3,Celltrion,NA,https://clinicalzeros.gov/ct2/show/NCT04602000,0,0,0,0,0,0,"Korea, Republic of",0,ct-p59/placebo|ct-p59|placebo,NA
NCT04601077,2020-11-01,2021-06-01,Interventional,The Evaluation of Nitric Oxide Generating Lozenges on Outcome in Newly Diagnosed COVID-19 Patient of African Americans,Recruiting,Phase 1/Phase 2,Nitric Oxide Innovations LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04601077,0,0,0,0,1,1,United States,0,"nitric oxide lozenges, 30 mg|placebo",NA
NCT04600999,2020-10-07,2021-06-30,Interventional,Clinical Trial of Favipiravir Treatment of Patients With COVID-19,Recruiting,Phase 3,University of Pecs,NA,https://clinicalzeros.gov/ct2/show/NCT04600999,0,0,0,0,0,0,Hungary,0,favipiravir,NA
NCT04600440,2020-04-25,2021-12-31,Interventional,Convalescent Plasma in the Treatment of Covid-19,Recruiting,N/A,Skane University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04600440,0,0,0,0,0,0,Sweden,0,convalescent plasma,NA
NCT04599959,2020-10-26,2021-01-20,Interventional,COVID-19 Tests: Nasopharyngeal Swab vs Saliva Collected With SalivetteÂ® Cortisol for Viral RNA Sampling for RT-qPCR,Completed,N/A,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04599959,0,0,0,0,2,0,Mexico,0,sampling of sars-cov-2 rna from nasopharyngeal swab specimen/saliva collected via salivette cortisol|sampling of sars-cov-2 rna from nasopharyngeal swab specimen|saliva collected via salivette cortisol,NA
NCT04596839,2020-09-04,2021-02-28,Interventional,Antiviral Activity and Safety of Remdesivir in Bangladeshi Patients With Severe Coronavirus Disease (COVID-19),Recruiting,N/A,Beximco Pharmaceuticals Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04596839,0,0,0,0,3,0,Bangladesh,0,remdesivir|standard care,NA
NCT04597047,2020-08-20,2022-10-31,Interventional,Research & Evaluation of LumiraDx SARS-CoV-2 (COVID-19) Point of Care Ab Test,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04597047,0,0,0,0,0,1,United States,0,capillary collection/testing|venous draw/testing|capillary collection|testing|venous draw,NA
NCT04597034,2020-10-02,2021-12-30,Interventional,Efficacy and Safety of a Highly Selective Semipermeable Membrane (AN-69 Oxiris) vs (Standard AN-69) in COVID-19,Recruiting,N/A,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04597034,0,0,0,0,0,0,Mexico,0,an69-oxiris|an69-standard,NA
NCT04594668,2020-04-24,2021-04-24,Interventional,Senicapoc in COVID-19 Patients With Severe Respiratory Insufficiency,Recruiting,Phase 2,University of Aarhus,NA,https://clinicalzeros.gov/ct2/show/NCT04594668,0,0,0,0,0,0,Denmark,0,senicapoc,NA
NCT04596085,2020-09-16,2020-11-30,Interventional,"Study to Evaluate Efficacy and Safety of ""VIRACIDE"" IN THE MANAGEMENT OF CORONA VIRUS DISEASE 2019 (COVID-19)",Recruiting,N/A,"The Herb, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04596085,0,0,0,0,4,0,India,0,investigational product - viracide|placebo,NA
NCT04594330,2020-06-01,2020-12-31,Interventional,Virgin Coconut Oil (VCO) as a Potential Adjuvant Therapy in COVID-19 Patients,Recruiting,Phase 2,Gadjah Mada University,NA,https://clinicalzeros.gov/ct2/show/NCT04594330,0,0,0,0,0,0,Indonesia,0,virgin coconut oil (vco)|placebo,NA
NCT04593641,2020-09-04,2020-10-22,Interventional,"This is a Phase 1 Study to Evaluate the Safety,Tolerability and Virology of CT P59 in Patients With Mild Symptoms of Symptoms of Coronavirus Disease (COVID-19)","Active, not recruiting",Phase 1,Celltrion,NA,https://clinicalzeros.gov/ct2/show/NCT04593641,0,0,0,0,0,0,"Korea, Republic of",0,ct-p59,NA
NCT04593069,2020-10-07,2021-02-28,Interventional,The COGCOV Study in ICU Patients,Recruiting,N/A,Ziekenhuis Oost-Limburg,NA,https://clinicalzeros.gov/ct2/show/NCT04593069,0,0,0,0,1,0,Belgium,0,neurocognitive assessment,NA
NCT04592549,2020-12-04,2021-09-30,Interventional,"This is a Phase 1 Clinical Trial to Evaluate the Safety, Pharmacokinetics, and Immunogenicity of ADM03820, a Monoclonal Antibody Cocktail Being Tested for the Treatment and Prevention of COVID-19",Recruiting,Phase 1,Ology Bioservices,NA,https://clinicalzeros.gov/ct2/show/NCT04592549,0,0,0,0,2,1,United States,0,adm03820|placebo,NA
NCT04591600,2020-07-01,2020-09-30,Interventional,Effectiveness of Ivermectin and Doxycycline on COVID-19 Patients,Completed,Phase 1/Phase 2,Alkarkh Health Directorate-Baghdad,NA,https://clinicalzeros.gov/ct2/show/NCT04591600,0,0,0,0,0,0,Iraq,0,ivermectin/doxycyline|standard care|ivermectin|doxycyline,NA
NCT04592354,2020-10-15,2021-04-15,Interventional,Anhydrous Enol-Oxaloacetate (AEO) on Improving Fatigue in Post-COVID-19 Survivors,Recruiting,N/A,Terra Biological LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04592354,0,0,0,0,0,1,United States,0,oxaloacetate medical food/dietary supplement|oxaloacetate medical food|dietary supplement,NA
NCT04591158,2020-09-15,2021-09-30,Interventional,COVID-19 and Lung Ultrasound Utility,Recruiting,N/A,Bridge to Health Medical and Dental USA,NA,https://clinicalzeros.gov/ct2/show/NCT04591158,0,0,0,0,0,0,Canada,0,butterfly iq,NA
NCT04590053,2020-10-20,2021-02-28,Interventional,"Allocetra-OTS in COVID-19, Phase II",Recruiting,Phase 2,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04590053,0,0,0,0,2,0,Israel,0,allocetra-ots,NA
NCT04589117,2020-05-27,2020-08-02,Interventional,Expressive Writing for COVID-19 Resilience for Parents,Completed,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04589117,0,0,0,0,0,1,United States,0,expressive writing,NA
NCT04589104,2020-05-26,2020-08-17,Interventional,Expressive Writing for COVID-19 Resilience,Completed,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04589104,0,0,0,0,0,1,United States,0,expressive writing,NA
NCT04589949,2020-10-12,2022-11-01,Interventional,Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study),Recruiting,Phase 3,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04589949,0,0,0,0,0,0,Netherlands,0,convp|ffp,NA
NCT04589936,2020-09-03,2021-06-30,Interventional,Prone Position to Improve Oxygenation in COVID-19 Patients Outside Critical Care,Recruiting,N/A,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04589936,0,0,0,0,0,0,United Kingdom,0,prone positioning,NA
NCT04587921,2020-06-22,2021-01-22,Interventional,Feasibility and Impact of Remote Oximetry in Patients Hospitalized With Covid-19,Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04587921,0,0,0,0,0,0,Brazil,0,digital oximeter monitoring,NA
NCT04587414,2019-03-06,2020-10-31,Interventional,eHealth Intervention on Physical Activity for Type 2 Diabetics - Frustrated by COVID-19,"Active, not recruiting",N/A,UKK Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04587414,0,0,0,0,0,0,Finland,0,telehealth/counselling|telehealth|standard care|counselling,NA
NCT04587219,2020-10-22,2021-03-30,Interventional,"The Study of ""Gam-COVID-Vac"" Vaccine Against COVID-19 With the Participation of Volunteers of 60 y.o and Older","Active, not recruiting",Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04587219,0,0,0,1,5,0,Russian Federation,0,gam-covid-vac,NA
NCT04584593,2020-10-02,2022-02-28,Interventional,Pilot Study to Detect SARS-CoV-2 Virus in Sperm,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04584593,0,0,0,0,2,0,France,0,sample,NA
NCT04584580,2020-08-01,2020-10-31,Interventional,D-dimer Adjusted Versus Therapeutic Dose Low-molecular-weight Heparin in Patients With COVID-19 Pneumonia,Recruiting,Phase 4,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04584580,0,0,0,0,0,0,Egypt,0,low-molecular-weight heparin,NA
NCT04583995,2020-09-28,2021-01-31,Interventional,"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom",Recruiting,Phase 3,Novavax,NA,https://clinicalzeros.gov/ct2/show/NCT04583995,0,0,0,1,2,0,United Kingdom,0,sars-cov-2 rs/matrix m1-adjuvant|placebo|licensed seasonal influenza vaccine|sars-cov-2 rs|matrix m1-adjuvant,NA
NCT04583449,2020-08-19,2020-12-01,Interventional,Mental Imagery to Increase Face Covering Use in UK-based Public Places During the COVID-19 Pandemic,Recruiting,N/A,University of East London,NA,https://clinicalzeros.gov/ct2/show/NCT04583449,0,0,0,0,0,0,United Kingdom,0,mental imagery,NA
NCT04583189,2020-10-01,2020-11-25,Interventional,Evaluation of the Performance of the Covid-19 Ag BSS Rapid Antigenic Test in Symptomatic Children in a Pediatric Emergency Department,Completed,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04583189,0,0,0,0,2,0,France,0,performance of the test antigenic/test rt-pcr|performance of the test antigenic|test rt-pcr,NA
NCT04429724,2020-07-06,2021-04-30,Interventional,Health Professional Exposure Assessment to Covid-19,"Active, not recruiting",N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04429724,0,0,0,0,2,0,France,0,diagnostic test covid-19,NA
NCT04582318,2020-11-08,2021-06-30,Interventional,"A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-19",Recruiting,Phase 1/Phase 2,"NGM Biopharmaceuticals, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04582318,0,0,0,0,1,0,Australia,0,ngm621|placebo,NA
NCT04582214,2020-09-28,2021-01-01,Interventional,Oscillation and Lung Expansion Therapy in Patients With COVID-19,Recruiting,N/A,Hill-Rom,NA,https://clinicalzeros.gov/ct2/show/NCT04582214,0,0,0,0,0,1,United States,0,metanebâ® system|metanebâ® system,NA
NCT04581811,2020-11-10,2021-05-31,Interventional,Prolonged Prone Positioning for COVID-19-induced Acute Respiratory Distress Syndrome (ARDS),Recruiting,N/A,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04581811,0,0,0,0,1,1,United States,0,prolonged proned positioning|traditional proning arm,NA
NCT04581746,2020-11-25,2021-12-31,Interventional,Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2),Recruiting,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04581746,0,0,0,0,1,0,France,0,questionnaire,NA
NCT04581291,2020-01-01,2020-06-01,Interventional,The Effect of Aerobic Exercise on Immune Biomarkers and Symptoms Severity and Progression in Patients With COVID-19: A Pilot Randomized Control Trial,Completed,N/A,Istanbul Gelisim University,NA,https://clinicalzeros.gov/ct2/show/NCT04581291,0,0,0,0,0,0,Turkey,0,moderate intensity aerobic exercises,NA
NCT04579640,2020-10-27,2021-06-30,Interventional,Trial of Vitamin D to Reduce Risk and Severity of COVID-19 and Other Acute Respiratory Infections,"Active, not recruiting",Phase 3,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04579640,0,0,0,0,2,0,United Kingdom,0,vitamin d,NA
NCT04581161,2020-08-28,2020-10-31,Interventional,Proportional Open Ventilation (POV) Device and Its Efficacy in Managing Acute Respiratory Failure in COVID-19 Patients,Recruiting,N/A,Hill-Rom,NA,https://clinicalzeros.gov/ct2/show/NCT04581161,0,0,0,0,0,1,United States,0,life2000â® ventilator|life2000â® ventilator,NA
NCT04581018,2020-08-13,2021-10-30,Interventional,An Evaluation of a Synbiotic Formula for Patients With COVID-19 Infection,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04581018,0,0,0,0,1,0,Hong Kong,0,health supplements,NA
NCT04579549,2020-09-29,2021-09-30,Interventional,Repeat Testing for SARS-CoV-2,Enrolling by invitation,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04579549,0,0,0,0,2,1,United States,0,saliva assay,NA
NCT04577235,2020-06-05,2020-08-05,Interventional,Correlation Between Thoracic Ultrasound and Thorax Computed Tomography Scores.,Completed,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04577235,0,0,0,0,0,0,Turkey,0,severity of lung involvement with covid-19.,NA
NCT04576312,2020-06-29,2020-12-31,Interventional,Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19,"Active, not recruiting",Phase 1,UNION therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04576312,0,0,0,0,1,0,Denmark,0,uni911 inhalation,NA
NCT04577534,2020-08-14,2021-12-31,Interventional,COVID-19: Salvage TOcilizumab as a Rescue Measure,Recruiting,Phase 3,Turku University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04577534,0,0,0,0,1,0,Finland,0,iv tocillizumab (tcz),NA
NCT04575610,2020-11-30,2021-03-31,Interventional,IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC),Recruiting,Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04575610,0,0,0,0,2,1,United States,0,pf-06650833|placebo,NA
NCT04425720,2020-09-01,2021-06-01,Interventional,Use of Remote Monitoring for COVID-19 Patient,Recruiting,N/A,Montefiore Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04425720,0,0,0,0,4,1,United States,0,lifesignals biosensor 1ax*|standard care,NA
NCT04575064,2020-06-29,2022-03-31,Interventional,An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY,"Active, not recruiting",Phase 2/Phase 3,"Klinikum Bremen-Mitte, gGmbH",NA,https://clinicalzeros.gov/ct2/show/NCT04575064,0,0,0,0,0,0,Germany,0,standard care|remdesivir,NA
NCT04574219,2020-11-03,2022-10-31,Interventional,Virtual Parental Presence on Induction,Recruiting,N/A,"Children's Hospital Medical Center, Cincinnati",NA,https://clinicalzeros.gov/ct2/show/NCT04574219,0,0,0,0,1,1,United States|Canada,0,use of facetime with child/parents during induction|use of facetime with child|parents during induction,NA
NCT04573361,2020-05-02,2020-05-27,Interventional,Access to Chiropractic Care During the COVID-19 Healthcare Emergency in Spain,Completed,N/A,Real Centro Universitario Maria Cristina,NA,https://clinicalzeros.gov/ct2/show/NCT04573361,0,0,0,0,0,0,Spain,0,chiropractic care (one visit)|chiropractic care (more than one visit),NA
NCT04573322,2020-09-10,2021-11-14,Interventional,Safety and Efficacy of Trans Sodium Crocetinate (TSC) in SARS-CoV-2 (COVID-19) Infected Subjects,Recruiting,Phase 1/Phase 2,Diffusion Pharmaceuticals Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04573322,0,0,0,0,0,0,Romania,0,trans sodium crocetinate|saline,NA
NCT04573270,2020-04-24,2020-08-20,Interventional,Mesenchymal Stem Cells for the Treatment of COVID-19,Completed,Phase 1,Thomas Advanced Medical LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04573270,0,0,0,0,0,1,United States,0,primepro|placebo,NA
NCT04570462,2020-05-18,2020-12-31,Interventional,Mild Hypothermia for COVID-19 ARDS,Recruiting,N/A,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04570462,0,0,0,0,0,1,United States,0,hypothermia via cooling machine- arctic sun 5000,NA
NCT04572399,2020-10-30,2020-12-28,Interventional,UVA Light Device to Treat COVID-19,Completed,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04572399,0,0,0,0,3,1,United States,0,uv light treatment,NA
NCT04573153,2020-09-21,2021-01-31,Interventional,Metabolic Cofactor Supplementation and Hydroxychloroquine Combination in Covid-19 Patients,Recruiting,Phase 2/Phase 3,ScandiBio Therapeutics AB,NA,https://clinicalzeros.gov/ct2/show/NCT04573153,0,0,0,0,1,0,Turkey,0,hydroxychloroquine / metabolic cofactor supplementation|hydroxychloroquine / sorbitol|hydroxychloroquine|metabolic cofactor supplementation|sorbitol,NA
NCT04572412,2020-11-25,2021-04-30,Interventional,Low Dose Lung Radiotherapy to Treat COVID-19 Pneumonia,Recruiting,N/A,Lancashire Teaching Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04572412,0,0,0,0,2,0,United Kingdom,0,radiotherapy,NA
NCT04570397,2020-12-18,2021-05-31,Interventional,Ravulizumab and COVID-19,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04570397,0,0,0,0,1,1,United States,0,ravulizumab,NA
NCT04570254,2020-08-19,2020-10-15,Interventional,Antioxidants as Adjuvant Therapy to Standard Therapy in Patients With COVID-19,"Active, not recruiting",N/A,Unidad Temporal COVID-19 en Centro Citibanamex,NA,https://clinicalzeros.gov/ct2/show/NCT04570254,0,0,0,0,1,0,Mexico,0,vitamin c|vitamin e|melatonin|n-acetyl cysteine|pentoxifylline,NA
NCT04568876,2020-10-23,2021-11-30,Interventional,Micronized and Ultramicronized Palmitoylethanolamide in COVID-19 Patients,Recruiting,Phase 4,Epitech Group SpA,NA,https://clinicalzeros.gov/ct2/show/NCT04568876,0,0,0,0,2,0,Italy,0,"micronized/ultra-micronized palmitoylethanolamide (mpea/umpea, 300mg / 600mg) oral suspension|standard care|micronized|ultra-micronized palmitoylethanolamide (mpea|umpea, 300mg|600mg) oral suspension",NA
NCT04569877,2020-09-24,2022-12-25,Interventional,GM-CSF Inhalation to Prevent ARDS in COVID-19 Pneumonia,Recruiting,Phase 2,University of Giessen,NA,https://clinicalzeros.gov/ct2/show/NCT04569877,0,0,0,0,1,0,Germany,0,molgramostim nebuliser solution|placebo,NA
NCT04569383,2020-10-05,2021-05-31,Interventional,"Safety, Tolerability and Immunogenicity of the Candidate Vaccine MVA-SARS-2-S Against COVID-19",Recruiting,Phase 1,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04569383,0,0,0,1,1,0,Germany,0,mva-sars-2-s vaccinations (days 0/28)|mva-sars-2-s vaccinations (days 0|28),NA
NCT04569266,2020-08-07,2021-11-07,Interventional,Effectiveness of an Exercise Re-training Program on Dyspnea in Patients After Acute Respiratory Distress Syndrome Secondary to Severe COVID-19 Pneumonia in Post-ICU,Recruiting,N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04569266,0,0,0,0,0,0,France,0,specific exercise rehabilitation treatment,NA
NCT04568564,2020-10-01,2021-05-01,Interventional,Telerehabilitation in Lung Surgery Patients,Recruiting,N/A,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04568564,0,0,0,0,2,0,Turkey,0,"breathing exercise, intensive spirometry use, supported cough, progressive mobilisation/ambulation|exercise booklet|breathing exercise, intensive spirometry use, supported cough, progressive mobilisation|ambulation",NA
NCT04567953,2020-07-28,2021-01-30,Interventional,COVID-19 Tests With Saliva Specimens,"Active, not recruiting",N/A,Paradigm Laboratories LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04567953,0,0,0,0,0,1,United States,0,saliva,NA
NCT04567810,2020-09-18,2020-12-14,Interventional,"Safety, Tolerability, and Pharmacokinetics of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Chicken Egg Antibody (IgY) (COVID-19)",Completed,Phase 1,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04567810,0,0,0,0,2,0,Australia,0,anti-sars-cov-2 igy|placebo,NA
NCT04567173,2020-09-21,2021-06-30,Interventional,Convalescent Plasma as Adjunctive Therapy for Hospitalized Patients With COVID-19,Recruiting,Phase 2/Phase 3,University of the Philippines,NA,https://clinicalzeros.gov/ct2/show/NCT04567173,0,0,0,0,1,0,Philippines,0,convalescent plasma,NA
NCT04564716,2020-09-28,2021-03-28,Interventional,"Clinical Trial of Efficacy, Safety, and Immunogenicity of Gam-COVID-Vac Vaccine Against COVID-19 in Belarus","Active, not recruiting",Phase 3,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04564716,0,0,0,1,3,0,Belarus,0,gam-covid-vac|placebo,NA
NCT04565509,2020-11-20,2022-06-30,Interventional,Supporting the Health and Well-being of Children With Intellectual and Developmental Disability During COVID-19 Pandemic,Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04565509,0,0,0,0,1,1,United States,0,general communication message|focused/targeted message|best message alone|best message / augmented message/implementation strategy|focused|targeted message|best message|augmented message|implementation strategy,NA
NCT04565197,2020-05-01,2020-12-30,Interventional,Convalescent Plasma Therapy for COVID-19 Patients,"Active, not recruiting",Early Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04565197,0,0,0,0,1,0,Pakistan,0,convalescent plasma,NA
NCT04566770,2020-09-24,2021-08-21,Interventional,A Clinical Trial of A COVID-19 Vaccine Named Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector),Recruiting,Phase 2,CanSino Biologics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04566770,0,0,0,1,1,0,China,0,adenovirus type 5 vector|recombinant novel coronavirus vaccine (adenovirus type 5 vector) -placebo,NA
NCT04425707,2020-06-09,2020-07-01,Interventional,Ivermectin In Treatment of COVID 19 Patients,Recruiting,N/A,"Ministry of Health and Population, Egypt",NA,https://clinicalzeros.gov/ct2/show/NCT04425707,0,0,0,0,0,0,Egypt,0,ivermectin,NA
NCT04563208,2020-12-09,2021-02-28,Interventional,Study of Oral Administration of Ribavirin and Nitazoxamide Versus Placebo in COVID-19,Recruiting,Phase 2,"University of Witwatersrand, South Africa",NA,https://clinicalzeros.gov/ct2/show/NCT04563208,0,0,0,0,3,0,South Africa,0,placebo|duact,NA
NCT04563689,2020-06-18,2020-10-22,Interventional,Pilot Study to Evaluate Effect of CHX0.12/CPC 0.05 of SARS-CoV-2 Viral Load in COVID-19 Patients,Completed,N/A,Dentaid SL,NA,https://clinicalzeros.gov/ct2/show/NCT04563689,0,0,0,0,1,0,Colombia,0,chx0.12/cpc0.05 oral rinse (perioaidactive control)|placebo|chx0.12|cpc0.05 oral rinse (perioaidactive control),NA
NCT04563676,2020-09-22,2021-03-31,Interventional,Physiopathology and Sequelae of COVID-19 Infection,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04563676,0,0,0,0,0,0,France,0,blood test,NA
NCT04563650,2020-09-18,2021-05-31,Interventional,COVID-19 Serology and Immunosenescence,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04563650,0,0,0,0,0,0,France,0,blood sample,NA
NCT04561219,2020-04-19,2020-10-02,Interventional,Nitazoxanide Therapy for Patients With COVID-19 Pneumonia,Completed,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04561219,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04561154,2020-06-11,2021-06-11,Interventional,Identifying Functional and Psycho-social Complaints After Hospitalization for SARS-CoV-2 Infection( COVID 19)- REPERCOV,Recruiting,N/A,Centre Hospitalier le Mans,NA,https://clinicalzeros.gov/ct2/show/NCT04561154,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04561063,2020-12-08,2021-07-31,Interventional,COVID-19 Prophylaxis South Africa (COVER HCW),Recruiting,Phase 2,"University of Witwatersrand, South Africa",NA,https://clinicalzeros.gov/ct2/show/NCT04561063,0,0,0,0,2,0,South Africa,0,nitazoxanide|sofosbuvir/daclatasvir|sofosbuvir|daclatasvir,NA
NCT04560881,2020-09-16,2021-12-01,Interventional,"Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)","Active, not recruiting",Phase 3,Laboratorio Elea Phoenix S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04560881,0,0,0,1,2,0,Argentina,0,inactivated sars-cov-2 vaccine|placebo/aluminum adjuvant of inactivated sars-cov-2 vaccine|placebo|aluminum adjuvant of inactivated sars-cov-2 vaccine,NA
NCT04560257,2020-05-01,2020-12-30,Interventional,High Flow Nasal Cannula HFNC In Covid-19 Patients,Recruiting,N/A,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560257,0,0,0,0,3,0,Pakistan,0,high flow nasal cannula,NA
NCT04560231,2020-06-01,2020-11-30,Interventional,Remdesivir in COVID-19 Lahore General Hospital,Recruiting,Early Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560231,0,0,0,0,1,0,Pakistan,0,remdesivir,NA
NCT04560205,2020-05-01,2020-12-30,Interventional,Tocilizumab in COVID-19 Lahore General Hospital,Recruiting,Phase 1,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04560205,0,0,0,0,1,0,Pakistan,0,tocilizumab,NA
NCT04559113,2020-05-01,2020-12-30,Interventional,Methylprednisolone in COVID-19 Patients (Methyl19LGH),Recruiting,N/A,Lahore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04559113,0,0,0,0,1,0,Pakistan,0,methylprednisolone injectable product,NA
NCT04559074,2020-10-23,2021-04-30,Interventional,Personalised Electronic Record Supported Optimisation When Alone for Patients With Hypertension- Pilot Study for Remote Medical Management of Hypertension During the COVID-19 Pandemic,Recruiting,Phase 4,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04559074,0,0,0,0,2,0,United Kingdom,0,amlodipine,NA
NCT04558411,2020-09-12,2020-12-15,Interventional,"Pilot Study of a Brief, Scaleable Intervention for Coronavirus (COVID-19) Mental Health Sequelae in College Students",Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04558411,0,0,0,0,0,1,United States,0,dialectical behavioral therapy (dbt) skills,NA
NCT04558372,2020-04-01,2020-12-12,Interventional,Genosvid Diagnostic Test for Early Detection of COVID-19,Completed,N/A,Gadjah Mada University,NA,https://clinicalzeros.gov/ct2/show/NCT04558372,0,0,0,0,3,0,Indonesia,0,exhaled breath sampling,NA
NCT04558463,2020-04-16,2020-09-30,Interventional,The Effectivity and Safety of Favipiravir Compared to Oseltamivir as Adjuvant Therapy for COVID-19,Recruiting,Phase 3,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04558463,0,0,0,0,0,0,Indonesia,0,favipiravir|oseltamivir 75mg,NA
NCT04558021,2020-10-08,2021-01-30,Interventional,A Study To Evaluate The Efficacy And Safety Of a Novel Niclosamide Suspension Formulation For COVID-19,Recruiting,Phase 3,Imuneks Farma ilac San. Tic. A.S.,NA,https://clinicalzeros.gov/ct2/show/NCT04558021,0,0,0,0,1,0,Turkey,0,niclosamide suspension|placebo,NA
NCT04554992,2020-03-20,2022-06-30,Interventional,Convalescent Plasma for the Treatment of COVID-19 (Coronavirus Disease 2019),"Active, not recruiting",Phase 1,The Methodist Hospital System,NA,https://clinicalzeros.gov/ct2/show/NCT04554992,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04554264,2020-09-01,2021-09-30,Interventional,Complicated Grief in ICU in the Aftermath of COVID-19,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04554264,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04555148,2020-09-20,2020-12-30,Interventional,COVIDIG (COVID-19 Hyper-ImmunoGlobulin),Recruiting,Phase 2,Green Cross Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04555148,0,0,0,0,0,0,"Korea, Republic of",0,gc5131|placebo,NA
NCT04553705,2020-09-20,2020-11-04,Interventional,"Omega-3, Nigella Sativa, Indian Costus, Quinine, Anise Seed, Deglycyrrhizinated Licorice, Artemisinin, Febrifugine on Immunity of Patients With (COVID-19)",Recruiting,Phase 2/Phase 3,Beni-Suef University,NA,https://clinicalzeros.gov/ct2/show/NCT04553705,0,0,0,0,1,0,Saudi Arabia,0,omega 3/nigella sativa oil|omega 3/nigella sativa oil/indian costus|omega 3/nigella sativa oil/quinine pills|omega 3/nigella sativa oil/anise seed capsule|omega 3/nigella sativa oil/deglycyrrhizinated licorice|active comparator|omega-3|nigella sativa oil|indian costus|quinine|anise|deglycyrrhizinated licorice,NA
NCT04551547,2020-10-31,2021-02-28,Interventional,Safety and Immunogenicity Study of Inactivated Vaccine for Prevention of COVID-19,Recruiting,Phase 1/Phase 2,"Sinovac Biotech Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04551547,0,0,0,1,2,0,China,0,"two doses of low dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|two doses of medium dosage inactivated sars-cov-2 vaccine at the schedule of day 0,28|placebo",NA
NCT04552951,2020-04-04,2020-09-14,Interventional,Effect of Vitamin D on Morbidity and Mortality of the COVID-19,Recruiting,Phase 4,FundaciÃ³n para la InvestigaciÃ³n Biosanitaria del Principado de Asturias,NA,https://clinicalzeros.gov/ct2/show/NCT04552951,0,0,0,0,0,0,Spain,0,cholecalciferol,NA
NCT04552483,2020-06-08,2020-08-20,Interventional,Effects of Early Use of Nitazoxanide in Patients With COVID-19,Completed,Phase 2,Universidade Federal do Rio de Janeiro,NA,https://clinicalzeros.gov/ct2/show/NCT04552483,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04552379,2020-12-01,2021-04-30,Interventional,The Containing Coronavirus Disease 19 (COVID-19) Trial,Recruiting,Phase 3,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04552379,0,0,0,0,1,0,Chile,0,peginterferon beta-1a,NA
NCT04552366,2020-09-29,2020-12-31,Interventional,A Clinical Trial of a Recombinant Adenovirus 5 Vectored COVID-19 Vaccine (Ad5-nCoV) With Two Doses in Healthy Adults,"Active, not recruiting",Phase 1,"Institute of Biotechnology, Academy of Military Medical Sciences, PLA of China",NA,https://clinicalzeros.gov/ct2/show/NCT04552366,0,0,0,1,2,0,China,0,ad5-ncov,NA
NCT04551781,2020-04-01,2020-07-30,Interventional,Short Term Low Dose Corticosteroids for Management of Post covid19 Pulmonary Fibrosis,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04551781,0,0,0,0,0,0,Egypt,0,prednisone|control,NA
NCT04550325,2020-08-05,2020-11-26,Interventional,"Safety, PK and PD of Kamada Anti-SARS-CoV-2 in COVID-19",Completed,Phase 1/Phase 2,"Kamada, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04550325,0,0,0,0,1,0,Israel,0,kamada anti-sars-cov-2,NA
NCT04550351,2020-08-19,2020-12-18,Interventional,Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (â‰¥60 Years Old),"Active, not recruiting",Phase 1,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04550351,0,0,0,1,3,0,China,0,biological/vaccine: recombinant new coronavirus vaccine (cho cell) low-dose group|biological/vaccine: recombinant new coronavirus vaccine (cho cells) high-dose group|biological/vaccine: recombinant new coronavirus vaccine (cho cells) placebo group|biological|vaccine: recombinant new coronavirus vaccine (cho cell) low-dose group|vaccine: recombinant new coronavirus vaccine (cho cells) high-dose group|placebo,NA
NCT04549337,2020-09-25,2021-05-01,Interventional,Feasibility and Safety of High-intensity Exercise Training in Patients Surviving COVID-19,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04549337,0,0,0,0,2,0,Denmark,0,exercise training,NA
NCT04548544,2019-10-18,2020-05-20,Interventional,A Randomized Controlled Feasibility Study of Emotional Well-being of Adolescents Undergoing a Mindfulness Training During COVID-19,Completed,N/A,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04548544,0,0,0,0,0,1,United States,0,"training for awareness, resilience,/action (tara)|training for awareness, resilience,|action (tara)",NA
NCT04548531,2020-09-10,2021-04-30,Interventional,Engaging Patients in Colon Cancer Screening Decisions During COVID-19,Enrolling by invitation,N/A,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04548531,0,0,0,0,1,1,United States,0,shared decision making,NA
NCT04547634,2020-07-01,2020-11-30,Interventional,Telerehabilitation in Oncology Patients,Enrolling by invitation,N/A,University of Malaga,NA,https://clinicalzeros.gov/ct2/show/NCT04547634,0,0,0,0,0,0,Spain,0,therapeutic exercise/education|therapeutic exercise|education,NA
NCT04546841,2020-11-27,2021-09-30,Interventional,Safety and Immunogenicity Trial of Multi-peptide Vaccination to Prevent COVID-19 Infection in Adults,Recruiting,Phase 1,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04546841,0,0,0,1,1,0,Germany,0,multipeptide cocktail,NA
NCT04547283,2020-06-14,2020-09-20,Interventional,Awake-Prone Positioning Strategy for Hypoxic Patients With COVID-19,Recruiting,N/A,Atrium Health,NA,https://clinicalzeros.gov/ct2/show/NCT04547283,0,0,0,0,0,1,United States,0,standard care|apps,NA
NCT04546737,2020-09-08,2021-07-31,Interventional,"Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients",Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04546737,0,0,0,0,1,0,France,0,magnetic resonance spectroscopy (mrs).,NA
NCT04545541,2020-11-01,2022-04-30,Interventional,Nebulised Heparin in Patients With Severe COVID-19,Recruiting,Phase 2/Phase 3,Australian National University,NA,https://clinicalzeros.gov/ct2/show/NCT04545541,0,0,0,0,2,1,United States,0,nebulised unfractionated heparin (ufh),NA
NCT04543760,2020-10-01,2021-03-31,Interventional,Effect of Prone Positioning Combined With High Flow Oxygen Therapy on Oxygenation During Acute Respiratory Failure Due to COVID-19,Recruiting,N/A,"Hospital St. Joseph, Marseille, France",NA,https://clinicalzeros.gov/ct2/show/NCT04543760,0,0,0,0,2,0,France,0,prone positioning|supine position,NA
NCT04542967,2020-06-23,2020-09-02,Interventional,Study on the Safety and Efficacy of Convalescent Plasma in Patients With Severe COVID-19 Disease,Recruiting,Phase 2,Hospital Central Militar,NA,https://clinicalzeros.gov/ct2/show/NCT04542967,0,0,0,0,1,0,Mexico,0,biological,NA
NCT04542941,2020-06-16,2020-12-31,Interventional,Assessment of Safety and Efficacy of CCP,Completed,N/A,Makerere University,NA,https://clinicalzeros.gov/ct2/show/NCT04542941,0,0,0,0,1,0,Uganda,0,convalescent plasma,NA
NCT04542694,2020-05-21,2020-08-10,Interventional,Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,Completed,Phase 3,"Promomed, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04542694,0,0,0,0,3,0,Russian Federation,1,favipiravir|standard care,NA
NCT04542876,2020-05-01,2020-07-31,Interventional,Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04542876,0,0,0,0,0,0,India,0,guduchi ghan vati,NA
NCT04542421,2020-07-01,2021-07-01,Interventional,Lung Ultrasound Implementation in the Management of Patients Hospitalized With COVID-19,Recruiting,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04542421,0,0,0,0,1,1,United States,0,lung ultrasound use in patients hospitalized with covid,NA
NCT04542408,2020-11-12,2021-05-31,Interventional,Hamburg Edoxaban for Anticoagulation in COVID-19 Study,Recruiting,Phase 3,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04542408,0,0,0,0,2,0,Germany,0,anticoagulation agents (edoxaban and/or high dose lmwh)|low dose low molecular weight heparin/placebo|anticoagulation agents (edoxaban and|or high dose lmwh)|low dose low molecular weight heparin|placebo,NA
NCT04542343,2020-11-01,2021-09-30,Interventional,COVID-19 Risk Reduction Among African American Parishioners,Recruiting,N/A,Charles Drew University of Medicine and Science,NA,https://clinicalzeros.gov/ct2/show/NCT04542343,0,0,0,0,1,1,United States,0,"change in knowledge, motivation, skills, resources",NA
NCT04542447,2020-09-01,2020-09-30,Interventional,To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.,Recruiting,Phase 1,Natureceuticals Sdn Bhd,NA,https://clinicalzeros.gov/ct2/show/NCT04542447,0,0,0,0,1,0,India,0,nuvastatic,NA
NCT04542330,2020-09-15,2022-01-31,Interventional,Using BCG to Protect Senior Citizens During the COVID-19 Pandemic,Recruiting,Phase 3,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04542330,0,0,0,1,2,0,Denmark,0,bcg-denmark|saline,NA
NCT04540939,2020-10-19,2021-12-31,Interventional,Neural Mechanisms of Mindfulness-based Cognitive Therapy (MBCT) for Posttraumatic Stress Disorder (PTSD) - COVID Related Substudy,Recruiting,N/A,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04540939,0,0,0,0,2,1,United States,0,mindfulness-based cognitive therapy|muscle relaxation therapy,NA
NCT04540185,2020-11-01,2022-11-01,Interventional,A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19,Enrolling by invitation,Phase 3,"NeuroActiva, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04540185,0,0,0,1,1,1,United States|New Zealand,0,oral polio vaccine|placebo|na-831|polio vaccine/na-831|polio vaccine,NA
NCT04539275,2020-11-16,2022-06-20,Interventional,COVID-19 (VA CURES-1),Recruiting,Phase 3,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04539275,0,0,0,0,6,1,United States,0,convalescent plasma|masked saline placebo,NA
NCT04537962,2020-06-11,2020-09-30,Interventional,"Evaluationof the Load of SARS-CoV-2 Virus in Oral Cavity, Oropharinge and Saliva of Patients With Covid-19 After Disinfection With Oral Antimicrobial Solutions: a Pilot Study",Enrolling by invitation,N/A,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04537962,0,0,0,0,0,0,Brazil,0,colgate periogard mouthwash|colgate peroxyl mouthwash|colgate total mouthwash|placebo,NA
NCT04537351,2020-08-24,2021-03-31,Interventional,The MEseNchymal coviD-19 Trial: a Pilot Study to Investigate Early Efficacy of MSCs in Adults With COVID-19,Recruiting,Phase 1/Phase 2,Cynata Therapeutics Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04537351,0,0,0,0,2,0,Australia,0,cyp-001,NA
NCT04537663,2020-08-25,2020-11-30,Interventional,Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults,Recruiting,Phase 4,UMC Utrecht,NA,https://clinicalzeros.gov/ct2/show/NCT04537663,0,0,0,1,0,0,Netherlands,0,bacille calmette-guã©rin (bcg)|placebo|bacille calmette-guã©rin (bcg),NA
NCT04536441,2020-04-01,2020-05-30,Interventional,Ultra-brief Online Mindfulness-based Intervention During COVID-19 Movement Control Order,Completed,N/A,Universiti Tunku Abdul Rahman,NA,https://clinicalzeros.gov/ct2/show/NCT04536441,0,0,0,0,0,0,Malaysia,0,ultra brief online mindfulness-based intervention|control,NA
NCT04536051,2020-06-02,2021-09-30,Interventional,A Study of a Candidate COVID-19 Vaccine (COV003),Recruiting,Phase 3,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04536051,0,0,0,1,2,0,Brazil,0,chadox1 ncov-19 single dose / paracetamol|menacwy single dose / paracetamol|chadox1 ncov-19 two dose / paracetamol|menacwy prime/saline placebo boost / paracetamol|chadox1 ncov-19 single dose|paracetamol|menacwy single dose|chadox1 ncov-19 two dose|menacwy prime|saline placebo boost,NA
NCT04535856,2020-11-14,2021-01-14,Interventional,Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients,Completed,Phase 1,Ina-Respond,NA,https://clinicalzeros.gov/ct2/show/NCT04535856,0,0,0,0,6,0,Indonesia,0,allogeneic mesenchymal stem cell|placebo,NA
NCT04535791,2020-07-15,2021-05-31,Interventional,Efficacy of Vitamin D Supplementation to Prevent the Risk of Acquiring COVID-19 in Healthcare Workers,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04535791,0,0,0,0,0,0,Mexico,0,cholecalciferol,NA
NCT04535700,2020-09-18,2021-03-10,Interventional,Clinical Trial of Pioglitazone Treatment in Patients With Type 2 Diabetes Mellitus and Covid-19,Recruiting,Phase 4,Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04535700,0,0,0,0,1,0,Spain,0,pioglitazone 30 mg|standard care,NA
NCT04535063,2020-04-18,2020-12-30,Interventional,Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia,Recruiting,Phase 3,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicalzeros.gov/ct2/show/NCT04535063,0,0,0,0,1,0,Argentina,0,convalescent plasma,NA
NCT04534725,2020-12-17,2021-12-31,Interventional,COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;,Recruiting,Phase 3,"Peter MacCallum Cancer Centre, Australia",NA,https://clinicalzeros.gov/ct2/show/NCT04534725,0,0,0,0,4,0,Australia,0,interferon alfa|selinexor|lenzilumab,NA
NCT04534673,2020-08-05,2021-12-31,Interventional,Pegylated Interferon Lambda for Treatment of COVID-19 Infection,Recruiting,Phase 2,Soroka University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04534673,0,0,0,0,0,0,Israel,0,lambda 180 mcg s.c,NA
NCT04532931,2020-09-03,2021-06-30,Interventional,COVID-19 Treatment in South Africa,Recruiting,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04532931,0,0,0,0,4,0,South Africa,0,standard care|artesunate-amodiaquine|pyronaridine-artesunate|favipiravir/nitazoxanide|sofosbuvir/daclatasvir|favipiravir|nitazoxanide|sofosbuvir|daclatasvir,NA
NCT04532294,2020-09-08,2021-02-19,Interventional,"Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants",Recruiting,Phase 1,BeiGene,NA,https://clinicalzeros.gov/ct2/show/NCT04532294,0,0,0,0,4,0,Australia,0,bgb dxp593|placebo,NA
NCT04531774,2020-08-28,2021-06-01,Interventional,RECHARGE: A Brief Psychological Intervention to Build Resilience in Healthcare Workers During COVID-19,Recruiting,N/A,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04531774,0,0,0,0,2,0,Switzerland,0,recharge|self study,NA
NCT04531618,2020-08-13,2021-12-31,Interventional,Mother-infant Bonding During COVID-19,Recruiting,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04531618,0,0,0,0,1,1,United States,0,family nurture intervention (fni),NA
NCT04530604,2020-10-01,2021-10-01,Interventional,Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS),Recruiting,Phase 1,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04530604,0,0,0,0,1,1,United States,0,defibrotide,NA
NCT04530578,2020-06-01,2020-10-30,Interventional,Nebulized Heparin in Severe Acute Respiratory Syndrome COVID-19,Recruiting,Phase 4,"Clinica San Camilo, Argentina",NA,https://clinicalzeros.gov/ct2/show/NCT04530578,0,0,0,0,1,0,Argentina,0,heparin|enoxaparin,NA
NCT04530422,2020-04-15,2020-07-08,Interventional,Efficacy of Sofosbuvir Plus Ledipasvir in Egyptian Patients With COVID-19 Compared to Standard Treatment,Completed,Phase 3,Almaza Military Fever Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04530422,0,0,0,0,0,0,Egypt,0,sofosbuvir/ledipasvir|sofosbuvir|ledipasvir,NA
NCT04530370,2020-05-29,2020-09-30,Interventional,Efficacy and Safety of Recovered Covid 19 Plasma Transfusion to Covid 19 Severly Ill Patients,Recruiting,Early Phase 1,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04530370,0,0,0,0,0,0,Egypt,0,convalescent plasma,NA
NCT04530136,2020-11-30,2021-08-15,Interventional,Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19,Recruiting,Phase 2,Pharming Technologies B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04530136,0,0,0,0,2,1,United States,0,ruconest,NA
NCT04394208,2020-08-16,2021-01-30,Interventional,Silymarin in COVID-19 Pneumonia,Recruiting,Phase 3,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04394208,0,0,0,0,3,0,Egypt,0,silymarin|placebo,NA
NCT04527562,2020-07-14,2020-11-15,Interventional,Colchicine in Moderate Symptomatic COVID-19 Patients,Completed,N/A,Dhaka Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04527562,0,0,0,0,2,0,Bangladesh,0,colchicine|placebo,NA
NCT04527614,2020-09-24,2021-05-30,Interventional,Influence of Prior Infection With COVID-19 on Occurrence of Influenza-like Illness or Acute Respiratory Infection,Enrolling by invitation,N/A,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04527614,0,0,0,0,1,0,Belgium,0,qrt-pcr/serology|qrt-pcr|serology test,NA
NCT04527133,2020-06-11,2020-08-11,Interventional,An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19,"Active, not recruiting",N/A,Aviron LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04527133,0,0,0,0,0,0,Russian Federation,0,aprotinin,NA
NCT04527081,2020-08-31,2020-11-09,Interventional,Study of COVID-19 DNA Vaccine (AG0302-COVID19),"Active, not recruiting",Phase 1/Phase 2,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04527081,0,0,0,1,4,0,Japan,0,ag0302-covid19,NA
NCT04526990,2020-09-15,2021-12-30,Interventional,Phase III Trial of A COVID-19 Vaccine of Adenovirus Vector in Adults 18 Years Old and Above,Recruiting,Phase 3,CanSino Biologics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04526990,0,0,0,1,11,0,Mexico|Argentina|Chile|Pakistan|Russian Federation,0,adenovirus type 5 vector|placebo,NA
NCT04526054,2020-09-03,2021-09-03,Interventional,Morphological Abnormalities of the Olfactory Bulb on MRI and Olfactometry in Anosmic Versus Normosmic COVID-19 Patients,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04526054,0,0,0,0,1,0,France,0,ent exam|olfactometry|brain mri,NA
NCT04525742,2020-07-05,2020-08-30,Interventional,COVID-19 Pandemic and Parents of Disabled Children,Completed,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04525742,0,0,0,0,1,0,Turkey,0,difficulties lived by disabled children's parents in the period of covid-19 pandemic,NA
NCT04525378,2020-07-01,2020-09-30,Interventional,MSC-based Therapy in COVID-19-associated Acute Respiratory Distress Syndrome,Recruiting,Phase 1,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04525378,0,0,0,0,1,0,Brazil,0,mesenchymal stromal cell-based therapy,NA
NCT04524507,2020-08-27,2021-05-31,Interventional,COVID-19 Antibody Plasma Research Study in Hospitalized Patients,Recruiting,Phase 2,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04524507,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04523571,2020-07-28,2020-09-30,Interventional,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy Subjects,"Active, not recruiting",Phase 1,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04523571,0,0,0,1,2,0,China,0,bnt162b1|placebo,NA
NCT04523831,2020-06-01,2020-08-22,Interventional,Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection,Completed,Phase 3,Dhaka Medical College,NA,https://clinicalzeros.gov/ct2/show/NCT04523831,0,0,0,0,5,0,Bangladesh,1,ivermectin/doxycycline|standard care|ivermectin|doxycycline,NA
NCT04522128,2020-05-22,2022-03-31,Interventional,Does Quality of Life Decline During the COVID-19 Pandemic and Can we Change Behaviour to Improve Poor Quality of Life?,Recruiting,N/A,University of Manchester,NA,https://clinicalzeros.gov/ct2/show/NCT04522128,0,0,0,0,0,0,United Kingdom,0,behaviour change technique intervention to improve quality of life,NA
NCT04522466,2020-04-03,2020-05-28,Interventional,Evaluation of the Pharmacokinetics and Pharmacodynamics of Hydroxychloroquine in COVID-19 Intensive Care Unit Patients,Terminated,Phase 3,Centre Hospitalier Universitaire de Saint Etienne,Stop of the study by competent authority (ANSM),https://clinicalzeros.gov/ct2/show/NCT04522466,0,0,0,0,1,0,France,0,hydroxychloroquine,NA
NCT04522089,2020-08-24,2020-11-20,Interventional,A Study to Evaluate the Safety and Immunogenicity of COVID-19 (AdimrSC-2f) Vaccine,Recruiting,Phase 1,Adimmune Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04522089,0,0,0,1,3,0,Taiwan,0,adimrsc-2f,NA
NCT04521322,2020-07-24,2020-10-30,Interventional,Efficacy of a Nasal Spray Containing Iota-Carrageenan in the Prophylaxis of COVID-19 Disease in Health Personnel Dedicated to Patients Care With COVID-19 Disease,Recruiting,Phase 4,Centro de EducaciÃ³n Medica e Investigaciones ClÃ­nicas Norberto Quirno,NA,https://clinicalzeros.gov/ct2/show/NCT04521322,0,0,0,0,1,0,Argentina,0,iota-carrageenan,NA
NCT04519320,2020-05-18,2021-08-18,Interventional,Medium and Long Term Follow-up of COVID-19 Infected Patients: Research and Characterization of Pulmonary Sequelae,Recruiting,N/A,Centre Hospitalier Universitaire de Besancon,NA,https://clinicalzeros.gov/ct2/show/NCT04519320,0,0,0,0,1,0,France,0,pulmonary function testing,NA
NCT04519437,2020-07-26,2021-10-25,Interventional,"Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19","Active, not recruiting",Phase 1,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04519437,0,0,0,0,3,1,United States,0,regn10933 / regn10987|placebo|regn10933|regn10987,NA
NCT04519385,2020-03-01,2020-07-01,Interventional,Toclizumam Versus Dexamethasone in Severe Covid-19 Cases,Completed,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04519385,0,0,0,0,1,0,Egypt,0,tocilizumab|dexamethasone,NA
NCT04519216,2020-07-31,2021-06-30,Interventional,Breastfeeding Education in the Time of COVID-19,Recruiting,N/A,"University of California, Davis",NA,https://clinicalzeros.gov/ct2/show/NCT04519216,0,0,0,0,0,1,United States,0,telesimulation,NA
NCT04518969,2020-05-03,2020-12-01,Interventional,Determination of the Hemoadsorption Impact as Adjunctive Treatment Upon the Support Therapy of COVID-19,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04518969,0,0,0,0,0,0,Belgium,0,cytosorb,NA
NCT04518514,2020-04-20,2020-10-31,Interventional,Telemedical Risk Assessment and Preoperative Evaluation (TAPE),Recruiting,N/A,RWTH Aachen University,NA,https://clinicalzeros.gov/ct2/show/NCT04518514,0,0,0,0,0,0,Germany,0,tape-software,NA
NCT04516564,2020-09-30,2021-03-31,Interventional,"A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy Subjects",Recruiting,Phase 1,Akeso,NA,https://clinicalzeros.gov/ct2/show/NCT04516564,0,0,0,0,2,0,New Zealand,0,ak119|placebo,NA
NCT04517123,2020-09-01,2021-12-31,Interventional,"Prone Position and Respiratory Outcomes in Non-Intubated COVID-19 PatiEnts The ""PRONE"" Study",Recruiting,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04517123,0,0,0,0,2,1,United States,0,prone positioning,NA
NCT04516954,2020-08-01,2020-11-30,Interventional,Convalescent Plasma for COVID-19 Patients,Enrolling by invitation,Early Phase 1,Vinmec Research Institute of Stem Cell and Gene Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04516954,0,0,0,0,2,0,Vietnam,0,convalescent plasma,NA
NCT04516915,2020-06-15,2021-05-31,Interventional,IMU-838 and Oseltamivir in the Treatment of COVID-19,Recruiting,Phase 2,University Hospitals Coventry and Warwickshire NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04516915,0,0,0,0,1,0,United Kingdom,0,imu-838|oseltamivir,NA
NCT04516837,2020-08-31,2021-08-31,Interventional,Eltrombopag Plus rhTPO Versus Eltrombopag for ITP During the COVID-19 Pandemic (ELABORATE-19),Recruiting,Phase 2,Peking University People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04516837,0,0,0,0,2,0,China,0,eltrombopag|rhtpo,NA
NCT04515147,2020-09-28,2021-11-09,Interventional,"A Dose-Confirmation Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults for COVID-19","Active, not recruiting",Phase 2,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04515147,0,0,0,1,8,0,Panama|Peru,0,cvncov 6 î¼g|cvncov 12 î¼g|hepatitis a vaccine|pneumococcal vaccine|cvncov 12î¼g|cvncov 6 î¼g|cvncov 12 î¼g|cvncov 12î¼g,NA
NCT04514627,2020-07-13,2021-07-31,Interventional,Neuromodulation With Percutaneous Electrical Nerve Field Stimulation for Adults With COVID-19,Recruiting,N/A,Olive View-UCLA Education & Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04514627,0,0,0,0,1,1,United States,0,auricular percutaneous neurostimulation,NA
NCT04513990,2020-04-09,2021-04-30,Interventional,Novel Point-of-Care Diagnostic Test for SARS-CoV-2 (COVID-19),Recruiting,N/A,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04513990,0,0,0,0,1,1,United States,0,biospecimen collection|biospeciman collection|questionnaire,NA
NCT04513470,2020-08-01,2021-01-31,Interventional,Allocetra-OTS in COVID-19,"Active, not recruiting",Phase 1,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04513470,0,0,0,0,1,0,Israel,0,allocetra-ots,NA
NCT04513184,2020-07-14,2021-03-30,Interventional,Randomized Clinical Trial of Intranasal Dexamethasone as an Adjuvant in Patients With COVID-19,Recruiting,Phase 2,Universidad Nacional Autonoma de Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04513184,0,0,0,0,3,0,Mexico,0,dexamethasone,NA
NCT04513158,2020-08-14,2021-08-01,Interventional,Convalescent Plasma in the Early Treatment of High-Risk Patients With SARS-CoV-2 (COVID-19) Infection,Recruiting,Phase 2,Norton Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04513158,0,0,0,0,2,1,United States,0,convalescent plasma,NA
NCT04512027,2020-09-15,2020-09-19,Interventional,Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support.,Completed,N/A,Composite Interceptive Med Science,NA,https://clinicalzeros.gov/ct2/show/NCT04512027,0,0,0,0,3,0,India,0,prolectin-m; a (1-6)-alpha-d-mannopyranose class|standard care,NA
NCT04511650,2020-10-21,2021-02-28,Interventional,"A Study to Evaluate the Safety and Efficacy of Razuprotafib, a Novel Tie 2 Activator, in Hospitalized Subjects With Moderate to Severe Coronavirus Disease 2019 (COVID-19)",Recruiting,Phase 2,Aerpio Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04511650,0,0,0,0,7,1,United States,0,razuprotafib subcutaneous solution|placebo,NA
NCT04508439,2020-06-20,2020-08-30,Interventional,Effect of the Use of Anticoagulant Therapy During Hospitalization and Discharge in Patients With COVID-19 Infection,Recruiting,N/A,Hospital Regional de Alta especialidad de Ixtapaluca,NA,https://clinicalzeros.gov/ct2/show/NCT04508439,0,0,0,0,0,0,Mexico,0,enoxaparin,NA
NCT04510662,2020-08-31,2021-03-31,Interventional,Telmisartan in Respiratory Failure Due to COVID-19,Recruiting,Phase 2,Hospital Regional de Alta Especialidad de Zumpango,NA,https://clinicalzeros.gov/ct2/show/NCT04510662,0,0,0,0,0,0,Mexico,0,telmisartan,NA
NCT04510493,2020-10-23,2023-09-30,Interventional,Canakinumab in Patients With COVID-19 and Type 2 Diabetes,Recruiting,Phase 3,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04510493,0,0,0,0,4,0,Switzerland,0,canakinumab|placebo,NA
NCT04509999,2020-10-26,2022-09-30,Interventional,Bicalutamide to Block TMPRSS2 in Males With COVID-19 Infection,Recruiting,Phase 3,University of Florida,NA,https://clinicalzeros.gov/ct2/show/NCT04509999,0,0,0,0,5,1,United States,0,bicalutamide 150 mg oral tablet|placebo,NA
NCT04508868,2020-08-31,2020-12-23,Interventional,Treatment of Depressive Symptoms in Older Individuals in Isolation During Covid-19,Terminated,N/A,Uppsala University,"Study terminated due to changes in government restrictions. Collected data to be presented as a
    pilot study.",https://clinicalzeros.gov/ct2/show/NCT04508868,0,0,0,0,2,0,Sweden,0,behavioral|minimal attention control intervention,NA
NCT04505592,2020-09-25,2021-06-30,Interventional,Tenecteplase in Patients With COVID-19,Recruiting,Phase 2,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04505592,0,0,0,0,3,1,United States,0,tenecteplase|placebo,NA
NCT04504877,2020-06-16,2020-11-16,Interventional,Burnout and Distress preventiOn With caNnabidiol in Front-line Health Care workerS deAling wIth COVID-19,"Active, not recruiting",Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04504877,0,0,0,0,3,0,Brazil,0,cannabidiol,NA
NCT04502472,2020-06-06,2021-12-31,Interventional,Open-label Treatment of Severe Coronavirus Disease 2019 (COVID-19) With Convalescent Plasma,Recruiting,Phase 2/Phase 3,Inova Health Care Services,NA,https://clinicalzeros.gov/ct2/show/NCT04502472,0,0,0,0,0,1,United States,0,convalescent plasma,NA
NCT04502667,2020-07-15,2021-02-28,Interventional,Efficacy of Vitamin D Treatment in Pediatric Patients Hospitalized by COVID-19,Recruiting,Phase 3,"CoordinaciÃ³n de InvestigaciÃ³n en Salud, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04502667,0,0,0,0,0,0,Mexico,0,cholecalciferol,NA
NCT04502433,2021-01-06,2021-07-31,Interventional,Poractant Alfa - Curosurf and SARS-COV-19 ARDS (Covid-19),Recruiting,Phase 2,Chiesi Farmaceutici S.p.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04502433,0,0,0,0,1,0,United Kingdom,0,curosurfâ® (poractant alfa)|curosurfâ® (poractant alfa),NA
NCT04502342,2020-06-01,2020-08-30,Interventional,"Add on to Azythromycine, Phytomedicine and/or Antimalarial Drug vs Hydroxychloroquine in Uncomplicated COVID-19 Patients",Enrolling by invitation,Phase 2,Institute for Research and Development of Medicinal and Food Plants of Guinea,NA,https://clinicalzeros.gov/ct2/show/NCT04502342,0,0,0,0,1,0,Guinea,0,hydroxychloroquine / azithromycin|cospherunate/azythromycine|cospherunate/phytomedicine/azythromycien|hydroxychloroquine|azithromycin|cospherunate|phytomedicine,NA
NCT04502056,2020-07-31,2020-09-21,Interventional,Covid-19 Messaging to Underserved Communities - 2nd Experiment,"Active, not recruiting",N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04502056,0,0,0,0,1,1,United States,0,acknowledgement racial injustice ama|african american sender acknowledgement|african american sender in informational videos.|racial inequality highlighted|ama acknowledgement drug pricing|white sender in acknowledgement|white sender in informational videos|no racial inequality highlighting|placebo videos,NA
NCT04500132,2020-05-28,2021-08-31,Interventional,To Evaluate Safety and Efficacy of EC-18 in COVID-19 Infection to Pneumonia,Recruiting,Phase 2,Enzychem Lifesciences Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04500132,0,0,0,0,1,0,"Korea, Republic of",0,ec-18|placebo,NA
NCT04501783,2020-05-20,2020-07-29,Interventional,Study of Efficacy and Safety of TL-FVP-t vs. SOC in Patients With Mild to Moderate COVID-19,"Active, not recruiting",Phase 3,R-Pharm,NA,https://clinicalzeros.gov/ct2/show/NCT04501783,0,0,0,0,0,0,Russian Federation,0,favipiravir|standard care,NA
NCT04501445,2020-09-14,2021-08-01,Interventional,Psychological Symptoms and Families of COVID-19 Patients,Recruiting,N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04501445,0,0,0,0,2,1,United States,0,written summary of rounds,NA
NCT04500418,2020-08-25,2021-09-30,Interventional,CharitÃ© Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients,Recruiting,Phase 2,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04500418,0,0,0,0,2,0,Germany,0,cenicriviroc|placebo,NA
NCT04500366,2020-08-26,2021-04-30,Interventional,GERAS Frailty Rehabilitation at Home During COVID-19,Recruiting,N/A,McMaster University,NA,https://clinicalzeros.gov/ct2/show/NCT04500366,0,0,0,0,1,0,Canada,0,socialization|virtual group exercise|nutrition consult/protein supplementation|medication review|nutrition consult|protein supplementation,NA
NCT04500067,2020-05-07,2020-09-15,Interventional,"Intravenous Immunoglobulin (IVIG, Bioven) Efficacy Assess for COVID-19 / SARS-CoV-2 Severe Pneumonia Complex Treatment",Completed,Phase 3,Biopharma Plasma LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04500067,0,0,0,0,1,0,Ukraine,0,ivig,NA
NCT04499391,2020-12-04,2022-07-31,Interventional,COVID-19 Project ECHO in Nursing Homes,Recruiting,N/A,Milton S. Hershey Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04499391,0,0,0,0,3,1,United States,0,project echo,NA
NCT04499313,2020-08-02,2020-11-15,Interventional,Dexamethasone Vs Methylprednisolone for the Treatment of Patients With ARDS Caused by COVID-19,Recruiting,Phase 3,Chattogram General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04499313,0,0,0,0,4,0,Bangladesh,0,dexamethasone|methylprednisolone,NA
NCT04497948,2020-09-21,2020-11-18,Interventional,Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19,Terminated,Phase 1,Acerta Pharma BV,"Data from the CALAVI Phase II trials for Acalabrutinib in patients hospitalized with COVID-19
    did not meet their primary efficacy endpoints.

    Based on this higher management made the decision to prematurely terminate the D822FC00005 PK
    study.",https://clinicalzeros.gov/ct2/show/NCT04497948,0,0,0,0,2,1,Brazil|United States,0,acalabrutinib,NA
NCT04498936,2020-07-15,2020-10-30,Interventional,Sofosbuvir/Ledipasvir and Nitazoxanide for Treatment of COVID-19,Completed,Phase 4,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04498936,0,0,0,0,1,0,Egypt,0,sofosbuvir/ledipasvir|nitazoxanide|sofosbuvir|ledipasvir,NA
NCT04497649,2020-07-01,2021-04-01,Interventional,Sofosbuvir Containing Regimens in Treatment of COVID 19 Patients,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04497649,0,0,0,0,2,0,Egypt,0,sofosbuvir|daclatasvir,NA
NCT04497415,2020-10-21,2020-11-30,Interventional,The COVID-19 and Healthcare Workers: An Active Intervention,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04497415,0,0,0,0,4,1,United States,0,video-based intervention,NA
NCT04497623,2020-07-28,2020-08-13,Interventional,"Clinical Evaluation of Ventilador Innovation Product in Colombia in the SARS COVID 19 Pandemic, Unisabana Herons.",Completed,N/A,FundaciÃ³n Neumologica Colombiana,NA,https://clinicalzeros.gov/ct2/show/NCT04497623,0,0,0,0,1,0,Colombia,0,invasive mechanical ventilation using the unisabana-herons ventilator during 24 hours,NA
NCT04497272,2020-08-07,2021-08-07,Interventional,Assesment of the Metabolomic Signature in COVID-19 Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04497272,0,0,0,0,1,0,France,0,covid-19 patients,NA
NCT04497454,2020-05-08,2021-07-01,Interventional,Mechanical Ventilation Strategy for Coronavirus Disease 2019 (COVID-19),Recruiting,N/A,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04497454,0,0,0,0,0,0,Brazil,0,eit-group|ardsnet,NA
NCT04495842,2020-10-01,2021-03-31,Interventional,The Effect of Aromatherapy on COVID-19-induced Anxiety,Recruiting,N/A,Franklin School of Integrative Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04495842,0,0,0,0,1,1,United States,0,essential oil blend|control blend,NA
NCT04495543,2020-12-01,2021-08-31,Interventional,Mitigating Suicide Risk With Single Session 'Brief Skills for Safer Living',Recruiting,N/A,"St. Michael's Hospital, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04495543,0,0,0,0,1,0,Canada,0,brief skills for safer living,NA
NCT04494399,2020-07-29,2022-07-01,Interventional,IFN Beta-1b and Ribavirin for Covid-19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04494399,0,0,0,0,0,0,Hong Kong,0,interferon|ribavirin,NA
NCT04494867,2020-08-19,2020-12-31,Interventional,Core Warming in COVID-19 Patients Undergoing Mechanical Ventilation,Recruiting,N/A,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04494867,0,0,0,0,3,1,United States,0,core warming|standard care,NA
NCT04493359,2020-07-25,2022-02-14,Interventional,Switch of Renin-Angiotensin System Inhibitors in Patients With Covid-19,Recruiting,Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04493359,0,0,0,0,1,0,Brazil,0,renin-angiotensin system inhibitors,NA
NCT04494204,2020-08-07,2020-12-01,Interventional,Effect of a Combination of Treatment of Reginmune Capsule and Immunofree Tablets in the Treatment of Mild to Moderate COVID-19 Patients,Completed,Phase 2/Phase 3,Nutrin GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04494204,0,0,0,0,4,0,India,0,immunofree tablets/reginmune capsule|immunofree tablets|reginmune,NA
NCT04491994,2020-04-10,2020-05-31,Interventional,Clearing the Fog: Is Hydroxychloroquine Effective in Reducing COVID-19 Progression,Completed,Phase 3,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04491994,0,0,0,0,1,0,Pakistan,1,hydroxychloroquine,NA
NCT04492228,2020-09-01,2020-12-31,Interventional,Eucaloric Ketogenic Diet in COVID-19 Cytokine Storm Syndrome,Recruiting,N/A,Ospedale Policlinico San Martino,NA,https://clinicalzeros.gov/ct2/show/NCT04492228,0,0,0,0,1,0,Italy,0,ketogenic diet,NA
NCT04492891,2020-11-23,2025-11-23,Interventional,Cyclosporine For The Treatment Of COVID-19(+),Recruiting,Phase 2,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04492891,0,0,0,0,1,1,United States,0,cyclosporine|standard care,NA
NCT04492527,2020-07-28,2021-06-30,Interventional,Student-delivered Telehealth Program for COVID-19 Education and Health Promotion,Recruiting,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04492527,0,0,0,0,1,0,Canada,0,telehealth,NA
NCT04492501,2020-04-01,2020-07-20,Interventional,Investigational Treatments for COVID-19 in Tertiary Care Hospital of Pakistan,Completed,N/A,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04492501,0,0,0,0,0,0,Pakistan,0,therapeutic plasma exchange (tpe)|convalescent plasma|tocilizumab|remdesivir|mesenchymal stem cells,NA
NCT04492358,2020-10-22,2021-10-31,Interventional,"Treatment for Moderate/Severe COVID-19 in a Fragile and Vulnerable Population, Admitted to a Geriatric Hospital Unit or in a Transicional Care Center",Recruiting,Phase 2/Phase 3,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04492358,0,0,0,0,1,0,Spain,0,colchicine|prednisone tablet|standard care,NA
NCT04491240,2020-07-20,2020-10-01,Interventional,Evaluation of Safety and Efficiency of Method of Exosome Inhalation in SARS-CoV-2 Associated Pneumonia.,Completed,Phase 1/Phase 2,"State-Financed Health Facility ""Samara Regional Medical Center Dinasty""",NA,https://clinicalzeros.gov/ct2/show/NCT04491240,0,0,0,0,4,0,Russian Federation,1,exo 1 inhalation|exo 2 inhalation|placebo,NA
NCT04490278,2020-09-29,2021-07-30,Interventional,CoV-PICS: A Virtual Post-ICU Clinic,Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04490278,0,0,0,0,3,1,United States,0,medical record review - inpatient treatment|online questionnaires,NA
NCT04490850,2020-07-15,2021-07-15,Interventional,COVID-19 Seroprevalence Study in French Guiana,Recruiting,N/A,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04490850,0,0,0,0,0,0,French Guiana,0,blood sample,NA
NCT04490473,2020-07-24,2021-03-24,Interventional,Turkish of the SARS-CoV-2 Anxiety Scale,Recruiting,N/A,Eskisehir Osmangazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04490473,0,0,0,0,1,0,Turkey,0,survey,NA
NCT04487886,2020-11-18,2022-02-28,Interventional,Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19),Recruiting,Phase 2,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04487886,0,0,0,0,2,1,United States,0,duvelisib|placebo,NA
NCT04487444,2020-09-10,2021-03-31,Interventional,Thymalfasin (Thymosin Alpha 1) to Treat COVID-19 Infection,Recruiting,Phase 2,Rhode Island Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04487444,0,0,0,0,3,1,United States,0,thymalfasin,NA
NCT04487171,2020-07-21,2021-07-31,Interventional,Screening for Postpartum Depression and Associated Risk Factors Among Women Who Deliver in Four Hospital in France During the COVID-19 Epidemic,Recruiting,N/A,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04487171,0,0,0,0,0,0,France,0,questionnaire,NA
NCT04487639,2020-07-10,2021-07-31,Interventional,Presence of SARS-CoV-2 in Semen: Impact on Fertility Preservation in Male Oncological Patients ?,Recruiting,N/A,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04487639,0,0,0,0,0,0,France,0,"sars-cov-2 research in nasopharyngeal swab, sperm/serologics|sars-cov-2 research in nasopharyngeal swab, sperm|serology test",NA
NCT04487574,2020-07-25,2020-10-29,Interventional,A Study to Assess the Efficacy and Safety of XC221 in Patients With COVID-19,Completed,Phase 3,RSV Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04487574,0,0,0,0,2,0,Russian Federation,0,xc221|placebo,NA
NCT04485169,2020-04-01,2020-07-31,Interventional,Therapeutic Plasma Exchange for Coronavirus Disease-2019 Triggered Cytokine Release Storm;,Completed,N/A,UNICEF,NA,https://clinicalzeros.gov/ct2/show/NCT04485169,0,0,0,0,1,0,Pakistan,0,therapeutic plasma exchange (tpe),NA
NCT04485429,2020-07-20,2020-12-31,Interventional,Efficacy Assessment of Methylprednisolone and Heparin in Patients With COVID-19 Pneumonia,Recruiting,Phase 3,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04485429,0,0,0,0,0,0,Brazil,0,methylprednisolone|heparin,NA
NCT04483960,2020-07-28,2021-12-31,Interventional,Australasian COVID-19 Trial (ASCOT) ADAptive Platform Trial,Recruiting,Phase 3,University of Melbourne,NA,https://clinicalzeros.gov/ct2/show/NCT04483960,0,0,0,0,2,0,Australia,0,nafamostat mesilate|convalescent plasma|enoxaparin|dalteparin|tinzaparin|aspirin,NA
NCT04483752,2020-06-08,2021-02-08,Interventional,Predicting the Progression to Chronic Fibrosis of Lung Lesions Related to Covid-19 Infection From Chest CT Images,Recruiting,N/A,Centre Chirurgical Marie Lannelongue,NA,https://clinicalzeros.gov/ct2/show/NCT04483752,0,0,0,0,0,0,France,0,chest ct,NA
NCT04484207,2020-07-06,2020-10-20,Interventional,Addressing COVID-19 Mental Health Problems Among US Veterans,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04484207,0,0,0,0,2,1,United States,0,a short video intervention|a vignette intervention,NA
NCT04483830,2020-06-05,2020-08-06,Interventional,Suloexide in the Treatment of Early Stages of COVID-19,Completed,Phase 2/Phase 3,Clinedem,NA,https://clinicalzeros.gov/ct2/show/NCT04483830,0,0,0,0,2,0,Mexico,0,sulodexide|placebo,NA
NCT04482686,2020-12-09,2021-05-31,Interventional,Trial of Combination Therapy to Treat COVID-19 Infection,Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04482686,0,0,0,0,6,1,United States,0,ivermectin|doxycycline hcl|zinc|vitamin d|vitamin c,NA
NCT04483271,2020-10-02,2020-12-15,Interventional,The Effect of Omega-3 on Selected Cytokines Involved in Cytokine Storm,Enrolling by invitation,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04483271,0,0,0,0,1,0,Jordan,0,300 mg of omega3-fa,NA
NCT04482673,2020-07-31,2021-12-31,Interventional,Vitamin D Supplementation in the Prevention and Mitigation of COVID-19 Infection,Recruiting,Phase 4,Medical University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04482673,0,0,0,0,1,1,United States,0,vitamin d|placebo,NA
NCT04482621,2020-09-14,2021-05-31,Interventional,Decitabine for Coronavirus (COVID-19) Pneumonia- Acute Respiratory Distress Syndrome (ARDS) Treatment: DART Trial,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04482621,0,0,0,0,2,1,United States,0,decitabine|placebo,NA
NCT04482595,2020-11-11,2021-08-31,Interventional,BIO 300 Oral Suspension in Discharged COVID-19 Patients,Recruiting,Phase 2,Humanetics Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04482595,0,0,0,0,3,1,United States,0,bio 300 oral suspension|placebo,NA
NCT04482387,2020-07-24,2021-07-01,Interventional,DigiVis: Self-testing Vision App for Telephone Consultations,Recruiting,N/A,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04482387,0,0,0,0,1,0,United Kingdom,0,digivis visual acuity app,NA
NCT04480957,2020-08-04,2020-12-31,Interventional,Ascending Dose Study of Investigational SARS-CoV-2 Vaccine ARCT-021 in Healthy Adult Subjects,Recruiting,Phase 1/Phase 2,"Arcturus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04480957,0,0,0,1,1,0,Singapore,0,arct-021 dose 1|arct-021 dose 2|arct-021 dose 3|arct-021 dose 4|arct-021 dose regimen 1|arct-021 dose regimen 2|placebo,NA
NCT04481633,2020-09-09,2021-09-30,Interventional,Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04481633,0,0,0,0,2,0,France,0,covid 19 serology|covid 19 self-questionnaire,NA
NCT04480112,2020-06-02,2021-05-31,Interventional,Impact of Covid-19 on Frequent Social Interaction Through Communication Technologies in the Cognitive Status of Socially-isolated Older Adults,Enrolling by invitation,N/A,Boston University,NA,https://clinicalzeros.gov/ct2/show/NCT04480112,0,0,0,0,3,1,United States,0,technology based social interactions|no research related technology based social interactions,NA
NCT04479540,2020-05-26,2021-05-26,Interventional,Assessment of the Risk of Pulmonary Embolism and Coagulation Profile in Patients With COVID-19 Lung Disease,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04479540,0,0,0,0,1,0,France,0,angiography scanner,NA
NCT04479358,2020-09-10,2020-12-01,Interventional,Low-dose Tocilizumab Versus Standard of Care in Hospitalized Patients With COVID-19,Recruiting,Phase 2,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04479358,0,0,0,0,1,1,United States,0,tocilizumab|standard care,NA
NCT04478539,2020-06-01,2021-06-01,Interventional,Extracorporeal Blood Purification as a Treatment Modality for COVID-19,Recruiting,N/A,Zan Mitrev Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04478539,0,0,0,0,0,0,North Macedonia,0,extracorporeal blood purification using the oxirisâ® (an69st) hemofilter|extracorporeal blood purification using the oxirisâ® (an69st) hemofilter,NA
NCT04477954,2020-07-06,2020-11-06,Interventional,Hyperbaric Oxygen as an Adjuvant Treatment for Patients With Covid-19 Severe Hypoxemia,Terminated,Phase 2,AsociaciÃ³n Argentina de Medicina HiperbÃ¡rica e InvestigaciÃ³n,"Investigators and Ethic Committee endorsed early suspension of the protocol because of
    superiority and safety. For the interim analysys, the statistical methodology presented by
    Pocock was followed.",https://clinicalzeros.gov/ct2/show/NCT04477954,0,0,0,0,2,0,Argentina,0,oxygen,NA
NCT04478071,2020-08-22,2022-08-01,Interventional,Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,"The University of Texas Health Science Center, Houston",NA,https://clinicalzeros.gov/ct2/show/NCT04478071,0,0,0,0,1,1,United States,0,vadadustat|placebo,NA
NCT04476888,2020-04-26,2020-09-15,Interventional,Convalescent Plasma Treatment in COVID-19,Completed,N/A,Aga Khan University,NA,https://clinicalzeros.gov/ct2/show/NCT04476888,0,0,0,0,2,0,Pakistan,0,convalescent plasma|drugs/supportive care|drugs|supportive care,NA
NCT04477083,2020-07-15,2020-08-15,Interventional,"Development and Validation of ""Ready-to-Use"" Inhalable Forms of Hydroxychloroquine for Treatment of COVID-19","Active, not recruiting",N/A,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04477083,0,0,0,0,0,0,Egypt,0,hydroxychloroquine|supportive/symptomatic treatment|supportive care|symptomatic treatment,NA
NCT04476745,2020-10-05,2020-12-15,Interventional,The Effect of D3 on Selected Cytokines Involved in Cytokine Storm in the Covid-19 Uninfected Jordanian People,Enrolling by invitation,N/A,Applied Science Private University,NA,https://clinicalzeros.gov/ct2/show/NCT04476745,0,0,0,0,2,0,Jordan,0,vitamin d,NA
NCT04475588,2020-05-01,2020-07-08,Interventional,Efficacy and Safety of Itolizumab in COVID-19 Complications,Completed,Phase 2,Biocon Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04475588,0,0,0,0,0,0,India,0,itolizumab|best supportive care|antibiotics|hydroxychloroquine / oxygen,NA
NCT04475120,2020-04-15,2020-07-02,Interventional,Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients,Completed,Phase 2/Phase 3,University of Rome Tor Vergata,NA,https://clinicalzeros.gov/ct2/show/NCT04475120,0,0,0,0,0,0,Italy,0,liposomal,NA
NCT04474340,2020-05-21,2020-09-30,Interventional,COVID-19 Convalescent Plasma Treatment in SARS-CoV-2 Infected Patients,Recruiting,Phase 1,"Ministry of Health, Kuwait",NA,https://clinicalzeros.gov/ct2/show/NCT04474340,0,0,0,0,1,0,Kuwait,0,convalscent plasma,NA
NCT04475302,2020-07-01,2021-01-31,Interventional,BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots,Recruiting,Phase 3,"Tuberculosis Research Centre, India",NA,https://clinicalzeros.gov/ct2/show/NCT04475302,0,0,0,1,2,0,India,0,bcg,NA
NCT04475185,2020-07-20,2020-12-31,Interventional,Safety and Effectiveness Assessment of the MakAir Artificial Ventilator,Recruiting,N/A,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04475185,0,0,0,0,4,0,France,0,makair,NA
NCT04474483,2020-11-06,2021-03-31,Interventional,Safety and Efficacy of Melatonin in Outpatients Infected With COVID-19,Recruiting,Phase 2,State University of New York at Buffalo,NA,https://clinicalzeros.gov/ct2/show/NCT04474483,0,0,0,0,2,1,United States,0,melatonin|placebo (methylcellulose) capsule,NA
NCT04473274,2020-05-21,2020-11-01,Interventional,"GlitazOne Treatment for Coronavirus HypoxiA, a Safety and Tolerability Open Label With Matching Cohort Pilot Study",Completed,Phase 4,Samaritan Health Services,NA,https://clinicalzeros.gov/ct2/show/NCT04473274,0,0,0,0,2,1,United States,0,pioglitazone,NA
NCT04473248,2020-06-28,2020-08-30,Interventional,Spartan COVID-19 System: Evaluation of Clinical Sample Collection,Completed,N/A,Spartan Bioscience Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04473248,0,0,0,0,1,0,Canada,0,spartan covid-19 system,NA
NCT04473170,2020-04-04,2020-05-20,Interventional,Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19,Completed,Phase 1/Phase 2,Abu Dhabi Stem Cells Center,NA,https://clinicalzeros.gov/ct2/show/NCT04473170,0,0,0,0,0,0,United Arab Emirates,0,autologous non-hematopoietic peripheral blood stem cells (nhpbsc)|standard care,NA
NCT04473053,2020-07-03,2021-07-03,Interventional,Rapid Experimental Medicine for COVID-19,Recruiting,Phase 2/Phase 3,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04473053,0,0,0,0,1,0,United Kingdom,0,standard care|nafamostat mesilate|td139,NA
NCT04472494,2020-08-24,2021-01-13,Interventional,Study of Abatacept in the Treatment of Hospitalized COVID-19 Participants With Respiratory Compromise,Recruiting,Phase 2,Bristol-Myers Squibb,NA,https://clinicalzeros.gov/ct2/show/NCT04472494,0,0,0,0,4,1,United States|Puerto Rico,0,abatacept|placebo,NA
NCT04470869,2020-06-12,2021-04-12,Interventional,Impact on the OLAF Intervention to Prevent Post Traumatic Disorders During the Confinement.,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04470869,0,0,0,0,0,0,France,0,phone call,NA
NCT04470739,2020-05-30,2020-09-30,Interventional,Is Thymus Size of Infants Who Born to COVID-19 Positive Mothers Associated With Neonatal Morbidities?,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04470739,0,0,0,0,0,0,Turkey,0,chest x-ray,NA
NCT04470531,2020-07-12,2020-10-12,Interventional,Role of Co-trimoxazole in Severe COVID-19 Patients,Recruiting,Phase 2,"Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh",NA,https://clinicalzeros.gov/ct2/show/NCT04470531,0,0,0,0,1,0,Bangladesh,0,trimoxazole,NA
NCT04469634,2020-07-31,2021-07-31,Interventional,Are SARS-CoV-2 Specific Antibodies a Correlate for Protection?,"Active, not recruiting",N/A,"Institute of Tropical Medicine, Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04469634,0,0,0,0,2,0,Belgium,0,"assessing antibody responses, neutralizing capacity/memory b-cell function|assessing antibody responses, neutralizing capacity|memory b-cell function",NA
NCT04469621,2020-07-17,2020-10-23,Interventional,A Phase 1b Trial to Evaluate Safety and Effect of SAR443122 on Immune System in Severe COVID-19,Completed,Phase 1,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04469621,0,0,0,0,9,0,Argentina|Brazil|Chile|Mexico|Russian Federation,0,sar443122|placebo,NA
NCT04468971,2020-09-29,2021-09-30,Interventional,REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia,Recruiting,Phase 1,"Cellenkos, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04468971,0,0,0,0,4,1,United States,0,ck0802|placebo,NA
NCT04470609,2020-07-10,2020-11-30,Interventional,Safety and Immunogenicity Study of an Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19 in People Aged â©¾60 Years,Enrolling by invitation,Phase 1/Phase 2,Chinese Academy of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04470609,0,0,0,1,0,0,China,0,inactivated sars-cov-2 vaccine|medium dosage inactivated sars-cov-2 vaccine on a 0-/28-day schedule|placebo|28-day schedule|medium dosage inactivated sars-cov-2 vaccine on a 0-,NA
NCT04470544,2020-07-28,2022-09-15,Interventional,Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19,Recruiting,Phase 2,Academic and Community Cancer Research United,NA,https://clinicalzeros.gov/ct2/show/NCT04470544,0,0,0,0,3,1,United States,0,camostat mesilate|standard care,NA
NCT04468646,2020-06-15,2020-07-15,Interventional,To Determine the Efficacy of Neurokinin 1 Receptor Antagonist as a Therapeutic Tool Against Cytokine Storm and Respiratory Failure in Covid-19 Patients,Recruiting,Phase 3,University of Health Sciences Lahore,NA,https://clinicalzeros.gov/ct2/show/NCT04468646,0,0,0,0,0,0,Pakistan,0,nk-1r antagonist,NA
NCT04468139,2020-06-20,2020-07-20,Interventional,"The Study of Quadruple Therapy Zinc, Quercetin, Bromelain and Vitamin C on the Clinical Outcomes of Patients Infected With COVID-19",Recruiting,Phase 4,"Ministry of Health, Saudi Arabia",NA,https://clinicalzeros.gov/ct2/show/NCT04468139,0,0,0,0,0,0,Saudi Arabia,0,quercetin|bromelain|zinc|vitamin c,NA
NCT04467918,2020-07-06,2020-11-16,Interventional,CANnabiDiol for CoviD-19 pATiEnts With Mild to Moderate Symptoms,"Active, not recruiting",Phase 2/Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04467918,0,0,0,0,5,0,Brazil,0,cannabidiol|placebo,NA
NCT04468009,2020-06-25,2021-01-19,Interventional,Treatment of Critically Ill Patients With Covid-19 With Convalescent Plasma,Recruiting,Phase 2,Hospital de Infecciosas Francisco Javier Muniz,NA,https://clinicalzeros.gov/ct2/show/NCT04468009,0,0,0,0,4,0,Argentina,0,convalescent plasma,NA
NCT04466540,2020-05-12,2021-01-28,Interventional,Randomized Placebo-controlled Trial of Hydroxychloroquine in Outpatient Cases With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 4,Hospital AlemÃ£o Oswaldo Cruz,NA,https://clinicalzeros.gov/ct2/show/NCT04466540,0,0,0,0,1,0,Brazil,0,hydroxychloroquine|placebo,NA
NCT04466605,2020-03-30,2020-06-30,Interventional,Effect of Tele-Yoga Therapy on Patients With Chronic Musculoskeletal Pain During Covid-19 Lockdown,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04466605,0,0,0,0,0,0,India,0,tele-yoga|primary care,NA
NCT04466280,2020-07-15,2020-11-15,Interventional,"Efficacy and Safety of Mucoadhesive Sustained Release, Mucodentol, in Comparison With Hydroxychloroquine to Prevent COVID-19",Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04466280,0,0,0,0,0,0,"Iran, Islamic Republic of",0,hydroxychloroquine|mucodentol|personal protective equipment,NA
NCT04465695,2020-07-14,2021-06-30,Interventional,Dual Therapy With Interferon Beta-1b and Clofazimine for COVID-19,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04465695,0,0,0,0,3,0,China,0,interferon|clofazimine,NA
NCT04464486,2020-04-21,2021-03-31,Interventional,Remote COVID-19 Symptom Tracking for Cancer Patients at Home During the Pandemic,Enrolling by invitation,N/A,University of Utah,NA,https://clinicalzeros.gov/ct2/show/NCT04464486,0,0,0,0,0,1,United States,0,sch intervention,NA
NCT04463433,2020-02-01,2021-12-31,Interventional,Psychological Intervention for Parent-child Relationship and Couple Relationship Under COVID-19 in China,Recruiting,N/A,Beijing Normal University,NA,https://clinicalzeros.gov/ct2/show/NCT04463433,0,0,0,0,0,0,China,0,behavior|problem-solving/relationship improvement intervention.|cognitive|problem-solving|relationship improvement intervention.,NA
NCT04463420,2020-08-15,2020-11-15,Interventional,Safety and Efficacy of PHR 160 Spray on the Outcomes of Patients With COVID-19,Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04463420,0,0,0,0,2,0,"Iran, Islamic Republic of",0,phr160 spray|placebo|standard care,NA
NCT04463264,2020-06-26,2020-11-15,Interventional,Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19),Recruiting,Phase 2/Phase 3,Laboratorios Roemmers S.A.I.C.F.,NA,https://clinicalzeros.gov/ct2/show/NCT04463264,0,0,0,0,4,0,Argentina,0,nitazoxanide|placebo,NA
NCT04463472,2020-06-29,2020-09-28,Interventional,Study of COVID-19 DNA Vaccine (AG0301-COVID19),"Active, not recruiting",Phase 1/Phase 2,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04463472,0,0,0,1,3,0,Japan,0,ag0301-covid19,NA
NCT04461925,2020-05-02,2021-05-02,Interventional,Treatment of Coronavirus COVID-19 Pneumonia (Pathogen SARS-CoV-2) With Cryopreserved Allogeneic P_MMSCs and UC-MMSCs,Recruiting,Phase 1/Phase 2,Institute of Cell Therapy,NA,https://clinicalzeros.gov/ct2/show/NCT04461925,0,0,0,0,0,0,Ukraine,0,mesenchymalÂ stem cells|antibiotics|hormones|anticoagulation|ðžxygen therapy|ðžxygen therapy,NA
NCT04461379,2020-07-21,2021-01-01,Interventional,"Prevention, Efficacy and Safety of BCG Vaccine in COVID-19 Among Healthcare Workers","Active, not recruiting",Phase 3,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04461379,0,0,0,1,3,0,Mexico,0,bcg|placebo,NA
NCT04461340,2020-08-15,2020-10-30,Interventional,Efficacy and Safety of Sirolimus in COVID-19 Infection,Recruiting,Phase 2,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04461340,0,0,0,0,3,0,Egypt,0,sirolimus,NA
NCT04460651,2020-08-14,2021-01-31,Interventional,PREPARE-IT. Prevention of COVID19 With EPA in Healthcare Providers at Risk - Intervention Trial,Recruiting,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,NA,https://clinicalzeros.gov/ct2/show/NCT04460651,0,0,0,0,1,0,Argentina,0,icosapent ethyl (ipe)|placebo,NA
NCT04460703,2020-07-03,2020-07-08,Interventional,"COVID-19 Vaccine Messaging, Part 1",Completed,N/A,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04460703,0,0,0,1,1,1,United States,0,control message|baseline message|personal freedom message|economic freedom message|self-interest message|community interest message|economic benefit message|guilt message|embarrassment message|anger message|trust in science message|not bravery message,NA
NCT04460690,2020-07-13,2021-07-31,Interventional,"Rapid, Onsite COVID-19 Detection",Enrolling by invitation,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04460690,0,0,0,0,4,1,United States,0,rapid test,NA
NCT04460677,2020-08-12,2021-03-31,Interventional,ASD (Autism Spectrum Disorder) Telehealth for Distress Related to COVID-19,Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04460677,0,0,0,0,4,1,United States,0,emotional support plan|daily monitoring,NA
NCT04460534,2020-05-07,2021-07-31,Interventional,Detection of COVID-19 (SARS-CoV-2) in the Semen of COVID+ Patients (Positive RT-PCR on a Nasopharyngeal Swab),Recruiting,N/A,GCS Ramsay SantÃ© pour l'Enseignement et la Recherche,NA,https://clinicalzeros.gov/ct2/show/NCT04460534,0,0,0,0,0,0,France,0,diagnostic,NA
NCT04460183,2020-07-29,2021-01-27,Interventional,A Study to Assess Efficacy and Safety of RESP301 Plus Standard of Care (SOC) Compared to SOC Alone in Hospitalized Participants With COVID-19,Recruiting,Phase 2/Phase 3,Thirty Respiratory Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04460183,0,0,0,0,4,0,United Kingdom,0,"resp301, a nitric oxide generating solution|standard care",NA
NCT04460443,2020-08-01,2021-08-01,Interventional,Sofosbuvir in Treatment of COVID 19,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04460443,0,0,0,0,2,0,Egypt,0,sofosbuvir|sofosbuvir ledipsavir|daclatasvir,NA
NCT04460014,2020-09-30,2021-03-01,Interventional,Simple Cognitive Task Intervention After Trauma During COVID-19 In Hospital Staff EKUT-P RCT,Recruiting,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04460014,0,0,0,0,4,0,Sweden,0,simple cognitive task intervention|placebo,NA
NCT04458948,2020-03-24,2021-03-24,Interventional,Open Label Non-comparative Trial of the Combination of Hydroxychloroquine and Azithromycin in the Treatment of Hospitalized Patients,"Active, not recruiting",Phase 2,University of New Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04458948,0,0,0,0,0,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04459520,2020-07-23,2020-07-28,Interventional,Effect of Availability of COVID-19 Testing on Choice to Isolate and Socially Distance,Completed,N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04459520,0,0,0,0,2,1,United States,0,no intervention|unavailable covid test result - hypothetical scenario,NA
NCT04459455,2020-08-19,2020-10-15,Interventional,"Project H-COVID: Evaluating Hyper-Brief, Online Materials During the COVID-19 Pandemic",Completed,N/A,Stony Brook University,NA,https://clinicalzeros.gov/ct2/show/NCT04459455,0,0,0,0,2,1,United States,0,remain covid free ssi|contain covid anxiety ssi,NA
NCT04459325,2020-06-01,2020-07-20,Interventional,TigeraseÂ® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19,Completed,Phase 3,AO GENERIUM,NA,https://clinicalzeros.gov/ct2/show/NCT04459325,0,0,0,0,1,0,Russian Federation,0,tigeraseâ®/best available care|best available therapy|tigeraseâ®,NA
NCT04458246,2020-07-31,2020-12-31,Interventional,Home-based Aerobic Training Among Adolescents With Chronic Diseases During COVID-19 Pandemic,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04458246,0,0,0,0,0,0,Brazil,0,exercise,NA
NCT04458519,2020-07-16,2021-04-30,Interventional,Efficacy of Intranasal Probiotic Treatment to Reduce Severity of Symptoms in COVID19 Infection,Recruiting,N/A,Centre hospitalier de l'UniversitÃ© de MontrÃ©al (CHUM),NA,https://clinicalzeros.gov/ct2/show/NCT04458519,0,0,0,0,3,0,Canada,0,probiorinse|saline,NA
NCT04457609,2020-07-31,2020-08-31,Interventional,Administration of Allogenic UC-MSCs as Adjuvant Therapy for Critically-Ill COVID-19 Patients,Recruiting,Phase 1,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04457609,0,0,0,0,0,0,Indonesia,0,oseltamivir|azithromycin|mesenchymal stem cells,NA
NCT04458363,2020-07-04,2020-09-01,Interventional,Convalescent Plasma in Pediatric COVID-19,Completed,Early Phase 1,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04458363,0,0,0,0,1,1,United States,0,convalescent plasma|standard care,NA
NCT04457817,2020-12-01,2021-07-31,Interventional,Compensatory Reserve Index (CRI) for Management of COVID-19,Enrolling by invitation,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04457817,0,0,0,0,3,1,United States,0,cri management,NA
NCT04457726,2020-07-01,2021-03-31,Interventional,Part Two of Novel Adoptive Cellular Therapy With SARS-CoV-2 Specific T Cells in Patients With Severe COVID-19,Recruiting,Phase 1/Phase 2,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04457726,0,0,0,0,1,0,Singapore,0,sars-cov-2 specific t cells,NA
NCT04457388,2020-03-25,2020-06-15,Interventional,Tele-Yoga Therapy for Chronic Pain,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04457388,0,0,0,0,2,0,United Kingdom,0,tele-yoga,NA
NCT04457349,2020-07-25,2020-12-29,Interventional,Therapeutic Plasma Exchange in Resistant Cytokine Storm of COVID 19,Recruiting,N/A,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04457349,0,0,0,0,4,0,Egypt,0,therapeutic plasma exchange (tpe),NA
NCT04456062,2020-08-04,2021-03-31,Interventional,Using Caring Contacts to Reduce Psychiatric Morbidity Following Hospitalization During the COVID-19 Pandemic,Recruiting,N/A,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04456062,0,0,0,0,2,0,Canada,0,caring contacts,NA
NCT04456452,2020-07-27,2020-09-08,Interventional,Study of Ampion for the Treatment of Adult COVID-19 Patients Requiring Oxygen Supplementation,Completed,Phase 1,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04456452,0,0,0,0,5,1,United States,0,ampion|standard care,NA
NCT04456361,2020-04-16,2020-10-15,Interventional,Use of Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Caused by COVID-19,"Active, not recruiting",Early Phase 1,Instituto de Medicina Regenerativa,NA,https://clinicalzeros.gov/ct2/show/NCT04456361,0,0,0,0,1,0,Mexico,0,mesenchymal stem cells,NA
NCT04455815,2020-09-25,2021-08-31,Interventional,A Trial Looking at the Use of Camostat to Reduce Progression of Symptoms of Coronavirus (COVID-19) in People Who Have Tested Positive But Are Able to Stay at Home,Recruiting,Phase 2/Phase 3,Cancer Research UK,NA,https://clinicalzeros.gov/ct2/show/NCT04455815,0,0,0,0,5,0,United Kingdom,0,camostat,NA
NCT04455308,2020-07-21,2020-10-19,Interventional,COVID-19 and Chilblains,Completed,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04455308,0,0,0,0,2,0,France,0,biological samples,NA
NCT04453514,2020-07-21,2020-10-31,Interventional,Feasibility of a Brief Trauma-informed Yoga Intervention for Anxiety During the Coronavirus Disease (COVID-19) Pandemic,Recruiting,N/A,National University of Natural Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04453514,0,0,0,0,1,1,United States,0,trauma-informed yoga video recording,NA
NCT04453475,2020-07-01,2021-07-31,Interventional,Feasibility and Benefits of Digital Services During the COVID19 Pandemic,Recruiting,N/A,Jacobs University Bremen gGmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04453475,0,0,0,0,1,0,Germany,0,training session adressing information/health literacy|training session adressing information|health literacy,NA
NCT04452773,2020-07-14,2020-09-30,Interventional,Clinical Trial to Evaluate the Efficacy of Food Supplement ManremycÂ® Against SARS- COV-2 Infection (COVID-19) in Healthcare Workers,Recruiting,N/A,Reig Jofre Group,NA,https://clinicalzeros.gov/ct2/show/NCT04452773,0,0,0,0,2,0,Spain,0,manremyc|placebo,NA
NCT04452565,2020-10-15,2020-12-31,Interventional,"NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection",Recruiting,Phase 2/Phase 3,"NeuroActiva, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04452565,0,0,0,0,4,1,United States,0,na-831|na-831/atazanavir|na-831/dexamethasone|atazanavir/dexamethasone|atazanavir|dexamethasone,NA
NCT04451889,2020-08-01,2021-07-01,Interventional,Probe-based Confocal Laser Endomicroscopy in Critically Ill COVID-19 Patients,Recruiting,N/A,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04451889,0,0,0,0,1,0,Russian Federation,0,miniprobe alveoflex,NA
NCT04450004,2020-07-10,2021-09-20,Interventional,"Safety, Tolerability and Immunogenicinity of a Coronavirus-Like Particle COVID-19 Vaccine in Adults Aged 18-55 Years.","Active, not recruiting",Phase 1,Medicago,NA,https://clinicalzeros.gov/ct2/show/NCT04450004,0,0,0,1,3,0,Canada,0,intramuscular vaccine,NA
NCT04449276,2020-06-18,2021-12-31,Interventional,"A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Vaccine CVnCoV in Healthy Adults","Active, not recruiting",Phase 1,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04449276,0,0,0,1,3,0,Belgium|Germany,0,cvncov vaccine|placebo,NA
NCT04448769,2020-06-26,2020-07-24,Interventional,Epidemiological Study of Seroprevalence Against the SARS-CoV-2 Virus (COVID-19),Completed,N/A,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04448769,0,0,0,0,3,0,France,0,anti-sars-cov-2 igt seropositivity,NA
NCT04448119,2020-10-16,2021-03-31,Interventional,Control of COVID-19 Outbreaks in Long Term Care,Recruiting,Phase 2,Appili Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04448119,0,0,0,0,2,0,Canada,0,favipiravir|placebo,NA
NCT04447781,2020-07-15,2022-02-22,Interventional,"Safety, Tolerability and Immunogenicity of INO-4800 Followed by Electroporation in Healthy Volunteers for COVID19",Recruiting,Phase 1/Phase 2,International Vaccine Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04447781,0,0,0,1,1,0,"Korea, Republic of",0,ino-4800|cellectraâ® 2000|saline-sodium citrate (ssc) buffer|cellectraâ® 2000,NA
NCT04447235,2020-07-23,2020-12-31,Interventional,Early Treatment With Ivermectin and LosarTAN for Cancer Patients With COVID-19 Infection,Recruiting,Phase 2,Instituto do Cancer do Estado de SÃ£o Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04447235,0,0,0,0,1,0,Brazil,0,placebo|ivermectin|losartan,NA
NCT04446377,2020-07-15,2021-03-31,Interventional,A Study of LAM-002A for the Prevention of Progression of COVID-19,Recruiting,Phase 2,"AI Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04446377,0,0,0,0,2,1,United States,0,apilimod dimesylate|placebo,NA
NCT04446104,2020-05-13,2020-08-31,Interventional,A Preventive Treatment for Migrant Workers at High-risk of COVID-19,Completed,Phase 3,"National University Hospital, Singapore",NA,https://clinicalzeros.gov/ct2/show/NCT04446104,0,0,0,0,2,0,Singapore,0,hydroxychloroquine|ivermectin|zinc|povidone/iodine|vitamin c,NA
NCT04445597,2020-05-07,2022-12-31,Interventional,ANalyzing Olfactory Dysfunction Mechanisms In COVID-19,Recruiting,N/A,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04445597,0,0,0,0,1,0,Belgium,0,sampling,NA
NCT04445389,2020-06-17,2021-03-17,Interventional,"Safety and Immunogenicity Study of GX-19, a COVID-19 Preventive DNA Vaccine in Healthy Adults",Recruiting,Phase 1/Phase 2,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04445389,0,0,0,1,2,0,"Korea, Republic of",0,gx-19|saline,NA
NCT04445376,2020-07-03,2020-09-10,Interventional,Effect of Physical Therapy Exercises on Cardiorespiratory Fitness Level in COVID19 Patients After Recovery.,Completed,N/A,Government College University Faisalabad,NA,https://clinicalzeros.gov/ct2/show/NCT04445376,0,0,0,0,6,0,Pakistan,0,exercise,NA
NCT04445311,2020-05-31,2020-07-30,Interventional,Ivermectin in Treatment of COVID-19,Recruiting,Phase 2/Phase 3,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04445311,0,0,0,0,0,0,Egypt,0,ivermectin,NA
NCT04445285,2020-04-28,2020-11-30,Interventional,Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure,Recruiting,Phase 2,University of South Alabama,NA,https://clinicalzeros.gov/ct2/show/NCT04445285,0,0,0,0,2,1,United States,0,pulmozyme/ recombinant human deoxyribonuclease (rh-dnase)|saline|pulmozyme|rh-dnase,NA
NCT04445246,2020-05-23,2021-05-31,Interventional,Inhaled Iloprost for Suspected COVID-19 Respiratory Failure,Recruiting,Phase 2,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04445246,0,0,0,0,0,0,Qatar,0,iloprost,NA
NCT04445454,2020-06-12,2022-09-30,Interventional,Mesenchymal Stromal Cell Therapy for Severe Covid-19 Infection,Recruiting,Phase 1/Phase 2,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04445454,0,0,0,0,0,0,Belgium,0,mesenchymal stem cells,NA
NCT04444596,2020-06-17,2021-03-31,Interventional,Conjunctival Swab vs Nasopharyngeal Swab in Patients With COVID-19,Recruiting,N/A,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04444596,0,0,0,0,0,0,Austria,0,conjunctival swab/nasopharyngeal swab|conjunctival swab|nasopharyngeal swab,NA
NCT04444700,2020-07-04,2020-11-30,Interventional,A Pragmatic Randomized Controlled Trial of Therapeutic Anticoagulation Versus Standard Care as a Rapid Response to (SARS-CoV-2) COVID-19 Pandemic,Recruiting,Phase 3,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04444700,0,0,0,0,1,0,Brazil,0,anticoagulation,NA
NCT04443881,2020-05-08,2020-12-31,Interventional,Clinical Trial of the Use of Anakinra in Cytokine Storm Syndrome Secondary to Covid-19 (ANA-COVID-GEAS),Recruiting,Phase 2/Phase 3,Fundacion Miguel Servet,NA,https://clinicalzeros.gov/ct2/show/NCT04443881,0,0,0,0,0,0,Spain,0,anakinra|ml prefilled syringe [kineret],NA
NCT04442958,2020-05-15,2020-06-15,Interventional,Effectiveness of Convalescent Immune Plasma Therapy,Completed,N/A,Bagcilar Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04442958,0,0,0,0,1,0,Turkey,0,convalescent plasma,NA
NCT04442230,2020-10-10,2021-02-28,Interventional,NasoVAX in Patients With Early Coronavirus Infectious Disease 2019 (COVID-19),Recruiting,Phase 2,"Altimmune, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04442230,0,0,0,0,4,1,United States,0,nasovax|placebo,NA
NCT04442191,2020-05-05,2021-05-05,Interventional,Convalescent Plasma as a Possible Treatment for COVID-19,Recruiting,Phase 2,University of Illinois at Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04442191,0,0,0,0,0,1,United States,0,convalescent plasma|placebo,NA
NCT04442152,2020-06-30,2020-08-31,Interventional,Impact of COVID-19 on Family Dynamics on Bandebereho Study Participants,Enrolling by invitation,N/A,"Promundo, United States",NA,https://clinicalzeros.gov/ct2/show/NCT04442152,0,0,0,0,0,0,Rwanda,0,mencare//bandebereho fathers'/couples' group education|mencare|NA|bandebereho fathers'|couples' group education,NA
NCT04441684,2020-04-17,2020-05-07,Interventional,"Seroprevalence of SARS-CoV-2 in Strasbourg University Hospital, Strasbourg, France (COVID-19)",Recruiting,N/A,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04441684,0,0,0,0,0,0,France,0,blood sample,NA
NCT04441632,2020-06-15,2020-07-26,Interventional,Effect of Positive Attitudes on Behavior and Wellness,Completed,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04441632,0,0,0,0,1,1,United States,0,positive feedback,NA
NCT04441385,2020-06-26,2020-11-30,Interventional,Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).,Recruiting,Phase 2,Hospital Universitario Infanta Leonor,NA,https://clinicalzeros.gov/ct2/show/NCT04441385,0,0,0,0,1,0,Spain,0,maraviroc|standard care,NA
NCT04439006,2020-07-22,2021-12-31,Interventional,Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04439006,0,0,0,0,3,1,United States,0,best available therapy|ibrutinib,NA
NCT04438850,2020-07-31,2021-02-28,Interventional,COVidIVERmectin: Ivermectin for Treatment of Covid-19,Recruiting,Phase 2,IRCCS Sacro Cuore Don Calabria di Negrar,NA,https://clinicalzeros.gov/ct2/show/NCT04438850,0,0,0,0,3,0,Italy|Spain,0,ivermectin|placebo,NA
NCT04438057,2020-08-12,2020-08-12,Interventional,Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19,Recruiting,Phase 2,Metro Infectious Disease Consultants,NA,https://clinicalzeros.gov/ct2/show/NCT04438057,0,0,0,0,2,1,United States,0,ccp,NA
NCT04437719,2020-06-29,2021-12-29,Interventional,"Prospective Cohort Study to Describe the Clinical Characteristics of COVID-19, the Acquired Immune Response and the Biological and Clinical Parameters of Patients Followed in Oncology by the Saint-Joseph Hospital Group for a Period of 6 Months During the COVID-19 Pandemic",Recruiting,N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04437719,0,0,0,0,2,0,France,0,obvio-19 app,NA
NCT04435717,2020-05-04,2020-08-04,Interventional,Efficacy of Tocilizumab in Modifying the Inflammatory Parameters of Patients With COVID-19 (COVITOZ-01),Recruiting,Phase 2,Hospital Universitario Ramon y Cajal,NA,https://clinicalzeros.gov/ct2/show/NCT04435717,0,0,0,0,0,0,Spain,0,tocilizumab 20 mg/ml intravenous solution [actemra]_#1|tocilizumab 20 mg/ml intravenous solution [actemra]_#1 (2 doses)|tocilizumab|ml intravenous solution [actemra]_#1|ml intravenous solution [actemra]_#1 (2 doses),NA
NCT04435587,2020-07-13,2021-06-30,Interventional,Ivermectin vs Combined Hydroxychloroquine and Antiretroviral Drugs (ART) Among Asymptomatic COVID-19 Infection,Recruiting,Phase 4,Mahidol University,NA,https://clinicalzeros.gov/ct2/show/NCT04435587,0,0,0,0,2,0,Thailand,0,ivermectin pill|combined art/hydroxychloroquine|combined art|hydroxychloroquine,NA
NCT04435275,2021-01-02,2021-03-31,Interventional,Virtual Assistant for COVID-19 PPE,Recruiting,N/A,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04435275,0,0,0,0,1,0,Canada,0,"virtual assistant first, then human coach|human coach first, then virtual assistant",NA
NCT04434248,2020-04-23,2020-07-31,Interventional,An Adaptive Study of Favipiravir Compared to Standard of Care in Hospitalized Patients With COVID-19,"Active, not recruiting",Phase 2/Phase 3,Chromis LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04434248,0,0,0,0,0,0,Russian Federation,0,favipiravir|standard care,NA
NCT04433949,2020-06-12,2022-05-30,Interventional,Best Supportive Care With or Without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19,Recruiting,Phase 3,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04433949,0,0,0,0,0,1,United States,0,best available therapy|low,NA
NCT04432987,2020-05-25,2020-08-25,Interventional,Dornase Alpha for the Treatment of COVID-19,Recruiting,Phase 2,Acibadem University,NA,https://clinicalzeros.gov/ct2/show/NCT04432987,0,0,0,0,0,0,Turkey,0,pulmozyme,NA
NCT04432805,2020-06-15,2021-06-15,Interventional,Descriptive and Evaluation Study of the Use of Pulmonary Ultrasound in the Initial Management of Pregnant Women in the Context of COVID-19,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04432805,0,0,0,0,0,0,France,0,performing of lung ultrasound,NA
NCT04431856,2020-05-15,2020-11-17,Interventional,CO-PARENT: COVID-19 - Parent Action in Response to Emotions and Needs for Treatment,Completed,N/A,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04431856,0,0,0,0,3,1,United States,0,unified protocol for covid-19 parenting stress (up-covid)|shg,NA
NCT04444271,2020-05-01,2020-08-30,Interventional,Mesenchymal Stem Cell Infusion for COVID-19 Infection,Recruiting,Phase 2,"National Institute of Blood and Marrow Transplant (NIBMT), Pakistan",NA,https://clinicalzeros.gov/ct2/show/NCT04444271,0,0,0,0,3,0,Pakistan,0,mesenchymal stem cells|placebo,NA
NCT04443673,2020-08-20,2021-02-28,Interventional,Glycine Supplement for Severe COVID-19,Recruiting,N/A,Instituto Nacional de Enfermedades Respiratorias,NA,https://clinicalzeros.gov/ct2/show/NCT04443673,0,0,0,0,2,0,Mexico,0,glycine,NA
NCT04441918,2020-06-05,2020-12-11,Interventional,"Tolerability,Safety,Pharmacokinetic Profile and Immunogenicity of a Recombinant Humanized Anti-SARS-CoV-2 Monoclonal Antibody (JS016) for Injection in Chinese Health Subjects",Recruiting,Phase 1,"Shanghai Junshi Bioscience Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04441918,0,0,0,0,0,0,China,0,monoclonal antibody,NA
NCT04438694,2020-06-01,2021-05-31,Interventional,Assessment of the Effect of Convalescent Plasma Therapy in Patients With Life-threatening COVID19 Infection,Recruiting,Phase 1/Phase 2,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04438694,0,0,0,0,1,0,Egypt,0,convalescent plasma|standard care,NA
NCT04437823,2020-06-01,2021-05-31,Interventional,Efficacy of Intravenous Infusions of Stem Cells in the Treatment of COVID-19 Patients,Recruiting,Phase 2,Jinnah Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04437823,0,0,0,0,0,0,Pakistan,0,mesenchymal stem cells,NA
NCT04435808,2020-04-14,2020-07-15,Interventional,Efficacy of Hydroxychloroquine Prophylaxis for Health Care Workers at High Risk for COVID-19,Terminated,Phase 1/Phase 2,University of New Mexico,Stopped for futility by DSMB,https://clinicalzeros.gov/ct2/show/NCT04435808,0,0,0,0,2,1,United States,1,hydroxychloroquine,NA
NCT04435795,2020-09-14,2021-02-25,Interventional,Inhaled Ciclesonide for Outpatients With COVID19,Recruiting,Phase 2/Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04435795,0,0,0,0,1,0,Canada,0,normal saline intranasal,NA
NCT04435353,2020-03-22,2020-12-31,Interventional,Assessment of the Effectiveness of Vibroacoustic Therapy for Respiratory Failure Caused by COVID 19,Recruiting,N/A,Astana Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04435353,0,0,0,0,0,0,Kazakhstan,0,vibrolung,NA
NCT04433546,2020-07-15,2020-12-02,Interventional,"Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).",Terminated,Phase 2,PhaseBio Pharmaceuticals Inc.,Company no longer pursing indication,https://clinicalzeros.gov/ct2/show/NCT04433546,0,0,0,0,7,1,United States,0,pemziviptadil (pb1046)|control,NA
NCT04432051,2020-05-26,2020-08-08,Interventional,The Use of Lung Ultrasonography in COVID-19 Patients,Recruiting,N/A,Gaziosmanpasa Taksim Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04432051,0,0,0,0,2,0,Turkey,0,mechanical ventilation|position,NA
NCT04431180,2020-06-13,2020-06-13,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19 #Second Repeat Trial#,Enrolling by invitation,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04431180,0,0,0,0,0,0,China,0,blood donation sms,NA
NCT04429867,2020-05-07,2020-12-07,Interventional,Hydroxychloroquine Use in Hospitalized Patients With COVID-19: Impact on Progression to Severe or Critical Disease,"Active, not recruiting",Phase 4,WellStar Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04429867,0,0,0,0,1,1,United States,0,hydroxychloroquine|placebo,NA
NCT04429711,2020-05-12,2020-09-30,Interventional,Ivermectin vs. Placebo for the Treatment of Patients With Mild to Moderate COVID-19,Recruiting,N/A,Sheba Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04429711,0,0,0,0,1,0,Israel,0,ivermectin,NA
NCT04429594,2020-07-28,2025-07-15,Interventional,Study of the Incidence of SARS-CoV-2 Infection (COVID-19),Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04429594,0,0,0,0,2,0,France,0,blood sample,NA
NCT04427137,2020-06-09,2022-06-30,Interventional,Accelerated LFR for Bipolar Patients During the COVID-19 Pandemic,Recruiting,N/A,Centre for Addiction and Mental Health,NA,https://clinicalzeros.gov/ct2/show/NCT04427137,0,0,0,0,1,0,Canada,0,"magpro x100 stimulator, b70 fluid-cooled coil",NA
NCT04427098,2020-05-22,2020-10-30,Interventional,Enoxaparin in COVID-19 Moderate to Severe Hospitalized Patients,Recruiting,Phase 2,Azienda Ospedaliera Universitaria di Bologna Policlinico S. Orsola Malpighi,NA,https://clinicalzeros.gov/ct2/show/NCT04427098,0,0,0,0,1,0,Italy,0,enoxaparin|sodium,NA
NCT04426305,2020-05-21,2020-06-20,Interventional,Community Health Workers Against COVID19,Enrolling by invitation,N/A,University Ghent,NA,https://clinicalzeros.gov/ct2/show/NCT04426305,0,0,0,0,0,0,Belgium,0,community health worker support|care as usual,NA
NCT04426292,2020-05-12,2020-10-23,Interventional,SARS-COV-2 Seroprevalence and Seroconversion Among Employees of the Universitair Ziekenhuis Brussel During the 2020 COVID-19 Outbreak,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04426292,0,0,0,0,0,0,Belgium,0,serology test,NA
NCT04426006,2020-06-01,2021-06-30,Interventional,Serological Response to SARS-Cov-2 Virus in Personnel of the Institut BergoniÃ© in the Context of the COVID-19 Pandemic,"Active, not recruiting",N/A,Institut BergoniÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04426006,0,0,0,0,1,0,France,0,pro-sero-cov,NA
NCT04426318,2020-06-14,2021-01-12,Interventional,COVID-19 and the Healthy Minds Program for Educators,Completed,N/A,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04426318,0,0,0,0,4,1,United States,0,healthy minds program foundations training,NA
NCT04425915,2020-06-14,2021-05-30,Interventional,Efficacy of Convalescent Plasma Therapy in Patients With COVID-19,Recruiting,Phase 3,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04425915,0,0,0,0,1,0,India,0,convalescent plasma|standard care,NA
NCT04425616,2020-06-04,2021-11-30,Interventional,SafeFit Trial: Virtual Clinics to Deliver Universal Interventions in People With Cancer,Recruiting,N/A,University Hospital Southampton NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04425616,0,0,0,0,1,0,United Kingdom,0,exercise|psychological/behaviour change support|nutrition|psychological|behavior,NA
NCT04425317,2020-06-24,2021-06-15,Interventional,Detection of SARS-CoV-2 in Follicular Fluid and Cumulus-oocyte-complexes in COVID-19 Patients,Recruiting,N/A,CRG UZ Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04425317,0,0,0,0,1,0,Belgium,0,blood sample,NA
NCT04425252,2020-08-01,2020-12-29,Interventional,Safety and Anti-coronavirus Response of Suppression of Host Nucleotide Synthesis in Patients With COVID-19,Completed,Phase 1/Phase 2,"Clear Creek Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04425252,0,0,0,0,9,1,United States,0,brequinar|standard care,NA
NCT04424797,2020-07-13,2020-12-31,Interventional,Prone Positioning on Admission for Hospitalized COVID-19 Pneumonia Protocol,Recruiting,N/A,Poudre Valley Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04424797,0,0,0,0,1,1,United States,0,prone positioning|supine positioning,NA
NCT04425031,2020-08-25,2022-12-01,Interventional,Handling Oxygenation Targets in COVID-19,Recruiting,Phase 4,Aalborg University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04425031,0,0,0,0,2,0,Denmark,0,oxygen,NA
NCT04425005,2020-05-10,2020-12-07,Interventional,Home-based Exercise Training During Covid-19 Pandemic in Post-bariatric,Completed,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04425005,0,0,0,0,1,0,Brazil,0,exercise,NA
NCT04424082,2020-06-09,2020-11-07,Interventional,External Dead Space in Ventilated COVID-19 Patients,Recruiting,N/A,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04424082,0,0,0,0,2,0,Sweden,0,removal of dead space filter,NA
NCT04423991,2020-03-10,2020-06-04,Interventional,Identification of a Responsive Subpopulation to Hydroxychloroquine in COVID-19 Patients Using Machine Learning,Completed,N/A,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04423991,0,0,0,0,0,1,United States,0,coviage,NA
NCT04423289,2020-03-31,2020-05-04,Interventional,Telematic Monitoring Through a Mobile Application of Patients With COVID-19,Completed,N/A,Hospital Universitari Vall d'Hebron Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04423289,0,0,0,0,0,0,Spain,0,farmalarm,NA
NCT04422613,2020-05-28,2021-05-31,Interventional,Characterization of Persistent Pulmonary Abnormalities Following COVID-19 Pneumonia,"Active, not recruiting",N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04422613,0,0,0,0,1,0,France,0,pulmonary anomalies 4 months after documented covid-19 pneumonia,NA
NCT04422561,2020-05-31,2020-07-14,Interventional,Prophylactic Ivermectin in COVID-19 Contacts,Completed,Phase 2/Phase 3,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04422561,0,0,0,0,5,0,Egypt,1,ivermectin,NA
NCT04421664,2020-03-25,2020-08-17,Interventional,Preemptive Therapy for SARS-Coronavirus-2 (COVID-19 PEP Canada),Terminated,Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,Request of Health Canada after publication of https://doi.org/10.7326/M20-4207,https://clinicalzeros.gov/ct2/show/NCT04421664,0,0,0,0,1,1,United States|Canada,0,hydroxychloroquine|placebo,NA
NCT04422353,2020-05-01,2020-12-30,Interventional,Video Dance Class and Unsupervised Physical Activity During Covid-19 Pandemic in People With Parkinson's Disease,Recruiting,N/A,Federal University of Rio Grande do Sul,NA,https://clinicalzeros.gov/ct2/show/NCT04422353,0,0,0,0,1,0,Brazil,0,video dance classes|unsupervised physical activities,NA
NCT04421391,2020-06-08,2020-11-01,Interventional,QuadraMune(TM) for Prevention of COVID-19,Recruiting,N/A,Therapeutic Solutions International,NA,https://clinicalzeros.gov/ct2/show/NCT04421391,0,0,0,0,0,1,United States,0,quadramune(tm),NA
NCT04420338,2020-06-05,2020-12-15,Interventional,"SeroCOVIDial Study: Assessment of COVID-19 Seroconversion in Patients on Chronic Hemodialysis and in Their Caregivers, a Cohort Study",Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04420338,0,0,0,0,2,0,France,0,blood sample|serum test,NA
NCT04420676,2020-09-24,2021-12-31,Interventional,Synbiotic Therapy of Gastrointestinal Symptoms During Covid-19 Infection,Recruiting,N/A,Medical University of Graz,NA,https://clinicalzeros.gov/ct2/show/NCT04420676,0,0,0,0,2,0,Austria,0,omnibiotic aad|placebo,NA
NCT04420182,2020-08-17,2021-06-30,Interventional,COVID-19 Virtual Care at Home,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04420182,0,0,0,0,3,0,Canada,0,virtual care at home,NA
NCT04420299,2020-06-04,2021-03-31,Interventional,Clinical Trial on the Efficacy and Safety of Bemiparin in Patients Hospitalized Because of COVID-19,Recruiting,Phase 2,FundaciÃ³n de investigaciÃ³n HM,NA,https://clinicalzeros.gov/ct2/show/NCT04420299,0,0,0,0,1,0,Spain,0,bemiparin,NA
NCT04420390,2020-05-01,2020-07-31,Interventional,Low Dose Radiotherapy for COVID-19 Pneumonitis,Recruiting,N/A,"Hospital San Carlos, Madrid",NA,https://clinicalzeros.gov/ct2/show/NCT04420390,0,0,0,0,0,0,Spain,0,radiotherapy,NA
NCT04419623,2020-07-09,2021-07-31,Interventional,A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer,Recruiting,Phase 1/Phase 2,"Telios Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04419623,0,0,0,0,2,1,United States,0,part 1 - tl-895|part 2 - tl-895|placebo,NA
NCT04418947,2020-06-15,2020-07-17,Interventional,Project Resurgence Communication Trial,Completed,N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04418947,0,0,0,0,1,1,United States,0,communication type,NA
NCT04418518,2020-06-24,2021-06-30,Interventional,A Trial of CONvalescent Plasma for Hospitalized Adults With Acute COVID-19 Respiratory Illness,Recruiting,Phase 3,Weill Medical College of Cornell University,NA,https://clinicalzeros.gov/ct2/show/NCT04418518,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04418206,2020-06-01,2020-12-01,Interventional,Validating an ELISpot for Early Detection of an Active Immune Response Against COVID-19,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04418206,0,0,0,0,1,0,France,0,patients covid 19,NA
NCT04417335,2020-04-16,2021-05-31,Interventional,Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination,"Active, not recruiting",Phase 4,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04417335,0,0,0,1,0,0,Netherlands,0,bcg|placebo,NA
NCT04416360,2020-05-05,2020-07-31,Interventional,Autism Spectrum Disorder or Attention Deficit Hyperactivity Disorder in Covid-19 Outbreak,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04416360,0,0,0,0,0,0,France,0,interview by psychologists,NA
NCT04416139,2020-05-01,2021-04-30,Interventional,Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04416139,0,0,0,0,0,0,Mexico,0,mesenchymal stem cells,NA
NCT04416334,2020-08-19,2021-08-25,Interventional,PREEMPTIVE THERAPY WITH COLCHICINE IN PATIENTS OLDER THAN 60 YEARS WITH HIGH RISK OF SEVERE PNEUMONIAE DUE TO CORONAVIRUS,Recruiting,Phase 3,Instituto de InvestigaciÃ³n MarquÃ©s de Valdecilla,NA,https://clinicalzeros.gov/ct2/show/NCT04416334,0,0,0,0,3,0,Spain,0,colchicine/symptomatic treatment (paracetamol)|symptomatic treatment (paracetamol/best symptomatic treatment based on doctor recommendations)|colchicine|symptomatic treatment (paracetamol)|symptomatic treatment (paracetamol|best symptomatic treatment based on doctor recommendations),NA
NCT04414124,2020-08-02,2021-02-28,Interventional,A Clinical Study to Assess the Natural History of COVID-19 and Effects of KB109 and Supportive Self-care in Outpatients With Mild-to-moderate COVID-19,"Active, not recruiting",N/A,Kaleido Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04414124,0,0,0,0,2,1,United States,0,kb109 / self supportive care (ssc)|self supportive care (ssc) alone|kb109|self supportive care (ssc),NA
NCT04414371,2020-05-20,2020-12-31,Interventional,Tools for Wellbeing COVID-19 National Study of Undergraduate Students,Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04414371,0,0,0,0,0,1,United States,0,yoga,NA
NCT04414267,2020-05-26,2021-05-25,Interventional,Bacillus Calmette-guÃ©rin Vaccination to Prevent COVID-19,Recruiting,Phase 4,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04414267,0,0,0,1,3,0,Greece,0,bcg|placebo,NA
NCT04415086,2020-06-01,2022-04-20,Interventional,Treatment of Patients With COVID-19 With Convalescent Plasma,Recruiting,Phase 2,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04415086,0,0,0,0,2,0,Brazil,0,convalescent plasma,NA
NCT04413864,2020-04-24,2021-02-28,Interventional,Immunomodulatory Profile of Dexmedetomidine Sedation in Patients Recovering After ARDS Covid-19,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04413864,0,0,0,0,0,0,France,0,inflammatory cytokines/chemokines profiles of patients with dexmedetomidine administration|inflammatory cytokines|chemokines profiles of patients with dexmedetomidine administration,NA
NCT04412772,2020-06-12,2021-12-31,Interventional,Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS,Recruiting,Phase 3,Queen's Medical Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04412772,0,0,0,0,1,1,United States,0,tocilizumab|placebo,NA
NCT04413006,2020-05-25,2020-12-31,Interventional,Self-compassion for Chronic Pain Virtual Group Treatment Program,Recruiting,N/A,University of Manitoba,NA,https://clinicalzeros.gov/ct2/show/NCT04413006,0,0,0,0,0,0,Canada,0,self-compassion for chronic pain virtual group treatment program,NA
NCT04412343,2020-05-23,2020-10-05,Interventional,The Seniors COvid-19 Pandemic and Exercise Study,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04412343,0,0,0,0,2,0,Canada,0,virtual group intervention|exercise,NA
NCT04412330,2020-05-01,2021-05-01,Interventional,Optimizing Outcomes With Physical Therapy Treatment for IndividuALs Surviving an ICU Admission for Covid-19,Recruiting,N/A,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04412330,0,0,0,0,2,1,United States,0,icu recovery / physical therapy|icu recovery|physical therapy,NA
NCT04412239,2020-04-20,2020-12-20,Interventional,To Assess the Efficiency and Satisfaction of Pharmacist Giving Patient-centred Advice on Telephone Consultation in TB Patients: Experience of the COVID-19 Pandemic,Recruiting,N/A,Health Science Center of Xi'an Jiaotong University,NA,https://clinicalzeros.gov/ct2/show/NCT04412239,0,0,0,0,1,0,Pakistan,0,patient-centred advice on telephone consultation in tb patients:,NA
NCT04412486,2020-06-01,2022-05-31,Interventional,COVID-19 Convalescent Plasma (CCP) Transfusion,Recruiting,Early Phase 1,University of Mississippi Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04412486,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04412018,2020-06-04,2020-12-31,Interventional,An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19,Recruiting,Phase 2,Canadian Medical and Surgical Knowledge Translation Research Group,NA,https://clinicalzeros.gov/ct2/show/NCT04412018,0,0,0,0,3,0,Canada,0,icosapent ethyl,NA
NCT04411667,2020-04-28,2020-11-01,Interventional,Study of SOC Plus IVIG Compared to SOC Alone in the Treatment of COVID-19,"Active, not recruiting",Phase 4,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04411667,0,0,0,0,1,1,United States,0,octagam,NA
NCT04411628,2020-05-28,2020-08-26,Interventional,A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19,Completed,Phase 1,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04411628,0,0,0,0,10,1,United States,0,ly3819253|placebo,NA
NCT04410692,2020-05-15,2020-05-16,Interventional,Can the Prediction Market Improve Predictions of COVID-19?,Completed,N/A,"National University, Singapore",NA,https://clinicalzeros.gov/ct2/show/NCT04410692,0,0,0,0,1,0,Singapore,0,prediction market,NA
NCT04410354,2020-06-16,2020-12-01,Interventional,Study of Merimepodib in Combination With Remdesivir in Adult Patients With Advanced COVID-19,Terminated,Phase 2,"ViralClear Pharmaceuticals, Inc.",Failure to meet primary endpoint,https://clinicalzeros.gov/ct2/show/NCT04410354,0,0,0,0,6,1,United States,0,merimepodib|placebo|remdesivir,NA
NCT04410536,2020-06-15,2021-12-31,Interventional,Home Detox in Medication Overuse Headache (MOH) During Covid-19 Emergency,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04410536,0,0,0,0,1,0,Italy,0,symptomatic drugs|bridge therapy|mindfulness,NA
NCT04410510,2020-09-30,2020-12-31,Interventional,P2Et Extract in the Symptomatic Treatment of Subjects With COVID-19,Recruiting,Phase 2/Phase 3,Hospital Universitario San Ignacio,NA,https://clinicalzeros.gov/ct2/show/NCT04410510,0,0,0,0,3,0,Colombia,0,p2et (caesalpinia spinosa extract)|placebo,NA
NCT04410458,2020-05-31,2020-05-31,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19 ï¼ˆRepeat Trialï¼‰,Enrolling by invitation,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04410458,0,0,0,0,0,0,China,0,blood donation sms,NA
NCT04410159,2020-06-22,2020-06-29,Interventional,Povidone-Iodine Vs Essential Oil Vs Tap Water Gargling For COVID-19 Patients,Completed,Phase 2,Universiti Sains Islam Malaysia,NA,https://clinicalzeros.gov/ct2/show/NCT04410159,0,0,0,0,5,0,Malaysia,1,povidone/iodine|essential oils|water,NA
NCT04409925,2020-12-25,2021-04-30,Interventional,DISmantling COvid iNduced Neutrophil ExtraCellular Traps (DISCONNECT-1),Recruiting,Phase 1,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04409925,0,0,0,0,7,0,Canada,0,rhdnase i,NA
NCT04410016,2020-05-25,2020-07-31,Interventional,Evaluation of Staff COVID-19 Wellbeing Centres in a Healthcare Workplace: COVID-WELL Study,Recruiting,N/A,University of Nottingham,NA,https://clinicalzeros.gov/ct2/show/NCT04410016,0,0,0,0,2,0,United Kingdom,0,staff wellbeing centres,NA
NCT04409834,2020-08-05,2021-05-31,Interventional,Prevention of Arteriovenous Thrombotic Events in Critically-Ill COVID-19 Patients Trial,Recruiting,Phase 4,The TIMI Study Group,NA,https://clinicalzeros.gov/ct2/show/NCT04409834,0,0,0,0,2,1,United States,0,unfractionated heparin iv|enoxaparin|clopidogrel|unfractionated heparin sc|kg|sodium,NA
NCT04409522,2020-05-12,2020-06-05,Interventional,Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients,Recruiting,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04409522,0,0,0,0,0,0,"Iran, Islamic Republic of",0,melatonin|standard care,NA
NCT04409509,2020-07-01,2021-01-12,Interventional,Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,CSL Behring,NA,https://clinicalzeros.gov/ct2/show/NCT04409509,0,0,0,0,11,1,United States,0,"garadacimab, factor xiia antagonist monoclonal antibody|placebo",NA
NCT04408456,2020-03-01,2020-07-31,Interventional,Efficacy of Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Completed,Phase 3,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04408456,0,0,0,0,2,0,India,0,hydroxychloroquine|standard care,NA
NCT04408131,2020-05-28,2021-01-27,Interventional,Morbi-mortality by COVID-19 Among Homeless People in Marseille: a Cohort Study,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04408131,0,0,0,0,0,0,France,0,blood sample,NA
NCT04408066,2020-04-30,2022-04-30,Interventional,COVID-19: A POC Test Under Research & Evaluation,Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04408066,0,0,0,0,1,0,United Kingdom,0,sample collection/performance evaluation (a)|sample collection/performance evaluation (b)|sample collection|performance evaluation,NA
NCT04407390,2020-06-01,2021-05-01,Interventional,Effects of Nicotinamide Riboside on the Clinical Outcome of Covid-19 in the Elderly,Recruiting,Phase 2,University of Copenhagen,NA,https://clinicalzeros.gov/ct2/show/NCT04407390,0,0,0,0,1,0,Denmark,0,nicotinamide riboside|placebo,NA
NCT04407208,2020-05-01,2020-06-22,Interventional,Convalescent Plasma Therapy in Patients With COVID-19,Completed,Phase 1,Biofarma,NA,https://clinicalzeros.gov/ct2/show/NCT04407208,0,0,0,0,2,0,Indonesia,0,convalescent plasma,NA
NCT04407182,2020-05-04,2020-08-01,Interventional,Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19,Completed,Phase 2,Catalysis SL,NA,https://clinicalzeros.gov/ct2/show/NCT04407182,0,0,0,0,4,0,Ecuador,0,viusid/asbrip|viusid|asbrip,NA
NCT04407286,2020-05-19,2020-08-30,Interventional,Vitamin D Testing and Treatment for COVID 19,Completed,Phase 1,Arizona State University,NA,https://clinicalzeros.gov/ct2/show/NCT04407286,0,0,0,0,2,1,United States,0,vitamin d,NA
NCT04406493,2020-04-28,2021-04-28,Interventional,Monitoring COVID-19 Patients' Lung Fluid Using Impedance Technique,Recruiting,N/A,Hillel Yaffe Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04406493,0,0,0,0,0,0,Israel,0,lung impedance,NA
NCT04406389,2020-10-13,2021-06-30,Interventional,Anticoagulation in Critically Ill Patients With COVID-19 (The IMPACT Trial),Recruiting,Phase 4,Weill Medical College of Cornell University,NA,https://clinicalzeros.gov/ct2/show/NCT04406389,0,0,0,0,4,1,United States,0,enoxaparin|heparin|fondapariniux|argatroban,NA
NCT04406181,2020-05-18,2020-12-31,Interventional,Psychological Well-being of Patients Awaiting for Cardiac Surgery During the COVID-19 Pandemic,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04406181,0,0,0,0,1,0,Belgium,0,hads|survey,NA
NCT04405999,2020-05-14,2020-08-09,Interventional,Prevention of Infection and Incidence of COVID-19 in Medical Personnel Assisting Patients With New Coronavirus Disease,Completed,Phase 4,"Federal State Budgetary Institution, V. A. Almazov Federal North-West Medical Research Centre, of the Ministry of Health",NA,https://clinicalzeros.gov/ct2/show/NCT04405999,0,0,0,0,1,0,Russian Federation,0,bromhexine hydrochloride,NA
NCT04405310,2020-05-20,2020-11-20,Interventional,Convalescent Plasma of Covid-19 to Treat SARS-COV-2 a Randomized Doble Blind 2 Center Trial,Completed,Phase 2,Grupo Mexicano para el Estudio de la Medicina Intensiva,NA,https://clinicalzeros.gov/ct2/show/NCT04405310,0,0,0,0,2,0,Mexico,0,convalescent plasma|placebo|albumine,NA
NCT04405102,2020-09-16,2023-01-01,Interventional,COVID-19 Ozanimod Intervention Study,Recruiting,Phase 2,Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec,NA,https://clinicalzeros.gov/ct2/show/NCT04405102,0,0,0,0,2,0,Canada,0,ozanimod|standard care,NA
NCT04405544,2020-05-22,2020-07-22,Interventional,Determination of Acute Encephalopathy Predictors in Patients With COVID-19,Completed,N/A,"State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04405544,0,0,0,0,2,0,Russian Federation,0,ct-scan|eeg|ep|pulse oximetry|blood test,NA
NCT04404218,2020-08-04,2021-03-31,Interventional,The AÃ§aÃ­ Berry COVID-19 Anti-Inflammation Trial,Recruiting,Phase 2,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04404218,0,0,0,0,1,0,Canada,0,aã§aã­ palm berry extract - natural product|placebo|aã§aã­ palm berry extract - natural product,NA
NCT04403269,2020-05-05,2021-05-05,Interventional,"NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE",Recruiting,Phase 2,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04403269,0,0,0,0,0,0,France,0,igiv,NA
NCT04402983,2020-05-27,2020-12-01,Interventional,The Effectiveness of Telerehabilitation-Based Physiotherapy in COVID 19 Patients,Completed,N/A,Istanbul Medipol University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04402983,0,0,0,0,2,0,Turkey,0,physiotherapy,NA
NCT04402879,2020-11-10,2021-12-01,Interventional,CORONA (COvid pRONe hypoxemiA): Prone Positioning for Hypoxemic COVID-19 Patients With Do-not-intubate Goals,Recruiting,N/A,University of Calgary,NA,https://clinicalzeros.gov/ct2/show/NCT04402879,0,0,0,0,5,0,Canada,0,prone positioning,NA
NCT04402840,2020-04-24,2021-12-31,Interventional,Stellate Ganglion Block (SGB) for COVID-19 Acute Respiratory Distress Syndrome (ARDS),Recruiting,N/A,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04402840,0,0,0,0,1,1,United States,0,stellate ganglion block,NA
NCT04402203,2020-05-31,2020-07-31,Interventional,Study on Safety and Efficacy of Favipiravir (Favipira) for COVID-19 Patient in Selected Hospitals of Bangladesh,Recruiting,Phase 2/Phase 3,Bangladesh Medical Research Council (BMRC),NA,https://clinicalzeros.gov/ct2/show/NCT04402203,0,0,0,0,0,0,Bangladesh,0,favipiravir|standard care,NA
NCT04402060,2020-05-28,2021-01-31,Interventional,A Study of APL-9 in Adults With Mild to Moderate ARDS Due to COVID-19,Recruiting,Phase 1/Phase 2,"Apellis Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04402060,0,0,0,0,3,1,United States|Brazil,0,apl-9|vehicle control,NA
NCT04400929,2020-06-02,2021-06-30,Interventional,Using GM-CSF as a Host Directed Therapeutic Against COVID-19,Recruiting,Phase 2,Singapore General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04400929,0,0,0,0,1,0,Singapore,0,sargramostim|saline,NA
NCT04401046,2020-05-20,2020-10-30,Interventional,COVID-19 and Reorganisation of Cancer Patient Care: Self- Evaluation of Potential Post-traumatic Stress Disorder,Recruiting,N/A,Institut Paoli-Calmettes,NA,https://clinicalzeros.gov/ct2/show/NCT04401046,0,0,0,0,2,0,France,0,survey|anxiety|6 months later,NA
NCT04400279,2020-06-01,2020-11-28,Interventional,The COVID-19 Pandemic and Exercise Study,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04400279,0,0,0,0,4,0,Canada,0,yoga group|high intensity interval training|combination,NA
NCT04399889,2020-06-18,2021-04-01,Interventional,hCT-MSCs for COVID19 ARDS,Recruiting,Phase 1/Phase 2,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04399889,0,0,0,0,1,1,United States,0,mesenchymalÂ stem cells,NA
NCT04399681,2020-05-10,2020-08-10,Interventional,The Utility of Bedside Lung Ultrasonography on Diagnosis of COVID-19,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04399681,0,0,0,0,0,0,Turkey,0,lung ultrasound,NA
NCT04399967,2020-06-13,2021-06-30,Interventional,"COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via ""Quit to Win"" Contest 2020",Recruiting,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04399967,0,0,0,0,5,0,China,0,chat-based support|award/covid-specific advice|award advice|covid-19 related health warning leaflet|health warning leaflet|sms-based support|referral card|cosh self-help smoking cessation booklet|award|covid-specific advice,NA
NCT04399746,2020-03-15,2020-05-20,Interventional,Ivermectin-Azithromycin-Cholecalciferol (IvAzCol) Combination Therapy for COVID-19,Recruiting,N/A,Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado,NA,https://clinicalzeros.gov/ct2/show/NCT04399746,0,0,0,0,0,0,Mexico,0,ivermectin|azithromycin|cholecalciferol,NA
NCT04399109,2020-05-20,2021-05-19,Interventional,Evaluation of a Remote Monitoring Smartphone Application and Care Model of COVID-19 Patients in the Community (ReCOVER),Recruiting,N/A,"Prince of Wales Hospital, Sydney",NA,https://clinicalzeros.gov/ct2/show/NCT04399109,0,0,0,0,0,0,Australia,0,tcc-covid mhealth,NA
NCT04399005,2020-05-25,2020-06-05,Interventional,The Efficacy Comparing Daily and After-each-case Room Disinfection.,Completed,N/A,The First Affiliated Hospital of Zhejiang Chinese Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04399005,0,0,0,0,1,0,China,0,after-each-case room disinfection|daily room disinfection,NA
NCT04398277,2020-05-01,2021-04-30,Interventional,A Daily Coping Toolkit for Medical Personnel and First-Responders During COVID-19 Pandemic,Recruiting,N/A,Kent State University,NA,https://clinicalzeros.gov/ct2/show/NCT04398277,0,0,0,0,0,1,United States,0,daily coping toolkit,NA
NCT04398004,2020-05-06,2020-11-30,Interventional,Anti-inflammatory Clarithromycin for Improving COVID-19 Infection Early,Completed,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04398004,0,0,0,0,3,0,Greece,0,clarithromycin,NA
NCT04397692,2020-06-13,2020-09-30,Interventional,Inhaled NO for the Treatment of COVID-19 Caused by SARS-CoV-2 (US Trial),Recruiting,N/A,Beyond Air Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04397692,0,0,0,0,2,1,United States,0,nitric oxide delivered via lungfitâ„¢ system|nitric oxide delivered via lungfitâ„¢ system,NA
NCT04397562,2020-04-29,2020-07-03,Interventional,A Clinical Trial of the Efficacy and Safety of Levilimab (BCD-089) in Patients With Severe COVID-19,Completed,Phase 3,Biocad,NA,https://clinicalzeros.gov/ct2/show/NCT04397562,0,0,0,0,4,0,Russian Federation,0,levilimab|placebo,NA
NCT04397666,2020-05-15,2020-09-15,Interventional,RT-PCR on Conjunctival Sample for the Detection of SARS-CoV-2 in Patients With Covid-19,Recruiting,N/A,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04397666,0,0,0,0,1,0,France,0,pcr,NA
NCT04396106,2020-05-26,2021-03-31,Interventional,Safety and Efficacy of AT-527 in Subjects With Moderate Coronavirus Disease (COVID-19),Recruiting,Phase 2,"Atea Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04396106,0,0,0,0,6,1,"United States|Belgium|Brazil|Moldova, Republic of|Romania|South Africa|Ukraine",0,at-527|placebo,NA
NCT04395768,2020-09-09,2021-09-30,Interventional,International ALLIANCE Study of Therapies to Prevent Progression of COVID-19,Recruiting,Phase 2,"National Institute of Integrative Medicine, Australia",NA,https://clinicalzeros.gov/ct2/show/NCT04395768,0,0,0,0,1,0,Australia,0,vitamin c|hydroxychloroquine|azithromycin|zinc citrate|vitamin d|vitamin b,NA
NCT04394793,2020-06-13,2020-08-27,Interventional,Low Dose Radiation Therapy for Covid-19 Pneumonia,"Active, not recruiting",N/A,"All India Institute of Medical Sciences, New Delhi",NA,https://clinicalzeros.gov/ct2/show/NCT04394793,0,0,0,0,4,0,India,0,low,NA
NCT04394455,2020-06-30,2020-11-30,Interventional,Brief Cognitive Behavioral Therapy Versus Crisis Intervention Therapy Through Telepsychiatry on Psychiatric Symptoms,Enrolling by invitation,N/A,Universidad Nacional Autonoma de Honduras,NA,https://clinicalzeros.gov/ct2/show/NCT04394455,0,0,0,0,2,0,Honduras,0,behavioral|crisis intervention therapy,NA
NCT04394442,2020-03-21,2020-08-31,Interventional,Hydroxychloroquine in COVID-19 Patients,Recruiting,Phase 2,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04394442,0,0,0,0,0,0,Saudi Arabia,0,hydroxychloroquine,NA
NCT04394117,2020-06-19,2021-06-30,Interventional,Controlled evaLuation of Angiotensin Receptor Blockers for COVID-19 respIraTorY Disease,Recruiting,Phase 4,The George Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04394117,0,0,0,0,3,0,Australia|India,0,arb|placebo,NA
NCT04394169,2020-05-25,2020-09-25,Interventional,Early Care Program for the Management of Post-ICU Syndrome and Chronic Pain After COVID-19 Infection.,Recruiting,N/A,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04394169,0,0,0,0,1,0,Spain,0,intervention program,NA
NCT04393961,2020-04-05,2020-07-29,Interventional,At-Home COVID-19 Antibody Test Usability Assessment & Behavior Change Study,Recruiting,N/A,ProofPilot,NA,https://clinicalzeros.gov/ct2/show/NCT04393961,0,0,0,0,0,1,United States,0,igm/igg rapid test|igg|igm antibodytest,NA
NCT04393948,2020-06-30,2020-10-31,Interventional,Lung Irradiation for COVID-19 Pneumonia,Recruiting,N/A,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04393948,0,0,0,0,2,1,United States,0,phase 1|phase 2,NA
NCT04393636,2020-06-05,2022-12-31,Interventional,Digital Cardiac Counseling Trial: DCC Trial,Recruiting,N/A,Academisch Ziekenhuis Maastricht,NA,https://clinicalzeros.gov/ct2/show/NCT04393636,0,0,0,0,1,0,Netherlands,0,digital cardiac counseling,NA
NCT04393415,2020-05-25,2020-08-25,Interventional,Using PRP and Cord Blood in Treatment of Covid -19,Recruiting,N/A,Aljazeera Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04393415,0,0,0,0,2,0,Egypt,0,mesenchymal stem cells,NA
NCT04393792,2020-05-31,2020-08-31,Interventional,SINUS WASH Pilot Study in Adults Testing Positive for COVID-19,Recruiting,Phase 1,Hampshire Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04393792,0,0,0,0,0,0,United Kingdom,0,povidone/iodine|saline,NA
NCT04393038,2020-05-01,2020-12-30,Interventional,ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Abivax S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04393038,0,0,0,0,2,0,Belgium|Brazil|France|Germany|Italy|Mexico|Spain|United Kingdom,0,abx464|placebo,NA
NCT04392778,2020-04-01,2020-07-31,Interventional,Clinical Use of Stem Cells for the Treatment of Covid-19,Recruiting,Phase 1/Phase 2,SBÃœ Dr. Sadi Konuk EÄŸitim ve AraÅŸtÄ±rma Hastanesi,NA,https://clinicalzeros.gov/ct2/show/NCT04392778,0,0,0,0,0,0,Turkey,0,mesenchymal stem cells|saline,NA
NCT04392414,2020-05-01,2020-07-10,Interventional,Hyperimmune Convalescent Plasma in Moderate and Severe COVID-19 Disease,Completed,Phase 2,"Federal Research Clinical Center of Federal Medical & Biological Agency, Russia",NA,https://clinicalzeros.gov/ct2/show/NCT04392414,0,0,0,0,2,0,Russian Federation,0,convalescent plasma|plasma,NA
NCT04393077,2020-05-10,2020-05-15,Interventional,Emotional Freedom Technique (EFT) Effect on Nurses,Completed,N/A,Istanbul Saglik Bilimleri University,NA,https://clinicalzeros.gov/ct2/show/NCT04393077,0,0,0,0,2,0,Turkey,0,emotional freedom technique,NA
NCT04391712,2020-04-30,2020-05-15,Interventional,Photobiomodulation Laser Therapy for COVID-19 Positive Patients With Pulmonary Disease,Completed,Phase 2,Lowell General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04391712,0,0,0,0,1,1,United States,0,mls laser|standard care,NA
NCT04392232,2020-05-05,2020-12-31,Interventional,A Study of COVID 19 Convalescent Plasma in High Risk Patients With COVID 19 Infection,Recruiting,Phase 2,TriHealth Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04392232,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04392219,2020-04-10,2020-08-11,Interventional,"COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers",Completed,Phase 1,"Ridgeback Biotherapeutics, LP",NA,https://clinicalzeros.gov/ct2/show/NCT04392219,0,0,0,0,3,0,United Kingdom,0,eidd-2801|placebo,NA
NCT04391829,2020-08-31,2021-08-31,Interventional,Detection of SARS-CoV-2 in Semen of COVID-19 Positive Males,Recruiting,N/A,Universitair Ziekenhuis Brussel,NA,https://clinicalzeros.gov/ct2/show/NCT04391829,0,0,0,0,1,0,Belgium,0,ejaculated semen sample,NA
NCT04391127,2020-05-04,2020-11-06,Interventional,Hydroxychloroquine and Ivermectin for the Treatment of COVID-19 Infection,Completed,Phase 3,Centenario Hospital Miguel Hidalgo,NA,https://clinicalzeros.gov/ct2/show/NCT04391127,0,0,0,0,4,0,Mexico,0,hydroxychloroquine|ivermectin|placebo,NA
NCT04390178,2020-04-10,2020-06-30,Interventional,Convalescent Plasma as Treatment for Acute Coronavirus Disease (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04390178,0,0,0,0,0,0,Sweden,0,convalescent plasma,NA
NCT04390594,2020-08-13,2021-02-12,Interventional,Efficacy and Safety Evaluation of Treatment Regimens in Adult COVID-19 Patients in Senegal,Recruiting,Phase 3,Institut Pasteur de Dakar,NA,https://clinicalzeros.gov/ct2/show/NCT04390594,0,0,0,0,4,0,Senegal,0,nafamostat mesilate,NA
NCT04390516,2020-03-24,2020-05-04,Interventional,Respiratory Decompensation and Model for the Triage of COVID-19 Patients,Completed,N/A,Dascena,NA,https://clinicalzeros.gov/ct2/show/NCT04390516,0,0,0,0,3,1,United States,0,coviage,NA
NCT04390477,2020-05-04,2021-07-31,Interventional,Study to Evaluate the Effect of a Probiotic in COVID-19,Recruiting,N/A,Bioithas SL,NA,https://clinicalzeros.gov/ct2/show/NCT04390477,0,0,0,0,1,0,Spain,0,probiotic,NA
NCT04390412,2020-05-04,2020-08-30,Interventional,Low Dose Radiotherapy in COVID-19 Pneumonia,"Active, not recruiting",Phase 1/Phase 2,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04390412,0,0,0,0,2,0,"Iran, Islamic Republic of",0,radiotherapy,NA
NCT04389944,2020-03-31,2020-06-30,Interventional,Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19,Completed,N/A,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04389944,0,0,0,0,2,0,Switzerland,0,convalescent plasma,NA
NCT04390152,2020-01-13,2021-12-31,Interventional,Safety and Efficacy of Intravenous Wharton's Jelly Derived Mesenchymal Stem Cells in Acute Respiratory Distress Syndrome Due to COVID 19,Recruiting,Phase 1/Phase 2,BioXcellerator,NA,https://clinicalzeros.gov/ct2/show/NCT04390152,0,0,0,0,3,0,Colombia,0,"wharton's jelly derived mesenchymal stem cells.|hydroxychloroquine, lopinavir/ritonavir/azithromycin/placebo (standard therapy)|hydroxychloroquine, lopinavir|ritonavir|azithromycin|placebo (standard therapy)",NA
NCT04389710,2020-04-15,2021-04-14,Interventional,Convalescent Plasma for the Treatment of COVID-19,Recruiting,Phase 2,Thomas Jefferson University,NA,https://clinicalzeros.gov/ct2/show/NCT04389710,0,0,0,0,1,1,United States,0,convalescent plasma,NA
NCT04389450,2020-10-01,2021-05-31,Interventional,"Double-Blind, Multicenter, Study to Evaluate the Efficacy of PLX PAD for the Treatment of COVID-19",Recruiting,Phase 2,Pluristem Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04389450,0,0,0,0,8,1,United States,0,plx-pad|placebo,NA
NCT04389333,2020-03-26,2020-04-26,Interventional,Feasibility of Non-contact Magnetically-controlled Capsule Endoscopy During COVID-19 Pandemic,Completed,N/A,Changhai Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04389333,0,0,0,0,1,0,China,0,endoscopy,NA
NCT04389385,2020-05-01,2020-09-30,Interventional,COVID-19 Specific T Cell Derived Exosomes (CSTC-Exo),"Active, not recruiting",Phase 1,TC Erciyes University,NA,https://clinicalzeros.gov/ct2/show/NCT04389385,0,0,0,0,0,0,Turkey,0,t cell derived exosom,NA
NCT04389372,2020-03-15,2021-03-31,Interventional,"Effectiveness and Acceptability of MINDFULNESS by Smartphone, for Patients With Chronic Migraine and Medication Overuse",Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04389372,0,0,0,0,1,0,Italy,0,mindfulness,NA
NCT04387409,2020-05-25,2021-05-01,Interventional,Study to Assess VPM1002 in Reducing Healthcare Professionals' Absenteeism in COVID-19 Pandemic,"Active, not recruiting",Phase 3,Vakzine Projekt Management GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04387409,0,0,0,0,3,0,Germany,0,vpm1002|placebo,NA
NCT04387955,2020-04-30,2021-05-31,Interventional,Analysis of Chilblains pROfile During coVID-19 Epidemic (ACROVID),Recruiting,N/A,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04387955,0,0,0,0,1,0,France,0,biological samples,NA
NCT04388514,2020-04-08,2020-10-08,Interventional,Blood Ozonization in Patients With SARS-CoV-2 Respiratory Failure,Recruiting,N/A,Azienda Sanitaria-Universitaria Integrata di Udine,NA,https://clinicalzeros.gov/ct2/show/NCT04388514,0,0,0,0,0,0,Italy,0,ozone,NA
NCT04388410,2020-08-25,2020-11-30,Interventional,Safety and Efficacy of Convalescent Plasma Transfusion for Patients With COVID-19,Recruiting,Phase 2/Phase 3,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04388410,0,0,0,0,2,0,Mexico,0,convalescent plasma,NA
NCT04387253,2020-05-23,2021-07-23,Interventional,Study of Late Fetal Loss in Poitou-Charentes. GYNE-COVID,Recruiting,N/A,Poitiers University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04387253,0,0,0,0,3,0,France,0,pcr,NA
NCT04387292,2020-09-07,2021-05-31,Interventional,Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic,Recruiting,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04387292,0,0,0,0,2,0,France,0,ophthalmologic exam,NA
NCT04386850,2020-04-14,2020-11-15,Interventional,Oral 25-hydroxyvitamin D3 and COVID-19,Recruiting,Phase 2/Phase 3,Tehran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04386850,0,0,0,0,1,0,"Iran, Islamic Republic of",0,hydroxyvitamin,NA
NCT04386668,2020-05-26,2020-07-12,Interventional,Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic,Terminated,N/A,"University College, London",Interim analysis indicated adaptations to intervention may be required.,https://clinicalzeros.gov/ct2/show/NCT04386668,0,0,0,0,4,0,United Kingdom,0,let it out (lio)-c|neutral writing control,NA
NCT04386798,2020-07-25,2020-12-22,Interventional,Stress and Anxiety Levels of Mothers Lying in the Baby Newborn Intensive Care Unit,Recruiting,N/A,Eskisehir Osmangazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04386798,0,0,0,0,2,0,Turkey,0,survey,NA
NCT04386694,2020-05-18,2020-09-17,Interventional,Photobiomodulation Therapy Combined With Static Magnetic Field in Patients With COVID-19,Completed,N/A,University of Nove de Julho,NA,https://clinicalzeros.gov/ct2/show/NCT04386694,0,0,0,0,6,0,Brazil,0,pbmt/smf|placebo|pbmt|smf,NA
NCT04386291,2020-05-25,2021-05-19,Interventional,Meditation and Kundalini Yoga for Heightened Anxiety Related to COVID-19,Recruiting,N/A,"Research Foundation for Mental Hygiene, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04386291,0,0,0,0,4,1,United States,0,anxiety reduction training|kundalini yoga/anxiety reduction training|meditation/anxiety reduction training|kundalini yoga|meditation,NA
NCT04386239,2021-01-31,2021-01-31,Interventional,Study on the Use of Sarilumab in Patients With COVID-19 Infection,Recruiting,Early Phase 1,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04386239,0,0,0,0,1,0,Italy,0,sarilumab prefilled syringe,NA
NCT04385836,2020-06-01,2020-09-01,Interventional,Trial of Alpha One Antitrypsin Inhalation in Treating Patient With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2),Recruiting,Early Phase 1,"Ministry of Health, Saudi Arabia",NA,https://clinicalzeros.gov/ct2/show/NCT04385836,0,0,0,0,0,0,Saudi Arabia,0,alpha one antitrypsin,NA
NCT04385810,2020-04-27,2020-07-29,Interventional,Description of Ophthalmologic Injuries in Intensive Care During the SARS-CoV2 Epidemic - COVID19,Completed,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04385810,0,0,0,0,1,0,France,0,ophthalmologic exam,NA
NCT04385199,2020-05-04,2020-08-01,Interventional,Convalescent Plasma for Patients With COVID-19,Recruiting,Phase 2,Henry Ford Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04385199,0,0,0,0,0,1,United States,0,convalescent plasma,NA
NCT04385108,2020-03-04,2021-12-31,Interventional,Predictive Immune Biomarkers for COVID-19 Pathogenesis,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04385108,0,0,0,0,2,0,France,0,blood sample|blood collection on their first consultation/10 to 14 days later|longitudinally|10 to 14 days later,NA
NCT04384900,2020-05-11,2020-11-30,Interventional,Accelerated Prone Position Ventilation of Patients With COVID-19,Recruiting,N/A,Nordsjaellands Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384900,0,0,0,0,1,0,Denmark,0,prone positioning,NA
NCT04384588,2020-04-07,2021-04-06,Interventional,COVID19-Convalescent Plasma for Treating Patients With Active Symptomatic COVID 19 Infection (FALP-COVID),Recruiting,Phase 2/Phase 3,Fundacion Arturo Lopez Perez,NA,https://clinicalzeros.gov/ct2/show/NCT04384588,0,0,0,0,0,0,Chile,0,convalescent plasma,NA
NCT04384549,2020-05-20,2021-02-20,Interventional,Efficacy of BCG Vaccination in the Prevention of COVID19 Via the Strengthening of Innate Immunity in Health Care Workers,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04384549,0,0,0,1,1,0,France,0,bcg|placebo,NA
NCT04384497,2020-05-07,2020-06-30,Interventional,Convalescent Plasma for Treatment of COVID-19: An Exploratory Dose Identifying Study,Recruiting,Phase 1/Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384497,0,0,0,0,1,0,Sweden,0,convalescent plasma,NA
NCT04384458,2020-07-20,2020-09-10,Interventional,Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis,Recruiting,N/A,Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara,NA,https://clinicalzeros.gov/ct2/show/NCT04384458,0,0,0,0,3,0,Brazil,0,hydroxychloroquine|ivermectin,NA
NCT04382924,2020-08-05,2022-01-31,Interventional,Safety and Efficacy of NP-120 (Ifenprodil) for the Treatment of Hospitalized Patient With Confirmed COVID-19 Disease,"Active, not recruiting",Phase 2/Phase 3,Algernon Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04382924,0,0,0,0,4,1,United States|Australia|Philippines|Romania,0,np-120 (ifenprodil),NA
NCT04382729,2020-04-17,2020-07-31,Interventional,Neuromuscular Electrical Stimulation in Patients With COVID19 Associated Pneumonia,Recruiting,N/A,"University of Turin, Italy",NA,https://clinicalzeros.gov/ct2/show/NCT04382729,0,0,0,0,0,0,Italy,0,neuromuscular electrical stimulation|exercise,NA
NCT04382846,2020-05-08,2030-12-01,Interventional,Novel Regimens in COVID-19 Treatment,Recruiting,Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04382846,0,0,0,0,1,0,Egypt,0,nitazoxanide,NA
NCT04382547,2020-05-11,2021-06-30,Interventional,Treatment of Covid-19 Associated Pneumonia With Allogenic Pooled Olfactory Mucosa-derived Mesenchymal Stem Cells,Enrolling by invitation,Phase 1/Phase 2,Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus,NA,https://clinicalzeros.gov/ct2/show/NCT04382547,0,0,0,0,1,0,Belarus,0,mesenchymal stem cells|standard care,NA
NCT04382131,2020-06-23,2020-10-31,Interventional,Hypertonic Saline Nasal Irrigation and Gargling in Suspected or Confirmed COVID-19 (ELVIS COVID-19),Recruiting,N/A,University of Edinburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04382131,0,0,0,0,2,0,United Kingdom,0,saline,NA
NCT04381884,2020-05-18,2020-09-29,Interventional,Ivermectin Effect on SARS-CoV-2 Replication in Patients With COVID-19,Completed,Phase 2,Laboratorio Elea Phoenix S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04381884,0,0,0,0,7,0,Argentina,0,ivermectin (iver pâ®) arm will receive ivm 600 âµg / kg once daily/standard care. control arm will receive standard care.|ivermectin (iver pâ®) arm will receive ivm 600 âµg|kg once daily|standard care,NA
NCT04381858,2020-05-06,2020-11-26,Interventional,Convalescent Plasma vs Human Immunoglobulin to Treat COVID-19 Pneumonia,Completed,Phase 3,Centenario Hospital Miguel Hidalgo,NA,https://clinicalzeros.gov/ct2/show/NCT04381858,0,0,0,0,2,0,Mexico,0,convalescent plasma|immunoglobulin,NA
NCT04382092,2020-03-23,2020-04-24,Interventional,Co-infection Management in COVID-19 Critically Ill,Completed,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04382092,0,0,0,0,0,0,Belgium,0,filmarray pneumonia,NA
NCT04382066,2020-05-12,2020-12-23,Interventional,Proof of Concept Study to Evaluate the Safety Profile of Plitidepsin in Patients With COVID-19,Completed,Phase 1,PharmaMar,NA,https://clinicalzeros.gov/ct2/show/NCT04382066,0,0,0,0,10,0,Spain,0,plitidepsin|day,NA
NCT04381000,2020-04-01,2020-05-29,Interventional,Quarantine and Telerehabilitation in Chronic Pain Patients During COVID-19 Pandemic.,Completed,N/A,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,https://clinicalzeros.gov/ct2/show/NCT04381000,0,0,0,0,2,0,Greece,0,exercise,NA
NCT04380935,2020-05-18,2020-10-31,Interventional,Effectiveness and Safety of Convalescent Plasma Therapy on COVID-19 Patients With Acute Respiratory Distress Syndrome,Recruiting,Phase 2/Phase 3,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04380935,0,0,0,0,1,0,Indonesia,0,convalescent plasma|standard care,NA
NCT04380688,2020-06-13,2020-11-16,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04380688,0,0,0,0,3,1,United States,0,acalabrutinib,NA
NCT04729491,2020-06-30,2020-09-15,Interventional,EAT-DUTA AndroCoV Trial,Completed,Phase 2/Phase 3,Corpometria Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04729491,0,0,0,0,0,0,Brazil,0,dutasteride 0.5 mg|azithromycin|nitazoxanide|placebo,NA
NCT04380532,2020-05-15,2021-05-15,Interventional,Tableted COVID-19 Therapeutic Vaccine,"Active, not recruiting",Phase 1/Phase 2,Immunitor LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04380532,0,0,0,1,1,0,Canada|Mongolia,0,v-sars,NA
NCT04380519,2020-04-23,2020-07-10,Interventional,Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19),Completed,Phase 2/Phase 3,R-Pharm,NA,https://clinicalzeros.gov/ct2/show/NCT04380519,0,0,0,0,2,0,Russian Federation,0,rph-104|olokizumab|placebo,NA
NCT04380376,2020-04-30,2020-10-30,Interventional,Low-doses Melphalan Inhalation in Patients With COVID-19 (CoronavIrus Disease 2019) Pneumonia,Recruiting,Phase 2,"Federal State Budgetary Institution, Pulmonology Scientific Research Institute",NA,https://clinicalzeros.gov/ct2/show/NCT04380376,0,0,0,0,1,0,Russian Federation,0,standard care|melphalan,NA
NCT04379661,2020-05-07,2020-07-07,Interventional,SUNLIGHT Study: Online Support Groups for MS to Address COVID-19,Completed,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04379661,0,0,0,0,2,1,United States,0,online support group,NA
NCT04379531,2020-04-25,2020-05-22,Interventional,LDCT in COVID-19 Pneumonia: a Prospective Moscow Study,Completed,N/A,Research and Practical Clinical Center for Diagnostics and Telemedicine Technologies of the Moscow Health Care Department,NA,https://clinicalzeros.gov/ct2/show/NCT04379531,0,0,0,0,2,0,Russian Federation,0,chest ct,NA
NCT04379375,2020-07-27,2020-09-30,Interventional,Nudges to Improve Health Behaviors That Limit COVID-19 Spread,Terminated,N/A,Medical College of Wisconsin,Slow enrollment rate,https://clinicalzeros.gov/ct2/show/NCT04379375,0,0,0,0,6,1,United States,0,nudge,NA
NCT04379336,2020-05-04,2021-04-28,Interventional,BCG Vaccination for Healthcare Workers in COVID-19 Pandemic,Recruiting,Phase 3,TASK Applied Science,NA,https://clinicalzeros.gov/ct2/show/NCT04379336,0,0,0,1,0,0,South Africa,0,bacille calmette-guã©rin (bcg)|placebo|bacille calmette-guã©rin (bcg),NA
NCT04379037,2020-06-27,2020-09-01,Interventional,Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients,Recruiting,N/A,Nemechek Technologies,NA,https://clinicalzeros.gov/ct2/show/NCT04379037,0,0,0,0,1,0,Argentina,0,transcutaneous auricular vagus nerve stimulation,NA
NCT04378803,2020-05-13,2020-08-04,Interventional,Mindfulness Training for Seniors,Completed,N/A,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04378803,0,0,0,0,3,1,United States,0,mindfullness training,NA
NCT04378712,2020-01-21,2020-03-23,Interventional,Hydrogen/Oxygen Mixed Gas Inhalation for Coronavirus Disease 2019 (COVID-19),Completed,N/A,Guangzhou Institute of Respiratory Disease,NA,https://clinicalzeros.gov/ct2/show/NCT04378712,0,0,0,0,2,0,China,0,hydrogen oxygen generator with nebulizer|standard care,NA
NCT04377672,2020-05-28,2021-05-28,Interventional,Human Convalescent Plasma for High Risk Children Exposed or Infected With SARS-CoV-2 (COVID-19),Recruiting,Phase 1,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04377672,0,0,0,0,2,1,United States,0,convalescent plasma,NA
NCT04377477,2020-05-10,2021-08-10,Interventional,COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19),Recruiting,N/A,Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia,NA,https://clinicalzeros.gov/ct2/show/NCT04377477,0,0,0,0,2,0,Italy,0,radiological,NA
NCT04377750,2020-04-08,2020-04-29,Interventional,The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation,Recruiting,Phase 4,Hadassah Medical Organization,NA,https://clinicalzeros.gov/ct2/show/NCT04377750,0,0,0,0,0,0,Israel,0,tocilizumab,NA
NCT04377659,2020-05-01,2022-05-01,Interventional,Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection,"Active, not recruiting",Phase 2,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04377659,0,0,0,0,5,1,United States,0,tocilizumab,NA
NCT04377308,2020-05-01,2021-04-20,Interventional,Fluoxetine to Reduce Intubation and Death After COVID19 Infection,Recruiting,Phase 4,University of Toledo Health Science Campus,NA,https://clinicalzeros.gov/ct2/show/NCT04377308,0,0,0,0,0,1,United States,0,fluoxetine,NA
NCT04376593,2020-05-01,2021-05-31,Interventional,PET/CT Imaging in COVID-19 Patients,Enrolling by invitation,Early Phase 1,"University of California, Davis",NA,https://clinicalzeros.gov/ct2/show/NCT04376593,0,0,0,0,1,1,United States,0,18f-î±vî²6-bp|18f-î±vî²6-bp,NA
NCT04376476,2020-05-05,2021-06-05,Interventional,Host-pathogen Interactions During SARS-CoV-2 Infection,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04376476,0,0,0,0,1,0,France,0,blood sample|low/upper respiratory tract sample|stool collection|phone call|low|respiratory tract sample|swab,NA
NCT04376840,2020-05-28,2022-01-28,Interventional,Prevalence of Long-term Respiratory Complications of Severe SARS-CoV-2 Pneumonia - COVID-19,Recruiting,N/A,CHU de Reims,NA,https://clinicalzeros.gov/ct2/show/NCT04376840,0,0,0,0,1,0,France,0,blood sample/data record|blood sample|data record,NA
NCT04376814,2020-03-29,2020-04-05,Interventional,Favipiravir Plus Hydroxychloroquine and Lopinavir/Ritonavir Plus Hydroxychloroquine in COVID-19,Completed,N/A,Baqiyatallah Medical Sciences University,NA,https://clinicalzeros.gov/ct2/show/NCT04376814,0,0,0,0,2,0,"Iran, Islamic Republic of",0,favipiravir|hydroxychloroquine|lopinavir/ritonavir|lopinavir|ritonavir,NA
NCT04376788,2020-05-20,2020-07-01,Interventional,Exchange Transfusion Versus Plasma From Convalescent Patients With Methylene Blue in Patients With COVID-19,Recruiting,Phase 2,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04376788,0,0,0,0,1,0,Egypt,0,plasma|convalescent plasma|methylene blue|methylprednisolone,NA
NCT04374019,2020-05-01,2021-05-31,Interventional,Novel Agents for Treatment of High-risk COVID-19 Positive Patients,Recruiting,Phase 2,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04374019,0,0,0,0,3,1,United States,0,ivermectin|camostat mesilate|artemesia annua|artesunate,NA
NCT04376034,2020-04-16,2021-03-30,Interventional,Convalescent Plasma Collection and Treatment in Pediatrics and Adults,Recruiting,Phase 3,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04376034,0,0,0,0,0,1,United States,0,convalescent plasma|standard care,NA
NCT04375774,2020-05-31,2020-05-31,Interventional,Verification of Alternative Do-it-yourself Equipment Respirators for the COVID-19 Personal Protective Equipment (PPE),Recruiting,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04375774,0,0,0,0,0,0,Belgium,0,ffp2|facial mask|mfs,NA
NCT04374084,2020-05-10,2021-12-31,Interventional,Moxibustion Plus Cupping in Convalescent Patients With COVID-19,Recruiting,N/A,Guang'anmen Hospital of China Academy of Chinese Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04374084,0,0,0,0,2,0,China,0,moxibustion/cupping|moxibustion|cupping,NA
NCT04375202,2020-04-18,2021-06-30,Interventional,Colchicine in COVID-19: a Pilot Study,Recruiting,Phase 2,University Of Perugia,NA,https://clinicalzeros.gov/ct2/show/NCT04375202,0,0,0,0,1,0,Italy,0,colchicine,NA
NCT04375124,2020-04-25,2020-08-31,Interventional,Treatment of Angiotensin Peptide (1-7) for COVID-19,Recruiting,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04375124,0,0,0,0,2,0,Turkey,0,angiotensin peptide (1-7) derived plasma|biological,NA
NCT04374591,2020-08-01,2020-11-01,Interventional,The Role of Sodium Bicarbonate as Adjuvant Treatment of Computed Tomography Identified COVID-19 Pneumonia,"Active, not recruiting",N/A,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04374591,0,0,0,0,3,0,Egypt,0,sodium bicarbonate,NA
NCT04374565,2020-05-05,2021-04-05,Interventional,Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia,"Active, not recruiting",Phase 2,University of Virginia,NA,https://clinicalzeros.gov/ct2/show/NCT04374565,0,0,0,0,4,1,United States,0,convalescent plasma,NA
NCT04374539,2020-04-29,2021-05-05,Interventional,Plasma Exchange in Patients With COVID-19 Disease and Invasive Mechanical Ventilation: a Randomized Controlled Trial,Recruiting,Phase 2,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04374539,0,0,0,0,1,0,Spain,0,plasma|standard care,NA
NCT04374487,2020-05-09,2021-08-09,Interventional,Assess the Safety and Efficacy of Convalescent Plasma to Limit COVID-19 Associated Complications,"Active, not recruiting",Phase 2,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04374487,0,0,0,0,1,0,India,0,convalescent plasma|standard care,NA
NCT04374032,2020-05-01,2020-10-07,Interventional,Clinical Trial to Evaluate the Efficacy and Safety of an Immunomodulatory Therapy for the Treatment of Patients With Moderate to Severe COVID-19 Infection,Completed,Phase 2/Phase 3,Bosnalijek D.D,NA,https://clinicalzeros.gov/ct2/show/NCT04374032,0,0,0,0,3,0,Bosnia and Herzegovina,0,metenkefalin / tridecactide|standard care|metenkefalin|tridecactide,NA
NCT04373382,2020-07-27,2022-02-28,Interventional,Peer Champion Support for Hospital Staff During and After the COVID-19 Pandemic,"Active, not recruiting",N/A,"Mount Sinai Hospital, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04373382,0,0,0,0,3,0,Canada,0,peer resilience champion|enriched survey feedback,NA
NCT04373161,2020-03-20,2020-04-22,Interventional,Home Pulse Oximeter Use in Patients With COVID-19,Completed,N/A,Swedish Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04373161,0,0,0,0,2,1,United States,0,home pulse oximetry monitoring,NA
NCT04373824,2020-04-25,2020-07-25,Interventional,Max Ivermectin- COVID 19 Study Versus Standard of Care Treatment for COVID 19 Cases. A Pilot Study,Recruiting,N/A,Max Healthcare Insititute Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04373824,0,0,0,0,0,0,India,0,ivermectin,NA
NCT04373135,2020-05-08,2021-02-28,Interventional,"Understanding Community Considerations, Opinions, Values, Impacts, and Decisions for COVID-19","Active, not recruiting",N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04373135,0,0,0,0,3,1,United States,0,educational video,NA
NCT04373096,2020-12-07,2021-08-31,Interventional,Enhanced Hood PPE to Minimize COVID-19 Transmission to Front-line Health Care Workers,Recruiting,N/A,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04373096,0,0,0,0,3,0,Canada,0,current ipac-uhn ppe|modified ipac-uhn ppe,NA
NCT04373044,2020-05-01,2021-05-01,Interventional,"Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients With Moderate and Severe COVID-19",Recruiting,Phase 2,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04373044,0,0,0,0,3,1,United States,0,baricitinib|hydroxychloroquine|placebo,NA
NCT04372979,2020-09-14,2021-05-31,Interventional,Efficacy of Convalescent Plasma Therapy in the Early Care of COVID-19 Patients.,Recruiting,Phase 3,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04372979,0,0,0,0,3,0,France,0,transfusion of sars-cov-2 convalescent plasma.|transfusion of standard plasma.,NA
NCT04372693,2020-09-01,2021-01-30,Interventional,Unplanned Shifting to Online Distance Learning: Nursing Students' Perception and Achievement,Enrolling by invitation,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04372693,0,0,0,0,5,0,Egypt,0,distance learning,NA
NCT04372017,2020-05-14,2020-06-04,Interventional,Hydroxychloroquine as Post-Exposure Prophylaxis Against COVID-19 Infection,"Active, not recruiting",Phase 3,Sanford Health,NA,https://clinicalzeros.gov/ct2/show/NCT04372017,0,0,0,0,2,1,United States,0,hydroxychloroquine|vitamin d,NA
NCT04372004,2020-05-08,2021-05-31,Interventional,Comparison of the Efficacy of Rapid Tests to Identify COVID-19 Infection (CATCh COVID-19),Recruiting,Phase 1,Texas Cardiac Arrhythmia Research Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04372004,0,0,0,0,2,1,United States,0,diagnostic tests for covid-19 infection,NA
NCT04371601,2020-03-01,2021-12-31,Interventional,Safety and Effectiveness of Mesenchymal Stem Cells in the Treatment of Pneumonia of Coronavirus Disease 2019,"Active, not recruiting",Early Phase 1,Fuzhou General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04371601,0,0,0,0,0,0,China,0,oseltamivir|hormones|oxygen|mesenchymal stem cells,NA
NCT04371510,2020-04-22,2020-10-22,Interventional,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Chronic Haemodialysis Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04371510,0,0,0,0,0,0,France,0,blood sample,NA
NCT04371367,2020-04-27,2021-03-01,Interventional,"Avdoralimab an Anti-C5aR Antibody, in Patients With COVID-19 Severe Pneumonia ( FORCE )","Active, not recruiting",Phase 2,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04371367,0,0,0,0,2,0,France,0,avdoralimab|placebo,NA
NCT04370886,2020-04-30,2020-04-30,Interventional,Recruit Blood Donors Via SMS During Epidemic of COVID-19,Completed,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04370886,0,0,0,0,2,0,China,0,blood donation sms,NA
NCT04371029,2020-04-28,2020-09-28,Interventional,Impact of Neck Inspiratory Muscle Activation During Sleep in ICU Patients After a COVID 19 ARDS,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04371029,0,0,0,0,2,0,France,0,psg,NA
NCT04370834,2020-05-28,2021-01-14,Interventional,Tocilizumab for Patients With Cancer and COVID-19 Disease,Terminated,Phase 2,National Cancer Institute (NCI),Other - Randomized data no longer support continuation,https://clinicalzeros.gov/ct2/show/NCT04370834,0,0,0,0,14,1,United States,0,tocilizumab,NA
NCT04370782,2020-04-28,2020-09-30,Interventional,Hydroxychloroquine and Zinc With Either Azithromycin or Doxycycline for Treatment of COVID-19 in Outpatient Setting,Completed,Phase 4,"St. Francis Hospital, New York",NA,https://clinicalzeros.gov/ct2/show/NCT04370782,0,0,0,0,2,1,United States,0,hydroxychloroquine|azithromycin|zinc|doxycycline,NA
NCT04370262,2020-04-07,2020-09-07,Interventional,Multi-site Adaptive Trials for COVID-19,Completed,Phase 3,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04370262,0,0,0,0,3,1,United States,0,soc / intravenous famotidine|soc / placebo|standard care|famotidine|placebo,NA
NCT04369820,2020-03-31,2020-09-30,Interventional,C5a Receptor Expression - COVID-19 (C5-COV),Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04369820,0,0,0,0,1,0,France,0,blood draw,NA
NCT04369794,2020-08-10,2021-06-30,Interventional,"COVID-19: BCG As Therapeutic Vaccine, Transmission Limitation, and Immunoglobulin Enhancement",Recruiting,Phase 4,"University of Campinas, Brazil",NA,https://clinicalzeros.gov/ct2/show/NCT04369794,0,0,0,1,1,0,Brazil,0,bcg|placebo,NA
NCT04369365,2020-04-27,2020-08-27,Interventional,"A Single-blinded, Randomized, Placebo Controlled Phase II Trial of Prophylactic Treatment With Oral Azithromycin Versus Placebo in Cancer Patients Undergoing Antineoplastic Treatment During the Corona Virus Disease 19 (COVID-19) Pandemic",Recruiting,Phase 2,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04369365,0,0,0,0,1,0,Austria,0,azithromycin|placebo,NA
NCT04369456,2020-04-22,2020-10-22,Interventional,Blood Biomarkers as Predictors of COVID-19 Disease Progression in Recently Infected Kidney Transplant Patients,Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04369456,0,0,0,0,1,0,France,0,blood sample,NA
NCT04368260,2020-04-24,2020-07-31,Interventional,Clinical Validation of New Injection Molded Flocked Nasopharyngeal Swabs in Response to the COVID-19 Pandemic,Recruiting,N/A,University of Virginia,NA,https://clinicalzeros.gov/ct2/show/NCT04368260,0,0,0,0,0,1,United States,0,control swab|prototype,NA
NCT04707534,2021-01-21,2021-05-21,Interventional,Dexamethasone for COVID-19,Recruiting,Phase 4,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04707534,0,0,0,0,1,1,United States,0,dexamethasone,NA
NCT04368299,2020-05-01,2021-10-31,Interventional,Telemedicine for Follow-up of Systemic Lupus Erythematosus,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04368299,0,0,0,0,1,0,Hong Kong,0,telehealth|standard care,NA
NCT04367662,2020-04-09,2020-05-14,Interventional,Study of the Vascular Compartment and Hypercoagulability During Coronavirus Infection COVID-19,Completed,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04367662,0,0,0,0,1,0,France,0,blood sample,NA
NCT04368000,2020-04-29,2020-08-06,Interventional,Prone Positioning in Awake Patients With COVID-19 Requiring Hospitalization,Terminated,N/A,University of Utah,Study was terminated due to lack of adherence to the protocol in the intervention arm.,https://clinicalzeros.gov/ct2/show/NCT04368000,0,0,0,0,3,1,United States,0,intermittent|usual care positioning with no instructions,NA
NCT04367545,2020-04-16,2020-05-17,Interventional,Development of a Molecular Diagnostic Strategy for SARS-CoV2 Based on Saliva in the Context of the COVID-19 Pandemic,Completed,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04367545,0,0,0,0,2,0,France,0,saliva,NA
NCT04367168,2020-05-27,2021-04-27,Interventional,Colchicine Twice Daily During 10 Days as an Option for the Treatment of Symptoms Induced by Inflammation in Patients With Mild and Severe Coronavirus Disease,Recruiting,Phase 2,Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran,NA,https://clinicalzeros.gov/ct2/show/NCT04367168,0,0,0,0,2,0,Mexico,0,colchicine|placebo,NA
NCT04366947,2020-04-14,2020-09-20,Interventional,Intravascular Access in Suspected/Confirmed COVID-19 Patient,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04366947,0,0,0,0,1,0,Poland,0,nioâ® (intraosseous access)|standard care|nioâ® (intraosseous access),NA
NCT04689542,2021-01-01,2021-08-01,Interventional,Surgical Face Mask Effects in Patients With COVID-19,Recruiting,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04689542,0,0,0,0,2,0,Belgium,0,sit-to-stand test,NA
NCT04366856,2020-06-26,2020-12-31,Interventional,PROne Positioning in coVID-19 Oxygeno-dependent Patients in Spontaneous Ventilation (PROVID Study),Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04366856,0,0,0,0,1,0,France,0,prone positioning|no instruction regarding positioning,NA
NCT04366323,2020-04-27,2021-10-31,Interventional,Clinical Trial to Assess the Safety and Efficacy of Intravenous Administration of Allogeneic Adult Mesenchymal Stem Cells of Expanded Adipose Tissue in Patients With Severe Pneumonia Due to COVID-19,"Active, not recruiting",Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,NA,https://clinicalzeros.gov/ct2/show/NCT04366323,0,0,0,0,2,0,Spain,0,mesenchymal stem cells|allogeneic,NA
NCT04682041,2020-12-22,2021-06-30,Interventional,Evaluating the Impact of EnteraGam In People With COVID-19,Recruiting,N/A,"Entera Health, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04682041,0,0,0,0,1,0,Spain,0,bovine plasma-derived immunoglobulin concentrate|standard care,NA
NCT04366245,2020-04-23,2021-12-31,Interventional,Clinical Trial to Evaluate the Efficacy of Treatment With Hyperimmune Plasma Obtained From Convalescent Antibodies of COVID-19 Infection,Recruiting,Phase 1/Phase 2,Andalusian Network for Design and Translation of Advanced Therapies,NA,https://clinicalzeros.gov/ct2/show/NCT04366245,0,0,0,0,3,0,Spain,0,convalescent plasma|standard care,NA
NCT04366180,2020-04-24,2020-06-30,Interventional,Evaluation of the Probiotic Lactobacillus Coryniformis K8 on COVID-19 Prevention in Healthcare Workers,Recruiting,N/A,Biosearch S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04366180,0,0,0,0,1,0,Spain,0,probiotic|control,NA
NCT04366063,2020-04-05,2020-06-06,Interventional,Mesenchymal Stem Cell Therapy for SARS-CoV-2-related Acute Respiratory Distress Syndrome,Recruiting,Phase 2/Phase 3,Royan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04366063,0,0,0,0,1,0,"Iran, Islamic Republic of",0,cell therapy protocol 1|cell therapy protocol 2,NA
NCT04365985,2020-04-29,2021-05-31,Interventional,Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19,Recruiting,Phase 2,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04365985,0,0,0,0,3,1,United States,0,naltrexone|ketamine|placebo,NA
NCT04365972,2020-04-23,2020-04-30,Interventional,Attention Bias Modification for Reducing Health Anxiety During the Coronavirus Pandemic,Completed,N/A,Tel Aviv University,NA,https://clinicalzeros.gov/ct2/show/NCT04365972,0,0,0,0,1,0,Israel,0,attention bias modification (abm),NA
NCT04366297,2020-01-12,2020-02-25,Interventional,Intravascular Access of COVID-19 Patient Under Personal Protective Equipment,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04366297,0,0,0,0,0,0,Poland,0,intravenous|intraosseous,NA
NCT04366271,2020-05-07,2020-07-31,Interventional,Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19,Recruiting,Phase 2,"Hospital Infantil Universitario NiÃ±o JesÃºs, Madrid, Spain",NA,https://clinicalzeros.gov/ct2/show/NCT04366271,0,0,0,0,1,0,Spain,0,mesenchymal stem cells|standard care,NA
NCT04365738,2020-03-11,2020-04-10,Interventional,Pulmonary Rehabilitation in Post-Acute Period of COVID-19 Infection,Completed,N/A,Istanbul Bilgi University,NA,https://clinicalzeros.gov/ct2/show/NCT04365738,0,0,0,0,0,0,Turkey,0,rehabilitation,NA
NCT04365257,2020-05-13,2021-06-30,Interventional,Prazosin to Prevent COVID-19 (PREVENT-COVID Trial),Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04365257,0,0,0,0,3,1,United States,0,prazosin|standard care,NA
NCT04365608,2020-03-20,2020-11-30,Interventional,Prehospital Intubation of COVID-19 Patient With Personal Protective Equipment,Completed,N/A,Lazarski University,NA,https://clinicalzeros.gov/ct2/show/NCT04365608,0,0,0,0,2,0,Poland,0,laryngoscopy,NA
NCT04365309,2020-02-10,2020-04-30,Interventional,Protective Effect of Aspirin on COVID-19 Patients,Enrolling by invitation,Phase 2/Phase 3,Xijing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04365309,0,0,0,0,0,0,China,0,aspirin,NA
NCT04364594,2020-03-26,2020-04-24,Interventional,COVID-19 Search in Conjunctival Cells,Completed,N/A,Fondazione Policlinico Universitario Agostino Gemelli IRCCS,NA,https://clinicalzeros.gov/ct2/show/NCT04364594,0,0,0,0,2,0,Italy,0,conjunctival swab,NA
NCT04364763,2020-08-05,2021-06-30,Interventional,A Study to Evaluate the Effect of RBT-9 on Progression of COVID-19 in High-Risk Individuals (The PREVENT Study),Recruiting,Phase 2,"Renibus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04364763,0,0,0,0,13,1,United States,0,rbt-9 (90 mg)|saline,NA
NCT04364009,2020-04-27,2020-10-20,Interventional,Anakinra for COVID-19 Respiratory Symptoms,Terminated,Phase 3,"University Hospital, Tours",Efficiency and safety reasons,https://clinicalzeros.gov/ct2/show/NCT04364009,0,0,0,0,5,0,France,0,anakinra/osoc|osoc|anakinra,NA
NCT04363450,2020-04-27,2021-03-31,Interventional,Hydroxychloroquine as Prophylaxis for COVID-19 in Healthcare Workers (HCQPreP),Recruiting,Phase 3,Louisiana State University Health Sciences Center in New Orleans,NA,https://clinicalzeros.gov/ct2/show/NCT04363450,0,0,0,0,2,1,United States,0,hydroxychloroquine|placebo,NA
NCT04363853,2020-06-01,2021-06-01,Interventional,Tocilizumab Treatment in Patients With COVID-19,"Active, not recruiting",Phase 2,Instituto Nacional de Cancerologia de Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04363853,0,0,0,0,3,0,Mexico,0,tocilizumab,NA
NCT04363814,2020-06-10,2021-07-01,Interventional,Clinical Impact of BACTEK-R in Subject With Mild Pneumonia Due to COVID-19 Infection,Recruiting,Phase 3,Inmunotek S.L.,NA,https://clinicalzeros.gov/ct2/show/NCT04363814,0,0,0,0,3,0,Dominican Republic,0,bactek-r,NA
NCT04363736,2020-05-05,2020-08-12,Interventional,A Study to Investigate Intravenous Tocilizumab in Participants With Moderate to Severe COVID-19 Pneumonia,Completed,Phase 2,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04363736,0,0,0,0,3,1,United States,0,tociliuzumab,NA
NCT04363541,2020-08-27,2022-04-30,Interventional,Local Thermotherapy for Patients With Mild-to-moderate COVID-19,Recruiting,N/A,Instituto Nacional de Perinatologia,NA,https://clinicalzeros.gov/ct2/show/NCT04363541,0,0,0,0,2,0,Mexico,0,electric pad for human external pain therapy,NA
NCT04363593,2020-05-04,2020-11-16,Interventional,Serology COVID-19 From the Cornwall Hospital Union,Completed,N/A,Centre Hospitalier de Cornouaille,NA,https://clinicalzeros.gov/ct2/show/NCT04363593,0,0,0,0,2,0,France,0,serology test|serum test,NA
NCT04363437,2020-04-26,2020-05-31,Interventional,COlchicine in Moderate-severe Hospitalized Patients Before ARDS to Treat COVID-19,Recruiting,Phase 2,Maimonides Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04363437,0,0,0,0,2,1,United States,0,standard care|colchicine,NA
NCT04363385,2020-05-31,2021-05-31,Interventional,Collection of Biological Samples With Clinical Characterization of Covid-19 Patients,Recruiting,N/A,Centre Hospitalier Intercommunal Creteil,NA,https://clinicalzeros.gov/ct2/show/NCT04363385,0,0,0,0,4,0,France,0,biological test,NA
NCT04363528,2020-04-24,2020-10-30,Interventional,Incidence of Deep Vein Thrombosis at Doppler Echo in Covid-19 Patients With SARS-Cov-2 Pneumopathy Hospitalized in ICU,Recruiting,N/A,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04363528,0,0,0,0,1,0,France,0,doppler echo,NA
NCT04363372,2020-06-30,2020-08-31,Interventional,A Study for Efficacy and Safety of Live Biotherapeutic MRx4DP0004 to Treat COVID-19,Recruiting,Phase 2,4D pharma plc,NA,https://clinicalzeros.gov/ct2/show/NCT04363372,0,0,0,0,1,0,United Kingdom,0,mrx-4dp0004|placebo,NA
NCT04362332,2020-04-14,2020-06-08,Interventional,"Chloroquine, Hydroxychloroquine or Only Supportive Care in Patients AdmItted With Moderate to Severe COVID-19",Terminated,Phase 4,UMC Utrecht,"Currently, almost no patients admitted to Dutch hospitals. If any effect of HCQ is to be
    expected we need more than 1000 inclusions",https://clinicalzeros.gov/ct2/show/NCT04362332,0,0,0,0,1,0,Netherlands,0,chloroquine|hydroxychloroquine|standard care,NA
NCT04362137,2020-05-02,2020-10-17,Interventional,"Phase 3 Randomized, Double-blind, Placebo-controlled Multi-center Study to Assess the Efficacy and Safety of Ruxolitinib in Patients With COVID-19 Associated Cytokine Storm (RUXCOVID)",Completed,Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04362137,0,0,0,0,18,1,United States|Argentina|Brazil|Colombia|France|Germany|Mexico|Peru|Russian Federation|Spain|Turkey|United Kingdom,0,ruxolitinib|placebo,NA
NCT04362111,2020-07-29,2021-01-31,Interventional,Early Treatment of Cytokine Storm Syndrome in Covid-19,Recruiting,Phase 3,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04362111,0,0,0,0,1,1,United States,0,anakinra|saline,NA
NCT04361916,2020-04-21,2020-06-30,Interventional,Home Care for Patients With COVID-19: Active Monitoring in Two Italian Health Units (Casale Monferrato and Torino),Terminated,N/A,Mario Negri Institute for Pharmacological Research,interrupted early due to the drastic reduction in the number of cases,https://clinicalzeros.gov/ct2/show/NCT04361916,0,0,0,0,2,0,Italy,0,home care monitoring,NA
NCT04361526,2020-04-17,2020-07-31,Interventional,Pilot Study on Cytokine Filtration in COVID-19 ARDS,Recruiting,N/A,Hospital Clinic of Barcelona,NA,https://clinicalzeros.gov/ct2/show/NCT04361526,0,0,0,0,0,0,Spain,0,cytokine adsorption,NA
NCT04361396,2020-06-16,2021-06-30,Interventional,Assessment of the Presence of the SARS-COV-2 Virus in the Peritoneum of COVID-19 Patients,Recruiting,N/A,Centre Hospitalier RenÃ© Dubos,NA,https://clinicalzeros.gov/ct2/show/NCT04361396,0,0,0,0,5,0,France,0,biological samples,NA
NCT04361214,2020-05-05,2021-02-28,Interventional,Leflunomide in Mild COVID-19 Patients,Recruiting,Phase 1,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04361214,0,0,0,0,5,1,United States,0,leflunomide,NA
NCT04358614,2020-03-16,2020-04-05,Interventional,Baricitinib Therapy in COVID-19,Completed,Phase 2/Phase 3,Hospital of Prato,NA,https://clinicalzeros.gov/ct2/show/NCT04358614,0,0,0,0,0,0,Italy,0,baricitinib,NA
NCT04361253,2020-04-30,2021-06-30,Interventional,Evaluation of SARS-CoV-2 (COVID-19) Antibody-containing Plasma thErapy,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04361253,0,0,0,0,2,1,United States,0,convalescent plasma|plasma,NA
NCT04360811,2020-04-17,2021-04-30,Interventional,"Assessment of Obstetric, Fetal and Neonatal Risks and Vertical SARS-CoV-2 Transmission During COVID-19 Pandemic",Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04360811,0,0,0,0,0,0,France,0,pcr,NA
NCT04360551,2020-07-01,2021-06-30,Interventional,Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients,Recruiting,Phase 2,University of Hawaii,NA,https://clinicalzeros.gov/ct2/show/NCT04360551,0,0,0,0,1,1,United States,0,telmisartan|placebo,NA
NCT04359862,2020-04-16,2021-03-31,Interventional,Sedation With Sevoflurane Versus Propofol in Patients With Acute Respiratory Distress Syndrome Caused by COVID19 Infection,Recruiting,Phase 4,FundaciÃ³n para la InvestigaciÃ³n del Hospital ClÃ­nico de Valencia,NA,https://clinicalzeros.gov/ct2/show/NCT04359862,0,0,0,0,3,0,Spain,0,sevoflurane|propofol,NA
NCT04359797,2020-04-27,2020-12-17,Interventional,COVID-19 Patient Positioning Pragmatic Trial,"Active, not recruiting",N/A,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04359797,0,0,0,0,12,1,United States,0,prone positioning|standard care,NA
NCT04359654,2020-06-16,2021-08-01,Interventional,Nebulised Dornase Alfa for Treatment of COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04359654,0,0,0,0,2,0,United Kingdom,0,pulmozyme,NA
NCT04359537,2020-05-01,2020-08-25,Interventional,Efficacy of Various Doses of Hydroxychloroquine in Pre-Exposure Prophylaxis for COVID 19,Recruiting,Phase 2,Shaheed Zulfiqar Ali Bhutto Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04359537,0,0,0,0,2,0,Pakistan,0,hydroxychloroquine|placebo,NA
NCT04359953,2020-04-25,2021-06-01,Interventional,"Efficacy of Hydroxychloroquine, Telmisartan and Azithromycin on the Survival of Hospitalized Elderly Patients With COVID-19",Recruiting,Phase 3,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04359953,0,0,0,0,1,0,France,0,hydroxychloroquine|azithromycin|telmisartan,NA
NCT04359290,2020-07-01,2020-12-31,Interventional,Ruxolitinib for Treatment of Covid-19 Induced Lung Injury ARDS,"Active, not recruiting",Phase 2,Philipps University Marburg Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04359290,0,0,0,0,5,0,Germany,0,ruxolitinib,NA
NCT04359264,2020-04-20,2020-05-29,Interventional,Direct Income SupporT and Advice Negating Spread of Epidemic COVID-19: a Randomized Controlled Trial,"Active, not recruiting",N/A,"St. Michael's Hospital, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04359264,0,0,0,0,2,0,Canada,0,cash transfer,NA
NCT04359251,2020-03-05,2020-03-25,Interventional,Different PEEP Settings of COVID-19 Induced ARDS,Completed,N/A,"Southeast University, China",NA,https://clinicalzeros.gov/ct2/show/NCT04359251,0,0,0,0,0,0,China,0,gas exchanges at different peep|lung mechanics at different peep|hemodynamics changes at different peep,NA
NCT04358809,2020-06-30,2021-02-28,Interventional,"Clinical Trial of Mycobacterium w in COVID-19 Positive Patients, Hospitalized But Not Critically Ill",Recruiting,Phase 3,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04358809,0,0,0,0,1,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04357990,2020-09-04,2021-03-31,Interventional,Viruxal Oral and Nasal Spray for Treating the Symptoms of COVID-19,Recruiting,N/A,Kerecis Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04357990,0,0,0,0,2,0,Iceland,0,viruxal oral/nasal spray|placebo|viruxal oral|nasal rinse,NA
NCT04357782,2020-04-16,2020-10-13,Interventional,Administration of Intravenous Vitamin C in Novel Coronavirus Infection (COVID-19) and Decreased Oxygenation,Completed,Phase 1/Phase 2,Hunter Holmes Mcguire Veteran Affairs Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04357782,0,0,0,0,3,1,United States,0,vitamin c,NA
NCT04357340,2020-04-02,2020-04-30,Interventional,The Effects of Pulmonary Physiotherapy Treatments on Patients With COVID-19,Completed,N/A,Tehran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04357340,0,0,0,0,1,0,"Iran, Islamic Republic of",0,pulmonary physiotherapy techniques,NA
NCT04357327,2020-04-16,2020-05-31,Interventional,Rapid Salivary Test to Detect SARS-CoV-2 (COVID-19),Completed,N/A,UniversitÃ  degli Studi dell'Insubria,NA,https://clinicalzeros.gov/ct2/show/NCT04357327,0,0,0,0,2,0,Italy,0,rapid salivary test,NA
NCT04356534,2020-04-19,2020-06-15,Interventional,Convalescent Plasma Trial in COVID -19 Patients,Completed,N/A,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04356534,0,0,0,0,3,0,Bahrain,0,convalescent plasma|standard care,NA
NCT04355143,2020-05-01,2021-04-25,Interventional,Colchicine to Reduce Cardiac Injury in COVID-19 (COLHEART-19),Recruiting,Phase 2,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04355143,0,0,0,0,3,1,United States,0,colchicine|current care per ucla treating physicians,NA
NCT04355897,2020-04-28,2020-07-31,Interventional,CoVID-19 Plasma in Treatment of COVID-19 Patients,Recruiting,Early Phase 1,The Christ Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04355897,0,0,0,0,3,1,United States,0,convalescent plasma,NA
NCT04355351,2020-05-05,2020-10-22,Interventional,Study of Immune Response During SARS-CoV-2 Infection - (COVID-19),Recruiting,N/A,Centre Hospitalier Universitaire de Nice,NA,https://clinicalzeros.gov/ct2/show/NCT04355351,0,0,0,0,2,0,France,0,blood sample|blood,NA
NCT04355247,2020-04-14,2020-07-31,Interventional,Prophylactic Corticosteroid to Prevent COVID-19 Cytokine Storm,Recruiting,Phase 2,Auxilio Mutuo Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04355247,0,0,0,0,0,0,Puerto Rico,0,methylprednisolone,NA
NCT04591613,2020-12-31,2022-08-31,Interventional,Late Clinical Events Associated With COVID-19 Infection,Recruiting,N/A,Tourcoing Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04591613,0,0,0,0,1,0,France|French Guiana,0,questionnaire|biocollection|follow-up visit,NA
NCT04355026,2020-04-10,2020-06-30,Interventional,Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia,Recruiting,Phase 4,General and Teaching Hospital Celje,NA,https://clinicalzeros.gov/ct2/show/NCT04355026,0,0,0,0,0,0,Slovenia,0,bromhexine oral tablet and/or hydroxychloroquine tablet|bromhexine hydrochloride|hydroxychloroquine,NA
NCT04354870,2020-04-03,2020-09-15,Interventional,COVID-19 PrEP HCW HCQ Study,Completed,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04354870,0,0,0,0,3,1,United States,0,hydroxychloroquine,NA
NCT04354831,2020-05-11,2022-05-01,Interventional,A Study Evaluating the Efficacy and Safety of High-Titer Anti-SARS-CoV-2 Plasma in Hospitalized Patients With COVID-19 Infection,"Active, not recruiting",Phase 2,Medical College of Wisconsin,NA,https://clinicalzeros.gov/ct2/show/NCT04354831,0,0,0,0,4,1,United States,0,convalescent plasma,NA
NCT04354610,2020-04-27,2020-12-19,Interventional,Cardiovascular and Renal Biomarkers to Predict Acute Heart or Kidney Injury in Severe Covid-19 Infection,"Active, not recruiting",N/A,"Central Hospital, Nancy, France",NA,https://clinicalzeros.gov/ct2/show/NCT04354610,0,0,0,0,4,0,France,0,biological samples|clinical examination|telephone follow-up,NA
NCT04353518,2020-06-30,2021-03-30,Interventional,Clinical Trial to Evaluate Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19,Recruiting,Phase 3,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04353518,0,0,0,0,2,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04353206,2020-06-27,2021-05-31,Interventional,Convalescent Plasma in ICU Patients With COVID-19-induced Respiratory Failure,Recruiting,Early Phase 1,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04353206,0,0,0,0,3,1,United States,0,convalescent plasma,NA
NCT04352933,2020-05-11,2020-10-31,Interventional,PROLIFIC ChemoprophylaxisTrial (COVID-19),Recruiting,Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04352933,0,0,0,0,1,0,United Kingdom,0,hydroxychloroquine|placebo,NA
NCT04353336,2020-03-23,2030-09-23,Interventional,Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04353336,0,0,0,0,5,0,Egypt,0,chloroquine/hydroxychloroquine|chloroquine|hydroxychloroquine,NA
NCT04353284,2020-06-19,2021-05-31,Interventional,Camostat Mesylate in COVID-19 Outpatients,Recruiting,Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04353284,0,0,0,0,7,1,United States,0,camostat mesilate|placebo,NA
NCT04353271,2020-04-17,2020-07-08,Interventional,Trial of Hydroxychloroquine In Covid-19 Kinetics,Terminated,Phase 2/Phase 3,University of South Alabama,"FDA recommendations to not use outside of the hospital setting or in a clinical trial due to
    the risk of cardiac arrhythmias",https://clinicalzeros.gov/ct2/show/NCT04353271,0,0,0,0,3,1,United States,0,hydroxychloroquine|placebo,NA
NCT04352751,2020-05-01,2021-04-30,Interventional,Experimental Use of Convalescent Plasma for Passive Immunization in Current COVID-19 Pandemic in Pakistan in 2020,Recruiting,N/A,Hilton Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04352751,0,0,0,0,4,0,Pakistan,0,convalescent plasma,NA
NCT04353128,2020-04-20,2020-10-31,Interventional,Efficacy of Melatonin in the Prophylaxis of Coronavirus Disease 2019 (COVID-19) Among Healthcare Workers.,Recruiting,Phase 2/Phase 3,Instituto de InvestigaciÃ³n Hospital Universitario La Paz,NA,https://clinicalzeros.gov/ct2/show/NCT04353128,0,0,0,0,2,0,Spain,0,melatonin|placebo,NA
NCT04352348,2020-03-31,2021-05-31,Interventional,Cohort of Patients Infected With SARS-CoV2 (COVID-19) or Suspected of Being,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04352348,0,0,0,0,4,0,France,0,blood sample|fecal sample|sweat samples (covidog ancillary study)|saliva|6 minutes walk test|phone call|urine samples,NA
NCT04351763,2020-04-27,2021-03-02,Interventional,Amiodarone or Verapamil in COVID-19 Hospitalized Patients With Symptoms,Recruiting,Phase 2/Phase 3,Nicolaus Copernicus University,NA,https://clinicalzeros.gov/ct2/show/NCT04351763,0,0,0,0,0,0,Poland,0,amiodarone|verapamil,NA
NCT04351620,2020-04-30,2020-06-30,Interventional,High-dose Hydroxychloroquine for the Treatment of Ambulatory Patients With Mild COVID-19,Recruiting,Phase 1,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04351620,0,0,0,0,0,1,United States,0,hydroxychloroquine,NA
NCT04351581,2020-05-18,2020-12-31,Interventional,Effects of Discontinuing Renin-angiotensin System Inhibitors in Patients With COVID-19,Recruiting,N/A,"University Hospital, Gentofte, Copenhagen",NA,https://clinicalzeros.gov/ct2/show/NCT04351581,0,0,0,0,3,0,Denmark,0,discontinuation of acei/arb|continuation of acei/arb|discontinuation of acei|arb|continuation of acei,NA
NCT04351542,2020-03-06,2020-04-06,Interventional,Ayurveda for Flu Like Illness During Covid-19 Outbreak,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04351542,0,0,0,0,0,0,United Kingdom,0,ayurveda|standard care,NA
NCT04351789,2020-05-01,2023-04-30,Interventional,Impact of a Minimal Psychoeducational Intervention on Anxiety Among Hospitalized COVID-19 Patients in Denmark,Recruiting,N/A,"Copenhagen University Hospital, Hvidovre",NA,https://clinicalzeros.gov/ct2/show/NCT04351789,0,0,0,0,1,0,Denmark,0,psychoeducational intervention,NA
NCT04350736,2020-04-23,2020-06-24,Interventional,"First in Human SAD and MAD Study of Inhaled TD-0903, a Potential Treatment for ALI Associated With COVID-19",Completed,Phase 1,Theravance Biopharma,NA,https://clinicalzeros.gov/ct2/show/NCT04350736,0,0,0,0,4,0,United Kingdom,0,td-0903|placebo,NA
NCT04350684,2020-04-15,2020-04-22,Interventional,Umifenovir in Hospitalized COVID-19 Patients,Enrolling by invitation,Phase 4,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04350684,0,0,0,0,1,0,"Iran, Islamic Republic of",0,umifenovir|interferon-î² 1a|lopinavir/ritonavir|hydroxychloroquine|standard care|interferon-î² 1a|lopinavir|ritonavir,NA
NCT04350671,2020-04-15,2020-04-20,Interventional,Interferon Beta 1a in Hospitalized COVID-19 Patients,Enrolling by invitation,Phase 4,Shahid Beheshti University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04350671,0,0,0,0,1,0,"Iran, Islamic Republic of",0,interferon|lopinavir/ritonavir|hydroxychloroquine|lopinavir|ritonavir,NA
NCT04350320,2020-04-30,2020-10-20,Interventional,Trial to Study the Benefit of Colchicine in Patients With COVID-19,Completed,Phase 3,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04350320,0,0,0,0,3,0,Spain,0,colchicine|standard care,NA
NCT04349098,2020-04-17,2020-10-05,Interventional,Evaluation of Activity and Safety of Oral Selinexor in Participants With Severe COVID-19 Infection,Completed,Phase 2,Karyopharm Therapeutics Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04349098,0,0,0,0,5,1,United States|Austria|France|Israel|Spain|United Kingdom,0,selinexor|placebo,NA
NCT04350281,2020-04-09,2020-07-01,Interventional,Double Therapy With IFN-beta 1b and Hydroxychloroquine,Completed,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04350281,0,0,0,0,2,0,Hong Kong,0,interferon|hydroxychloroquine,NA
NCT04498377,2021-01-26,2021-09-30,Interventional,Study of F-652 (IL-22:IgG2 Fusion Protein) in Patients With Moderate to Severe COVID-19,Recruiting,Phase 2,Generon (Shanghai) Corporation Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04498377,0,0,0,0,5,1,United States,0,f-652|placebo,NA
NCT04349410,2020-04-11,2020-09-14,Interventional,The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol,Completed,Phase 2/Phase 3,The Camelot Foundation,NA,https://clinicalzeros.gov/ct2/show/NCT04349410,0,0,0,0,8,1,United States,0,hydroxychloroquine / azithromycin|hydroxychloroquine/doxycycline|hydroxychloroquine/clindamycin|hydroxychloroquine/clindamycin/primaquine|remdesivir|tocilizumab|methylprednisolone|interferon|losartan|convalescent plasma,NA
NCT04349241,2020-04-18,2020-06-01,Interventional,Efficacy and Safety of Favipiravir in Management of COVID-19,Completed,Phase 3,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04349241,0,0,0,0,2,0,Egypt,0,favipiravir|standard care,NA
NCT04480138,2020-08-11,2021-04-15,Interventional,Pegylated Interferon - Î±2b With SARSCoV- 2 (COVID-19),Recruiting,Phase 2,Cadila Healthcare Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04480138,0,0,0,0,3,0,Mexico,0,pegylated interferon-î±2b|standard care|pegylated interferon-î±2b,NA
NCT04348409,2020-05-25,2020-07-31,Interventional,Efficacy and Safety of Nitazoxanide for the Treatment of Hospitalized Patients With Moderate COVID-19,Recruiting,N/A,Azidus Brasil,NA,https://clinicalzeros.gov/ct2/show/NCT04348409,0,0,0,0,2,0,Brazil,0,nitazoxanide|placebo,NA
NCT04348370,2020-04-20,2021-05-31,Interventional,BCG Vaccine for Health Care Workers as Defense Against COVID 19,Recruiting,Phase 4,Texas A&M University,NA,https://clinicalzeros.gov/ct2/show/NCT04348370,0,0,0,1,5,1,United States,0,bcg|placebo,NA
NCT04347980,2020-04-30,2020-06-30,Interventional,Dexamethasone Treatment for Severe Acute Respiratory Distress Syndrome Induced by COVID-19,Recruiting,Phase 3,Centre Chirurgical Marie Lannelongue,NA,https://clinicalzeros.gov/ct2/show/NCT04347980,0,0,0,0,1,0,France,0,dexamethasone/hydroxychloroquine|hydroxychloroquine|dexamethasone,NA
NCT04347954,2020-08-15,2020-12-13,Interventional,PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19),Completed,Phase 1/Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04347954,0,0,0,0,6,1,United States,0,povidone/iodine|saline,NA
NCT04347915,2020-05-06,2021-01-30,Interventional,The Phase 2 Study to Evaluate the Safety and Efficacy of Clevudine in Patients With Moderate COVID-19,Recruiting,Phase 2,Bukwang Pharmaceutical,NA,https://clinicalzeros.gov/ct2/show/NCT04347915,0,0,0,0,4,0,"Korea, Republic of",0,clevudine|placebo,NA
NCT04347382,2020-04-30,2020-08-30,Interventional,Honey & Nigella Sativa Trial Against COVID-19,Completed,Phase 3,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04347382,0,0,0,0,6,0,Pakistan,0,honey|nigella sativa / black cumin|placebo|nigella sativa|cumin,NA
NCT04462627,2020-04-14,2021-12-31,Interventional,Reduction of COVID 19 Transmission to Health Care Professionals,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04462627,0,0,0,0,1,0,Belgium,0,blood group determination|serology test|probiotic,NA
NCT04347538,2020-05-01,2021-06-30,Interventional,Impact of Nasal Saline Irrigations on Viral Load in Patients With COVID-19,"Active, not recruiting",N/A,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04347538,0,0,0,0,5,1,United States,0,saline|saline with baby shampoo nasal irrigation,NA
NCT04347031,2020-04-08,2020-11-01,Interventional,A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19,Completed,Phase 2/Phase 3,Burnasyan Federal Medical Biophysical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04347031,0,0,0,0,2,0,Russian Federation,0,mefloquine|hydroxychloroquine|mefloquine/azithromycin/ tocilizumab|hydroxychloroquine/azithromycin/ tocilizumab|azithromycin|NA|- tocilizumab,NA
NCT04347226,2020-04-16,2021-09-30,Interventional,Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04347226,0,0,0,0,3,1,United States,0,bms-986253,NA
NCT04347174,2020-04-30,2020-08-10,Interventional,A Clinical Trial of Mycobacterium w in Critically Ill COVID 19 Patients,Completed,N/A,Cadila Pharnmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04347174,0,0,0,0,6,0,India,0,suspension of heat killed (autoclaved) mycobacterium w|placebo,NA
NCT04346446,2020-04-20,2020-05-30,Interventional,Efficacy of Convalescent Plasma Therapy in Severely Sick COVID-19 Patients,Completed,Phase 2,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04346446,0,0,0,0,7,0,India,0,convalescent plasma|supportive care|plasma,NA
NCT04346797,2020-04-16,2020-09-30,Interventional,"CORIMUNO19-ECU: Trial Evaluating Efficacy and Safety of Eculizumab (Soliris) in Patients With COVID-19 Infection, Nested in the CORIMUNO-19 Cohort",Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04346797,0,0,0,0,1,0,France,0,eculizumab,NA
NCT04346693,2020-04-08,2020-11-01,Interventional,An Open Randomized Study of Dalargin Effectiveness in Patients With Severe and Critical Manifestations of SARS-COVID-19,Completed,Phase 3,Burnasyan Federal Medical Biophysical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04346693,0,0,0,0,2,0,Russian Federation,0,standard care|dalargin,NA
NCT04346589,2020-04-15,2020-08-31,Interventional,Convalescent Antibodies Infusion in Critically Ill COVID 19 Patients,Recruiting,N/A,A.O. Ospedale Papa Giovanni XXIII,NA,https://clinicalzeros.gov/ct2/show/NCT04346589,0,0,0,0,3,0,Italy,0,anti-coronavirus antibodies (immunoglobulins)obtained with dfpp from convalescent patients,NA
NCT04346420,2020-04-09,2020-05-01,Interventional,Impact of the Double-Trunk Mask on Oxygenation Titration in COVID-19,Completed,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04346420,0,0,0,0,1,0,Belgium,0,standard interface|mask,NA
NCT04346017,2020-03-20,2020-12-31,Interventional,Evaluation of Interleukine 6 (and Other Cytokines and Inflammatory Markers) in COVID-19 Patients With a Systemic Inflammatory Response Syndrome,Recruiting,N/A,Brugmann University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04346017,0,0,0,0,0,0,Belgium,0,cytokines|complement dosage,NA
NCT04345692,2020-03-26,2020-08-31,Interventional,A Randomized Controlled Clinical Trial: Hydroxychloroquine for the Treatment of COVID-19 in Hospitalized Patients,Terminated,Phase 3,Queen's Medical Centre,RECOVERY Trial results - no efficacy,https://clinicalzeros.gov/ct2/show/NCT04345692,0,0,0,0,2,1,United States,0,hydroxychloroquine,NA
NCT04345991,2020-04-15,2020-05-15,Interventional,"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort",Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04345991,0,0,0,0,1,0,France,0,convalescent plasma,NA
NCT04345861,2020-04-11,2020-06-08,Interventional,Hydroxychloroquine Plus Azithromycin Versus Hydroxychloroquine for COVID-19 Pneumonia (COVIDOC Trial),Terminated,Phase 2/Phase 3,"University Hospital, Montpellier",halted prematurely.,https://clinicalzeros.gov/ct2/show/NCT04345861,0,0,0,0,3,0,France,0,hydroxychloroquine/placebo|hydroxychloroquine / azithromycin|hydroxychloroquine|placebo|azithromycin,NA
NCT04345289,2020-05-01,2021-06-15,Interventional,Efficacy and Safety of Novel Treatment Options for Adults With COVID-19 Pneumonia,Recruiting,Phase 3,Hvidovre University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04345289,0,0,0,0,2,0,Denmark,0,convalescent plasma|placebo,NA
NCT04345276,2020-03-18,2020-04-15,Interventional,Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Phase 4,Huoshenshan Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04345276,0,0,0,0,1,0,China,0,danoprevir/ritonavir|danoprevir|ritonavir,NA
NCT04345549,2020-02-26,2020-03-30,Interventional,Ayurveda Self-Management for Flu Like Symptoms During the Covid-19 Outbreak,Completed,N/A,Aarogyam UK,NA,https://clinicalzeros.gov/ct2/show/NCT04345549,0,0,0,0,0,0,United Kingdom,0,ayurveda,NA
NCT04344561,2020-05-25,2021-05-01,Interventional,Incline Positioning in COVID-19 Patients for Improvement in Oxygen Saturation,Recruiting,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04344561,0,0,0,0,3,1,United States,0,postural positioning,NA
NCT04344457,2020-04-16,2020-06-20,Interventional,"Evaluate the Efficacy and Safety of Oral Hydroxychloroquine, Indomethacin and Zithromax in Subjects With Mild Symptoms of COVID-19",Recruiting,Phase 1/Phase 2,"Perseverance Research Center, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04344457,0,0,0,0,3,1,United States,0,hydroxychloroquine|indomethacin|zithromax,NA
NCT04344444,2020-04-13,2021-04-10,Interventional,Treatment in Patients With Suspected or Confirmed COVID-19 With Early Moderate or Severe Disease,"Active, not recruiting",Phase 3,LCMC Health,NA,https://clinicalzeros.gov/ct2/show/NCT04344444,0,0,0,0,1,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04344431,2020-04-14,2022-04-30,Interventional,Management by Hyperbaric Oxygen Therapy of Patients With Hypoxaemic Pneumonia With SARS-CoV-2 (COVID-19),Recruiting,Phase 2/Phase 3,Direction Centrale du Service de SantÃ© des ArmÃ©es,NA,https://clinicalzeros.gov/ct2/show/NCT04344431,0,0,0,0,2,0,France,0,hyperbaric oxygen|device),NA
NCT04344288,2020-04-21,2020-08-18,Interventional,Corticosteroids During Covid-19 Viral Pneumonia Related to SARS-Cov-2 Infection,Terminated,Phase 2,Hospices Civils de Lyon,Competent Authority's decision,https://clinicalzeros.gov/ct2/show/NCT04344288,0,0,0,0,4,0,France,0,control|prednisone,NA
NCT04344106,2020-04-01,2020-04-15,Interventional,Prone Positioning in Spontaneously Breathing Nonintubated Covid-19 Patient: a Pilot Study,Recruiting,N/A,Centre Hospitalier Intercommunal Aix-Pertuis,NA,https://clinicalzeros.gov/ct2/show/NCT04344106,0,0,0,0,0,0,France,0,prone positioning,NA
NCT04344236,2020-04-09,2020-05-01,Interventional,Gargling and Nasal Rinses to Reduce Oro- and Nasopharyngeal Viral Load in Patients With COVID-19,Recruiting,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04344236,0,0,0,0,0,1,United States,0,saline|povidone/iodine|chlorhexidine|nasal rinse|povidone|iodine,NA
NCT04344210,2020-04-17,2020-09-20,Interventional,Impact of Tele-interventions During the COVID-19 Pandemic in Patients With Diabetes Mellitus,Completed,N/A,Federal University of Rio Grande do Sul,NA,https://clinicalzeros.gov/ct2/show/NCT04344210,0,0,0,0,1,0,Brazil,0,tele-interventions related to diabetes management/mental well-being|tele-interventions related to diabetes management|mental well-being,NA
NCT04344015,2020-04-13,2021-04-12,Interventional,COVID-19 Plasma Collection,Recruiting,N/A,Thomas Jefferson University,NA,https://clinicalzeros.gov/ct2/show/NCT04344015,0,0,0,0,2,1,United States,0,plasma,NA
NCT04343989,2020-03-31,2021-01-30,Interventional,A Randomized Placebo-controlled Safety and Dose-finding Study for the Use of the IL-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,"Active, not recruiting",Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04343989,0,0,0,0,4,1,United States,0,clazakizumab|placebo,NA
NCT04343794,2020-04-01,2021-12-31,Interventional,Using BiovitalsÂ® Sentinel to Monitor Disease Progression in Subjects Quarantined for Suspected COVID-19,Recruiting,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04343794,0,0,0,0,1,0,Hong Kong,0,biovitals,NA
NCT04343755,2020-04-09,2021-04-30,Interventional,Convalescent Plasma as Treatment for Hospitalized Subjects With COVID-19 Infection,"Active, not recruiting",Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04343755,0,0,0,0,5,1,United States,0,convalescent plasma,NA
NCT04343651,2020-04-01,2020-07-21,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19,"Active, not recruiting",Phase 2,"CytoDyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04343651,0,0,0,0,7,1,United States,0,placebo|lenzilumab,NA
NCT04343092,2020-04-18,2020-05-31,Interventional,Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management,Completed,Phase 1,University of Baghdad,NA,https://clinicalzeros.gov/ct2/show/NCT04343092,0,0,0,0,4,0,Iraq,1,ivermectin,NA
NCT04342897,2020-04-20,2020-10-12,Interventional,A Study of LY3127804 in Participants With COVID-19,Terminated,Phase 2,Eli Lilly and Company,Trial terminated for futility.,https://clinicalzeros.gov/ct2/show/NCT04342897,0,0,0,0,19,1,United States,0,ly3127804|placebo,NA
NCT04342689,2020-06-03,2021-06-01,Interventional,The Role of Resistant Starch in COVID-19 Infection,Recruiting,Phase 2/Phase 3,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04342689,0,0,0,0,5,1,United States,0,dietary supplement containing resistant starch|placebo,NA
NCT04342650,2020-04-08,2020-05-14,Interventional,Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection,Completed,Phase 2,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicalzeros.gov/ct2/show/NCT04342650,0,0,0,0,2,0,Brazil,0,chloroquine|placebo,NA
NCT04342169,2020-04-04,2021-04-30,Interventional,University of Utah COVID-19 Hydrochloroquine Trial,Recruiting,Phase 2,University of Utah,NA,https://clinicalzeros.gov/ct2/show/NCT04342169,0,0,0,0,3,1,United States,0,hydroxychloroquine|placebo,NA
NCT04341675,2020-04-24,2020-07-31,Interventional,Sirolimus Treatment in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,University of Cincinnati,NA,https://clinicalzeros.gov/ct2/show/NCT04341675,0,0,0,0,4,1,United States,0,sirolimus|placebo,NA
NCT04341441,2020-04-07,2020-12-15,Interventional,Will Hydroxychloroquine Impede or Prevent COVID-19,Terminated,Phase 3,Henry Ford Health System,"Interim analysis did not reveal any safety concerns by the DSMB, but unblinded data did not
    provide support to continue. Event rate did not meet projected magnitude; given low recruitment
    potential, it is unlikely that a positive result will occur.",https://clinicalzeros.gov/ct2/show/NCT04341441,0,0,0,0,5,1,United States,0,hydroxychloroquine|placebo|monitoring visit|weekly assessment,NA
NCT04341207,2020-04-03,2022-04-30,Interventional,Epidemiology of SARS-CoV-2 and Mortality to Covid19 Disease in French Cancer Patients,Recruiting,Phase 2,"Gustave Roussy, Cancer Campus, Grand Paris",NA,https://clinicalzeros.gov/ct2/show/NCT04341207,0,0,0,0,0,0,France,0,hydroxychloroquine|azithromycin,NA
NCT04341116,2020-04-11,2021-12-31,Interventional,Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2/Phase 3,I-Mab Biopharma Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04341116,0,0,0,0,14,1,United States,0,tj003234|placebo,NA
NCT04340557,2020-03-27,2020-10-06,Interventional,Do Angiotensin Receptor Blockers Mitigate Progression to Acute Respiratory Distress Syndrome With SARS-CoV-2 Infection,Recruiting,Phase 4,Sharp HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04340557,0,0,0,0,1,1,United States,0,losartan,NA
NCT04368845,2020-05-11,2021-03-31,Interventional,Telerehabilitation in Patients With COVID-19 After Hospitalization. The ATHLOS Study,Recruiting,N/A,Clinical Exercise Physiology and Rehabilitation Reasearch Laboratory,NA,https://clinicalzeros.gov/ct2/show/NCT04368845,0,0,0,0,2,0,Greece,0,telehealth,NA
NCT04340544,2020-04-22,2020-10-12,Interventional,Hydroxychloroquine for the Treatment of Mild COVID-19 Disease,Terminated,Phase 2,University Hospital Tuebingen,"It appeared to be impossible for the study centres to recruit the targeted number of patients,
    due to reduced incidence and reduced acceptance to IMP",https://clinicalzeros.gov/ct2/show/NCT04340544,0,0,0,0,2,0,Germany,0,hydroxychloroquine|placebo,NA
NCT04350593,2020-04-22,2021-04-30,Interventional,Dapagliflozin in Respiratory Failure in Patients With COVID-19,"Active, not recruiting",Phase 3,Saint Luke's Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04350593,0,0,0,0,4,1,United States|Argentina|Brazil|Canada|India|Mexico|United Kingdom,0,dapagliflozin|placebo,NA
NCT04339712,2020-04-02,2020-12-01,Interventional,Personalised Immunotherapy for SARS-CoV-2 (COVID-19) Associated With Organ Dysfunction,Completed,Phase 2,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04339712,0,0,0,0,5,0,Greece,0,anakinra|tocilizumab,NA
NCT04339660,2020-02-01,2020-06-30,Interventional,Clinical Research of Human Mesenchymal Stem Cells in the Treatment of COVID-19 Pneumonia,Recruiting,Phase 1/Phase 2,Puren Hospital Affiliated to Wuhan University of Science and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04339660,0,0,0,0,0,0,China,0,mesenchymal stem cells|placebo,NA
NCT04339426,2020-04-20,2021-07-31,Interventional,Atovaquone and Azithromycin Combination for Confirmed COVID-19 Infection,Recruiting,Phase 2,HonorHealth Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04339426,0,0,0,0,5,1,United States,0,atovaquone/azithromycin|atovaquone|azithromycin,NA
NCT04337008,2020-04-03,2020-06-03,Interventional,Renin Angiotensin System - CoronaVirus,Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04337008,0,0,0,0,1,0,France,0,blood sample,NA
NCT04336904,2020-03-25,2020-07-31,Interventional,Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19,"Active, not recruiting",Phase 3,ASST Fatebenefratelli Sacco,NA,https://clinicalzeros.gov/ct2/show/NCT04336904,0,0,0,0,1,0,Italy,0,favipiravir|placebo,NA
NCT04336462,2020-02-15,2020-02-21,Interventional,Hydrogen-Oxygen Generator With Nebulizer in the Improvement of Symptoms in Patients Infected With COVID-19,Recruiting,N/A,Shanghai Asclepius Meditec Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04336462,0,0,0,0,0,0,China,0,oxyhydrogen|oxygen,NA
NCT04335851,2020-04-06,2020-05-15,Interventional,Video-Based Exercises and Well-Being During Social Isolation,Completed,N/A,Biruni University,NA,https://clinicalzeros.gov/ct2/show/NCT04335851,0,0,0,0,1,0,Turkey,0,exercise,NA
NCT04335552,2020-04-17,2020-06-17,Interventional,"Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection",Terminated,Phase 2,Duke University,"Poor recruitment, strong evidence from larger trials of no therapeutic benefit",https://clinicalzeros.gov/ct2/show/NCT04335552,0,0,0,0,3,1,United States,0,standard care|hydroxychloroquine|azithromycin,NA
NCT04335136,2020-04-30,2020-12-26,Interventional,Recombinant Human Angiotensin-converting Enzyme 2 (rhACE2) as a Treatment for Patients With COVID-19,Completed,Phase 2,Apeiron Biologics,NA,https://clinicalzeros.gov/ct2/show/NCT04335136,0,0,0,0,6,0,Austria|Denmark|Germany|Russian Federation|United Kingdom,0,rhace2|saline,NA
NCT04335097,2020-04-22,2021-04-08,Interventional,Sensor Based Vital Signs Monitoring of Covid 19 Patients During Home Isolation,Recruiting,N/A,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04335097,0,0,0,0,3,0,Norway,0,biosensor,NA
NCT04335071,2020-04-26,2020-09-27,Interventional,Tocilizumab in the Treatment of Coronavirus Induced Disease (COVID-19),Terminated,Phase 2,"University Hospital Inselspital, Berne","1.) Not possible to recruit the planned number of patients during the planned study period; 2.)
    ""Dexamethason"" was included in the standard of care for the study population during the course
    of the study and inclusion criteria could no longer be met.",https://clinicalzeros.gov/ct2/show/NCT04335071,0,0,0,0,4,0,Switzerland,0,tocilizumab|placebo,NA
NCT04334850,2020-04-20,2020-07-31,Interventional,Use of a Respiratory Multiplex PCR and Procalcitonin to Reduce Antibiotics Exposure in Patients With Severe Confirmed COVID-19 Pneumonia,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04334850,0,0,0,0,1,0,France,0,pcr|usual antibiotic treatment|procalcitonin,NA
NCT04334928,2020-04-15,2020-12-31,Interventional,Randomized Clinical Trial for the Prevention of SARS-CoV-2 Infection (COVID-19) in Healthcare Personnel,Recruiting,Phase 3,Plan Nacional sobre el Sida (PNS),NA,https://clinicalzeros.gov/ct2/show/NCT04334928,0,0,0,0,5,0,Spain,0,emtricitabine/tenofovir disoproxil|hydroxychloroquine|placebo|emtricitabine|tenofovir disoproxil,NA
NCT04335305,2020-04-09,2020-12-31,Interventional,Checkpoint Blockade in COVID-19 Pandemic,Recruiting,Phase 2,MedSIR,NA,https://clinicalzeros.gov/ct2/show/NCT04335305,0,0,0,0,8,0,Spain,0,tocilizumab|pembrolizumab,NA
NCT04334382,2020-04-02,2020-12-31,Interventional,Hydroxychloroquine vs. Azithromycin for Outpatients in Utah With COVID-19,Recruiting,Phase 3,"Intermountain Health Care, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04334382,0,0,0,0,1,1,United States,0,hydroxychloroquine|azithromycin,NA
NCT04334629,2020-05-26,2021-05-25,Interventional,LIBERATE Trial in COVID-19,Recruiting,Phase 4,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04334629,0,0,0,0,4,0,United Kingdom,0,ibuprofen,NA
NCT04333914,2020-04-15,2021-06-30,Interventional,Prospective Study in Patients With Advanced or Metastatic Cancer and SARS-CoV-2 Infection,Recruiting,Phase 2,Centre Leon Berard,NA,https://clinicalzeros.gov/ct2/show/NCT04333914,0,0,0,0,7,0,France,0,avdoralimab|autophagy inhibitor (gns651)|standard care|monalizumab,NA
NCT04333407,2020-04-03,2021-03-30,Interventional,Preventing Cardiac Complication of COVID-19 Disease With Early Acute Coronary Syndrome Therapy: A Randomised Controlled Trial.,Recruiting,N/A,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04333407,0,0,0,0,2,0,United Kingdom,0,aspirin|clopidogrel|rivaroxaban|atorvastatin|omeprazole,NA
NCT04333225,2020-04-03,2020-06-30,Interventional,Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers,Completed,Phase 2,Baylor Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04333225,0,0,0,0,4,1,United States,0,hydroxychloroquine,NA
NCT04333654,2020-04-12,2020-05-26,Interventional,Hydroxychloroquine in Outpatient Adults With COVID-19,Terminated,Phase 1,Sanofi,Rate of enrollment too slow to allow completion in a reasonable timeframe,https://clinicalzeros.gov/ct2/show/NCT04333654,0,0,0,0,7,1,United States|Belgium|France|Netherlands,0,hydroxychloroquine|placebo,NA
NCT04333628,2020-06-01,2020-09-01,Interventional,Chloroquine for Mild Symptomatic and Asymptomatic COVID-19,Terminated,Phase 2/Phase 3,"HaEmek Medical Center, Israel",Teminated due to changes in treatment guidelines .,https://clinicalzeros.gov/ct2/show/NCT04333628,0,0,0,0,3,0,Israel,0,chloroquine|standard care,NA
NCT04333368,2020-04-06,2021-01-30,Interventional,Cell Therapy Using Umbilical Cord-derived Mesenchymal Stromal Cells in SARS-CoV-2-related ARDS,"Active, not recruiting",Phase 1/Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04333368,0,0,0,0,4,0,France,0,mesenchymal stem cells|saline,NA
NCT04332380,2020-05-01,2020-07-28,Interventional,Convalescent Plasma for Patients With COVID-19: A Pilot Study,Completed,Phase 2,Universidad del Rosario,NA,https://clinicalzeros.gov/ct2/show/NCT04332380,0,0,0,0,2,0,Colombia,0,plasma,NA
NCT04332835,2020-08-08,2020-10-31,Interventional,"Convalescent Plasma for Patients With COVID-19: A Randomized, Single Blinded, Parallel, Controlled Clinical Study",Completed,Phase 2/Phase 3,Universidad del Rosario,NA,https://clinicalzeros.gov/ct2/show/NCT04332835,0,0,0,0,4,0,Colombia,0,plasma|standard care,NA
NCT04332081,2020-04-06,2020-05-29,Interventional,Hyperbaric Oxygen for COVID-19 Patients,Terminated,N/A,NYU Langone Health,"The IRB has determined that the design of this trial should be changed to a randomized
    controlled trial. A new record will be created for the redesigned study.",https://clinicalzeros.gov/ct2/show/NCT04332081,0,0,0,0,5,1,United States,0,hyperbaric oxygen,NA
NCT04331613,2020-01-27,2020-12-31,Interventional,Safety and Efficacy of CAStem for Severe COVID-19 Associated With/Without ARDS,Recruiting,Phase 1/Phase 2,Chinese Academy of Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04331613,0,0,0,0,0,0,China,0,castem,NA
NCT04331054,2020-04-13,2022-01-13,Interventional,Protective Role of Inhaled Steroids for Covid-19 Infection,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04331054,0,0,0,0,3,0,France,0,usual practice / symbicort rapihaler|standard care|symbicort,NA
NCT04329650,2020-04-15,2020-05-20,Interventional,Efficacy and Safety of Siltuximab vs. Corticosteroids in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,Fundacion Clinic per a la Recerca BiomÃ©dica,NA,https://clinicalzeros.gov/ct2/show/NCT04329650,0,0,0,0,3,0,Spain,0,siltuximab|methylprednisolone,NA
NCT04329611,2020-04-13,2020-07-20,Interventional,ALBERTA HOPE COVID-19 for the Prevention of Severe COVID19 Disease,Terminated,Phase 3,University of Calgary,"Enrolment was suspended on 22may2020, after Mehra et al (Lancet 2020) then stopped due to lack
    of Covid19 cases.",https://clinicalzeros.gov/ct2/show/NCT04329611,0,0,0,0,8,0,Canada,0,hydroxychloroquine,NA
NCT04328285,2020-04-14,2021-03-30,Interventional,Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare Workers,"Active, not recruiting",Phase 3,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04328285,0,0,0,0,7,0,France,0,hydroxychloroquine|placebo|lopinavir/ritonavir|lopinavir|ritonavir|r tablets,NA
NCT04328129,2020-03-23,2022-03-23,Interventional,Household Transmission Investigation Study for COVID-19 in Tropical Regions,Recruiting,N/A,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04328129,0,0,0,0,3,0,French Guiana|Guadeloupe|New Caledonia,0,biological samples,NA
NCT04327505,2020-06-03,2021-12-31,Interventional,Safety and Efficacy of Hyperbaric Oxygen for ARDS in Patients With COVID-19,Recruiting,Phase 2/Phase 3,Karolinska Institutet,NA,https://clinicalzeros.gov/ct2/show/NCT04327505,0,0,0,0,5,0,Germany|Romania|Sweden,0,oxygen,NA
NCT04327349,2020-03-28,2020-05-20,Interventional,Investigating Effect of Convalescent Plasma on COVID-19 Patients Outcome: A Clinical Trial,Enrolling by invitation,N/A,Mazandaran University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04327349,0,0,0,0,0,0,"Iran, Islamic Republic of",0,convalescent plasma,NA
NCT04326452,2020-03-27,2021-03-27,Interventional,Treating COVID-19 With a Bidirectional Oxygenation Valve,Recruiting,N/A,TMC HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04326452,0,0,0,0,2,1,United States,0,bidirectional oxygenation mouthpiece,NA
NCT04326426,2020-04-13,2020-08-01,Interventional,ODYSSEY: A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection,Enrolling by invitation,Phase 3,Vanda Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04326426,0,0,0,0,2,1,United States,0,tradipitant|placebo,NA
NCT04325867,2020-03-31,2020-10-01,Interventional,Integrated Distance Management Strategy for Patients With Cardiovascular Diseases in the Context of COVID-19,Recruiting,N/A,Grigore T. Popa University of Medicine and Pharmacy,NA,https://clinicalzeros.gov/ct2/show/NCT04325867,0,0,0,0,1,0,Romania,0,telehealth,NA
NCT04326075,2020-12-01,2021-03-31,Interventional,Early CPAP in COVID-19 Patients With Respiratory Failure.,Recruiting,N/A,Mario Negri Institute for Pharmacological Research,NA,https://clinicalzeros.gov/ct2/show/NCT04326075,0,0,0,0,3,0,Italy,0,cpap,NA
NCT04326036,2020-03-25,2021-11-01,Interventional,Use of cSVF Via IV Deployment for Residual Lung Damage After Symptomatic COVID-19 Infection,Recruiting,Early Phase 1,"Black Tie Medical, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04326036,0,0,0,0,2,1,United States,0,tsvf|centricyte 1000|csvf|liberase enzyme|saline,NA
NCT04325893,2020-04-01,2020-06-18,Interventional,Hydroxychloroquine Versus Placebo in COVID-19 Patients at Risk for Severe Disease,Terminated,Phase 3,"University Hospital, Angers",decrease in number of eligible patients,https://clinicalzeros.gov/ct2/show/NCT04325893,0,0,0,0,4,0,France|Monaco,0,hydroxychloroquine|placebo,NA
NCT04324996,2020-02-21,2022-02-20,Interventional,A Phase I/II Study of Universal Off-the-shelf NKG2D-ACE2 CAR-NK Cells for Therapy of COVID-19,Recruiting,Phase 1/Phase 2,Chongqing Public Health Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04324996,0,0,0,0,1,0,China,0,nk cells,NA
NCT04324190,2020-04-08,2020-06-30,Interventional,DIgital Online SuPport for COVID-19 StrEss,Recruiting,N/A,International Psychoanalytic University Berlin,NA,https://clinicalzeros.gov/ct2/show/NCT04324190,0,0,0,0,3,0,Germany,0,guided online support program|who recommendations (waiting condition),NA
NCT04324489,2020-03-06,2020-04-16,Interventional,DAS181 for Severe COVID-19: Compassionate Use,Completed,N/A,Renmin Hospital of Wuhan University,NA,https://clinicalzeros.gov/ct2/show/NCT04324489,0,0,0,0,2,0,China,0,das181,NA
NCT04324021,2020-04-02,2020-11-13,Interventional,Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.,Terminated,Phase 2/Phase 3,Swedish Orphan Biovitrum,"Standard of care evolved during the timeframe of the study and had critical impact on
    recruitment.

    Early termination is not based on safety reasons but because of recruitment issues.

    Patients ongoing will be completed. Planned LPLV 25Jan2021",https://clinicalzeros.gov/ct2/show/NCT04324021,0,0,0,0,7,1,United States|Italy,0,emapalumab|anakinra,NA
NCT04324073,2020-03-27,2021-03-27,Interventional,Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients - Sarilumab Trial - CORIMUNO-19 - SARI,"Active, not recruiting",Phase 2/Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04324073,0,0,0,0,2,0,France,0,sarilumab,NA
NCT04322773,2020-04-05,2020-10-08,Interventional,Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure,Terminated,Phase 2,Frederiksberg University Hospital,The study has been terminated due to changed clinical conditions and too few patients available,https://clinicalzeros.gov/ct2/show/NCT04322773,0,0,0,0,4,0,Denmark,0,roactemra|sarilumab|standard care,NA
NCT04323345,2020-04-15,2020-12-15,Interventional,Efficacy of Natural Honey Treatment in Patients With Novel Coronavirus,Recruiting,Phase 3,Misr University for Science and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04323345,0,0,0,0,1,0,Egypt,0,honey|standard care,NA
NCT04323228,2020-09-01,2020-12-01,Interventional,Anti-inflammatory/Antioxidant Oral Nutrition Supplementation in COVID-19,Recruiting,Phase 2/Phase 3,King Saud University,NA,https://clinicalzeros.gov/ct2/show/NCT04323228,0,0,0,0,6,0,Saudi Arabia,0,antioxidants|placebo,NA
NCT04322682,2020-03-23,2021-01-21,Interventional,Colchicine Coronavirus SARS-CoV2 Trial (COLCORONA),Completed,Phase 3,Montreal Heart Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04322682,0,0,0,0,12,1,United States|Brazil|Canada|South Africa|Spain,0,colchicine|placebo,NA
NCT04322565,2020-04-20,2020-12-20,Interventional,Colchicine Counteracting Inflammation in COVID-19 Pneumonia,Recruiting,Phase 2,Azienda Ospedaliero-Universitaria di Parma,NA,https://clinicalzeros.gov/ct2/show/NCT04322565,0,0,0,0,3,0,Italy,0,colchicine,NA
NCT04323514,2020-03-13,2021-03-13,Interventional,Use of Ascorbic Acid in Patients With COVID 19,Recruiting,N/A,University of Palermo,NA,https://clinicalzeros.gov/ct2/show/NCT04323514,0,0,0,0,0,0,Italy,0,vitamin c,NA
NCT04322344,2020-03-23,2020-06-30,Interventional,Escin in Patients With Covid-19 Infection,Recruiting,Phase 2/Phase 3,University of Catanzaro,NA,https://clinicalzeros.gov/ct2/show/NCT04322344,0,0,0,0,2,0,Italy,0,escin|standard care,NA
NCT04321993,2020-04-17,2022-02-28,Interventional,Treatment of Moderate to Severe Coronavirus Disease (COVID-19) in Hospitalized Patients,Recruiting,Phase 2,Nova Scotia Health Authority,NA,https://clinicalzeros.gov/ct2/show/NCT04321993,0,0,0,0,6,0,Canada,0,baricitinib,NA
NCT04321616,2020-03-28,2020-08-31,Interventional,The Efficacy of Different Anti-viral Drugs in COVID 19 Infected Patients,Recruiting,Phase 2/Phase 3,Oslo University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04321616,0,0,0,0,2,0,Norway,0,hydroxychloroquine|remdesivir|standard care,NA
NCT04320056,2020-04-20,2021-04-30,Interventional,Closed-Loop Oxygen to Verify That Healthcare Workers Interventions Decrease During SARS-CoV-2 Pneumonia (COVID-19),Recruiting,N/A,Laval University,NA,https://clinicalzeros.gov/ct2/show/NCT04320056,0,0,0,0,2,0,Canada,0,oxygen,NA
NCT04320238,2020-01-21,2020-05-31,Interventional,Experimental Trial of rhIFNÎ± Nasal Drops to Prevent 2019-nCOV in Medical Staff,Recruiting,Phase 3,Shanghai Jiao Tong University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04320238,0,0,0,0,1,0,China,0,interferon|thymosin,NA
NCT04319900,2020-03-05,2020-04-30,Interventional,Clinical Trial of Favipiravir Tablets Combine With Chloroquine Phosphate in the Treatment of Novel Coronavirus Pneumonia,Recruiting,Phase 2/Phase 3,Beijing Chao Yang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04319900,0,0,0,0,0,0,China,0,favipiravir/chloroquine|favipiravir|placebo|chloroquine,NA
NCT04318015,2020-04-14,2020-12-31,Interventional,Hydroxychloroquine Chemoprophylaxis in Healthcare Personnel in Contact With COVID-19 Patients (PHYDRA Trial),Recruiting,Phase 3,"National Institute of Respiratory Diseases, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04318015,0,0,0,0,1,0,Mexico,0,hydroxychloroquine|placebo,NA
NCT04315896,2020-04-14,2020-07-01,Interventional,Hydroxychloroquine Treatment for Severe COVID-19 Pulmonary Infection (HYDRA Trial),"Active, not recruiting",Phase 3,"National Institute of Respiratory Diseases, Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04315896,0,0,0,0,2,0,Mexico,0,hydroxychloroquine|placebo,NA
NCT04315298,2020-03-18,2020-07-24,Interventional,Evaluation of the Efficacy and Safety of Sarilumab in Hospitalized Patients With COVID-19,Completed,Phase 2/Phase 3,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04315298,0,0,0,0,7,1,United States,0,sarilumab|placebo,NA
NCT04313322,2020-03-16,2020-06-30,Interventional,Treatment of COVID-19 Patients Using Wharton's Jelly-Mesenchymal Stem Cells,Recruiting,Phase 1,Stem Cells Arabia,NA,https://clinicalzeros.gov/ct2/show/NCT04313322,0,0,0,0,0,0,Jordan,0,mesenchymal stem cells,NA
NCT04310228,2020-03-08,2020-05-31,Interventional,Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019,Recruiting,N/A,Peking University First Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04310228,0,0,0,0,1,0,China,0,favipiravir/tocilizumab|favipiravir|tocilizumab,NA
NCT04308317,2020-03-05,2021-03-01,Interventional,Tetrandrine Tablets Used in the Treatment of COVID-19,Enrolling by invitation,Phase 4,Henan Provincial People's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04308317,0,0,0,0,0,0,China,0,tetrandrine,NA
NCT04305106,2020-03-17,2020-06-30,Interventional,Bevacizumab in Severe or Critically Severe Patients With COVID-19 Pneumonia-RCT,Recruiting,N/A,Qilu Hospital of Shandong University,NA,https://clinicalzeros.gov/ct2/show/NCT04305106,0,0,0,0,2,0,China,0,bevacizumab,NA
NCT04306055,2020-03-13,2020-03-13,Interventional,Blood Donor Recruitment During Epidemic of COVID-19,Completed,N/A,Guangzhou Blood Center,NA,https://clinicalzeros.gov/ct2/show/NCT04306055,0,0,0,0,1,0,China,0,questionnaire|experimental: questionnaire without precaution information,NA
NCT04305457,2020-03-21,2021-04-01,Interventional,Nitric Oxide Gas Inhalation Therapy for Mild/Moderate COVID-19,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04305457,0,0,0,0,12,1,United States,0,nitric oxide,NA
NCT04304690,2020-03-16,2021-05-16,Interventional,"COVID-19 Seroconversion Among Front Line Medical and Paramedical Staff in Emergency, Intensive Care Units and Infectious Disease Departments During the 2020 Epidemic","Active, not recruiting",N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04304690,0,0,0,0,4,0,France,0,blood sample,NA
NCT04299724,2020-02-15,2023-07-31,Interventional,Safety and Immunity of Covid-19 aAPC Vaccine,Recruiting,Phase 1,Shenzhen Geno-Immune Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04299724,0,0,0,1,0,0,China,0,aapc,NA
NCT04291729,2020-02-17,2020-03-19,Interventional,Evaluation of Ganovo ï¼ˆDanoprevir ï¼‰ Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection,Completed,Phase 4,The Ninth Hospital of Nanchang,NA,https://clinicalzeros.gov/ct2/show/NCT04291729,0,0,0,0,3,0,China,0,ganovo/ritonavir//-interferon nebulization|ganovo|ritonavir|NA|-interferon nebulization,NA
NCT04276987,2020-02-15,2020-05-31,Interventional,A Pilot Clinical Study on Inhalation of Mesenchymal Stem Cells Exosomes Treating Severe Novel Coronavirus Pneumonia,Completed,Phase 1,Ruijin Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04276987,0,0,0,0,3,0,China,0,mesenchymal stem cells,NA
NCT04279197,2020-04-23,2021-12-31,Interventional,Treatment of Pulmonary Fibrosis Due to COVID-19 With Fuzheng Huayu,Recruiting,Phase 2,ShuGuang Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04279197,0,0,0,0,2,0,China,0,fuzheng huayu|vitamin c tablets|placebo|respiratory function rehabilitation training,NA
NCT04276896,2020-03-24,2023-07-31,Interventional,Immunity and Safety of Covid-19 Synthetic Minigene Vaccine,Recruiting,Phase 1/Phase 2,Shenzhen Geno-Immune Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04276896,0,0,0,1,2,0,China,0,lv-smenp-dc vaccine/antigen-specific ctls|injection|lv-smenp-dc vaccine|control,NA
NCT04273763,2020-02-16,2020-05-10,Interventional,Evaluating the Efficacy and Safety of Bromhexine Hydrochloride Tablets Combined With Standard Treatment/ Standard Treatment in Patients With Suspected and Mild Novel Coronavirus Pneumonia (COVID-19),"Active, not recruiting",N/A,Second Affiliated Hospital of Wenzhou Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04273763,0,0,0,0,4,0,China,0,bromhexine hydrochloride|arbidol|recombinant human interferon î±2b spray|recombinant human interferon î±2b spray,NA
NCT04269525,2020-02-06,2020-12-01,Interventional,Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia,Recruiting,Phase 2,Zhongnan Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04269525,0,0,0,0,3,0,China,0,mesenchymal stem cells,NA
NCT04263402,2020-02-01,2020-06-01,Interventional,The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia,Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04263402,0,0,0,0,3,0,China,0,methylprednisolone,NA
NCT04261270,2020-02-01,2020-05-01,Interventional,"A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV Pneumonia",Recruiting,Phase 3,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04261270,0,0,0,0,2,0,China,0,asc09f/oseltamivir|ritonavir/oseltamivir|oseltamivir|asc09|ritonavir,NA
NCT04255017,2020-02-01,2020-06-01,Interventional,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia",Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04255017,0,0,0,0,3,0,China,0,arbidol|oseltamivir|lopinavir/ritonavir|lopinavir|ritonavir,NA
NCT04254874,2020-02-01,2020-06-01,Interventional,"A Prospective/Retrospective,Randomized Controlled Clinical Study of Interferon Atomization in the 2019-nCoV Pneumonia",Recruiting,Phase 4,Tongji Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04254874,0,0,0,0,3,0,China,0,arbidol|arbidol hydrochloride/interferon atomization|interferon,NA
NCT04252118,2020-01-27,2020-12-31,Interventional,Mesenchymal Stem Cell Treatment for Pneumonia Patients Infected With COVID-19,Recruiting,Phase 1,Beijing 302 Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04252118,0,0,0,0,4,0,China,0,mesenchymal stem cells,NA
NCT04767087,2021-02-05,2021-06-15,Interventional,Honey and Nigella Sativa in COVID-19 Prophylaxis,Recruiting,Phase 2/Phase 3,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04767087,0,0,0,0,0,0,Pakistan,0,honey|nigella sativa seed|placebo,NA
NCT04701710,2020-10-15,2020-12-18,Interventional,Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan,Completed,Phase 1/Phase 2,"Ministry of Public Health, Argentina",NA,https://clinicalzeros.gov/ct2/show/NCT04701710,0,0,0,0,2,0,Argentina,0,ivermectin / iota-carrageenan|ivermectin|iota-carrageenan,NA
NCT04765839,2021-02-12,2021-03-22,Interventional,Community-Engaged Bidirectional Pandemic Crisis and Emergency Risk Communication With COVID-19 Vaccine Messages to Minority Populations,"Active, not recruiting",N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04765839,0,0,0,1,0,1,United States,0,"educational, culturally appropriate covid-19 messages",NA
NCT04527575,2020-07-27,2021-05-31,Interventional,"Study of the Safety, Reactogenicity and Immunogenicity of ""EpiVacCorona"" Vaccine for the Prevention of COVID-19","Active, not recruiting",Phase 1/Phase 2,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,https://clinicalzeros.gov/ct2/show/NCT04527575,0,0,0,1,3,0,Russian Federation,0,epivaccorona (epivaccorona vaccine based on peptide antigens for the prevention of covid-19)|placebo,NA
NCT04429555,2021-01-11,2021-06-30,Interventional,"Efficacy, Safety, Tolerability, and Biomarkers of MN-166 (Ibudilast) in Patients Hospitalized With COVID-19 and at Risk for ARDS",Recruiting,Phase 2,MediciNova,NA,https://clinicalzeros.gov/ct2/show/NCT04429555,0,0,0,0,5,1,United States,0,ibudilast|placebo,NA
NCT04384445,2020-09-08,2021-06-30,Interventional,Zofin (Organicell Flow) for Patients With COVID-19,Recruiting,Phase 1/Phase 2,Organicell Regenerative Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04384445,0,0,0,0,7,1,United States,0,zofin|placebo,NA
NCT04358783,2020-04-27,2021-05-01,Interventional,Convalescent Plasma Compared to the Best Available Therapy for the Treatment of SARS-CoV-2 Pneumonia,"Active, not recruiting",Phase 2,Hospital Universitario Dr. Jose E. Gonzalez,NA,https://clinicalzeros.gov/ct2/show/NCT04358783,0,0,0,0,2,0,Mexico,0,plasma|best available therapy,NA
NCT04358003,2020-05-20,2021-08-01,Interventional,Plasma Adsorption in Patients With Confirmed COVID-19,Recruiting,N/A,Marker Therapeutics AG,NA,https://clinicalzeros.gov/ct2/show/NCT04358003,0,0,0,0,8,1,United States,0,marker therapeutics d2000 cartridge (d2000) for use with the spectra optiaâ® apheresis system (optia spd protocol)|marker therapeutics d2000 cartridge (d2000) for use with the spectra optiaâ® apheresis system (optia spd protocol),NA
NCT04355962,2020-04-23,2022-03-31,Interventional,Sevoflurane in COVID-19 ARDS (SevCov),Recruiting,Phase 3,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04355962,0,0,0,0,6,0,Switzerland,0,sevoflurane|intravenous drug,NA
NCT04334460,2020-05-04,2020-11-11,Interventional,Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects,"Active, not recruiting",Phase 2,Blade Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04334460,0,0,0,0,10,1,United States|Brazil,0,bld-2660,NA
NCT04731116,2021-01-10,2021-12-31,Interventional,Cannabidiol Treatment for Severe and Critical Coronavirus (COVID-19) Pulmonary Infection,Recruiting,Phase 1/Phase 2,Rabin Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04731116,0,0,0,0,0,0,Israel,0,cannabidiol,NA
NCT04730284,2020-08-25,2021-09-30,Interventional,Evaluation of a Synbiotic Formula in Patient With COVID-19,Recruiting,N/A,Chinese University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04730284,0,0,0,0,0,0,Hong Kong,0,health supplements,NA
NCT04730427,2021-01-31,2021-05-31,Interventional,Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19,Recruiting,Phase 1,"Genexine, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04730427,0,0,0,0,0,0,"Korea, Republic of",0,gx-i7|gx-i7 vehicle,NA
NCT04723524,2020-09-22,2021-06-30,Interventional,Jinhua Qinggan Granules in the Treatment of COVID-19,Recruiting,Phase 2,University of Karachi,NA,https://clinicalzeros.gov/ct2/show/NCT04723524,0,0,0,0,2,0,Pakistan,0,"jinhua qinggan (jhqg) granules, traditional chinese medicine|placebo",NA
NCT04695301,2020-07-01,2021-07-01,Interventional,Functional Outcomes in COVID-19 Survivors and Use of a Digital Platform for Rehabilitation,Recruiting,N/A,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04695301,0,0,0,0,2,0,Brazil,0,rehabilitation protocol through a digital platform,NA
NCT04640233,2020-11-30,2021-08-31,Interventional,Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Ð¡ov-2) Infection,Recruiting,Phase 2/Phase 3,Dr. Reddy's Laboratories Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04640233,0,0,0,1,1,0,India,0,gam-covid-vac|placebo,NA
NCT04464395,2020-07-01,2021-03-31,Interventional,Study of CPI-006 as Immunotherapy for Hospitalized COVID-19 Patients,Recruiting,Phase 1,"Corvus Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04464395,0,0,0,0,4,1,United States,0,cpi-006|standard care,NA
NCT04459962,2020-06-29,2021-01-07,Interventional,Covid-19 Breath Test,Completed,N/A,Ancon Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04459962,0,0,0,0,1,0,United Kingdom,0,breath test/cheek swab|breath test|cheek swab,NA
NCT04412668,2020-06-12,2020-12-21,Interventional,Study to Evaluate the Safety and Efficacy of ATYR1923 In Patients With Severe Pneumonia Related to COVID-19,Completed,Phase 2,"aTyr Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04412668,0,0,0,0,9,1,United States|Puerto Rico,0,atyr1923|placebo|kg,NA
NCT04769297,2020-04-15,2021-04-30,Interventional,"Micro-Dose, Macro-Impact: Leveraging Psychedelics in Frontline Healthcare Workers During the COVID-19 Pandemic","Active, not recruiting",Phase 4,Limbic Medical,NA,https://clinicalzeros.gov/ct2/show/NCT04769297,0,0,0,0,0,1,United States,0,sublingual micro-dose ketamine,NA
NCT04700462,2021-02-05,2021-10-30,Interventional,COVID-19 Preventive Behavior in African Americans,Recruiting,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04700462,0,0,0,0,2,1,United States,0,sm-ema,NA
NCT04762628,2020-10-27,2021-11-01,Interventional,"Trial Efficacy of Saisei Pharma Dietary Supplements MAF Capsules, 148 mg and M Capsules, 148 mg in Hospitalized COVID-19 Patients","Active, not recruiting",N/A,Saisei Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04762628,0,0,0,0,1,0,Ukraine,0,maf capsules 148 mg|m capsules 148 mg|standard care,NA
NCT04723563,2021-02-22,2021-05-01,Interventional,Nebulized Heparin for the Treatment of COVID-19,Enrolling by invitation,Phase 4,Frederick Health,NA,https://clinicalzeros.gov/ct2/show/NCT04723563,0,0,0,0,1,1,United States,0,heparin|saline,NA
NCT04695197,2021-01-08,2022-11-01,Interventional,Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso,Recruiting,Phase 3,Liverpool School of Tropical Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04695197,0,0,0,0,1,0,Burkina Faso|Kenya,0,artemether-lumefantrine (al)|pyronaridine-artesunate (pa),NA
NCT04659707,2021-02-22,2021-12-31,Interventional,Hyperpolarized 129Xe MRI of Survivors of COVID-19,Recruiting,Phase 1,University of Kansas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04659707,0,0,0,0,2,1,United States,0,hyperpolarized xe129,NA
NCT04681053,2021-02-25,2021-04-30,Interventional,Inhaled Ivermectin and COVID-19,Recruiting,Phase 3,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04681053,0,0,0,0,2,0,Egypt,0,ivermectin powder,NA
NCT04679909,2021-02-28,2022-02-28,Interventional,Safety and Immunogenicity of AdCOVID in Healthy Adults (COVID-19 Vaccine Study),Recruiting,Phase 1,"Altimmune, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04679909,0,0,0,1,3,1,United States,0,adcovid|placebo,NA
NCT04494646,2020-09-08,2021-01-08,Interventional,BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19),Completed,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04494646,0,0,0,0,5,1,United States,0,bardoxolone methyl|placebo,NA
NCT04535869,2020-12-28,2021-04-01,Interventional,Efficacy and Safety of Direct Anti HCV Drugs in the Treatment of SARS-COV-2 (COVID-19),Recruiting,Phase 3,Mansoura University,NA,https://clinicalzeros.gov/ct2/show/NCT04535869,0,0,0,0,3,0,Egypt,0,sofosbuvir 400 mg/daclatasvir 200mg|sofosbuvir 400 mg|daclatasvir 200mg,NA
NCT04415151,2020-07-29,2021-03-31,Interventional,Tofacitinib for Treatment of Moderate COVID-19,Recruiting,Phase 2,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04415151,0,0,0,0,4,1,United States,0,tofacitinib|placebo,NA
NCT04365699,2020-04-08,2021-01-31,Interventional,Cardiovascular Effects of COVID-19,Completed,Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04365699,0,0,0,0,1,1,United States,0,at-001,NA
NCT04366141,2020-05-01,2021-02-01,Interventional,COVID-19 (Coronavirus Disease 2019) Intubation Barrier Box,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04366141,0,0,0,0,3,0,Canada,0,covid-19 barrier box,NA
NCT04394013,2020-08-26,2020-12-31,Interventional,A Web-Based Gentle Body Stretching to Alleviate Loneliness and Improve Mental Fitness During COVID-19 Isolation Period,Completed,N/A,Monash University Malaysia,NA,https://clinicalzeros.gov/ct2/show/NCT04394013,0,0,0,0,2,0,Malaysia,0,mindfulness|non-mindfulness intervention,NA
NCT04734912,2021-01-13,2021-06-15,Interventional,Evaluation of Transnasal Endoscopy During COVID-19 Pandemic,Recruiting,N/A,Johannes Gutenberg University Mainz,NA,https://clinicalzeros.gov/ct2/show/NCT04734912,0,0,0,0,0,0,Germany,0,gastroscopy in transnasal techique,NA
NCT04734717,2021-01-12,2021-04-12,Interventional,Coordination and Locomotor Problems in Patients With Covid-19 Virus,Enrolling by invitation,N/A,Somogy Megyei Kaposi MÃ³r Teaching Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04734717,0,0,0,0,0,0,Hungary,0,neurology test,NA
NCT04734886,2020-11-27,2021-08-30,Interventional,The Effect of Probiotic Supplementation on SARS-CoV-2 Antibody Response After COVID-19,Recruiting,N/A,"Ã–rebro University, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04734886,0,0,0,0,0,0,Sweden,0,l. reuteri dsm 17938 / vitamin d|placebo / vitamin d|l. reuteri dsm 17938|vitamin d|placebo,NA
NCT04733833,2021-01-26,2022-06-30,Interventional,A Study to Evaluate the Efficacy and Safety of VB-201 in Patients With COVID-19,Recruiting,Phase 2,Vascular Biogenics Ltd. operating as VBL Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04733833,0,0,0,0,0,0,Israel,0,vb-201 / standard of care|standard care|vb-201,NA
NCT04734171,2020-04-02,2020-04-16,Interventional,"Social Activity, Loneliness and Stigma During COVID-19 Outbreak",Completed,N/A,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04734171,0,0,0,0,0,1,United States,0,digital social activity video intervention|informational sheet|stigma awareness video intervention,NA
NCT04733625,2020-09-15,2020-12-17,Interventional,The Effect of Vitamin D Therapy on Morbidity and Moratlity in Patients With SARS-CoV 2 Infection,Completed,N/A,Kasr El Aini Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04733625,0,0,0,0,0,0,Egypt,0,cholecalciferol|placebo,NA
NCT04728594,2021-01-15,2021-01-17,Interventional,Emails Promoting COVID-19 Vaccination Among Healthcare Workers,Completed,N/A,Geisinger Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04728594,0,0,0,1,1,1,United States,0,social proof|reframing|scarcity message,NA
NCT04726163,2021-01-29,2021-06-14,Interventional,Tele-expertise in Patients With Diabetes Hospitalized for Covid-19 Infection,Recruiting,N/A,"University Hospital, Strasbourg, France",NA,https://clinicalzeros.gov/ct2/show/NCT04726163,0,0,0,0,1,0,France,0,continuous blind glucose measurement device (free style pro),NA
NCT04713488,2021-01-15,2021-07-20,Interventional,"An Open Study on the Safety, Tolerability, and Immunogenicity of ""Sputnik Light"" Vaccine","Active, not recruiting",Phase 1/Phase 2,"Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation",NA,https://clinicalzeros.gov/ct2/show/NCT04713488,0,0,0,1,2,0,Russian Federation,0,sputnik light,NA
NCT04674644,2020-10-16,2020-10-23,Interventional,Analysing the Psychosocial Effects of COVID-19 Pandemic on Dental Professionals Using the Turkish Version of the Fear of COVID-19 and Coronavirus Anxiety Scales,Completed,N/A,Suleyman Demirel University,NA,https://clinicalzeros.gov/ct2/show/NCT04674644,0,0,0,0,2,0,Turkey,1,the psychosocial effects of covid-19 pandemic on dental professionals,NA
NCT04639375,2020-11-15,2021-04-18,Interventional,Polio Vaccine (IPV) for SARS-CoV-2 and Prevention of Coronavirus Disease (COVID-19),Recruiting,Phase 4,E-MO Biology Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04639375,0,0,0,1,4,1,United States,0,vaccinated with polio vaccine (ipv),NA
NCT04635605,2020-11-05,2021-12-31,Interventional,Methylene Blue Treatment of COVID-19,Recruiting,Phase 2,Fondazione Epatocentro Ticino,NA,https://clinicalzeros.gov/ct2/show/NCT04635605,0,0,0,0,1,0,Switzerland,0,methylene blue|control test,NA
NCT04646603,2021-01-28,2021-04-01,Interventional,MRG-001 as an Immunoregulatory and Regenerative Therapy for COVID-19 Patients,Recruiting,Phase 1/Phase 2,MedRegen LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04646603,0,0,0,0,5,1,United States,0,mrg-001|placebo,NA
NCT04548934,2020-09-13,2020-10-31,Interventional,Effect of Wearing Personal Protective Equipment (PPE) on CPR Quality in Times of the COVID-19-pandemic,Completed,N/A,Institute of Mountain Emergency Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04548934,0,0,0,0,1,0,Italy,0,personal protective equipment (ppe)|no personal protective equipment (ppe),NA
NCT04623021,2020-09-25,2020-12-12,Interventional,A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia,Completed,Phase 2,Chong Kun Dang Pharmaceutical,NA,https://clinicalzeros.gov/ct2/show/NCT04623021,0,0,0,0,1,0,Russian Federation,0,nafamostat mesilate,NA
NCT04528667,2021-01-06,2021-05-31,Interventional,Study of the Safety and Efficacy of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized Due to COVID-19,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04528667,0,0,0,0,2,0,Brazil,0,sti-5656|placebo,NA
NCT04528368,2020-12-11,2021-04-30,Interventional,Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support,Recruiting,Phase 2,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04528368,0,0,0,0,1,0,Brazil,0,convalescent plasma,NA
NCT04519411,2020-05-21,2021-12-31,Interventional,Transpulmonary Pressure Measurements in Intubated Children With Covid-19 Respiratory Failure,Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04519411,0,0,0,0,1,1,United States,0,transpulmonary pressure measurements,NA
NCT04498442,2020-05-22,2020-10-22,Interventional,"A Study on Prevalence, Protection and Recovery From COVID-19 in Seasoned Yoga Practitioners in Comparison to Age and Gender Matched Controls",Completed,N/A,Beth Israel Deaconess Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04498442,0,0,0,0,3,1,United States,0,simha kriya|reading a book,NA
NCT04488575,2020-08-26,2021-07-06,Interventional,Safety and Efficacy of EDP1815 in the Treatment of Patients Hospitalized With COVID-19 Infection,Recruiting,Phase 2,"Evelo Biosciences, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04488575,0,0,0,0,4,1,United States,0,edp1815|placebo,NA
NCT04486001,2020-12-15,2022-01-15,Interventional,Study of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19,Recruiting,Phase 1,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04486001,0,0,0,0,4,1,United States,0,psc-04,NA
NCT04469114,2020-09-16,2021-03-01,Interventional,Tofacitinib in Hospitalized Patients With COVID-19 Pneumonia,"Active, not recruiting",Phase 2,Hospital Israelita Albert Einstein,NA,https://clinicalzeros.gov/ct2/show/NCT04469114,0,0,0,0,5,0,Brazil,0,tofacitinib|placebo,NA
NCT04452669,2020-09-15,2021-05-01,Interventional,VentaProst in Subjects With COVID-19 Requiring Mechanical Ventilation,Recruiting,Phase 2,Aerogen Pharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04452669,0,0,0,0,3,1,United States,0,ventaprost (inhaled epoprostenol delivered via a dedicated delivery system),NA
NCT04435379,2020-06-18,2021-09-30,Interventional,Study to Assess VPM1002 in Reducing Hospital Admissions and/or Severe Respiratory Infectious Diseases in Elderly in COVID-19 Pandemic,"Active, not recruiting",Phase 3,Vakzine Projekt Management GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04435379,0,0,0,0,11,0,Germany,0,vpm1002|placebo,NA
NCT04411433,2020-05-08,2020-12-31,Interventional,Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19,"Active, not recruiting",Phase 3,"Ministry of Health, Turkey",NA,https://clinicalzeros.gov/ct2/show/NCT04411433,0,0,0,0,1,0,Turkey,0,favipiravir|favipiravir/hydroxychloroquine|favipiravir/azithromycin|hydroxychloroquine|hydroxychloroquine / azithromycin|1200 mg)|1600 mg)|azithromycin,NA
NCT04363346,2020-05-14,2022-01-31,Interventional,Study of FT516 for the Treatment of COVID-19 in Hospitalized Patients With Hypoxia,"Active, not recruiting",Phase 1,"Masonic Cancer Center, University of Minnesota",NA,https://clinicalzeros.gov/ct2/show/NCT04363346,0,0,0,0,3,1,United States,0,nk cells,NA
NCT04388683,2020-05-12,2021-04-30,Interventional,Inhaled Nitric Oxide for Preventing Progression in COVID-19,"Active, not recruiting",Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04388683,0,0,0,0,2,1,United States,0,nitric oxide,NA
NCT04334044,2020-09-01,2021-03-01,Interventional,Treatment of SARS Caused by COVID-19 With Ruxolitinib,Recruiting,Phase 1/Phase 2,Grupo Cooperativo de HemopatÃ­as Malignas,NA,https://clinicalzeros.gov/ct2/show/NCT04334044,0,0,0,0,2,0,Mexico,0,ruxolitinib,NA
NCT04771585,2021-03-15,2022-01-31,Interventional,Quantification of Exhaled Particles to Identify Airborne Transmission Risks of COVID-19,Recruiting,N/A,Fraunhofer-Institute of Toxicology and Experimental Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04771585,0,0,0,0,0,0,Germany,0,community mask|surgical mask|ffp2 respirator|ffp3 respirator,NA
NCT04346199,2020-06-12,2020-11-17,Interventional,Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19.,Completed,Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04346199,0,0,0,0,5,0,Argentina|Brazil|Chile|France|Germany|India|Italy|Japan|Mexico|Peru|Russian Federation|South Africa|Turkey,0,acalabrutinib,NA
NCT04341584,2020-04-08,2020-05-10,Interventional,CORIMUNO-ANA: Trial Evaluating Efficacy Of Anakinra In Patients With Covid-19 Infection,Completed,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04341584,0,0,0,0,2,0,France,0,anakinra,NA
NCT04568707,2020-10-23,2022-10-15,Interventional,Evaluation of Biological Response to SARS-COV2 (COVID-19) in Patients With Pre-existing Neurological Disease or Newly Neurological Symptoms (BIO-COCO-NEUROSCIENCES),Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04568707,0,0,0,0,1,0,France,0,blood sample,NA
NCT04614844,2021-01-06,2022-09-15,Interventional,COVID-19 Responsive Intervention: Systems Improvement Simulations (CRI:SIS),Recruiting,N/A,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04614844,0,0,0,0,3,1,United States,0,simulation intervention|control,NA
NCT04769999,2020-06-04,2020-10-16,Interventional,Computer Assisted Lessening of Intrusive Memories in the Emergency Department,Completed,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04769999,0,0,0,0,0,0,United Kingdom,0,simple cognitive task,NA
NCT04757857,2020-09-29,2021-02-28,Interventional,COVID-19 Antithrombotic Rivaroxaban Evaluation,Recruiting,Phase 4,Hospital AlemÃ£o Oswaldo Cruz,NA,https://clinicalzeros.gov/ct2/show/NCT04757857,0,0,0,0,1,0,Brazil,0,rivaroxaban 10 mg,NA
NCT04677660,2021-01-21,2022-03-03,Interventional,A Study of TAK-919 in Healthy Japanese Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Takeda,NA,https://clinicalzeros.gov/ct2/show/NCT04677660,0,0,0,0,4,0,Japan,0,tak-919|placebo,NA
NCT04541979,2020-06-04,2021-05-01,Interventional,Aerosoliserat DNase for Treatment of Respiratory Failure in Severe COVID-19,Recruiting,Phase 2,Region Skane,NA,https://clinicalzeros.gov/ct2/show/NCT04541979,0,0,0,0,1,0,Sweden,0,aerosolized dnase|sodium,NA
NCT04410549,2020-06-01,2021-12-31,Interventional,Pulmonary Optical Coherence Tomography in COVID-19 Patients,Recruiting,N/A,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04410549,0,0,0,0,2,0,Brazil|Italy,0,optical coherence tomography (oct),NA
NCT04678700,2021-03-01,2021-06-01,Interventional,Implementation of a Respiratory Physiotherapy Program in Post COVID-19 Patients Through Tele-assistance,Recruiting,N/A,European University of Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04678700,0,0,0,0,1,0,Spain,0,chest physiotherapy post-covid19,NA
NCT04345679,2020-04-14,2021-06-01,Interventional,Anti COVID-19 Convalescent Plasma Therapy,Recruiting,Early Phase 1,Orthosera Kft.,NA,https://clinicalzeros.gov/ct2/show/NCT04345679,0,0,0,0,3,0,Hungary,0,convalescent plasma,NA
NCT04678687,2021-01-01,2021-06-01,Interventional,COVID-19 and Tissue Damage in Vital Organs,"Active, not recruiting",N/A,Dokuz Eylul University,NA,https://clinicalzeros.gov/ct2/show/NCT04678687,0,0,0,0,1,0,Turkey,0,"liver, lung, heart/kidney biopsy|liver, lung, heart|kidney biopsy",NA
NCT04325633,2020-04-24,2020-12-15,Interventional,Efficacy of Addition of Naproxen in the Treatment of Critically Ill Patients Hospitalized for COVID-19 Infection,Terminated,Phase 3,Assistance Publique - HÃ´pitaux de Paris,Stop inclusions for insufficient recruitment,https://clinicalzeros.gov/ct2/show/NCT04325633,0,0,0,0,2,0,France,0,naproxen|standard care,NA
NCT04581200,2021-01-25,2021-07-31,Interventional,Lift Mobile Mindfulness for COVID-19 Distress Symptoms,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04581200,0,0,0,0,4,1,United States,0,lift,NA
NCT04529499,2020-08-20,2021-03-31,Interventional,Clinical Trial Evaluating the Efficacy and Safety of Favipiravir in Moderate to Severe COVID-19 Patients,"Active, not recruiting",Phase 3,Dr. Reddy's Laboratories Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04529499,0,0,0,0,2,0,Kuwait,0,avigan|placebo,NA
NCT04525417,2020-04-25,2020-09-25,Interventional,Rapid Screening Test for Covid-19 Antibodies in Healthcare Workers,Completed,N/A,Groupe d'Etude sur le Risque d'Exposition des Soignants aux Agents Infectieux,NA,https://clinicalzeros.gov/ct2/show/NCT04525417,0,0,0,0,1,0,France,0,aaz covid-19 rapid test,NA
NCT04511949,2020-07-12,2020-09-30,Interventional,COVID-19: Epidemiological Study of the Spread of SARS-CoV-2 in the Household of a Person Who Has Had a COVID-19 Disease,Completed,N/A,Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida,NA,https://clinicalzeros.gov/ct2/show/NCT04511949,0,0,0,0,2,0,France,0,igm/igg rapid test|igg|igm antibodytest,NA
NCT04409821,2020-05-29,2022-02-28,Interventional,Tele-based Psychological Emotional Support for Informal CARegivers of COVID-19 Patients in Intensive Care,Recruiting,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04409821,0,0,0,0,1,0,Denmark,0,tele-delivered psychological intervention,NA
NCT04446429,2020-09-15,2020-12-24,Interventional,Anti-Androgen Treatment for COVID-19,Completed,N/A,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04446429,0,0,0,0,7,0,Brazil,1,proxalutamide|standard care,NA
NCT04445272,2020-05-22,2020-12-23,Interventional,Clinical Trial to Evaluate the Effectiveness and Safety of Tocilizumab for Treating Patients With COVID-19 Pneumonia,Completed,Phase 2,Fundacion SEIMC-GESIDA,NA,https://clinicalzeros.gov/ct2/show/NCT04445272,0,0,0,0,1,0,Spain,0,tocilizumab,NA
NCT04384731,2020-05-29,2021-05-29,Interventional,CurosurfÂ® in Adult Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Phase 2,Versailles Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04384731,0,0,0,0,2,0,France,0,poractant alfa,NA
NCT04369066,2020-04-28,2021-04-28,Interventional,"COVID-19 Study of the Serological Response Against the Severe Acute Respiratory Syndrome (SARS) Coronavirus 2 (CoV-2) Virus in 2 Types of Employees, Hospital and Non-hospital, at Institute Curie and Institute Pasteur",Recruiting,N/A,Institut Curie,NA,https://clinicalzeros.gov/ct2/show/NCT04369066,0,0,0,0,5,0,France,0,blood sample|nasopharyngeal swabs,NA
NCT04358926,2020-04-30,2020-10-15,Interventional,Hyperbaric Oxygen Therapy Effect in COVID-19 RCT (HBOTCOVID19),Completed,N/A,Assaf-Harofeh Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04358926,0,0,0,0,5,0,Israel,0,oxygen,NA
NCT04334434,2020-07-30,2020-09-15,Interventional,Telerehabilitation in Individuals Over 65 Years of Age Having Social Isolation Due to Coronavirus (Covid-19),Completed,N/A,Istanbul University-Cerrahpasa,NA,https://clinicalzeros.gov/ct2/show/NCT04334434,0,0,0,0,4,0,Turkey,0,telehealth,NA
NCT04776941,2020-08-07,2021-12-31,Interventional,Expressive Writing for the Management of Stress in Cancer Survivors,Recruiting,N/A,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04776941,0,0,0,0,0,1,United States,0,behavioral intervention|quality-of-life assessment|questionnaire,NA
NCT04739410,2020-05-01,2020-06-30,Interventional,Effectiveness of Ivermectin in SARS-CoV-2/COVID-19 Patients,Completed,Phase 4,FMH College of Medicine and Dentistry,NA,https://clinicalzeros.gov/ct2/show/NCT04739410,0,0,0,0,0,0,Pakistan,0,ivermectin,NA
NCT04703036,2021-01-11,2021-12-31,Interventional,"Glutathione, Oxidative Stress and Mitochondrial Function in COVID-19",Recruiting,Early Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04703036,0,0,0,0,2,1,United States,0,glycine|n-acetylcysteine|alanine,NA
NCT04647747,2020-11-30,2021-03-30,Interventional,Silent Hypoxia and Awake Proning in COVID-19 Patients,Recruiting,N/A,Ostfold Hospital Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04647747,0,0,0,0,2,0,Norway,0,self measurement with pulse oximeter,NA
NCT04466241,2020-11-27,2021-03-26,Interventional,Combination Therapies to Reduce Carriage of SARS-Cov-2 and Improve Outcome of COVID-19 in Ivory Coast: a Phase Randomized IIb Trial,Recruiting,Phase 2/Phase 3,French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS),NA,https://clinicalzeros.gov/ct2/show/NCT04466241,0,0,0,0,3,0,CÃ´te D'Ivoire,0,lopinavir/ritonavir 200 mg-50 mg oral tablet|telmisartan 40mg oral tablet|atorvastatin 20 mg oral tablet|lopinavir|ritonavir 200 mg-50 mg oral tablet,NA
NCT04760132,2021-02-08,2024-12-31,Interventional,National Cohort Study of Effectiveness and Safety of SARS-CoV-2/COVID-19 Vaccines (ENFORCE),Recruiting,Phase 4,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04760132,0,0,0,1,1,0,Denmark,0,comirnaty - biontech manufacturing gmbh|covid-19 vaccine moderna dispersion for injection - moderna biotech|covid-19 vaccine astrazeneca suspension for injection,NA
NCT04435522,2020-10-01,2020-12-31,Interventional,Maraviroc in Patients With Moderate and Severe COVID-19,Completed,Phase 1,Rhode Island Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04435522,0,0,0,0,3,1,United States,0,maraviroc,NA
NCT04361344,2020-05-19,2020-10-25,Interventional,Neurodegeneration Markers and Neurological Course in Severe Covid-19 Infection,Terminated,N/A,Centre Hospitalier de PAU,objective of the study demonstrated by other research teams,https://clinicalzeros.gov/ct2/show/NCT04361344,0,0,0,0,2,0,France,0,blood sample,NA
NCT04407130,2020-06-16,2020-10-30,Interventional,Efficacy and Safety of Ivermectin and Doxycycline in Combination or IVE Alone in Patients With COVID-19 Infection.,Completed,Phase 2,"International Centre for Diarrhoeal Disease Research, Bangladesh",NA,https://clinicalzeros.gov/ct2/show/NCT04407130,0,0,0,0,5,0,Bangladesh,0,ivermectin / doxycycline / placebo|ivermectin / placebo|placebo|ivermectin|doxycycline,NA
NCT04747158,2020-08-10,2020-12-10,Interventional,COVID-19 Convalescent Plasma Therapy,Completed,Phase 2/Phase 3,Universidad Nacional de AsunciÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04747158,0,0,0,0,1,0,Paraguay,0,convalescent plasma,NA
NCT04701502,2020-11-09,2021-02-15,Interventional,Efficacy and Safety of Viusid and Asbrip in Hospitalized Patients With Mild and Moderate COVID-19,Completed,Phase 2,Catalysis SL,NA,https://clinicalzeros.gov/ct2/show/NCT04701502,0,0,0,0,2,0,Bulgaria,0,viusid|asbrip|standard care,NA
NCT04652102,2020-12-14,2021-03-05,Interventional,A Study to Determine the Safety and Efficacy of SARS-CoV-2 mRNA Vaccine CVnCoV in Adults for COVID-19,Recruiting,Phase 2/Phase 3,CureVac AG,NA,https://clinicalzeros.gov/ct2/show/NCT04652102,0,0,0,1,5,0,Belgium|Germany|Mexico|Netherlands|Peru|Spain,0,cvncov|placebo,NA
NCT04651790,2020-11-27,2022-01-31,Interventional,"Efficacy, Safety, and Immunogenicity of Two Vaccination Schedules of an Inactivated Vaccine Against COVID-19 in Adults",Recruiting,Phase 3,Pontificia Universidad Catolica de Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04651790,0,0,0,1,2,0,Chile,0,sars-cov-2 inactivated vaccine,NA
NCT04627584,2020-12-29,2021-05-31,Interventional,A Phase 2 Clinical Trial of MW33 Injection in Patients With COVID-19,Recruiting,Phase 2,"Mabwell (Shanghai) Bioscience Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04627584,0,0,0,0,3,0,China,0,mw33 injection|mw33 injection placebo,NA
NCT04613739,2020-12-08,2021-09-01,Interventional,Asthma in Families Facing Out-of-pocket Requirements Due to COVID-19,Recruiting,N/A,Harvard Pilgrim Health Care,NA,https://clinicalzeros.gov/ct2/show/NCT04613739,0,0,0,0,2,1,United States,0,insurance navigation,NA
NCT04604145,2021-02-03,2021-06-30,Interventional,Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR,Recruiting,N/A,David Grant U.S. Air Force Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04604145,0,0,0,0,1,1,United States,0,sars-cov-2 testing on the eppendorf thermal cycler pcr system using self-collected saliva as the specimen,NA
NCT04603781,2020-12-04,2021-12-31,Interventional,CBD Oil for Reducing Emotional Impact of COVID-19,Recruiting,Phase 2/Phase 3,University of Texas at Austin,NA,https://clinicalzeros.gov/ct2/show/NCT04603781,0,0,0,0,4,1,United States,0,cbd isolate|full spectrum cbd oil|broad-spectrum cbd oil|placebo oil,NA
NCT04588415,2021-01-03,2021-12-01,Interventional,Supporting Family Members With Severe Grief Reaction During the COVID-19 Pandemic,Enrolling by invitation,N/A,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04588415,0,0,0,0,1,0,Canada,0,bereavement virtual support group,NA
NCT04535674,2020-10-09,2021-02-28,Interventional,Asunercept in Patients With Severe COVID-19,Recruiting,Phase 2,Apogenix AG,NA,https://clinicalzeros.gov/ct2/show/NCT04535674,0,0,0,0,5,0,Russian Federation|Spain,0,asunercept,NA
NCT04542850,2020-11-15,2021-06-15,Interventional,"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC in Subjects With COVID-19",Recruiting,N/A,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04542850,0,0,0,0,3,0,Bahrain,0,5-ala-phosphate / sfc (5-ala / sfc)|5-ala-phosphate|sfc (5-ala|sfc),NA
NCT04541680,2020-10-29,2021-03-31,Interventional,Nintedanib for the Treatment of SARS-Cov-2 Induced Pulmonary Fibrosis,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04541680,0,0,0,0,2,0,France,0,nintedanib 150 mg [ofev]|placebo,NA
NCT04456413,2020-11-06,2021-11-30,Interventional,Convalescent Plasma as Treatment for Subjects With Early COVID-19 Infection,Recruiting,Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04456413,0,0,0,0,3,1,United States,0,convalescent plasma|best supportive care,NA
NCT04475913,2018-07-11,2020-07-11,Interventional,Digital vs Analog Impression in Cases of All-on-4 - Prosthesis,Completed,N/A,October University for Modern Sciences and Arts,NA,https://clinicalzeros.gov/ct2/show/NCT04475913,0,0,0,0,1,0,Egypt,0,dig axial|dig tilted|cig axial|cig tilted,NA
NCT04505774,2020-09-04,2021-09-30,Interventional,Anti-thrombotics for Adults Hospitalized With COVID-19 (ACTIV-4),Recruiting,Phase 4,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04505774,0,0,0,0,5,1,United States|Spain,0,theraputic heparin|heparin|p2y12,NA
NCT04472611,2020-10-30,2021-10-30,Interventional,Colchicine/Statins for the Prevention of COVID-19 Complications (COLSTAT) Trial,Recruiting,Phase 3,Yale University,NA,https://clinicalzeros.gov/ct2/show/NCT04472611,0,0,0,0,2,1,United States,0,standard of care (soc)/colchicine/rosuvastatin|standard care|colchicine|rosuvastatin,NA
NCT04427254,2020-06-26,2023-01-31,Interventional,Study of the Sars-Cov2 Neuroinvasiveness - COVID19,Recruiting,N/A,Fondation Ophtalmologique Adolphe de Rothschild,NA,https://clinicalzeros.gov/ct2/show/NCT04427254,0,0,0,0,2,0,France,0,"cerebrospinal fluid sampling, meningeal/brain parenchyma biopsies|cerebrospinal fluid sampling, meningeal|brain parenchyma biopsies",NA
NCT04417270,2020-06-12,2020-11-30,Interventional,Reliability of the Freestyle Libre CGM in the Inpatient Setting During the COVID-19 Surge,Completed,N/A,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04417270,0,0,0,0,4,1,United States,0,freestyle libre 14 day cgm system|accuchek inform ii platform,NA
NCT04411680,2020-08-18,2021-03-31,Interventional,Study of Sargramostim in Patients With COVID-19,"Active, not recruiting",Phase 2,"Partner Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04411680,0,0,0,0,13,1,United States,0,sargramostim|standard care,NA
NCT04411602,2020-04-07,2021-05-03,Interventional,Intermediate IND Severe Illness COVID-19 CP,Recruiting,Phase 1,Ascension South East Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04411602,0,0,0,0,1,1,United States,0,plasma,NA
NCT04355728,2020-04-25,2020-10-31,Interventional,Use of UC-MSCs for COVID-19 Patients,Completed,Phase 1/Phase 2,University of Miami,NA,https://clinicalzeros.gov/ct2/show/NCT04355728,0,0,0,0,6,1,United States,0,mesenchymalÂ stem cells/heparin|vehicle / heparin along with best supportive care|mesenchymal stem cells|heparin|vehicle,NA
NCT04363749,2020-04-27,2021-04-27,Interventional,COVID-19 Infection: Exploration of Respiratory Control Center Abnormalities,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04363749,0,0,0,0,1,0,France,0,"hypoxia : 14.3/12.7% fio2, hypercapnia 7% co2, inspiratory mechanical constraint|hypoxia : 14.3|12.7% fio2, hypercapnia 7% co2, inspiratory mechanical constraint",NA
NCT04397523,2020-04-30,2021-04-29,Interventional,Efficacy and Safety of COVID-19 Convalescent Plasma,Recruiting,N/A,Institute for Transfusion Medicine of RNM,NA,https://clinicalzeros.gov/ct2/show/NCT04397523,0,0,0,0,2,0,North Macedonia,0,convalescent plasma,NA
NCT04351724,2020-04-16,2021-12-01,Interventional,Austrian CoronaVirus Adaptive Clinical Trial (COVID-19),Recruiting,Phase 2/Phase 3,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04351724,0,0,0,0,3,0,Austria,0,chloroquine/hydroxychloroquine|lopinavir/ritonavir|standard care|rivaroxaban|thromboprophylaxis|candesartan|antihypertensives|remdesivir|asunercept 400mg|asunercept 100mg|asunercept 25mg|pentaglobin|chloroquine|hydroxychloroquine|lopinavir|ritonavir,NA
NCT04353596,2020-04-20,2021-02-16,Interventional,Stopping ACE-inhibitors in COVID-19,Completed,Phase 4,Medical University Innsbruck,NA,https://clinicalzeros.gov/ct2/show/NCT04353596,0,0,0,0,3,0,Austria|Germany,0,"ace inhibitor, angiotensin receptor blocker",NA
NCT04311697,2020-05-15,2021-02-22,Interventional,Intravenous Aviptadil for Critical COVID-19 With Respiratory Failure,Completed,Phase 2/Phase 3,"NeuroRx, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04311697,0,0,0,0,20,1,United States,0,aviptadil/standard care|saline/standard care|aviptadil|standard care|saline,NA
NCT04663945,2020-12-11,2021-06-01,Interventional,Predictors of Recovery and the App-Facilitated Tele-Rehabilitation (AFTER) Program for COVID-19 Survivors,Recruiting,N/A,"University of Colorado, Denver",NA,https://clinicalzeros.gov/ct2/show/NCT04663945,0,0,0,0,3,1,United States,0,biobehavioral tele-rehabilitation sessions,NA
NCT04584567,2020-11-20,2021-02-01,Interventional,"OD-doxy-PNV-COVID-19 Old Drug "" DOXY "" for Prevention of New Virus "" COVID-19 """,Recruiting,Phase 3,"General Administration of Military Health, Tunisia",NA,https://clinicalzeros.gov/ct2/show/NCT04584567,0,0,0,0,3,0,Tunisia,0,doxycyclin,NA
NCT04370236,2020-10-21,2021-02-28,Interventional,INB03 for the Treatment of Pulmonary Complications From COVID-19,Recruiting,Phase 2/Phase 3,"Inmune Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04370236,0,0,0,0,3,1,United States,0,inb03|placebo,NA
NCT04404426,2020-11-02,2021-09-15,Interventional,CACOLAC : Citrulline Administration in the Hospital Patient in Intensive Care for COVID-19 Acute Respiratory Distress Syndrome,Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04404426,0,0,0,0,3,0,France,0,l-citrulline|placebo,NA
NCT04358549,2020-04-17,2020-11-01,Interventional,Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19,"Active, not recruiting",Phase 2,"Fujifilm Pharmaceuticals U.S.A., Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04358549,0,0,0,0,9,1,United States,0,favipiravir / standard care|standard care|favipiravir,NA
NCT04780698,2021-03-31,2021-10-31,Interventional,DCI COVID-19 Surveillance Project,Recruiting,N/A,Temple University,NA,https://clinicalzeros.gov/ct2/show/NCT04780698,0,0,0,0,0,1,United States,0,sars-cov-2 rt-pcr assay for detection of covid-19 infection,NA
NCT04780685,2021-03-20,2021-08-31,Interventional,A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19,Recruiting,Phase 2,"Stemedica Cell Technologies, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04780685,0,0,0,0,0,1,United States,0,hmsc,NA
NCT04780659,2021-02-23,2022-12-31,Interventional,COVID-19 Vaccination of Immunodeficient Persons (COVAXID),Recruiting,Phase 4,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04780659,0,0,0,1,0,0,Sweden,0,"comirnaty (covid-19, mrna vaccine)",NA
NCT04780581,2021-02-01,2021-12-01,Interventional,Glucocorticoid Therapy in Coronavirus Disease COVID-19 Patients,Recruiting,Phase 4,FundaciÃ³n Instituto de Estudios de Ciencias de la Salud de Castilla y LeÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04780581,0,0,0,0,0,0,Spain,0,dexamethasone|methylprednisolone,NA
NCT04779879,2021-02-18,2021-04-30,Interventional,"Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19",Recruiting,Phase 2,"Vir Biotechnology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04779879,0,0,0,0,0,1,United States,0,vir-7831 (gen1)|vir-7831 (gen2),NA
NCT04780035,2020-11-18,2021-08-31,Interventional,"Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19","Active, not recruiting",Phase 3,"Federal Budgetary Research Institution State Research Center of Virology and Biotechnology ""Vector""",NA,https://clinicalzeros.gov/ct2/show/NCT04780035,0,0,0,1,0,0,Russian Federation,0,"epivaccorona (epivaccorona vaccine based on peptide antigens for the prevention of covid-19)|placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections)",NA
NCT04779450,2021-03-31,2021-08-31,Interventional,"Effect of Telemonitoring on Upper Limb Function, Quality of Life and Risk of Lymphedema During and After Pandemic COVID-19 in Women Submitted to Treatment for Breast Cancer",Recruiting,N/A,University of the State of Santa Catarina,NA,https://clinicalzeros.gov/ct2/show/NCT04779450,0,0,0,0,0,0,Brazil,0,kinesiotherapy protocol|usual orientations,NA
NCT04770740,2021-02-22,2021-06-01,Interventional,Randomized Controlled Clinical Trial to Investigate Effects of Vitamin K2 in COVID-19,Recruiting,Phase 2,Canisius-Wilhelmina Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04770740,0,0,0,0,1,0,Netherlands,0,vitamin k2 in the form of menaquinone-7 (mk-7)|placebo,NA
NCT04732949,2021-01-12,2021-06-01,Interventional,Study to Assess Efficacy and Safety of Inhaled Interferon-Î² Therapy for COVID-19,Recruiting,Phase 3,Synairgen Research Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04732949,0,0,0,0,1,1,United States|United Kingdom,0,sng001|placebo,NA
NCT04690413,2020-09-01,2020-12-31,Interventional,NOWDx Test for the Detection of Antibodies to COVID-19,Completed,N/A,"NOWDiagnostics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04690413,0,0,0,0,1,1,United States,0,nowdx covid-19 test,NA
NCT04713176,2021-02-02,2021-06-30,Interventional,Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 Patients,Recruiting,Phase 3,Daewoong Pharmaceutical Co. LTD.,NA,https://clinicalzeros.gov/ct2/show/NCT04713176,0,0,0,0,2,0,"Korea, Republic of",0,dwj1248 with remdesivir|placebo with remdesivir,NA
NCT04649424,2020-12-22,2021-04-30,Interventional,COVID-19 Nasal Swab Trial,Recruiting,N/A,Orthopaedic Innovation Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04649424,0,0,0,0,1,0,Canada,0,canswab,NA
NCT04668950,2020-12-22,2021-07-31,Interventional,Fluvoxamine for Early Treatment of Covid-19 (Stop Covid 2),Recruiting,Phase 3,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04668950,0,0,0,0,6,1,United States|Canada,0,fluvoxamine|placebo,NA
NCT04659772,2020-12-03,2021-02-01,Interventional,A Study to Evaluate Clazakizumab in Patients With Life-threatening COVID-19 Infection,Completed,Phase 2,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04659772,0,0,0,0,1,1,United States,0,clazakizumab|placebo,NA
NCT04617262,2021-01-05,2021-08-31,Interventional,Pilot Feasibility Study of Remote Problem Management Plus for Adults Affected by COVID-19,Recruiting,N/A,The New School,NA,https://clinicalzeros.gov/ct2/show/NCT04617262,0,0,0,0,2,1,United States,0,remote problem management plus,NA
NCT04604704,2021-01-28,2021-08-31,Interventional,Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome,Recruiting,Phase 2,AgelessRx,NA,https://clinicalzeros.gov/ct2/show/NCT04604704,0,0,0,0,4,1,United States,0,naltrexone|nad/|placebo|nad|NA,NA
NCT04632043,2020-11-18,2021-05-01,Interventional,Early Versus Delayed Intubation of Patients With COVID-19,Recruiting,N/A,Evangelismos Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04632043,0,0,0,0,1,0,Greece,0,endotracheal intubation,NA
NCT04619706,2020-12-14,2021-08-14,Interventional,Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19,Recruiting,Phase 2,"FSD Pharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04619706,0,0,0,0,3,1,United States,0,fsd201|placebo,NA
NCT04547127,2020-04-29,2021-02-04,Interventional,A Study to Evaluate Safety and Efficacy of Convalescent Methylene Blue Treated (MBT) Plasma From Donors Recovered From Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04547127,0,0,0,0,3,0,Spain,0,convalescent plasma|standard care,NA
NCT04542993,2020-09-08,2021-02-05,Interventional,Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy,"Active, not recruiting",Phase 2,Swedish Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04542993,0,0,0,0,2,1,United States,0,zinc picolinate|resveratrol|placebo,NA
NCT04555213,2020-09-30,2021-05-31,Interventional,A Dose Escalation and Dose Expansion Study of NOX66 in the Treatment of COVID-19,Recruiting,Phase 1,Noxopharm Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04555213,0,0,0,0,3,0,"Moldova, Republic of",0,nox66,NA
NCT04490200,2021-03-01,2021-12-30,Interventional,Effectiveness of a Novel Respirator With Chitosan Nanoparticles,Recruiting,N/A,University of Brasilia,NA,https://clinicalzeros.gov/ct2/show/NCT04490200,0,0,0,0,2,0,Brazil,0,vesta respirator|conventional n95 respirator,NA
NCT04382040,2020-05-08,2020-11-05,Interventional,"A Phase II, Controlled Clinical Study Designed to Evaluate the Effect of ArtemiC in Patients Diagnosed With COVID-19",Completed,Phase 2,MGC Pharmaceuticals d.o.o,NA,https://clinicalzeros.gov/ct2/show/NCT04382040,0,0,0,0,6,0,India|Israel,0,artemic|placebo,NA
NCT04420273,2020-07-02,2021-03-01,Interventional,Targeted Melanoma Detection With Skin Self-Examination During COVID-19 Restricted Physician Access,Completed,N/A,Northwestern University,NA,https://clinicalzeros.gov/ct2/show/NCT04420273,0,0,0,0,3,1,United States,0,sse educational intervention|home sample collection of concerning mole with physician supervision|active control:healthy living,NA
NCT04782700,2021-03-15,2025-03-03,Interventional,P-Co-Li (Pulmonary Covid-19 Study),Recruiting,N/A,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04782700,0,0,0,0,1,1,United States,0,steroid taper (prednisone),NA
NCT04782336,2020-12-12,2022-03-31,Interventional,"Sample Collection Study to Aid Evaluation of an Influenza A/B, Respiratory Syncytial Virus & COVID-19 Virus POC Test",Recruiting,N/A,LumiraDx UK Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04782336,0,0,0,0,0,0,United Kingdom,0,group a (sample collection)|group b (sample collection)|on-site testing (lumiradx),NA
NCT04747574,2020-09-25,2021-02-25,Interventional,Evaluation of the Safety of CD24-Exosomes in Patients With COVID-19 Infection,Recruiting,Phase 1,Tel-Aviv Sourasky Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04747574,0,0,0,0,1,0,Israel,0,exo-cd24,NA
NCT04569786,2020-10-29,2021-02-18,Interventional,Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001),Terminated,Phase 1,Merck Sharp & Dohme Corp.,The study was terminated based on an interim assessment of immunogenicity.,https://clinicalzeros.gov/ct2/show/NCT04569786,0,0,0,1,10,1,United States,0,v590|placebo,NA
NCT04551898,2020-12-02,2021-01-25,Interventional,Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Neutralizing Antibody BGB-DXP593 in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19),Completed,Phase 2,BeiGene,NA,https://clinicalzeros.gov/ct2/show/NCT04551898,0,0,0,0,1,1,United States|Australia|Brazil|Mexico|South Africa,0,bgb-dxp593|placebo,NA
NCT04469491,2020-09-20,2021-09-30,Interventional,Treatment of COVID-19 by Nebulization of Inteferon Beta 1b Efficiency and Safety Study,Recruiting,Phase 2,"Centre Hospitalier Universitaire, Amiens",NA,https://clinicalzeros.gov/ct2/show/NCT04469491,0,0,0,0,5,0,France,0,inhaled type i interferon|wfi water nebulization,NA
NCT04469179,2020-08-20,2021-03-31,Interventional,"Safety, Tolerability, and Pharmacokinetics of SAB-185 in Ambulatory Participants With COVID-19","Active, not recruiting",Phase 1,"SAb Biotherapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04469179,0,0,0,0,2,1,United States,0,sab-185|saline,NA
NCT04409496,2020-06-02,2021-01-22,Interventional,Chat-based Support for Preventing Smoking Relapse,Completed,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04409496,0,0,0,0,4,0,Hong Kong,0,chat-based instant messaging support|sms message support|self-help booklet,NA
NCT04372680,2020-04-22,2021-10-22,Interventional,WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound,Recruiting,N/A,"University Hospital, Toulouse",NA,https://clinicalzeros.gov/ct2/show/NCT04372680,0,0,0,0,1,0,France,0,ctus examination,NA
NCT04345601,2021-02-12,2022-10-31,Interventional,Mesenchymal Stromal Cells for the Treatment of SARS-CoV-2 Induced Acute Respiratory Failure (COVID-19 Disease),Recruiting,Phase 1/Phase 2,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04345601,0,0,0,0,8,1,United States,0,mesenchymal stem cells|supportive care,NA
NCT04334980,2020-11-02,2022-02-08,Interventional,"Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19","Active, not recruiting",Phase 1,Symvivo Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04334980,0,0,0,1,8,0,Australia,0,bactrl-spike,NA
NCT04720378,2021-03-31,2021-08-31,Interventional,Safety and Tolerability Study of IV ST266 in COVID-19 Subjects,Recruiting,Phase 1,"Noveome Biotherapeutics, formerly Stemnion",NA,https://clinicalzeros.gov/ct2/show/NCT04720378,0,0,0,0,2,1,United States,0,st266,NA
NCT04716556,2020-07-16,2021-05-31,Interventional,TranSfUsion of coNvalescent plAsma for the Early Treatment of pneuMonIa in COVID-19 Patients,"Active, not recruiting",N/A,Istituto Superiore di SanitÃ ,NA,https://clinicalzeros.gov/ct2/show/NCT04716556,0,0,0,0,1,0,Italy,0,convalescent plasma,NA
NCT04756466,2021-01-01,2021-04-30,Interventional,Effect of the Consumption of a Lactobacillus Strain on the Incidence of Covid-19 in the Elderly,"Active, not recruiting",N/A,Biosearch S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04756466,0,0,0,0,2,0,Spain,0,placebo|lactobacillus,NA
NCT04465604,2021-02-01,2021-11-01,Interventional,Hypertonic Saline for COVID-19 Symptoms,Recruiting,N/A,King Faisal Specialist Hospital & Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04465604,0,0,0,0,1,0,Saudi Arabia,0,wearing surgical face mask sprayed with hypertonic saline,NA
NCT04363463,2020-08-28,2022-08-28,Interventional,Impact of Prone Position in Patients Under Spontaneous Breathing on Intubation or Non-invasive Ventilation or Death Incidence During COVID-19 Acute Respiratory Distress,Recruiting,N/A,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04363463,0,0,0,0,3,0,France|Monaco,0,prone positioning,NA
NCT04649151,2020-12-09,2022-06-30,Interventional,"A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19","Active, not recruiting",Phase 2/Phase 3,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04649151,0,0,0,1,7,1,United States,0,mrna-1273|placebo,NA
NCT04590430,2020-10-20,2021-04-30,Interventional,"Study to Assess the Safety, Tolerability, and Pharmacokinetics of HFB30132A Against COVID-19 in Healthy Adults","Active, not recruiting",Phase 1,HiFiBiO Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04590430,0,0,0,0,3,1,United States,0,hfb30132a|placebo,NA
NCT04416919,2020-05-20,2020-06-01,Interventional,Assessment of N-95 Facemask for Use in COVID-19 Pandemic in Case of Shortage of Personal Protective Equipment,"Active, not recruiting",N/A,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04416919,0,0,0,0,2,1,United States,0,assembled mask,NA
NCT04403555,2020-06-01,2030-12-01,Interventional,Ivermectin as a Novel Therapy in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04403555,0,0,0,0,5,0,Egypt,0,ivermectin,NA
NCT04402918,2020-05-17,2020-05-19,Interventional,Study of Viral Load and Maternal-fetal Serology in the Interpretation of the Vertical Transmission of SARS Cov-2 (COVID-19) During Pregnancy,Recruiting,N/A,Centre Hospitalier Universitaire de Besancon,NA,https://clinicalzeros.gov/ct2/show/NCT04402918,0,0,0,0,1,0,France,0,biological samples,NA
NCT04730401,2021-01-27,2021-08-31,Interventional,Convalescent Plasma in the Treatment of Covid-19,Recruiting,Phase 2,Helsinki University Central Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04730401,0,0,0,0,1,0,Finland,0,convalescent plasma|placebo,NA
NCT04786483,2020-11-01,2021-01-30,Interventional,The Effect of Laughter Therapy on Students in the COVID-19 Pandemic,"Active, not recruiting",N/A,Zonguldak Bulent Ecevit University,NA,https://clinicalzeros.gov/ct2/show/NCT04786483,0,0,0,0,0,0,Turkey,0,laughter theraphy,NA
NCT04785898,2020-11-09,2020-12-22,Interventional,Diagnostic Performance of the ID Nowâ„¢ COVID-19 Screening Test Versus Simplexaâ„¢ COVID-19 Direct Assay,"Active, not recruiting",N/A,Groupe Hospitalier Paris Saint Joseph,NA,https://clinicalzeros.gov/ct2/show/NCT04785898,0,0,0,0,0,0,France,0,id nowâ„¢ covid-19 screening test|id nowâ„¢ covid-19 screening test,NA
NCT04780152,2021-03-31,2022-08-31,Interventional,TDCS in Pediatric and Teenage Patients With Major Depressive Disorder During COVID-19 Pandemic,Recruiting,Phase 2/Phase 3,El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez,NA,https://clinicalzeros.gov/ct2/show/NCT04780152,0,0,0,0,1,0,Mexico,0,transcranial direct current stimulation|placebo-simulation of transcranial direct current stimulation|fluoxetine tablets,NA
NCT04706403,2021-01-04,2021-06-01,Interventional,Views on COVID-19 and Vaccination,"Active, not recruiting",N/A,"University of Massachusetts, Worcester",NA,https://clinicalzeros.gov/ct2/show/NCT04706403,0,0,0,1,1,1,United States,0,healthcare providers' communication about the covid-19 vaccine,NA
NCT04703205,2020-09-16,2021-09-30,Interventional,Study in COvid-19 Patients With iveRmectin (CORVETTE-01),Recruiting,Phase 2,Kitasato University,NA,https://clinicalzeros.gov/ct2/show/NCT04703205,0,0,0,0,2,0,Japan,0,ivermectin 3 mg|placebo,NA
NCT04530435,2020-10-06,2021-04-30,Interventional,PEP Flute-selfcare in COVID-19,"Active, not recruiting",N/A,Bispebjerg Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04530435,0,0,0,0,3,0,Denmark,0,pep flute,NA
NCT04517396,2020-08-18,2021-10-31,Interventional,FEnofibRate as a Metabolic INtervention for COVID-19,Enrolling by invitation,Phase 2,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04517396,0,0,0,0,6,1,United States,0,fenofibrate/fenofibric acid|placebo|standard care|fenofibrate|fenofibric acid,NA
NCT04471766,2020-07-20,2021-06-30,Interventional,Locally Produced Cloth Face Mask and COVID-19 Like Illness Prevention,"Active, not recruiting",N/A,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04471766,0,0,0,0,4,0,Guinea-Bissau,0,certified cloth face mask/preventive information|preventive information|certified cloth face mask,NA
NCT04359901,2020-04-10,2022-04-30,Interventional,Sarilumab for Patients With Moderate COVID-19 Disease,"Active, not recruiting",Phase 2,VA Boston Healthcare System,NA,https://clinicalzeros.gov/ct2/show/NCT04359901,0,0,0,0,6,1,United States,0,sarilumab,NA
NCT04397718,2020-07-06,2021-07-06,Interventional,Hormonal Intervention for the Treatment in Veterans With COVID-19 Requiring Hospitalization,Recruiting,Phase 2,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04397718,0,0,0,0,11,1,United States,0,degarelix|saline,NA
NCT04390503,2021-03-31,2022-04-30,Interventional,Convalescent Plasma for Early Treatment of COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04390503,0,0,0,0,1,0,Brazil,0,convalescent plasma|control,NA
NCT04671017,2020-12-16,2021-02-26,Interventional,"Dose Finding Study to Evaluate Safety, Tolerability and Immunogenicity of an Inactiviated Adjuvanted Sars-Cov-2 Virus Vaccine Candidate Against Covid-19 in Healthy Adults","Active, not recruiting",Phase 1/Phase 2,Valneva Austria GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04671017,0,0,0,1,4,0,United Kingdom,0,vla2001,NA
NCT04629989,2020-11-13,2021-03-05,Interventional,Comparison of the Surgical Facemask With the Double-trunk Mask on Oxygenation in COVID-19,Completed,N/A,Cliniques universitaires Saint-Luc- UniversitÃ© Catholique de Louvain,NA,https://clinicalzeros.gov/ct2/show/NCT04629989,0,0,0,0,3,0,Belgium,0,standard oxygen delivery system|mask|surgical mask,NA
NCT04788355,2020-07-01,2020-11-15,Interventional,Prevention of Complications (SARS-CoV-2): Clinical Study,Completed,Phase 3,Universidade do Vale do Sapucai,NA,https://clinicalzeros.gov/ct2/show/NCT04788355,0,0,0,0,0,0,Brazil,0,control group (standard hospital treatment)|group hydroxychloroquine|group hydroxychloroquine/apixaban|group apixaban|apixaban,NA
NCT04447469,2020-07-27,2021-12-31,Interventional,Study of Mavrilimumab (KPL-301) in Participants Hospitalized With Severe Corona Virus Disease 2019 (COVID-19) Pneumonia and Hyper-inflammation,Recruiting,Phase 2/Phase 3,"Kiniksa Pharmaceuticals, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04447469,0,0,0,0,6,1,United States|Brazil|Chile|Peru|South Africa,0,mavrilimumab|placebo,NA
NCT04494386,2020-07-23,2021-10-30,Interventional,Umbilical Cord Lining Stem Cells (ULSC) in Patients With COVID-19 ARDS,Recruiting,Phase 1/Phase 2,"Restem, LLC.",NA,https://clinicalzeros.gov/ct2/show/NCT04494386,0,0,0,0,3,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04470622,2020-07-20,2021-06-30,Interventional,Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1),Recruiting,Phase 2,Heron Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04470622,0,0,0,0,7,1,United States|Puerto Rico,0,aprepitant injectable emulsion|placebo,NA
NCT04400890,2020-09-12,2021-01-11,Interventional,"Randomized Proof-of-Concept Trial to Evaluate the Safety and Explore the Effectiveness of Resveratrol, a Plant Polyphenol, for COVID-19","Active, not recruiting",Phase 2,Mount Carmel Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04400890,0,0,0,0,6,1,United States,0,resveratrol|vitamin d,NA
NCT04387760,2020-08-11,2021-04-14,Interventional,Favipiravir vs Hydroxychloroquine vs Control in COVID -19,Recruiting,Phase 2,Royal College of Surgeons in Ireland - Medical University of Bahrain,NA,https://clinicalzeros.gov/ct2/show/NCT04387760,0,0,0,0,4,0,Bahrain,0,hydroxychloroquine|favipiravir|standard care,NA
NCT04377165,2020-05-06,2020-08-26,Interventional,Innovative Tool to Limit Spread of COVID 19 in Residential Aged Care Facilities,Terminated,N/A,The University of Queensland,"Engagement issues, poor recruitment to study",https://clinicalzeros.gov/ct2/show/NCT04377165,0,0,0,0,3,0,NA,0,gamification|news,NA
NCT04402866,2020-06-24,2021-04-30,Interventional,TD-0903 for ALI Associated With COVID-19,Recruiting,Phase 2,Theravance Biopharma,NA,https://clinicalzeros.gov/ct2/show/NCT04402866,0,0,0,0,10,1,"United States|Brazil|Finland|Moldova, Republic of|Romania|Ukraine|United Kingdom",0,td-0903|placebo,NA
NCT04348305,2020-04-17,2020-09-10,Interventional,Hydrocortisone for COVID-19 and Severe Hypoxia,"Active, not recruiting",Phase 3,Scandinavian Critical Care Trials Group,NA,https://clinicalzeros.gov/ct2/show/NCT04348305,0,0,0,0,13,0,Denmark,0,hydrocortisone|saline|methylprednisolone,NA
NCT04746365,2020-12-06,2021-01-31,Interventional,Ivermectin Role in Covid-19 Clinical Trial,Completed,Phase 4,Elaraby Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04746365,0,0,0,0,0,0,Egypt,0,ivermectin|hydroxychloroquine|placebo,NA
NCT04745442,2020-04-27,2020-12-20,Interventional,Pilot Study of Antithrombin as Prophylaxis of Acute Respiratory Distress Syndrome in Patients With COVID-19,Completed,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,https://clinicalzeros.gov/ct2/show/NCT04745442,0,0,0,0,0,0,Spain,0,antithrombin / best available treatment|best available therapy|antithrombin,NA
NCT04743349,2021-01-26,2021-10-31,Interventional,Steam Inhalations in COVID-19 Patients,Recruiting,N/A,Meyer Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04743349,0,0,0,0,0,0,Italy,0,steam inhalations,NA
NCT04742595,2020-12-18,2022-03-31,Interventional,SARS-CoV-2 Specific Cytotoxic T Lymphocytes for the Treatment of COVID-19 in Patients With Cancer,Recruiting,Early Phase 1,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04742595,0,0,0,0,0,1,United States,0,sars-cov-2 antigen-specific cytotoxic t-lymphocytes,NA
NCT04739462,2021-02-03,2022-02-28,Interventional,SMS Maama Project COVID-19,Recruiting,N/A,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04739462,0,0,0,0,1,1,United States|Uganda,0,mhealth platform,NA
NCT04730661,2020-12-21,2021-12-21,Interventional,Efficacy of the Sit to Stand Test in the Decision to Hospitalize a Patient Consulting the Emergency Dept for COVID 19,Recruiting,N/A,"University Hospital, Rouen",NA,https://clinicalzeros.gov/ct2/show/NCT04730661,0,0,0,0,1,0,France,0,sit to stand test,NA
NCT04668625,2020-11-30,2020-12-20,Interventional,"Risk of Infection of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2), COVID-19, in a Massive Musical Show With Transmission Prevention Measures",Completed,N/A,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04668625,0,0,0,0,4,0,Spain,0,participate in a massive musical event,NA
NCT04584710,2020-10-13,2021-02-28,Interventional,A Phase 2 Study of RTB101 as COVID-19 Post-Exposure Prophylaxis in Older Adults,"Active, not recruiting",Phase 2,Restorbio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04584710,0,0,0,0,3,1,United States,0,rtb101|placebo,NA
NCT04534790,2020-07-24,2020-12-12,Interventional,Anti-inflammatory Effect of Low-Dose Whole-Lung Radiation for COVID-19 Pneumonia,Completed,N/A,Instituto Mexicano del Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04534790,0,0,0,0,1,0,Mexico,0,radiotherapy,NA
NCT04510454,2020-11-02,2021-05-31,Interventional,Evaluation of a ddPCR Technology for the SARS-CoV-2 Detection in Symptomatic Patients With Suspicion of COVID-19,Recruiting,N/A,Centre Leon Berard,NA,https://clinicalzeros.gov/ct2/show/NCT04510454,0,0,0,0,1,0,France,0,nasopharyngeal/throat/oropharyngeal swabs analyses by rt-pcr/ddpcr|nasopharyngeal|throat|oropharyngeal swabs analyses by rt-pcr|ddpcr,NA
NCT04547660,2020-07-16,2021-01-07,Interventional,Convalescent Plasma for Severe COVID-19 Patients,Completed,Phase 3,Hospital de Clinicas de Porto Alegre,NA,https://clinicalzeros.gov/ct2/show/NCT04547660,0,0,0,0,1,0,Brazil,0,convalescent plasma|best supportive care,NA
NCT04536376,2021-01-15,2021-08-02,Interventional,First Responder Resiliency Program During COVID-19,Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04536376,0,0,0,0,3,1,United States,0,resilience program,NA
NCT04453657,2021-02-04,2021-09-30,Interventional,"Tele-Wellness Supported App for Family Child Care Home Providers and Families to Promote Health, Family Engagement, and School Readiness Amid COVID-19",Enrolling by invitation,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04453657,0,0,0,0,8,1,United States,0,familychildcare (provisional name of app),NA
NCT04394403,2020-05-14,2021-12-31,Interventional,Pilot Internet-based Self-Help Program for Managing Corona (COVID-19) Stress,Recruiting,N/A,Hebrew University of Jerusalem,NA,https://clinicalzeros.gov/ct2/show/NCT04394403,0,0,0,0,2,0,Israel,0,internet-based guided self-help based on cbt principles,NA
NCT04385901,2020-05-19,2020-09-19,Interventional,Long Term Functional Outcomes of COVID-19 Patients Treated by Rehabilitation Services viaTelehealth,Completed,N/A,University of Missouri-Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04385901,0,0,0,0,3,1,United States,0,therapy intervention,NA
NCT04408027,2020-06-01,2021-06-01,Interventional,Mental Health Support for SickKids Children and Families During COVID-19 Using Established eHealth Interventions,Recruiting,N/A,The Hospital for Sick Children,NA,https://clinicalzeros.gov/ct2/show/NCT04408027,0,0,0,0,1,0,Canada,0,virtual-care cognitive behavioural therapy,NA
NCT04359680,2020-05-13,2021-03-29,Interventional,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection,"Active, not recruiting",Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04359680,0,0,0,0,5,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04335084,2020-06-22,2021-12-31,Interventional,"A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection",Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04335084,0,0,0,0,6,1,United States,0,hydroxychloroquine|vitamin c|vitamin d|zinc,NA
NCT04344184,2020-12-18,2021-05-31,Interventional,SAFEty Study of Early Infusion of Vitamin C for Treatment of Novel Coronavirus Acute Lung Injury (SAFE EVICT CORONA-ALI),Recruiting,Phase 2,Virginia Commonwealth University,NA,https://clinicalzeros.gov/ct2/show/NCT04344184,0,0,0,0,7,1,United States,0,vitamin c|placebo,NA
NCT04348383,2020-04-08,2021-04-15,Interventional,Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.,Recruiting,Phase 2,Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia,NA,https://clinicalzeros.gov/ct2/show/NCT04348383,0,0,0,0,4,0,Spain,0,defibrotide 25 mg/kg 24 hours continuous infusion for 15 days|placebo|defibrotide|kg 24 hours continuous infusion for 15 days,NA
NCT04344730,2020-04-10,2021-12-31,Interventional,Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia,"Active, not recruiting",N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04344730,0,0,0,0,2,0,France,0,dexamethasone|placebo|oxygen|cpap|mechanical ventilation,NA
NCT04748120,2020-12-28,2021-06-28,Interventional,Operative vs Non-Operative Management of Acute Appendicitis and Acute Cholecystitis in COVID-19 Positive Patients,Enrolling by invitation,N/A,The Cleveland Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04748120,0,0,0,0,0,1,United States,0,operative management|non-operative management,NA
NCT04747132,2020-07-20,2020-10-20,Interventional,Effectiveness of a Telegeriatric Intervention in Older Adults During the Covid-19 Contingency,Completed,N/A,"Universidad Iberoamericana A.C., Mexico",NA,https://clinicalzeros.gov/ct2/show/NCT04747132,0,0,0,0,0,0,Mexico,0,telegeriatric intervention,NA
NCT04743232,2021-03-01,2021-12-31,Interventional,COVID-19 Resuscitation Plans and Decisions on Escalation and Limitation of Treatment,Recruiting,N/A,Erasmus Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04743232,0,0,0,0,1,0,Netherlands,0,decision tool for clinicians,NA
NCT04739020,2021-01-18,2021-06-30,Interventional,Respiratory Aerosols in Patients With COVID-19 and Healthy Controls,Recruiting,N/A,Johann Wolfgang Goethe University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04739020,0,0,0,0,1,0,Germany,0,resp-aer-meter|spirometry|qualitative/quantitative virus pcr of respiratory secretions in patients with high aerosol concentrations|qualitative|quantitative virus pcr of respiratory secretions in patients with high aerosol concentrations,NA
NCT04659239,2021-01-28,2021-09-30,Interventional,"The Efficacy, Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine for Preventing Against COVID-19",Enrolling by invitation,Phase 3,Chinese Academy of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04659239,0,0,0,1,2,0,Brazil|Malaysia,0,inactivated sars-cov-2 vaccine|placebo,NA
NCT04643678,2020-10-30,2021-04-30,Interventional,Anakinra in the Management of COVID-19 Infection,Recruiting,Phase 2/Phase 3,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04643678,0,0,0,0,2,0,Qatar,0,anakinra|standard care,NA
NCT04642950,2020-12-17,2021-10-31,Interventional,A Phase II/III Study of Sargramostim,Recruiting,Phase 2/Phase 3,Nobelpharma,NA,https://clinicalzeros.gov/ct2/show/NCT04642950,0,0,0,0,2,0,Japan,0,sargramostim|placebo,NA
NCT04582201,2020-09-21,2021-04-24,Interventional,An Experiment to Evaluate the Safety of agenT-797 in COVID-19 Patients With Severe Difficulty Breathing.,Recruiting,Phase 1,Agenus Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04582201,0,0,0,0,2,1,United States,0,agent-797,NA
NCT04568889,2020-09-28,2020-10-26,Interventional,Minnesota COVID-19 Testing Project,"Active, not recruiting",N/A,Harvard University,NA,https://clinicalzeros.gov/ct2/show/NCT04568889,0,0,0,0,1,1,United States,0,a $10 survey incentive|a $20 survey incentive|emphasis of government involvement|emphasis of academic researchers involvement|cost-benefit frame|duty frame|racial/ethnic frame|no messaging|racial|ethnic frame,NA
NCT04568811,2020-09-26,2020-10-25,Interventional,The Phase I Clinical Trial of Booster Vaccination of Adenovirus Type-5 Vectored COVID-19 Vaccine,"Active, not recruiting",Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04568811,0,0,0,1,1,0,China,0,adenovirus type-5 vectored covid-19 vaccine,NA
NCT04661839,2020-12-24,2021-09-30,Interventional,A COVID-19 Study to Evaluate Safety and Pharmacokinetics of COVID-HIGIV Administered in Healthy Adults,Recruiting,Phase 1,Emergent BioSolutions,NA,https://clinicalzeros.gov/ct2/show/NCT04661839,0,0,0,0,1,1,United States,0,covid-higiv|placebo (saline),NA
NCT04511923,2020-12-23,2021-12-31,Interventional,Nebulised Heparin to Reduce COVID-19 Induced Acute Lung Injury,Recruiting,Phase 1/Phase 2,University College Hospital Galway,NA,https://clinicalzeros.gov/ct2/show/NCT04511923,0,0,0,0,2,0,Ireland,0,nebulised heparin,NA
NCT04349371,2020-04-21,2021-01-07,Interventional,Saved From COVID-19,Terminated,Phase 2,Columbia University,Low enrollment.,https://clinicalzeros.gov/ct2/show/NCT04349371,0,0,0,0,2,1,United States,0,chloroquine|placebo,NA
NCT04392531,2020-04-16,2021-03-31,Interventional,Clinical Trial to Assess Efficacy of cYclosporine Plus Standard of Care in Hospitalized Patients With COVID19,Recruiting,Phase 4,Instituto de InvestigaciÃ³n Sanitaria de la FundaciÃ³n JimÃ©nez DÃ­az,NA,https://clinicalzeros.gov/ct2/show/NCT04392531,0,0,0,0,2,0,Spain,0,cyclosporine|standard care,NA
NCT04372602,2020-10-12,2021-11-30,Interventional,Duvelisib to Combat COVID-19,Recruiting,Phase 2,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04372602,0,0,0,0,5,1,United States,0,duvelisib|blood draw|placebo,NA
NCT04409327,2020-07-11,2020-12-27,Interventional,Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes,Terminated,Phase 2,Restorbio Inc.,Insufficient accrual rate,https://clinicalzeros.gov/ct2/show/NCT04409327,0,0,0,0,5,1,United States,0,rtb101|placebo,NA
NCT04346147,2020-05-07,2021-06-30,Interventional,Clinical Trial to Evaluate Efficacy of 3 Types of Treatment in Patients With Pneumonia by COVID-19,Recruiting,Phase 2,Hospital Universitario de Fuenlabrada,NA,https://clinicalzeros.gov/ct2/show/NCT04346147,0,0,0,0,4,0,Spain,0,imatinib|baricitinib|supportive tratment,NA
NCT04333355,2020-05-08,2020-08-20,Interventional,Safety in Convalescent Plasma Transfusion to COVID-19,Terminated,Phase 1,Hospital San Jose Tec de Monterrey,"Other clinical trails probed that the use of convalescent plasma for patients with COVID-19 is
    safe .",https://clinicalzeros.gov/ct2/show/NCT04333355,0,0,0,0,3,0,Mexico,0,convalescent plasma,NA
NCT04337918,2020-05-08,2021-01-31,Interventional,Nitric Oxide Releasing Solutions to Prevent and Treat Mild/Moderate COVID-19 Infection,Completed,Phase 2,Sanotize Research and Development corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04337918,0,0,0,0,7,0,Canada,0,nitric oxide,NA
NCT04751604,2021-02-01,2021-09-30,Interventional,Improvement of the Nutritional Status Regarding Nicotinamide (Vitamin B3) and the Disease Course of COVID-19,Recruiting,N/A,University Hospital Schleswig-Holstein,NA,https://clinicalzeros.gov/ct2/show/NCT04751604,0,0,0,0,0,0,Germany,0,nicotinamide|placebo,NA
NCT04751617,2021-01-01,2021-01-31,Interventional,Pulmonary Rehabilitation of Patients With a History of COVID-19,Enrolling by invitation,N/A,University of Rzeszow,NA,https://clinicalzeros.gov/ct2/show/NCT04751617,0,0,0,0,0,0,Poland,0,pulmonary rehabilitation,NA
NCT04749121,2020-04-01,2021-02-05,Interventional,Ultraviolet Germicidal Irradiation on the New Silicone Half-Piece Elastometric Respirators,Completed,N/A,Bangkok Metropolitan Administration Medical College and Vajira Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04749121,0,0,0,0,0,0,Thailand,0,uvc irradiation|fit test|tensile strength,NA
NCT04662671,2020-11-18,2020-12-09,Interventional,"Phase I/II Randomized, Dose Escalation Study to Evaluate the Safety and Antiviral Activity of the RD-X19 Device in SARS-CoV-2 Infected Individuals With Uncomplicated COVID-19",Completed,Phase 1/Phase 2,KNOWBio Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04662671,0,0,0,0,1,1,United States,0,rd-x19,NA
NCT04652765,2021-02-03,2023-01-31,Interventional,Camostat With Bicalutamide for COVID-19,Recruiting,Phase 1,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins,NA,https://clinicalzeros.gov/ct2/show/NCT04652765,0,0,0,0,2,1,United States,0,camostat mesilate|bicalutamide 150 mg,NA
NCT04652596,2021-02-08,2022-06-30,Interventional,Reducing Food Insecurity During COVID-19,Enrolling by invitation,N/A,Boston Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04652596,0,0,0,0,1,1,United States,0,produce prescription program|grocery store gift cards,NA
NCT04621461,2020-12-20,2021-02-08,Interventional,Placebo Controlled Trial to Evaluate Zinc for the Treatment of COVID-19 in the Outpatient Setting,Completed,Phase 4,"St. Francis Hospital, New York",NA,https://clinicalzeros.gov/ct2/show/NCT04621461,0,0,0,0,2,1,United States,0,zinc sulfate 220 mg|placebo,NA
NCT04535778,2020-11-16,2021-06-01,Interventional,COMPASS Study: an Online Cognitive-behavioural Therapy (CBT) Program Treating Anxiety and Low Mood in Long-term Conditions During the COVID-19 Pandemic,Recruiting,N/A,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04535778,0,0,0,0,1,0,United Kingdom,0,compass|standard charity resources,NA
NCT04581863,2020-11-30,2021-02-05,Interventional,COVID-19 Watch + COVID-19 Pulse,"Active, not recruiting",N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04581863,0,0,0,0,6,1,United States,0,pulse oximeter|covid watch,NA
NCT04530656,2020-08-28,2020-10-28,Interventional,Phase I Trial of a Recombinant SARS-CoV-2 Vaccine (Sf9 Cell),"Active, not recruiting",Phase 1,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04530656,0,0,0,1,2,0,China,0,"two doses of middle-dose recombinant sars-cov-2 vaccine (sf9 cell) at the schedule of day 0, 28|two doses of high-dose recombinant sars-cov-2 vaccine (sf9 cell) at the schedule of day 0, 28|three doses of high-dose recombinant sars-cov-2 vaccine (sf9 cell) at the schedule of day 0, 14, 28|two doses of placebo at the schedule of day 0, 28ï¼ˆmiddle-dose groupï¼‰|two doses of placebo at the schedule of day 0, 28ï¼ˆhigh-dose groupï¼‰|three doses of placebo at the schedule of day 0, 14, 28ï¼ˆhigh-dose groupï¼‰|two doses of placebo at the schedule of day 0, 28ï¼ˆmiddle-dose groupï¼‰|two doses of placebo at the schedule of day 0, 28ï¼ˆhigh-dose groupï¼‰|three doses of placebo at the schedule of day 0, 14, 28ï¼ˆhigh-dose groupï¼‰",NA
NCT04512079,2020-09-08,2021-12-31,Interventional,FREEDOM COVID-19 Anticoagulation Strategy,Recruiting,Phase 4,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04512079,0,0,0,0,3,1,United States|Brazil|Colombia|India|Mexico,0,enoxaparin|apixaban,NA
NCT04490824,2020-10-01,2021-03-30,Interventional,Inhalation of KELEA Excellerated Water in Covid-19 Infected Individuals,Recruiting,N/A,Institute of Progressive Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04490824,0,0,0,0,4,1,United States,0,kelea water|water without an elevated level of kelea,NA
NCT04397705,2020-10-12,2021-04-30,Interventional,Remote Monitoring of Cancer Patients With Suspected Covid-19,Recruiting,Phase 1,The Christie NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04397705,0,0,0,0,1,0,United Kingdom,0,patient status engine,NA
NCT04456595,2020-07-21,2020-12-17,Interventional,Clinical Trial of Efficacy and Safety of Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine in Healthcare Professionals,"Active, not recruiting",Phase 3,Butantan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04456595,0,0,0,1,4,0,Brazil,0,adsorbed covid-19 (inactivated) vaccine|placebo,NA
NCT04449588,2020-07-23,2021-08-07,Interventional,Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS,Recruiting,Phase 2/Phase 3,"Staidson (Beijing) Biopharmaceuticals Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04449588,0,0,0,0,2,0,Bangladesh|China|India|Indonesia|Spain,0,"bdb-001 injection|conventional medicines (oxygen therapy, alfa interferon via aerosol inhalation,/lopinavir/ritonavir)/traditional chinese medicines (tcms) granules",NA
NCT04389294,2020-05-05,2020-06-16,Interventional,HSS Covid-19 Antibody Serology Among Surgeons & Anesthesiologists,Completed,N/A,"Hospital for Special Surgery, New York",NA,https://clinicalzeros.gov/ct2/show/NCT04389294,0,0,0,0,1,1,United States,0,antibody test,NA
NCT04382586,2020-07-06,2021-02-02,Interventional,Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants,"Active, not recruiting",Phase 2,BeiGene,NA,https://clinicalzeros.gov/ct2/show/NCT04382586,0,0,0,0,8,1,United States,0,zanubrutinib|supportive care|placebo,NA
NCT04336332,2020-04-01,2021-04-30,Interventional,Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19,"Active, not recruiting",Phase 2,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04336332,0,0,0,0,4,1,United States,0,hydroxychloroquine / azithromycin|hydroxychloroquine|azithromycin,NA
NCT04331600,2020-04-16,2020-12-17,Interventional,Chloroquine as Antiviral Treatment in Coronavirus Infection 2020,Completed,Phase 4,Wroclaw Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04331600,0,0,0,0,2,0,Poland,0,chloroquine|telehealth,NA
NCT04723394,2021-01-28,2021-06-30,Interventional,Phase III Study of AZD7442 for Treatment of COVID-19 in Outpatient Adults,Recruiting,Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04723394,0,0,0,0,1,1,United States|Germany|Hungary|Mexico|United Kingdom,0,azd7442|placebo,NA
NCT04753645,2020-09-19,2021-05-31,Interventional,BRAC Institute of Governance and Development-Hygiene Behavioural Change and Coalition,"Active, not recruiting",N/A,BRAC University,NA,https://clinicalzeros.gov/ct2/show/NCT04753645,0,0,0,0,0,0,Bangladesh,0,handwashing stations at the public places|no activities of the hbcc project,NA
NCT04750317,2020-05-11,2020-08-01,Interventional,Efficacy and Safety of Tofacitinib in Patients With COVID-19 Pneumonia,Completed,Phase 2,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04750317,0,0,0,0,1,0,Russian Federation,0,tofacitinib,NA
NCT04703140,2021-02-11,2022-08-11,Interventional,COVIDISC: Rapid Diagnostic Tests on Nasopharyngeal Swabs for the Detection of COVID-19,Recruiting,N/A,CMC Ambroise ParÃ©,NA,https://clinicalzeros.gov/ct2/show/NCT04703140,0,0,0,0,2,0,France,0,rapid diagnostic test vs pcr,NA
NCT04649021,2020-12-04,2021-12-31,Interventional,Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population,"Active, not recruiting",Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04649021,0,0,0,1,2,0,China,0,bnt162b2|placebo,NA
NCT04638634,2021-02-02,2021-05-31,Interventional,"Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects",Recruiting,Phase 1,CSL Behring,NA,https://clinicalzeros.gov/ct2/show/NCT04638634,0,0,0,0,3,0,Australia,0,csl760,NA
NCT04591210,2021-01-27,2021-12-31,Interventional,The COVID-RASi Trial (COVID-19),Recruiting,Phase 3,Ottawa Heart Institute Research Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04591210,0,0,0,0,1,0,Canada,0,ace inhibitor|angiotensin ii receptor blockers,NA
NCT04414293,2020-10-01,2021-07-31,Interventional,Low Dose Pulmonary Irradiation in Patients With COVID-19 Infection of Bad Prognosis,Recruiting,N/A,Hospital Provincial de Castellon,NA,https://clinicalzeros.gov/ct2/show/NCT04414293,0,0,0,0,3,0,Spain,0,lung low dose radiation,NA
NCT04392453,2020-10-26,2021-12-31,Interventional,Upper Limb Robotic Rehabilitation During COVID-19 Outbreak,Recruiting,N/A,Fondazione Don Carlo Gnocchi Onlus,NA,https://clinicalzeros.gov/ct2/show/NCT04392453,0,0,0,0,1,0,Italy,0,robotic therapy,NA
NCT04384965,2020-05-12,2022-05-01,Interventional,Accelerated iTBS for Depressed Patients During the COVID-19 Pandemic,Recruiting,N/A,Centre for Addiction and Mental Health,NA,https://clinicalzeros.gov/ct2/show/NCT04384965,0,0,0,0,2,0,Canada,0,"magpro x100 stimulator, b70 fluid-cooled coil",NA
NCT04366908,2020-05-07,2021-06-30,Interventional,Prevention and Treatment With Calcifediol of COVID-19 Induced Acute Respiratory Syndrome,Recruiting,Phase 2,MaimÃ³nides Biomedical Research Institute of CÃ³rdoba,NA,https://clinicalzeros.gov/ct2/show/NCT04366908,0,0,0,0,2,0,Spain,0,bat / calcifediol|bat|calcifediol,NA
NCT04361448,2020-04-20,2020-06-30,Interventional,Performance of 3 Sampling Methods for the Detection of SARS-CoV-2 (COVID-19) With Real-time Reverse Transcriptase PCR,Terminated,N/A,Jessa Hospital,Insufficient sample number,https://clinicalzeros.gov/ct2/show/NCT04361448,0,0,0,0,1,0,Belgium,0,sampling of oropharynx/nasopharynx|sampling of oropharynx|nasopharynx,NA
NCT04349618,2020-04-15,2023-04-15,Interventional,Ultraprotective Ventilation Without Extracorporeal Circulation During COVID 19 Pneumonia,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04349618,0,0,0,0,2,0,France,0,protective ventilation|ultraprotective ventilation,NA
NCT04755972,2021-01-29,2021-07-29,Interventional,Mucolytics in Patients on Invasive Mechanical Ventilation Due to Severe Acute Respiratory Syndrome Coronavirus 2,Recruiting,N/A,"Clinical Hospital Center, Split",NA,https://clinicalzeros.gov/ct2/show/NCT04755972,0,0,0,0,0,0,Croatia,0,"inhalation of n-acetylcysteine|inhalation of 5% sodium chloride|inhalation of 8,4% sodium bicarbonate",NA
NCT04749173,2020-11-21,2021-03-28,Interventional,"To Assess the Safety, Tolerability and Pharmacokinetic Properties of Niclosamide Injectable (DWRX2003) Which is the Treatment of COVID-19 in Healthy Volunteers.",Recruiting,Phase 1,Daewoong Pharmaceutical Co. LTD.,NA,https://clinicalzeros.gov/ct2/show/NCT04749173,0,0,0,0,1,0,"Korea, Republic of",0,dwrx2003,NA
NCT04646590,2020-12-16,2022-04-30,Interventional,A Phase III Clinical Trial to Determine the Safety and Efficacy of ZF2001 for Prevention of COVID-19,Recruiting,Phase 3,"Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04646590,0,0,0,1,4,0,China|Ecuador|Indonesia|Pakistan|Uzbekistan,0,recombinant new coronavirus vaccine (cho cell) group|placebo,NA
NCT04540419,2020-09-11,2021-05-30,Interventional,Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) Against COVID-19,"Active, not recruiting",Phase 3,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04540419,0,0,0,1,3,0,Russian Federation,0,adenovirus type 5 vector|placebo,NA
NCT04530539,2020-10-05,2021-09-01,Interventional,The Effect of Melatonin and Vitamin C on COVID-19,Recruiting,N/A,Lancaster General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04530539,0,0,0,0,2,1,United States,0,vitamin c|melatonin|placebo|symptom survey,NA
NCT04530409,2020-08-26,2021-04-01,Interventional,Timing of Corticosteroids in COVID-19,Recruiting,Phase 4,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04530409,0,0,0,0,3,0,Egypt,0,early-dexamethasone|dexamethasone,NA
NCT04501458,2020-08-10,2021-06-10,Interventional,Western Kenya Integrated COVID-19 Response,"Active, not recruiting",N/A,Surgical Systems Research Group,NA,https://clinicalzeros.gov/ct2/show/NCT04501458,0,0,0,0,3,0,Kenya,0,"training of youth, community health assistants/community health workers.|training clinicians in basic critical care/the management of severe covid-19 cases|training of youth, community health assistants|community health workers.|training clinicians in basic critical care|the management of severe covid-19 cases",NA
NCT04492410,2020-07-21,2021-05-31,Interventional,COVID-19 Infection Screening in Cancer Patients (NEOSCREENCOVID),"Active, not recruiting",N/A,Centre Antoine Lacassagne,NA,https://clinicalzeros.gov/ct2/show/NCT04492410,0,0,0,0,1,0,France,0,serology test,NA
NCT04419025,2020-09-23,2021-03-31,Interventional,Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease,Recruiting,Phase 2,Cambridge Health Alliance,NA,https://clinicalzeros.gov/ct2/show/NCT04419025,0,0,0,0,4,1,United States,0,n-acetylcysteine,NA
NCT04338074,2020-06-01,2021-12-15,Interventional,TXA and Corona Virus 2019 (COVID19) in Outpatients,Recruiting,Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04338074,0,0,0,0,6,1,United States,0,placebo|tranexamic acid,NA
NCT04381377,2020-04-29,2021-04-30,Interventional,Efficacy and Safety of PolyoxidoniumÂ® in Hospitalized Patients With Coronavirus Disease COVID-19,"Active, not recruiting",Phase 2/Phase 3,NPO Petrovax,NA,https://clinicalzeros.gov/ct2/show/NCT04381377,0,0,0,0,2,0,Russian Federation|Slovakia,0,azoximer bromide|placebo,NA
NCT04378920,2020-04-14,2021-06-30,Interventional,"A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes",Recruiting,Phase 1/Phase 2,Institut de cancÃ©rologie Strasbourg Europe,NA,https://clinicalzeros.gov/ct2/show/NCT04378920,0,0,0,0,6,0,France,0,leaf-4l6715,NA
NCT04373733,2020-05-01,2021-03-31,Interventional,Early Intervention in COVID-19: Favipiravir Verses Standard Care,Recruiting,Phase 3,Chelsea and Westminster NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04373733,0,0,0,0,3,0,United Kingdom,0,favipiravir|standard care,NA
NCT04426201,2020-12-20,2021-04-30,Interventional,InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ),Recruiting,Phase 2,Revimmune,NA,https://clinicalzeros.gov/ct2/show/NCT04426201,0,0,0,0,3,1,United States,0,cyt107|placebo,NA
NCT04363502,2020-05-07,2021-06-30,Interventional,Use of the Interleukin-6 Inhibitor Clazakizumab in Patients With Life-threatening COVID-19 Infection,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04363502,0,0,0,0,6,1,United States,0,clazakizumab|placebo,NA
NCT04328012,2020-04-06,2021-06-01,Interventional,COVID MED Trial - Comparison Of Therapeutics for Hospitalized Patients Infected With COVID-19,Recruiting,Phase 2/Phase 3,Bassett Healthcare,NA,https://clinicalzeros.gov/ct2/show/NCT04328012,0,0,0,0,3,1,United States,0,losartan|placebo,NA
NCT04335201,2020-05-20,2021-06-20,Interventional,Defibrotide in COVID-19 Pneumonia,Recruiting,Phase 2,IRCCS San Raffaele,NA,https://clinicalzeros.gov/ct2/show/NCT04335201,0,0,0,0,1,0,Italy,0,defibrotide,NA
NCT04348864,2020-04-16,2021-04-30,Interventional,COVID-19 Diagnostic Self-testing Using Virtual Point-of-care,Recruiting,N/A,Neuroganics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04348864,0,0,0,0,10,1,United States,0,"covid-19 antigen/antibody rapid testing, mobile device image capture/telemedicine support|telehealth|covid-19 antigen|rapid test",NA
NCT04338828,2020-04-18,2021-04-30,Interventional,Nitric Oxide Inhalation Therapy for COVID-19 Infections in the ED,"Active, not recruiting",Phase 2,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04338828,0,0,0,0,2,1,United States,0,nitric oxide|oxygen,NA
NCT04758286,2020-07-01,2021-02-01,Interventional,Anesthetic & Surgical Protocol for Emergency Surgeries During the Era of COVID-19,Completed,N/A,Benha University,NA,https://clinicalzeros.gov/ct2/show/NCT04758286,0,0,0,0,0,0,Egypt,0,emergency surgical procedures,NA
NCT04758273,2020-10-07,2021-06-30,Interventional,A Safety and Immunogenicity Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Active, not recruiting",Phase 1,"Beijing Minhai Biotechnology Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04758273,0,0,0,1,0,0,China,0,medium dosage inactivated sars-cov-2 vaccine|high dosage inactivated sars-cov-2 vaccine|placebo,NA
NCT04758962,2021-02-15,2021-06-11,Interventional,A Study of the Safety of and Immune Response to Varying Doses of a Vaccine Against COVID-19 in Healthy Adults,Recruiting,Phase 1,GlaxoSmithKline,NA,https://clinicalzeros.gov/ct2/show/NCT04758962,0,0,0,1,0,1,United States,0,1 âµg cov2 sam (lnp)|3 âµg cov2 sam (lnp)|10 âµg cov2 sam (lnp)|30 âµg cov2 sam (lnp)|1 âµg cov2 sam (lnp)|3 âµg cov2 sam (lnp)|10 âµg cov2 sam (lnp)|30 âµg cov2 sam (lnp),NA
NCT04757818,2021-02-04,2021-03-25,Interventional,"Double-blind, Randomized, Parallel, Placebo-controlled Clinical Study to Evaluate the Viral Load of SARS-CoV-2 in the Oral Cavity of SARS-CoV-2 Positive Subjects After the Use of a Mouthwash Containing Cetylpyridinium Chloride 0,07%.",Recruiting,N/A,Dentaid SL,NA,https://clinicalzeros.gov/ct2/show/NCT04757818,0,0,0,0,0,0,Spain,0,0.07% cetylpyridinium chloride (cpc) in mouthwash|distilled water with the same colorant as the experimental product,NA
NCT04756323,2020-10-27,2021-06-30,Interventional,A Study to Evaluate Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 18 Years and Above(COVID-19),"Active, not recruiting",Phase 2,"Beijing Minhai Biotechnology Co., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04756323,0,0,0,1,1,0,China,0,medium dosage inactivated sars-cov-2 vaccine|high dosage inactivated sars-cov-2 vaccine|placebo,NA
NCT04753619,2021-01-03,2021-05-03,Interventional,Effectiveness of Niclosamide as Add-on Therapy to the Standard of Care Measures in COVID-19 Management,Recruiting,Phase 2,University of Baghdad,NA,https://clinicalzeros.gov/ct2/show/NCT04753619,0,0,0,0,1,0,Iraq,0,niclosamide oral tablet,NA
NCT04583410,2020-10-22,2021-12-31,Interventional,Efficacy of Nicotine in Preventing COVID-19 Infection,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04583410,0,0,0,0,4,0,France,0,nicotine patch|placebo patch,NA
NCT04472585,2020-11-14,2021-08-15,Interventional,Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients,Recruiting,Phase 1/Phase 2,Sheikh Zayed Federal Postgraduate Medical Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04472585,0,0,0,0,2,0,Pakistan,0,ivermectin|injectable placebo|zinc|placebo empty capsule|oral ivermectin,NA
NCT04463849,2020-06-30,2021-06-30,Interventional,Effects of COVID-19 Infection on Beta-cell Function in Euglycemic Patients,Recruiting,N/A,University of Milan,NA,https://clinicalzeros.gov/ct2/show/NCT04463849,0,0,0,0,1,0,Italy,0,stimulation test with arginine infusion in order to verify the possible existence of damage to the beta cell function induced by covid-19 infection,NA
NCT04644198,2021-04-01,2021-12-01,Interventional,Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica,Recruiting,Phase 2,The University of The West Indies,NA,https://clinicalzeros.gov/ct2/show/NCT04644198,0,0,0,0,3,0,Jamaica,0,convalescent plasma infusion,NA
NCT04364828,2020-10-21,2022-04-30,Interventional,NGS Diagnostic in COVID-19 Hosts - Genetic Cause Relating to the Course of Disease Progression,Recruiting,N/A,University Hospital Tuebingen,NA,https://clinicalzeros.gov/ct2/show/NCT04364828,0,0,0,0,3,0,Germany,0,dalargin|t-cell receptor|sars-cov-2 viral composition,NA
NCT04386616,2020-06-02,2021-01-02,Interventional,A Study to Evaluate the Safety and Efficacy of MSTT1041A (Astegolimab) or UTTR1147A in Patients With Severe COVID-19 Pneumonia,Completed,Phase 2,"Genentech, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04386616,0,0,0,0,18,1,United States|Brazil|Mexico|Spain,0,mstt1041a|placebo|uttr1147a,NA
NCT04379076,2020-05-14,2021-10-30,Interventional,InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort,Recruiting,Phase 2,Revimmune,NA,https://clinicalzeros.gov/ct2/show/NCT04379076,0,0,0,0,4,0,United Kingdom,0,interleukin|placebo,NA
NCT04346615,2020-04-25,2021-07-31,Interventional,Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen,Recruiting,Phase 2/Phase 3,"Biohaven Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04346615,0,0,0,0,13,1,United States,0,zavegepant (bhv-3500)|placebo,NA
NCT04760743,2020-12-17,2021-04-30,Interventional,Safety and Immunogenicity of a SARS-CoV-2 Vaccine (NBP2001) in Healthy Adults (COVID-19),"Active, not recruiting",Phase 1,"SK Chemicals Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04760743,0,0,0,1,0,0,"Korea, Republic of",0,nbp2001 adjuvanted with alum (rbd 30î¼g/dose)|nbp2001 adjuvanted with alum (rbd 50î¼g/dose)|saline|nbp2001 adjuvanted with alum (rbd 30î¼g|dose)|nbp2001 adjuvanted with alum (rbd 50î¼g,NA
NCT04703608,2021-01-22,2022-03-31,Interventional,Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia,Recruiting,Phase 3,London School of Hygiene and Tropical Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04703608,0,0,0,0,3,0,Gambia,0,ivermectin|asp|placebo,NA
NCT04750759,2021-02-03,2021-06-30,Interventional,Safety and Preliminary Efficacy of the Combination of Niclosamide and Camostat,Recruiting,Phase 2,CharitÃ© Research Organisation GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04750759,0,0,0,0,2,0,Germany,0,niclosamide / camostat|placebo|niclosamide|camostat,NA
NCT04757298,2021-02-12,2022-01-30,Interventional,COVID-19 Treatment Cascade Optimization Study,Recruiting,N/A,University of Illinois at Urbana-Champaign,NA,https://clinicalzeros.gov/ct2/show/NCT04757298,0,0,0,0,1,1,United States,0,navigation services|critical dialogue|brief counseling|referral/digital brochure|referral|digital brochure,NA
NCT04756128,2021-01-25,2021-12-31,Interventional,Impact of Colchicine and Low-dose Naltrexone on COVID-19,Enrolling by invitation,Phase 2,HealthPartners Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04756128,0,0,0,0,1,1,United States,0,colchicine 0.6 mg|naltrexone,NA
NCT04698798,2021-01-02,2021-05-31,Interventional,Skeletal Muscle Wasting in SARS-CoV-2,Recruiting,N/A,Hasselt University,NA,https://clinicalzeros.gov/ct2/show/NCT04698798,0,0,0,0,2,0,Belgium,0,muscle biopsy,NA
NCT04673292,2021-02-08,2021-08-31,Interventional,Community Collaboration to Combat COVID-19 (C-FORWARD),Enrolling by invitation,N/A,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04673292,0,0,0,0,2,1,United States,0,"fixed site standard of care testing|community-based, mobile van testing|self-collected, home-based testing",NA
NCT04476953,2020-08-03,2021-07-31,Interventional,COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation,Enrolling by invitation,Phase 2,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04476953,0,0,0,0,2,1,United States,0,placebo|fisetin,NA
NCT04473898,2020-06-19,2020-10-19,Interventional,Telerehabilitation After Coronavirus,Completed,N/A,KTO Karatay University,NA,https://clinicalzeros.gov/ct2/show/NCT04473898,0,0,0,0,2,0,Turkey,0,exercise|education,NA
NCT04477668,2021-02-08,2021-12-31,Interventional,Helmet Non-Invasive Ventilation for COVID-19 Patients,Recruiting,N/A,King Abdullah International Medical Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04477668,0,0,0,0,2,0,Saudi Arabia,0,helmet non-invasive ventilation,NA
NCT04425538,2020-06-01,2021-01-22,Interventional,A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).,Completed,Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04425538,0,0,0,0,2,1,United States,0,infliximab,NA
NCT04377789,2020-03-20,2020-07-31,Interventional,Effect of Quercetin on Prophylaxis and Treatment of COVID-19,Completed,N/A,Kanuni Sultan Suleyman Training and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04377789,0,0,0,0,5,0,Turkey,0,quercetin,NA
NCT04412291,2020-06-11,2021-03-31,Interventional,"A Study in Patients With COVID-19 and Respiratory Distress Not Requiring Mechanical Ventilation, to Compare Standard-of-care With Anakinra and Tocilizumab Treatment The Immunomodulation-CoV Assessment (ImmCoVA) Study",Recruiting,Phase 2,Karolinska University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04412291,0,0,0,0,3,0,Sweden,0,anakinra|tocilizumab|standard care,NA
NCT04331366,2020-04-08,2020-08-31,Interventional,Bidirectional Oxygenation Valve in the Management of Pulmonary Complications of COVID-19,Completed,N/A,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04331366,0,0,0,0,5,1,United States,1,go2 peep mouthpiece,NA
NCT04765436,2021-01-14,2021-04-30,Interventional,"PTX-COVID19-B, an mRNA Humoral Vaccine, is Intended for Prevention of COVID-19 in a General Population. This Study is Designed to Evaluate Safety, Tolerability, and Immunogenicity of PTX-COVID19-B Vaccine in Healthy Seronegative Adults Aged 18-64",Recruiting,Phase 1,Providence Therapeutics Holdings Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04765436,0,0,0,1,0,0,Canada,0,ptx-covid19-b|placebo,NA
NCT04764981,2021-05-31,2022-05-31,Interventional,Olfactory Training for Olfactory Dysfunction After Coronavirus Disease - 19 (COVID-19),Enrolling by invitation,N/A,Universidade do Estado do ParÃ¡,NA,https://clinicalzeros.gov/ct2/show/NCT04764981,0,0,0,0,0,0,Brazil,0,essence oils,NA
NCT04763681,2021-01-01,2021-08-31,Interventional,Couple HOPES (Helping Overcome PTSD and Enhance Satisfaction),Recruiting,N/A,York University,NA,https://clinicalzeros.gov/ct2/show/NCT04763681,0,0,0,0,0,0,Canada,0,"couple hopes guided, internet-delivered, self-help intervention",NA
NCT04657809,2020-10-01,2021-02-18,Interventional,Clinical Assessment of Insulin Fast Dissolving Film in Treatment of Post Infection Anosmia,"Active, not recruiting",Phase 2,Deraya University,NA,https://clinicalzeros.gov/ct2/show/NCT04657809,0,0,0,0,2,0,Egypt,0,insulin film|fast dissolving film,NA
NCT04760821,2020-12-10,2021-04-30,Interventional,Prevention of Acute Myocardial Injury by Trimetazidine in Patients Hospitalized for COVID-19,Recruiting,Phase 2,"Ministry of Health, Brazil",NA,https://clinicalzeros.gov/ct2/show/NCT04760821,0,0,0,0,1,0,Brazil,0,trimetazidine,NA
NCT04756271,2021-02-11,2021-08-31,Interventional,Safety and Immunogenicity of Inactivated Vaccine Against COVID-19 Infection,Recruiting,Phase 3,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04756271,0,0,0,1,1,0,Egypt,0,sars-cov-2 neutralizing antibody titer,NA
NCT04600141,2020-11-10,2021-10-20,Interventional,Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection,Recruiting,Phase 3,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04600141,0,0,0,0,1,0,Brazil,0,tocilizumab|heparin - therapeutic dosage|heparin - prophylactic dosage,NA
NCT04483635,2021-02-08,2021-09-30,Interventional,PRevention of COVID-19 With Oral Vitamin D Supplemental Therapy in Essential healthCare Teams,Recruiting,Phase 3,St. Justine's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04483635,0,0,0,0,2,0,Canada,0,placebo|vitamin d,NA
NCT04533347,2021-02-19,2021-06-08,Interventional,Tafenoquine in Patients With Mild to Moderate COVID-19,Recruiting,Phase 2,60 Degrees Pharmaceuticals LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04533347,0,0,0,0,2,1,United States,0,tafenoquine oral tablet|placebo,NA
NCT04456153,2020-07-22,2021-01-31,Interventional,Atovaquone for Treatment of COVID-19,Completed,Phase 2,University of Texas Southwestern Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04456153,0,0,0,0,5,1,United States,0,experimental group|placebo,NA
NCT04424212,2020-06-10,2021-06-30,Interventional,ICBT for Mental Health Problems Related to the Coronavirus Pandemic,"Active, not recruiting",N/A,Linkoeping University,NA,https://clinicalzeros.gov/ct2/show/NCT04424212,0,0,0,0,2,0,Sweden,0,intervention group coronacope,NA
NCT04395430,2020-09-18,2021-06-30,Interventional,A Novel School-clinic-community Online Model of Child Obesity Treatment in Singapore During COVID-19,Recruiting,N/A,KK Women's and Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04395430,0,0,0,0,2,0,Singapore,0,standard care|online kkh sports singapore program with usual care,NA
NCT04408287,2020-09-15,2021-02-28,Interventional,Improving Activity Engagement Among Persons With SCI During COVID-19,Recruiting,N/A,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04408287,0,0,0,0,2,0,Canada,0,webex physical activity program,NA
NCT04408040,2020-07-14,2024-07-31,Interventional,Use of Convalescent Plasma for COVID-19,Recruiting,Phase 2,"Northside Hospital, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04408040,0,0,0,0,2,1,United States,0,convalescent plasma,NA
NCT04367636,2020-04-30,2021-09-30,Interventional,The Effects of Attention Training on Emotion Regulation and Stress Related Complaints During COVID-19,Recruiting,N/A,University Ghent,NA,https://clinicalzeros.gov/ct2/show/NCT04367636,0,0,0,0,1,0,Belgium,0,ocat|psycho-education video,NA
NCT04361838,2020-05-21,2021-06-30,Interventional,The COVID-19 ICU PRAYER Study,Recruiting,N/A,Kansas City Heart Rhythm Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04361838,0,0,0,0,2,1,United States,0,prayer,NA
NCT04803370,2020-07-08,2021-09-01,Interventional,Efficacy of Reinforcing Standard Therapy in COVID-19 Patients With Repeated Transfusion of Convalescent Plasma,Recruiting,N/A,Hospital Son Llatzer,NA,https://clinicalzeros.gov/ct2/show/NCT04803370,0,0,0,0,0,0,Spain,0,convalescent plasma with antibody against sars-cov-2.|standard care,NA
NCT04803227,2021-03-11,2021-04-30,Interventional,Safety and Tolerability of Emricasan in Symptomatic Outpatients Diagnosed With Mild-COVID-19,Recruiting,Phase 1,Histogen,NA,https://clinicalzeros.gov/ct2/show/NCT04803227,0,0,0,0,0,1,United States,0,emricasan|placebo,NA
NCT04802187,2020-12-01,2022-08-31,Interventional,Implementation of SARS-CoV Testing Strategies in Community Health Centers,Recruiting,N/A,Massachusetts General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04802187,0,0,0,0,0,1,United States,0,radx chcs testing intervention strategy|usual care control,NA
NCT04801836,2020-11-19,2021-06-30,Interventional,Estetrol (E4) for the Treatment of Patients With Confirmed SARS-COV-2 Infection,Recruiting,Phase 2,NEURALIS s.a.,NA,https://clinicalzeros.gov/ct2/show/NCT04801836,0,0,0,0,0,0,Belgium|Hungary|Poland|Russian Federation,0,estetrol monohydrate 15 mg|placebo,NA
NCT04800120,2021-02-15,2021-12-31,Interventional,Use of Hyperbaric Oxygen Therapy to Treat COVID-19 Patients With Respiratory Distress,Recruiting,N/A,"Steward St. Elizabeth's Medical Center of Boston, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04800120,0,0,0,0,0,1,United States,0,oxygen,NA
NCT04797936,2020-05-01,2020-12-19,Interventional,BNO 1030 Extract (Imupret) in the Treatment of Mild Forms of COVID-19,Completed,Phase 4,Ivano-Frankivsk National Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04797936,0,0,0,0,0,0,Ukraine,0,bno 1030|standard care,NA
NCT04797871,2021-03-08,2022-03-15,Interventional,Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19,Enrolling by invitation,N/A,Universidad PÃºblica de Navarra,NA,https://clinicalzeros.gov/ct2/show/NCT04797871,0,0,0,0,0,0,Spain,0,resistance training|standard care,NA
NCT04798599,2020-12-01,2021-06-30,Interventional,Information and Communication Technologies (ICTS) in Dentistry for SUS,Recruiting,N/A,University of Sao Paulo,NA,https://clinicalzeros.gov/ct2/show/NCT04798599,0,0,0,0,0,0,Brazil,0,telemonitoring/teleorientation|control group - waiting list|telemonitoring|teleorientation,NA
NCT04796064,2020-03-30,2020-11-05,Interventional,Low Versus High-Intensity Aerobic Training in Community-dwelling Older Men With Post-COVID 19 (SARS-CoV-2) Sarcopenia,Completed,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04796064,0,0,0,0,0,0,Egypt,0,low-intensity aerobic training,NA
NCT04793984,2021-03-08,2021-06-30,Interventional,Efficacy and Safety Evaluation of Inhaleen Inhalation in Hospitalized COVID-19 Patients,Recruiting,N/A,Marinomed Biotech AG,NA,https://clinicalzeros.gov/ct2/show/NCT04793984,0,0,0,0,0,0,Austria,0,carragelose|sodium,NA
NCT04794803,2020-05-05,2020-11-30,Interventional,Reparixin in COVID-19 Pneumonia - Efficacy and Safety,Terminated,Phase 2/Phase 3,DompÃ© Farmaceutici S.p.A,"The sponsor has decided to start with a separate protocol for phase 3 and therefore this study
    was terminated with only phase 2.",https://clinicalzeros.gov/ct2/show/NCT04794803,0,0,0,0,1,0,Brazil|Italy,0,reparixin|standard care,NA
NCT04794374,2020-11-16,2022-01-16,Interventional,Effects of Telerehabilitation After Discharge in COVID-19 Survivors,Recruiting,N/A,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04794374,0,0,0,0,1,0,Turkey,0,telehealth,NA
NCT04792021,2021-03-09,2021-06-30,Interventional,Effect of N-acetylcysteine on Oxidative Stress in COVID-19 Patients,Recruiting,Phase 3,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04792021,0,0,0,0,0,0,Egypt,0,n-acetylcysteine,NA
NCT04791241,2021-03-03,2021-05-03,Interventional,A Check-list Including Lung Ultrasound for ED Patients With ARF,Recruiting,N/A,Centre Hospitalier Metropole Savoie,NA,https://clinicalzeros.gov/ct2/show/NCT04791241,0,0,0,0,0,0,France,0,check-list including lung ultrasound,NA
NCT04793997,2021-02-01,2022-02-01,Interventional,Microbiome Therapy in Covid-19 Primary Care Support,Recruiting,N/A,"University Hospital, Antwerp",NA,https://clinicalzeros.gov/ct2/show/NCT04793997,0,0,0,0,0,0,Belgium,0,microbiome spray|placebo spray,NA
NCT04793243,2020-08-17,2020-10-10,Interventional,Vitamin D3 Levels in COVID-19 Outpatients From Western Mexico,Completed,N/A,University of Guadalajara,NA,https://clinicalzeros.gov/ct2/show/NCT04793243,0,0,0,0,0,0,Mexico,0,vitamin d,NA
NCT04790851,2021-02-23,2021-10-31,Interventional,Evaluation of Immunogenicity and Safety of Combined Immunization of COVIV and PPV23 / IIV4,Recruiting,Phase 4,China National Biotec Group Company Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04790851,0,0,0,1,1,0,China,0,coviv/iiv4; coviv/ppv23|coviv only (1st/2nd dose)|iiv4 for the 1st dose/ppv23 for the 2nd dose|coviv|iiv4; coviv|ppv23|coviv only (1st|2nd dose)|iiv4 for the 1st dose|ppv23 for the 2nd dose,NA
NCT04790240,2021-02-01,2022-12-31,Interventional,Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID),Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04790240,0,0,0,0,0,1,United States,0,inflammation (i)|inflammation (ii)|inflammation (iii)|standard care,NA
NCT04776044,2021-03-31,2021-12-31,Interventional,Clinical Trial to Evaluate the Safety and Efficacy of ATR-002 in Adult Hospitalized Patients With COVID-19,Recruiting,Phase 2,Atriva Therapeutics GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04776044,0,0,0,0,2,0,Germany|India|Netherlands|South Africa|Spain,0,atr-002|placebo,NA
NCT04789525,2020-03-10,2020-10-01,Interventional,Physical Training and Diet for Childhood Obesity,Completed,N/A,Cairo University,NA,https://clinicalzeros.gov/ct2/show/NCT04789525,0,0,0,0,1,0,Egypt,0,high-intensity aerobic training with high protein diet,NA
NCT04788459,2021-02-25,2021-09-30,Interventional,"Safety and Immunogenicity of COVID-eVax, a Candidate Plasmid DNA Vaccine for COVID-19, in Healthy Adult Volunteers",Recruiting,Phase 1/Phase 2,Takis,NA,https://clinicalzeros.gov/ct2/show/NCT04788459,0,0,0,1,1,0,Italy,0,covid-evax|cliniporatorâ®/epsgun|cliniporatorâ®|epsgun,NA
NCT04788407,2020-12-01,2021-04-30,Interventional,Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19 in Household Contacts,Recruiting,Phase 4,FundaciÃ³n HuÃ©sped,NA,https://clinicalzeros.gov/ct2/show/NCT04788407,0,0,0,0,1,0,Argentina,0,nitazoxanide|placebo,NA
NCT04779047,2020-10-01,2021-03-10,Interventional,Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.,Recruiting,Phase 4,October 6 University,NA,https://clinicalzeros.gov/ct2/show/NCT04779047,0,0,0,0,2,0,Egypt,0,remdesivir|hydroxychloroquine|tocilizumab|lopinavir/ ritonavir|ivermectin|lopinavir|ritonavir,NA
NCT04780672,2021-03-09,2021-08-19,Interventional,Clinical Study in the Treatment of Patients With COVID-19,Recruiting,Phase 3,Pharma VAM,NA,https://clinicalzeros.gov/ct2/show/NCT04780672,0,0,0,0,1,0,Russian Federation,0,molixan|placebo,NA
NCT04780425,2021-01-26,2021-05-22,Interventional,"Structured Diabetes Self-Management Education and Care Outcomes in Adults liVIng With Type 2 Diabetes in Accra, Ghana","Active, not recruiting",N/A,"Korle-Bu Teaching Hospital, Accra, Ghana",NA,https://clinicalzeros.gov/ct2/show/NCT04780425,0,0,0,0,1,0,Ghana,0,desmond|standard care,NA
NCT04750720,2020-08-27,2023-12-31,Interventional,Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection,Recruiting,N/A,Centre Hospitalier RÃ©gional d'OrlÃ©ans,NA,https://clinicalzeros.gov/ct2/show/NCT04750720,0,0,0,0,3,0,France,0,sampling by venipuncture (and eventually by nasopharyngeal swab),NA
NCT04746339,2021-03-04,2021-08-31,Interventional,Apixaban for PrOphyLaxis of thromboemboLic Outcomes in COVID-19,Recruiting,Phase 4,Brazilian Clinical Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04746339,0,0,0,0,1,0,Brazil,0,apixaban 2.5 mg|placebo,NA
NCT04738045,2020-11-01,2021-03-28,Interventional,Comparison of Remdesivir Versus Lopinavir/ Ritonavir and Remdesivir Combination in COVID-19 Patients,Recruiting,Phase 4,October 6 University,NA,https://clinicalzeros.gov/ct2/show/NCT04738045,0,0,0,0,2,0,Egypt,0,remdesivir|lopinavir/ ritonavir/remdesivir combination|lopinavir|ritonavir|remdesivir combination,NA
NCT04698993,2021-02-12,2021-03-31,Interventional,DrÃ¤ger COVID-19 Antigen Test Clinical Performance Study,Recruiting,N/A,DrÃ¤gerwerk AG & Co. KGaA,NA,https://clinicalzeros.gov/ct2/show/NCT04698993,0,0,0,0,1,0,Germany,0,drã¤ger antigen test sars-cov-2|drã¤ger antigen test sars-cov-2,NA
NCT04723459,2021-01-23,2021-02-19,Interventional,Efficacy of Nano-Ivermectin Impregnated Masks in Prevention of Covid-19 Among Healthy Contacts and Medical Staff,Recruiting,N/A,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04723459,0,0,0,0,3,0,Egypt,0,ivermectin impregnated mask,NA
NCT04713111,2020-05-04,2020-11-30,Interventional,Stress and Recovery in Frontline COVID-19 Workers,Completed,N/A,4YouandMe,NA,https://clinicalzeros.gov/ct2/show/NCT04713111,0,0,0,0,1,1,United States,0,lifestyle (meditation)|lifestyle (exercise),NA
NCT04727775,2020-11-25,2021-01-25,Interventional,Antiviral Drugs on the Treatment of SARS-CoV-2,Recruiting,Phase 1,Astana Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04727775,0,0,0,0,1,0,Kazakhstan,0,favipiravir|remdesivir,NA
NCT04716569,2021-01-20,2021-02-20,Interventional,Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19,Recruiting,Phase 2/Phase 3,South Valley University,NA,https://clinicalzeros.gov/ct2/show/NCT04716569,0,0,0,0,7,0,Egypt,0,intranasal ivermectin spray,NA
NCT04715932,2021-02-18,2021-05-31,Interventional,Study of Hesperidin Therapy on COVID-19 Symptoms (HESPERIDIN),Recruiting,Phase 2,Montreal Heart Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04715932,0,0,0,0,3,0,Canada,0,hesperidin|placebo,NA
NCT04710303,2021-03-02,2022-04-30,Interventional,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04710303,0,0,0,1,4,0,South Africa,0,had5-s-fusion/n-etsd vaccine|had5-s-fusion|n-etsd vaccine,NA
NCT04663737,2020-12-03,2021-05-31,Interventional,"Evaluating Safety, Pharmacokinetics and Clinical Benefit of Silmitasertib (CX-4945) in Subjects With Moderate COVID-19",Recruiting,Phase 2,"Senhwa Biosciences, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04663737,0,0,0,0,3,1,United States,0,silmitasertib|standard care,NA
NCT04661540,2021-03-02,2021-05-31,Interventional,A Study of Auxora in Patients With Critical COVID-19 Pneumonia,Recruiting,Phase 2,"CalciMedica, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04661540,0,0,0,0,2,1,United States,0,cm4620-ie (injectable emulsion)|placebo,NA
NCT04667247,2020-12-03,2021-06-01,Interventional,Mushroom-based Product for COVID-19,Recruiting,Phase 1/Phase 2,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04667247,0,0,0,0,1,1,United States,0,fotv,NA
NCT04666441,2020-12-15,2021-03-04,Interventional,COVID-19 Study Assessing the Virologic Efficacy of REGN10933+REGN10987 Across Different Dose Regimens in Adult Outpatients With SARS-CoV-2 Infection,"Active, not recruiting",Phase 2,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04666441,0,0,0,0,2,1,United States,0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,NA
NCT04657471,2020-12-08,2021-03-08,Interventional,Hospitalization or Outpatient ManagEment of Patients With SRAS-CoV-2 Infection - Revised HOME-CoV Score Study,Completed,N/A,"University Hospital, Angers",NA,https://clinicalzeros.gov/ct2/show/NCT04657471,0,0,0,0,3,0,France,0,revised home-cov score,NA
NCT04657497,2020-11-09,2021-05-31,Interventional,A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19),Recruiting,Phase 3,Ono Pharmaceutical Co. Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04657497,0,0,0,0,1,0,Japan,0,foy-305|placebo,NA
NCT04627675,2020-12-30,2021-05-31,Interventional,CORVax12: SARS-CoV-2 Spike (S) Protein Plasmid DNA Vaccine Trial for COVID-19 (SARS-CoV-2),"Active, not recruiting",Phase 1,Providence Health & Services,NA,https://clinicalzeros.gov/ct2/show/NCT04627675,0,0,0,1,2,1,United States,0,corvax|il-12 plasmid|cliniporator,NA
NCT04644120,2020-12-10,2021-09-05,Interventional,Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 1,AbbVie,NA,https://clinicalzeros.gov/ct2/show/NCT04644120,0,0,0,0,4,1,United States|Hungary|Israel|Netherlands|Puerto Rico,0,abbv-47d11|placebo for abbv-47d11|abbv-2b04|placebo for abbv-2b04,NA
NCT04637906,2020-11-18,2021-04-18,Interventional,Short and Long-term Effects of Adding Oral L-arginine to Standard Therapy in Patients With COVID-19 (SARS-CoV-2),Recruiting,N/A,"University of Campania ""Luigi Vanvitelli""",NA,https://clinicalzeros.gov/ct2/show/NCT04637906,0,0,0,0,3,0,Italy,0,bioargininaâ®|bioargininaâ®,NA
NCT04619719,2021-03-15,2021-06-15,Interventional,Hyperbaric Oxygen for COVID-19 Patients With Moderate to Severe Hypoxemia,Recruiting,N/A,Legacy Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04619719,0,0,0,0,6,1,United States,0,hyperbaric oxygen,NA
NCT04621123,2020-10-30,2021-06-15,Interventional,Plasma for Early Treatment in Non-hospitalised Mild or Moderate COVID-19 Patients,Recruiting,Phase 2,"FundaciÃ³n FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la PromociÃ³n de la Salud y la Ciencia",NA,https://clinicalzeros.gov/ct2/show/NCT04621123,0,0,0,0,1,0,Spain,0,convalescent plasma|control,NA
NCT04604223,2021-01-18,2021-06-29,Interventional,Effect of Pioglitazone on T2DM Patients With COVID-19,Recruiting,Phase 4,Dasman Diabetes Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04604223,0,0,0,0,1,0,Kuwait|Qatar,0,pioglitazone 45 mg,NA
NCT04545008,2020-10-20,2021-09-30,Interventional,Trial of Famotidine & N-Acetyl Cysteine for Outpatients With COVID-19,Recruiting,Phase 1,Prisma Health-Upstate,NA,https://clinicalzeros.gov/ct2/show/NCT04545008,0,0,0,0,1,1,United States,0,famotidine|n-acetyl cysteine,NA
NCT04575038,2020-11-19,2021-04-28,Interventional,CRISIS2: A Phase 2 Study of the Safety and Antiviral Activity of Brequinar in Non-hospitalized Pts With COVID-19,"Active, not recruiting",Phase 2,"Clear Creek Bio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04575038,0,0,0,0,9,1,United States,0,brequinar|placebo,NA
NCT04568031,2020-08-23,2021-11-15,Interventional,Study of AZD1222 for the Prevention of COVID-19 in Japan,"Active, not recruiting",Phase 1/Phase 2,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04568031,0,0,0,1,4,0,Japan,0,azd1222|0.9% (w/v) saline|0.9% (w|v) saline,NA
NCT04565379,2020-09-25,2021-04-30,Interventional,Clinical Trial to Investigate the Efficacy and Safety of NuSepinÂ® in COVID-19 Pneumonia Patients,Recruiting,Phase 2,Shaperon,NA,https://clinicalzeros.gov/ct2/show/NCT04565379,0,0,0,0,3,0,Romania,0,nusepinâ® 0.1 mg|nusepinâ® 0.2 mg|placebo|nusepinâ® 0.1 mg|nusepinâ® 0.2 mg,NA
NCT04525820,2020-12-15,2021-05-31,Interventional,"High Dose Vitamin-D Substitution in Patients With COVID-19: a Randomized Controlled, Multi Center Study",Recruiting,N/A,"Cantonal Hosptal, Baselland",NA,https://clinicalzeros.gov/ct2/show/NCT04525820,0,0,0,0,3,0,Switzerland,0,single high dose vitamin d|placebo|treatment as usual vitamin d,NA
NCT04539626,2020-10-01,2021-07-31,Interventional,Estrogen Therapy in Non-severe COVID-19 Patients,Recruiting,N/A,"CMN ""20 de Noviembre""",NA,https://clinicalzeros.gov/ct2/show/NCT04539626,0,0,0,0,2,0,Mexico,0,estrogen therapy,NA
NCT04536935,2020-11-30,2021-04-30,Interventional,Mobile Mental Health Apps for Suicide Prevention,Enrolling by invitation,N/A,University of Washington,NA,https://clinicalzeros.gov/ct2/show/NCT04536935,0,0,0,0,3,1,United States,0,mobile mental health app - 1|mobile mental health app - 2|mobile mental health app - 3|mobile mental health app - 4,NA
NCT04508075,2020-08-10,2021-01-09,Interventional,"Efficacy, Safety and Immunogenicity Study of SARS-CoV-2 Inactivated Vaccine","Active, not recruiting",Phase 3,PT Bio Farma,NA,https://clinicalzeros.gov/ct2/show/NCT04508075,0,0,0,1,2,0,Indonesia,0,inactivated vaccine|placebo,NA
NCT04506268,2020-09-09,2020-10-30,Interventional,COVID-19 SAFE Enrollment,Completed,N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04506268,0,0,0,0,6,1,United States,0,opt-out recruitment email|opt-in recruitment email,NA
NCT04504240,2020-08-01,2021-04-10,Interventional,Role of Famotidine in the Clinical Improvement of COVID-19 Patients.,"Active, not recruiting",Phase 3,Chattogram General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04504240,0,0,0,0,2,0,Bangladesh,0,famotidine,NA
NCT04498247,2020-08-27,2021-03-05,Interventional,"A Study to Assess Safety, Tolerability, and Immunogenicity of V591 (COVID-19 Vaccine) in Healthy Participants (V591-001)",Terminated,Phase 1/Phase 2,Merck Sharp & Dohme Corp.,The study was terminated based on an interim assessment of immunogenicity,https://clinicalzeros.gov/ct2/show/NCT04498247,0,0,0,1,11,1,United States|Austria|Belgium,0,v591|placebo,NA
NCT04495803,2020-09-01,2022-08-01,Interventional,Augmented CBGT for Perinatal Anxiety During a Global Pandemic (COVID-19),Recruiting,N/A,St. Joseph's Healthcare Hamilton,NA,https://clinicalzeros.gov/ct2/show/NCT04495803,0,0,0,0,1,0,Canada,0,cognitive behavioural group therapy for perinatal anxiety,NA
NCT04439825,2020-07-20,2020-09-03,Interventional,Impact of Botox Treatment Into the Upper One Third of the Face an Area on Mood and Self -Appearance Satisfaction,Completed,Phase 1,DeNova Research,NA,https://clinicalzeros.gov/ct2/show/NCT04439825,0,0,0,0,3,1,United States,0,botulinum neurotoxin|placebo,NA
NCT04445220,2020-11-19,2021-06-30,Interventional,A Study of Cell Therapy in COVID-19 Subjects With Acute Kidney Injury Who Are Receiving Renal Replacement Therapy,Recruiting,Phase 1/Phase 2,"Sentien Biotechnologies, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04445220,0,0,0,0,5,1,United States,0,sbi-101,NA
NCT04487691,2020-12-08,2021-06-01,Interventional,Nebulized PL for Post-COVID-19 Syndrome,"Active, not recruiting",N/A,"Regenexx, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04487691,0,0,0,0,3,1,United States,0,nebulized platelet lysate|nebulized sterile saline,NA
NCT04470999,2020-04-15,2021-09-30,Interventional,Changes in Cellular Immune Profile During COVID-19 Infection,Recruiting,N/A,Seraph Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04470999,0,0,0,0,3,1,United States,0,leukapheresis,NA
NCT04466683,2020-08-28,2021-12-31,Interventional,Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04466683,0,0,0,0,2,1,United States|Colombia,0,radiotherapy|high dose radiation 100 cgy,NA
NCT04432324,2020-06-02,2021-03-03,Interventional,Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19),Completed,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04432324,0,0,0,0,4,0,Spain,0,immune globulin|standard care,NA
NCT04427566,2020-07-23,2021-12-31,Interventional,Low Dose Whole Lung Radiation Therapy for Patients With COVID-19 and Respiratory Compromise,Recruiting,Phase 2,Ohio State University Comprehensive Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04427566,0,0,0,0,6,1,United States,0,radiotherapy,NA
NCT04379154,2020-04-14,2021-04-30,Interventional,Analysis of Volatile Organic Compounds by Electronic Noses in Hospitalised Patients for an Infection by SARS-COV-2 (COVID-19),Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04379154,0,0,0,0,3,0,France,0,volatile organic compounds analysis,NA
NCT04409262,2020-06-16,2021-02-01,Interventional,A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia,Completed,Phase 3,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04409262,0,0,0,0,9,1,United States|Brazil|Russian Federation|Spain,0,remdesivir|tocilizumab|placebo,NA
NCT04400058,2020-06-01,2021-01-07,Interventional,Octagam 10% Therapy in COVID-19 Patients With Severe Disease Progression,Completed,Phase 3,Octapharma,NA,https://clinicalzeros.gov/ct2/show/NCT04400058,0,0,0,0,16,1,United States|Russian Federation|Ukraine,0,octagam|placebo,NA
NCT04399356,2020-10-01,2021-04-30,Interventional,Niclosamide for Mild to Moderate COVID-19,Recruiting,Phase 2,Tufts Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04399356,0,0,0,0,4,1,United States,0,niclosamide|placebo|telehealth monitoring,NA
NCT04397796,2020-08-03,2021-06-30,Interventional,Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04397796,0,0,0,0,4,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04382391,2020-05-08,2021-09-01,Interventional,Study Assessing Vagus Nerve Stimulation in CoViD-19 Respiratory Symptoms,Recruiting,N/A,Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute),NA,https://clinicalzeros.gov/ct2/show/NCT04382391,0,0,0,0,3,1,United States,0,gammacoreâ® sapphire (non-invasive vagus nerve stimulator)|standard care|gammacoreâ® sapphire (non-invasive vagus nerve stimulator),NA
NCT04382378,2021-02-01,2021-09-30,Interventional,Effects of NMES in Critically Ill Patients,Recruiting,N/A,Escola Superior de Ciencias da Saude,NA,https://clinicalzeros.gov/ct2/show/NCT04382378,0,0,0,0,4,0,Brazil,0,neuromuscular electrical stimulation,NA
NCT04408157,2020-05-20,2021-08-22,Interventional,A Research Study to Evaluate the Benefits of a Self-management Booklet to Promote Wellbeing During the COVID-19 Pandemic,"Active, not recruiting",N/A,King's College London,NA,https://clinicalzeros.gov/ct2/show/NCT04408157,0,0,0,0,4,0,United Kingdom,0,self-management booklet (switch: stay well during covid-19),NA
NCT04414618,2020-07-02,2020-11-26,Interventional,A Study of Opaganib in Coronavirus Disease 2019 Pneumonia,Completed,Phase 2,RedHill Biopharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04414618,0,0,0,0,17,1,United States|Israel,0,opaganib|placebo,NA
NCT04390191,2020-05-07,2022-04-30,Interventional,Early CPAP in COVID-19 Confirmed or Suspected Patients,Recruiting,N/A,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04390191,0,0,0,0,1,1,United States,0,continuous positive airway pressure,NA
NCT04388826,2020-06-18,2020-12-18,Interventional,COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111,"Active, not recruiting",Phase 2,Veru Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04388826,0,0,0,0,17,1,United States,0,veru-111,NA
NCT04374461,2020-05-01,2023-05-31,Interventional,A Study of N-acetylcysteine in Patients With COVID-19 Infection,Recruiting,Phase 2,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04374461,0,0,0,0,9,1,United States,0,n-acetylcysteine|blood,NA
NCT04373200,2020-05-25,2021-05-25,Interventional,Human Ab Response & immunoMONItoring of COVID-19 Patients,Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04373200,0,0,0,0,4,0,France,0,blood sample|saliva,NA
NCT04371978,2020-10-01,2021-06-30,Interventional,Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19,Recruiting,Phase 3,Rabin Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04371978,0,0,0,0,3,0,Israel,0,linagliptin 5 mg,NA
NCT04358406,2020-07-30,2021-05-01,Interventional,Rhu-pGSN for Severe Covid-19 Pneumonia,"Active, not recruiting",Phase 2,BioAegis Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04358406,0,0,0,0,4,0,Romania|Spain,0,recombinant human plasma gelsolin (rhu-pgsn)|placebo,NA
NCT04377620,2020-05-24,2021-02-26,Interventional,Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT),Terminated,Phase 3,Incyte Corporation,Study terminated by sponsor,https://clinicalzeros.gov/ct2/show/NCT04377620,0,0,0,0,7,1,United States|Russian Federation,0,placebo|ruxolitinib,NA
NCT04351191,2020-04-15,2020-08-23,Interventional,PRophylaxis of Exposed COVID-19 Individuals With Mild Symptoms Using choloroquinE Compounds,Terminated,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",Poor accrual,https://clinicalzeros.gov/ct2/show/NCT04351191,0,0,0,0,2,0,Pakistan,0,hydroxychloroquine|chloroquine|placebo,NA
NCT04353037,2020-04-07,2020-07-11,Interventional,PATCH 2&3:Prevention & Treatment of COVID-19 (Severe Acute Respiratory Syndrome Coronavirus 2) With Hydroxychloroquine,Terminated,Phase 2,UnitedHealth Group,"As enrollment began external studies called into question the safety and efficacy of
    hydroxychloroquine as a treatment which resulted in controversy. The timing of the controversy
    significantly impacted our ability to enroll and retain participants.",https://clinicalzeros.gov/ct2/show/NCT04353037,0,0,0,0,2,1,United States,0,hydroxychloroquine|control,NA
NCT04351347,2020-06-16,2030-12-01,Interventional,The Efficacy of Ivermectin in Larger Doses in COVID-19 Treatment,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04351347,0,0,0,0,5,0,Egypt,0,ivermectin,NA
NCT04346667,2020-04-14,2020-08-23,Interventional,Post-Exposure Prophylaxis for Asymptomatic SARS-CoV-2 COVID-19 Patients With choloroquinE Compounds,Terminated,Phase 4,"Government of Punjab, Specialized Healthcare and Medical Education Department",Poor accrual.,https://clinicalzeros.gov/ct2/show/NCT04346667,0,0,0,0,2,0,Pakistan,0,hydroxychloroquine|chloroquine|placebo,NA
NCT04345653,2020-04-14,2020-06-05,Interventional,Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers,"Active, not recruiting",Phase 2,Hackensack Meridian Health,NA,https://clinicalzeros.gov/ct2/show/NCT04345653,0,0,0,0,5,1,United States,0,hydroxychloroquine,NA
NCT04345419,2020-06-16,2029-12-31,Interventional,Remdesivir Efficacy in Coronavirus Disease,Recruiting,Phase 2/Phase 3,Tanta University,NA,https://clinicalzeros.gov/ct2/show/NCT04345419,0,0,0,0,5,0,Egypt,0,remdesivir|standard care,NA
NCT04324528,2020-03-27,2021-01-27,Interventional,Cytokine Adsorption in Severe COVID-19 Pneumonia Requiring Extracorporeal Membrane Oxygenation,Completed,N/A,University Hospital Freiburg,NA,https://clinicalzeros.gov/ct2/show/NCT04324528,0,0,0,0,3,0,Germany,0,vv-ecmo / cytokine adsorption|vv-ecmo|cytokine adsorption,NA
NCT04303299,2020-08-19,2021-12-31,Interventional,Fight COVID-19 Trial,Recruiting,Phase 3,Rajavithi Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04303299,0,0,0,0,7,0,Thailand,0,oral,NA
NCT04805684,2021-01-01,2021-03-05,Interventional,Different Lung Ultrasound Imaging Protocols in COVID-19 Pneumonia,Completed,N/A,Bursa YÃ¼ksek Ä°htisas Education and Research Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04805684,0,0,0,0,0,0,Turkey,0,lus twelve area|lus fourteen area,NA
NCT04805203,2020-12-16,2022-12-31,Interventional,Analysis of the Immune Parameters of COVID-19 Infection in Patients With Multiple Myeloma,Recruiting,N/A,Intergroupe Francophone du Myelome,NA,https://clinicalzeros.gov/ct2/show/NCT04805203,0,0,0,0,0,0,France,0,blood sample analyses,NA
NCT04805086,2021-03-08,2022-06-01,Interventional,The MONACO Cell Therapy Study: Monocytes as an Anti-fibrotic Treatment After COVID-19,Recruiting,Phase 1/Phase 2,Guy's and St Thomas' NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04805086,0,0,0,0,0,0,United Kingdom,0,mon002,NA
NCT04728802,2021-02-02,2021-03-22,Interventional,Proxalutamide Treatment for Hospitalized COVID-19 Patients,"Active, not recruiting",Phase 3,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04728802,0,0,0,0,2,0,Brazil,0,proxalutamide|standard care,NA
NCT04610502,2020-09-06,2020-10-06,Interventional,Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients,Completed,Phase 2,Caja Costarricense de Seguro Social,NA,https://clinicalzeros.gov/ct2/show/NCT04610502,0,0,0,0,2,0,Costa Rica,0,administration of equine immunoglobulin anti sars-cov-2,NA
NCT04568863,2020-06-20,2020-11-30,Interventional,Efficacy of Intravenous Melatonin on Mortality in Adult Patients Admitted to the Intensive Care Unit With COVID-19,Completed,Phase 2,Pharmamel S.L.,NA,https://clinicalzeros.gov/ct2/show/NCT04568863,0,0,0,0,1,0,Spain,0,melatonin intravenous|placebo,NA
NCT04522986,2020-08-21,2021-02-02,Interventional,An Exploratory Study of ADR-001 in Patients With Severe Pneumonia Caused by SARS-CoV-2 Infection,Completed,Phase 1,"Rohto Pharmaceutical Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04522986,0,0,0,0,2,0,Japan,0,mesenchymalÂ stem cells,NA
NCT04497324,2020-09-21,2021-04-30,Interventional,PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19,Recruiting,Phase 2,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04497324,0,0,0,0,3,0,Peru,0,convalescent plasma,NA
NCT04380402,2020-06-25,2021-12-31,Interventional,Atorvastatin as Adjunctive Therapy in COVID-19,Recruiting,Phase 2,Mount Auburn Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04380402,0,0,0,0,2,1,United States,0,atorvastatin,NA
NCT04821934,2021-03-26,2021-06-30,Interventional,Tele-rehabilitation Program After Hospitalization for COVID-19,Recruiting,N/A,Istituti Clinici Scientifici Maugeri SpA,NA,https://clinicalzeros.gov/ct2/show/NCT04821934,0,0,0,0,0,0,Italy,0,tr|tsu,NA
NCT04820803,2021-02-03,2021-04-23,Interventional,Assessment of the Impact of Oral Intervention With Cetylpyridinium Chloride to Decrease SARS-CoV-2 Viral Load in Patients With COVID-19,Recruiting,N/A,Instituto de InvestigaciÃ³n Sanitaria AragÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04820803,0,0,0,0,0,0,Spain,0,oral intervention with cetylpyridinium chloride|placebo,NA
NCT04313023,2020-06-09,2021-05-31,Interventional,The Use PUL-042 to Reduce the Infection Rate and Progression to COVID-19 in Adults Exposed to SARS-CoV-2,Recruiting,Phase 2,"Pulmotect, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04313023,0,0,0,0,11,1,United States,0,pul-042|placebo,NA
NCT04312997,2020-06-16,2021-04-30,Interventional,The Use of PUL-042 Inhalation Solution to Reduce the Severity of COVID-19 in Adults Positive for SARS-CoV-2 Infection,Recruiting,Phase 2,"Pulmotect, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04312997,0,0,0,0,14,1,United States,0,pul-042|placebo,NA
NCT04805931,2021-03-15,2021-05-01,Interventional,VEText Message Framing and Covid-19 Vaccine Uptake Among at Risk Veterans,Recruiting,N/A,VA Puget Sound Health Care System,NA,https://clinicalzeros.gov/ct2/show/NCT04805931,0,0,0,1,0,1,United States,0,behavioral economics,NA
NCT04805892,2021-03-17,2021-04-27,Interventional,"Open Label, Single-Center Study Utilizing BIOZEK COVID-19 Antigen Rapid Test as Compared to Standard Testing Technique. Test Performed by a Professional Versus Self-collection and Standard of Care",Recruiting,N/A,Mach-E B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04805892,0,0,0,0,0,1,United States,0,biozek covid-19 antigen rapid test,NA
NCT04803812,2021-01-26,2021-05-04,Interventional,Supporting the Wellness of Ontario Physicians During COVID-19,Recruiting,N/A,Ontario Medical Association,NA,https://clinicalzeros.gov/ct2/show/NCT04803812,0,0,0,0,0,0,Canada,0,"remote sms (short message service, also known as ""text message"") delivery",NA
NCT04750265,2021-01-21,2021-11-30,Interventional,Robotic Assisted Early Mobilization in Ventilated ICU Patients With COVID-19,Recruiting,N/A,"Charite University, Berlin, Germany",NA,https://clinicalzeros.gov/ct2/show/NCT04750265,0,0,0,0,2,0,Germany,0,robotic assisted early mobilization,NA
NCT04649086,2020-06-05,2021-10-05,Interventional,Muscular Rehabilitation by Eccentric Exercise After Severe COVID-19 Infection,Recruiting,N/A,"University Hospital, Clermont-Ferrand",NA,https://clinicalzeros.gov/ct2/show/NCT04649086,0,0,0,0,2,0,France,0,rehabilitation by concentric exercises|rehabilitation by eccentric exercises,NA
NCT04641481,2020-11-16,2021-01-08,Interventional,An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers,"Active, not recruiting",Phase 3,Bharat Biotech International Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04641481,0,0,0,1,3,0,India,0,bbv152|placebo,NA
NCT04611399,2021-03-05,2022-03-05,Interventional,MIND-VR: Virtual Reality for COVID-19 Operators' Psychological Support,Recruiting,N/A,Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta,NA,https://clinicalzeros.gov/ct2/show/NCT04611399,0,0,0,0,2,0,Italy,0,vr for psychoeducation/relaxation|text material for psychoeducation/audio for relaxation techniques|vr for psychoeducation|relaxation|text material for psychoeducation|audio for relaxation techniques,NA
NCT04551339,2020-09-28,2021-06-14,Interventional,Zinc Versus Multivitamin Micronutrient Supplementation in the Setting of COVID-19,"Active, not recruiting",N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04551339,0,0,0,0,3,1,United States,0,preservision areds formulation soft gels/tablets|multivitamin with 11mg of zinc|preservision areds formulation soft gels|tablets,NA
NCT04391179,2020-05-31,2021-02-22,Interventional,Dipyridamole to Prevent Coronavirus Exacerbation of Respiratory Status (DICER) in COVID-19,Completed,Phase 2,University of Michigan,NA,https://clinicalzeros.gov/ct2/show/NCT04391179,0,0,0,0,7,1,United States,0,dipyridamole|placebo,NA
NCT04383613,2020-05-15,2021-06-01,Interventional,Prone Positioning for Patients on General Medical Wards With COVID19,Recruiting,N/A,Unity Health Toronto,NA,https://clinicalzeros.gov/ct2/show/NCT04383613,0,0,0,0,5,0,Canada,0,prone positioning,NA
NCT04332107,2020-05-22,2021-09-30,Interventional,Azithromycin for COVID-19 Treatment in Outpatients Nationwide,"Active, not recruiting",Phase 3,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04332107,0,0,0,0,9,1,United States,0,azithromycin|placebo,NA
NCT04822285,2020-01-22,2020-04-22,Interventional,Effect Psychological Triaging Intervention on Students' Psychological Distress and Resilience Capacity,Completed,N/A,Alexandria University,NA,https://clinicalzeros.gov/ct2/show/NCT04822285,0,0,0,0,0,0,Egypt,0,psychological triaging intervention|routine psychological support,NA
NCT04821973,2020-09-22,2021-05-15,Interventional,Respiratory Tele Monitoring COVID 19 (TMR COVID-19),Recruiting,N/A,Assistance Publique Hopitaux De Marseille,NA,https://clinicalzeros.gov/ct2/show/NCT04821973,0,0,0,0,0,0,France,0,radius ppg tetherless pulse oximetry (masimo)|usual monitoring,NA
NCT04818489,2021-03-25,2021-05-25,Interventional,Colchicine and Post-COVID-19 Pulmonary Fibrosis,Recruiting,Phase 4,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04818489,0,0,0,0,1,0,Egypt,0,colchicine 0.5 mg|the standard protocol only,NA
NCT04817371,2021-03-01,2022-03-31,Interventional,Analysis of Volatile Organic Compounds in Exhaled Air and Sweat: Interest in Rapid Screening for COVID-19 Infection.,Recruiting,N/A,Hopital Foch,NA,https://clinicalzeros.gov/ct2/show/NCT04817371,0,0,0,0,1,0,France,0,volatile organic compounds analysis (e-noses)|canine odor detection of volatile organic compounds|volatile organic compounds analysis (mass spectrometry)|volatile organic compounds analysis in sweat (mass spectrometry),NA
NCT04817332,2020-06-05,2021-02-28,Interventional,STOP-COVID19: Superiority Trial Of Protease Inhibition in COVID-19,Completed,Phase 3,University of Dundee,NA,https://clinicalzeros.gov/ct2/show/NCT04817332,0,0,0,0,0,0,United Kingdom,0,brensocatib|placebo,NA
NCT04816682,2021-03-17,2021-06-30,Interventional,Silymarin in COVID-19 Patients Admitted to Hospital With Elevated Liver Enzymes,Recruiting,Phase 4,F.D. Roosevelt Teaching Hospital with Policlinic Banska Bystrica,NA,https://clinicalzeros.gov/ct2/show/NCT04816682,0,0,0,0,0,0,Slovakia,0,silymarin,NA
NCT04816656,2020-08-03,2021-02-01,Interventional,An Integrated Digital PROM-platform for Cancer Patients During the COVID-19 Pandemic,Completed,N/A,Jessa Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04816656,0,0,0,0,1,0,Belgium,0,eproms assessment,NA
NCT04816084,2020-11-05,2020-12-01,Interventional,SERUR: COVID-19 Serological Survey of Staff From the University Reims-Champagne Ardennes,Completed,N/A,UniversitÃ© de Reims Champagne-Ardenne,NA,https://clinicalzeros.gov/ct2/show/NCT04816084,0,0,0,0,0,0,France,0,serology test,NA
NCT04816942,2020-04-23,2020-07-21,Interventional,Clinical Efficacy of Early Administration of Convalescent Plasma Among COVID-19 Cases in Egypt,Completed,Phase 3,"Ministry of Health and Population, Egypt",NA,https://clinicalzeros.gov/ct2/show/NCT04816942,0,0,0,0,0,0,Egypt,0,convalescent plasma,NA
NCT04815096,2021-04-15,2023-03-01,Interventional,Imaging Immune Activation in COVID-19,Recruiting,Early Phase 1,"CellSight Technologies, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04815096,0,0,0,0,2,1,United States,0,[18f]f-arag (2'-deoxy-2'-fluoro-9-î²-d-arabinofuranosylguanine)|[18f]f-arag (2'-deoxy-2'-fluoro-9-î²-d-arabinofuranosylguanine),NA
NCT04813796,2021-03-11,2022-04-13,Interventional,"A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines in Healthy Adults Between 18 Years and 55 Years of Age",Recruiting,Phase 1,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04813796,0,0,0,1,0,1,United States,0,mrna-1283|mrna-1273|placebo,NA
NCT04813575,2021-04-01,2022-04-01,Interventional,COVID-19 Pathophysiology of Long Term Implications,Enrolling by invitation,N/A,King Faisal Specialist Hospital & Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04813575,0,0,0,0,0,0,Saudi Arabia,0,cryo lung biopsies,NA
NCT04813562,2021-03-23,2021-07-30,Interventional,Immunogenicity and Safety of Recombinant COVID-19 Vaccine (CHO Cells),Recruiting,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04813562,0,0,0,1,0,0,China,0,"a middle-dose recombinant covid-19 vaccine (cho cell) (18-59 years) at the schedule of day 0, 28, 56|a high-dose recombinant covid-19 vaccine (cho cell) (18-59 years) at the schedule of day 0, 28, 56|a middle-dose recombinant covid-19 vaccine (cho cell) (60-85 years) at the schedule of day 0, 28, 56|a high-dose recombinant covid-19 vaccine (cho cell) (60-85 years) at the schedule of day 0, 28, 56|a middle-dose placebo (18-59 years) at the schedule of day 0, 28, 56|a high-dose placebo (18-59 years) at the schedule of day 0, 28, 56|a middle-dose placebo (60-85 years) at the schedule of day 0, 28, 56|a high-dose placebo (60-85 years) at the schedule of day 0, 28, 56",NA
NCT04813497,2021-02-05,2021-05-30,Interventional,Monitoring of COVID-19 Seroprevalence Among GHdC Staff Members,Recruiting,N/A,Grand HÃ´pital de Charleroi,NA,https://clinicalzeros.gov/ct2/show/NCT04813497,0,0,0,0,0,0,Belgium,0,serology to determine sars-cov-2 infection,NA
NCT04813471,2021-01-20,2021-03-20,Interventional,Managing Endothelial Dysfunction in Critically Ill COVID-19 Patients at LAUMCRH,Recruiting,Phase 3,Lebanese American University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04813471,0,0,0,0,0,0,Lebanon,0,endothelial protocol,NA
NCT04810949,2020-08-05,2021-03-01,Interventional,Vitamine D3 Supplementation in Patients With Serum Values +/- 20ng/ml,Terminated,N/A,Hospital Clinica Nova,patients enrolled got vaccinated vs COVID-19 and Influenza,https://clinicalzeros.gov/ct2/show/NCT04810949,0,0,0,0,0,0,Mexico,0,vitamine d3 supplementation|diet/sun exposure|diet|sun exposure,NA
NCT04811859,2021-01-10,2022-01-10,Interventional,The Effect of Inspiratory Muscle Training in Post COVID-19 Patients,Recruiting,N/A,Istinye University,NA,https://clinicalzeros.gov/ct2/show/NCT04811859,0,0,0,0,0,0,Turkey,0,inspiratory muscle training,NA
NCT04811339,2020-09-02,2023-08-31,Interventional,Studies of COVID-19 Patients Treated With Oral Bismuth Subsalicylate (Pepto-Bismol),Recruiting,Phase 4,University of Louisville,NA,https://clinicalzeros.gov/ct2/show/NCT04811339,0,0,0,0,1,1,United States,0,open label bss (pepto bismol),NA
NCT04810689,2021-03-01,2022-03-01,Interventional,"Pilot Trial of XFBD, a TCM, in Persons With COVID-19",Recruiting,Phase 2,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04810689,0,0,0,0,0,1,United States,0,xuanfei baidu granules|placebo,NA
NCT04794946,2021-03-19,2022-03-19,Interventional,"Safety and Efficacy of a Non-replicating ChAdOx1 Vector Vaccine AZD1222 (COVISHIELD), for Prevention of COVID-19 in Patients With Liver Cirrhosis",Recruiting,N/A,"Institute of Liver and Biliary Sciences, India",NA,https://clinicalzeros.gov/ct2/show/NCT04794946,0,0,0,1,1,0,India,0,covishield,NA
NCT04810637,2020-11-01,2021-06-30,Interventional,A Study to Evaluate the Safety and Efficacy of GX-I7 in Elderly Patients With Asymptomatic or Mild Symptoms of COVID-19,Recruiting,Phase 2,PT Kalbe Genexine Biologics,NA,https://clinicalzeros.gov/ct2/show/NCT04810637,0,0,0,0,1,0,Indonesia,0,gx-i7,NA
NCT04809272,2021-03-08,2021-07-01,Interventional,ePLH Pilot Study: Online Support Parent Groups - ParentChat,Recruiting,N/A,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04809272,0,0,0,0,0,0,United Kingdom,0,parentchat for parents of children ages 2-17,NA
NCT04600895,2020-11-30,2021-08-31,Interventional,The Prevent Severe COVID-19 (PRESECO) Study,Recruiting,Phase 3,Appili Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04600895,0,0,0,0,4,1,United States,0,favipiravir|placebo,NA
NCT04806074,2020-08-14,2020-12-06,Interventional,FOODLIT-PRO: Improving Food Literacy and Food Sustainability Amidst the COVID-19 Pandemic,"Active, not recruiting",N/A,"ISPA - Instituto Universitario de Ciencias Psicologicas, Sociais e da Vida",NA,https://clinicalzeros.gov/ct2/show/NCT04806074,0,0,0,0,1,0,Portugal,0,experimental group|comparison group,NA
NCT04802018,2021-03-09,2021-06-30,Interventional,Clinical Decision Support System Based on Non-invasive Tele-monitoring of COVID-19 Patients,"Active, not recruiting",N/A,Increase-Tech,NA,https://clinicalzeros.gov/ct2/show/NCT04802018,0,0,0,0,1,0,Spain,0,clinical decision support system based on non-invasive multimodal monitoring,NA
NCT04801524,2021-02-07,2021-12-31,Interventional,Text-based Reminders to Promote COVID-19 Vaccinations,Enrolling by invitation,N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04801524,0,0,0,1,1,1,United States,0,self-benefit|prosocial-benefit|early access|fresh start,NA
NCT04800965,2021-01-31,2021-12-31,Interventional,Text-based Interventions to Promote COVID-19 Vaccinations,Enrolling by invitation,N/A,"University of California, Los Angeles",NA,https://clinicalzeros.gov/ct2/show/NCT04800965,0,0,0,1,1,1,United States,0,patient mychart scheduling link|patient educational video|enhanced follow through message,NA
NCT04794088,2021-03-14,2021-12-31,Interventional,Intravenous Imatinib in Mechanically Ventilated COVID-19 Patients,Recruiting,Phase 2,VU University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04794088,0,0,0,0,1,0,Netherlands,0,imatinib mesylate intravenous solution|placebo,NA
NCT04789356,2021-03-18,2021-06-30,Interventional,Effectiveness of the Adsorbed Vaccine COVID-19 (Coronavac) Among Education and Public Safety Workers With Risk Factors for Severity,Recruiting,Phase 4,FundaÃ§Ã£o de Medicina Tropical Dr. Heitor Vieira Dourado,NA,https://clinicalzeros.gov/ct2/show/NCT04789356,0,0,0,1,2,0,Brazil,0,adsorbed sars-cov-2 (inactivated) vaccine,NA
NCT04765475,2021-03-08,2022-02-28,Interventional,Protecting Native Families From COVID-19,Recruiting,N/A,Johns Hopkins Bloomberg School of Public Health,NA,https://clinicalzeros.gov/ct2/show/NCT04765475,0,0,0,0,1,1,United States,0,motivational interviewing|covid-19 symptom monitoring system|motivational interviewing/covid-19 symptom monitoring system|supportive services,NA
NCT04767958,2021-03-19,2022-02-28,Interventional,The RAPID COVID Study - Application of Point-of-Care COVID-19 Testing,Recruiting,N/A,Ottawa Heart Institute Research Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04767958,0,0,0,0,1,0,Canada,0,spartan covid-19 platform,NA
NCT04754698,2021-02-09,2021-12-31,Interventional,COVID-19 CoronaVac in Patients With Autoimmune Rheumatic Diseases and HIV/AIDS,Recruiting,Phase 4,University of Sao Paulo General Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04754698,0,0,0,0,3,0,Brazil,0,coronavac,NA
NCT04756141,2021-03-03,2022-01-28,Interventional,CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)),Recruiting,N/A,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04756141,0,0,0,0,2,1,United States,0,continuous glucose monitor (cgm),NA
NCT04751682,2021-03-01,2021-03-25,Interventional,Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19,"Active, not recruiting",Phase 1,Bharat Biotech International Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04751682,0,0,0,1,2,0,India,0,bbv154 vaccine,NA
NCT04705597,2021-03-18,2021-05-31,Interventional,"Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Participants â‰¥ 60 Years of Age and Hospitalized With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure",Recruiting,Phase 2,"BioAge Labs, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04705597,0,0,0,0,3,1,United States,0,bge-175|placebo,NA
NCT04727424,2021-01-19,2022-02-01,Interventional,Repurposed Approved Therapies for Outpatient Treatment of Patients With Early-Onset COVID-19 and Mild Symptoms,Recruiting,Phase 3,Cardresearch,NA,https://clinicalzeros.gov/ct2/show/NCT04727424,0,0,0,0,1,0,Brazil,0,fluvoxamine maleate 100 mg [luvox]|metformin extended release oral tablet|ivermectin oral tablets/sublingual waffles|placebo|ivermectin oral tablets|sublingual waffles,NA
NCT04707703,2021-03-16,2022-01-31,Interventional,Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis,Recruiting,Phase 3,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04707703,0,0,0,0,1,1,United States,0,isavuconazonium injection [cresemba]|placebo,NA
NCT04723290,2020-06-20,2020-10-31,Interventional,COVID-19 Seroconversion Study Among GHdC Staff Members - Summer 2020,Completed,N/A,Grand HÃ´pital de Charleroi,NA,https://clinicalzeros.gov/ct2/show/NCT04723290,0,0,0,0,3,0,Belgium,0,serological tests for sars cov-2,NA
NCT04713553,2021-02-15,2021-05-11,Interventional,"A Phase 3 Study to Evaluate the Safety, Tolerability, and Immunogenicity of Multiple Production Lots and Dose Levels of BNT162b2 Against COVID-19 in Healthy Participants",Recruiting,Phase 3,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04713553,0,0,0,1,3,1,United States,0,bnt162b2,NA
NCT04701606,2021-03-29,2021-10-15,Interventional,The Safety and Efficacy of Pyronaridine-artesunate (PyramaxÂ® or ArtecomÂ®)in COVID-19 Patients,Recruiting,Phase 2/Phase 3,Shin Poong Pharmaceutical Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04701606,0,0,0,0,2,0,Philippines,0,artecomâ® (pyronaridine-artesunate)|placebo|artecomâ® (pyronaridine-artesunate),NA
NCT04700163,2021-01-11,2021-06-15,Interventional,RU Anti-SARS-CoV-2 (COVID-19) mAbs in Healthy Volunteers,"Active, not recruiting",Phase 1,Rockefeller University,NA,https://clinicalzeros.gov/ct2/show/NCT04700163,0,0,0,0,3,1,United States,0,c144-ls/c-135-ls|c144-ls|c-135-ls,NA
NCT04689399,2020-12-26,2021-03-25,Interventional,Sensitivity and Specificity of SARS-CoV-2 Rapid Antigen Test Compared to RT-PCR Test,Completed,N/A,"Rigshospitalet, Denmark",NA,https://clinicalzeros.gov/ct2/show/NCT04689399,0,0,0,0,3,0,Denmark,0,"standard q covid-19 ag - test, produced by sd biosensor inc.",NA
NCT04695652,2020-12-30,2021-06-30,Interventional,A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult,"Active, not recruiting",Phase 2,Medigen Vaccine Biologics Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04695652,0,0,0,1,6,0,Taiwan|Vietnam,0,mvc-cov1901(s protein with adjuvant)|mvc-cov1901(saline),NA
NCT04668339,2021-01-07,2022-04-30,Interventional,A Trial Evaluating the Safety and Effects of an RNA Vaccine ARCT-021 in Healthy Adults,"Active, not recruiting",Phase 2,"Arcturus Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04668339,0,0,0,1,3,1,United States|Singapore,0,"arct-021 single dose priming|arct-021 two lower dose priming|arct-021 two higher dose priming|placebo (two doses), priming|randomized booster|placebo booster",NA
NCT04666012,2020-12-29,2021-03-31,Interventional,Safety and Immunogenicity Study of AdCLD-CoV19: A COVID-19 Preventive Vaccine in Healthy Volunteers,Recruiting,Phase 1/Phase 2,"Cellid Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04666012,0,0,0,1,2,0,"Korea, Republic of",0,adcld-cov19,NA
NCT04661813,2021-03-01,2022-12-31,Interventional,Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV,Recruiting,N/A,Case Western Reserve University,NA,https://clinicalzeros.gov/ct2/show/NCT04661813,0,0,0,0,1,1,United States,0,extra-cvd virtual care,NA
NCT04637477,2020-08-01,2020-12-31,Interventional,Virtual Enhanced Lifestyle for Metabolic Syndrome (ELM) Proof-of-Concept Study,"Active, not recruiting",N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04637477,0,0,0,0,1,1,United States,0,virtual elm,NA
NCT04642638,2020-11-30,2022-09-30,Interventional,"Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Healthy Seronegative Adults at High Risk of SARS-CoV-2 Exposure","Active, not recruiting",Phase 2/Phase 3,Inovio Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04642638,0,0,0,1,6,1,United States,0,ino-4800|cellectraâ® 2000|placebo|cellectraâ® 2000,NA
NCT04591717,2020-10-19,2021-11-19,Interventional,COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral-COVID-19 in Normal Healthy Volunteers,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04591717,0,0,0,1,7,1,United States,0,had5-s-fusion/n-etsd vaccine|had5-s-fusion|n-etsd vaccine,NA
NCT04640402,2020-11-17,2021-02-18,Interventional,A Phase â…¡ Clinical Trial of Recombinant Corona Virus Disease-19 (COVID-19) Vaccine (Sf9 Cells),Recruiting,Phase 2,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04640402,0,0,0,1,1,0,China,0,low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/two dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/two dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)/three dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/two dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/two dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)/three dose regimen|low-dose placebo (18-59 years)/two dose regimen|low-dose placebo (18-59 years)/three dose regimen|high-dose placebo (18-59 years)/two dose regimen|high-dose placebo (18-59 years)/three dose regimen|low-dose placebo (60-85 years)/two dose regimen|low-dose placebo (60-85 years)/three dose regimen|high-dose placebo (60-85 years)/two dose regimen|high-dose placebo (60-85 years)/three dose regimen|low-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)|two dose regimen|three dose regimen|high-dose recombinant covid-19 vaccine (sf9 cells) (18-59 years)|low-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)|high-dose recombinant covid-19 vaccine (sf9 cells) (60-85 years)|low-dose placebo (18-59 years)|high-dose placebo (18-59 years)|low-dose placebo (60-85 years)|high-dose placebo (60-85 years),NA
NCT04631536,2021-01-10,2021-05-31,Interventional,Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC,Recruiting,Phase 3,Lebanese American University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04631536,0,0,0,0,2,0,Lebanon,0,atorvastatin / l-arginine / folic acid / nicorandil / nebivolol|placebo|atorvastatin|l-arginine|folic acid|nicorandil|nebivolol,NA
NCT04606784,2020-10-28,2021-03-18,Interventional,Study of Nebulized Ampion for the Treatment of Adult COVID-19 Patients With Respiratory Distress,"Active, not recruiting",Phase 1,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04606784,0,0,0,0,2,1,United States,0,ampion|standard care,NA
NCT04631705,2020-12-14,2021-07-31,Interventional,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Inhalation,Recruiting,Phase 1/Phase 2,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04631705,0,0,0,0,1,0,Germany,0,dzif-10c|placebo,NA
NCT04631666,2020-12-08,2021-07-31,Interventional,SARS-CoV-2-Neutralizing Monoclonal COVID-19 Antibody DZIF-10c by Infusion,Recruiting,Phase 1/Phase 2,University of Cologne,NA,https://clinicalzeros.gov/ct2/show/NCT04631666,0,0,0,0,1,0,Germany,0,dzif-10c|placebo,NA
NCT04523246,2020-09-01,2021-07-01,Interventional,Training the Innate Immune System Against SARS-CoV-2 (COVID-19) Using the Shingrix Vaccine in Nursing Home Residents,Recruiting,Early Phase 1,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04523246,0,0,0,1,3,1,United States,0,"shingrix (zoster vaccine recombinant, adjuvanted)|saline",NA
NCT04565249,2020-10-22,2021-08-31,Interventional,"Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Acute Respiratory Distress Syndrome (ARDS) Associated With at Least Severe COVID-19",Recruiting,Phase 2,"Pliant Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04565249,0,0,0,0,5,1,United States,0,pln-74809|placebo,NA
NCT04545060,2020-08-27,2021-03-31,Interventional,VIR-7831 for the Early Treatment of COVID-19 in Outpatients,"Active, not recruiting",Phase 2/Phase 3,"Vir Biotechnology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04545060,0,0,0,0,14,1,United States|Austria|Brazil|Canada|Peru|Spain|United Kingdom,0,vir-7831|placebo,NA
NCT04542213,2020-08-01,2021-02-28,Interventional,Dipeptidyl Peptidase-4 Inhibitor (DPP4i) for the Control of Hyperglycemia in Patients With COVID-19,Completed,Phase 3,Hospital Regional de Alta Especialidad del Bajio,NA,https://clinicalzeros.gov/ct2/show/NCT04542213,0,0,0,0,1,0,Mexico,0,linagliptin|insulin,NA
NCT04528329,2020-08-30,2021-04-01,Interventional,Anosmia and / or Ageusia and Early Corticosteroid Use,Recruiting,Phase 4,ClinAmygate,NA,https://clinicalzeros.gov/ct2/show/NCT04528329,0,0,0,0,3,0,Egypt,0,early-dexamethasone|late dexamethazone,NA
NCT04595773,2021-01-22,2023-12-31,Interventional,"COVID-19, Chronic Adaptation and Response to Exercise (COVID-CARE)",Recruiting,Phase 1/Phase 2,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04595773,0,0,0,0,65,1,United States,0,exercise|education,NA
NCT04570202,2020-11-20,2021-08-20,Interventional,Health cAre woRkers exposeD to COVID-19,Recruiting,N/A,"University Hospital, Tours",NA,https://clinicalzeros.gov/ct2/show/NCT04570202,0,0,0,0,3,0,France,0,emdr,NA
NCT04487210,2020-10-07,2021-06-30,Interventional,A Study to Evaluate the Safety and Immunogenicity of MVC-COV1901 Against COVID-19,"Active, not recruiting",Phase 1,Medigen Vaccine Biologics Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04487210,0,0,0,0,4,0,Taiwan,0,mvc-cov1901,NA
NCT04483375,2020-07-24,2020-11-17,Interventional,"Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects",Completed,Phase 1,Sinocelltech Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04483375,0,0,0,0,4,0,China,0,scta01|placebo,NA
NCT04476680,2020-09-01,2021-04-28,Interventional,Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion,Recruiting,N/A,Royal Centre for Defence Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04476680,0,0,0,0,1,0,United Kingdom,0,vitamin d,NA
NCT04466098,2020-07-30,2021-12-01,Interventional,Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19),"Active, not recruiting",Phase 2,"Masonic Cancer Center, University of Minnesota",NA,https://clinicalzeros.gov/ct2/show/NCT04466098,0,0,0,0,3,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04447404,2020-09-21,2021-03-04,Interventional,"DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury",Terminated,Phase 2,Durect,low enrollment,https://clinicalzeros.gov/ct2/show/NCT04447404,0,0,0,0,3,1,United States,0,dur-928|placebo,NA
NCT04441996,2020-07-17,2021-03-18,Interventional,Therapeutic Plasma Exchange for COVID-19-associated Hyperviscosity,Completed,Phase 4,Emory University,NA,https://clinicalzeros.gov/ct2/show/NCT04441996,0,0,0,0,3,1,United States,0,therapeutic plasma exchange (tpe)|standard care,NA
NCT04439045,2020-06-24,2021-09-02,Interventional,Efficacy and Safety of VPM1002 in Reducing SARS-CoV-2 (COVID-19) Infection Rate and Severity,"Active, not recruiting",Phase 3,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04439045,0,0,0,0,4,0,Canada,0,vpm1002|placebo,NA
NCT04418505,2020-09-02,2021-06-01,Interventional,Vielight RX Plus for the Treatment of COVID-19 Respiratory Symptoms,Recruiting,N/A,Vielight Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04418505,0,0,0,0,5,1,United States|Canada,0,vielight rx plus,NA
NCT04400305,2020-05-20,2021-07-31,Interventional,"""Increasing Physical Activity in Canadian Adults Affected by COVID-19 Social Distancing Restrictions: A Feasibility Trial of an Online Intervention""",Recruiting,N/A,University of Victoria,NA,https://clinicalzeros.gov/ct2/show/NCT04400305,0,0,0,0,5,0,Canada,0,digital health online platform,NA
NCT04408183,2020-06-01,2021-08-31,Interventional,GLS-1200 Topical Nasal Spray to Prevent SARS-CoV-2 Infection (COVID-19) in Health Care Personnel,Recruiting,Phase 2,"GeneOne Life Science, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04408183,0,0,0,0,3,1,United States,0,gls-1200|placebo,NA
NCT04397614,2020-07-22,2021-12-31,Interventional,Mobile Health Study and Enhanced Symptom Monitoring in COVID-19 Cancer Patients,Recruiting,Phase 2,University of Oklahoma,NA,https://clinicalzeros.gov/ct2/show/NCT04397614,0,0,0,0,5,1,United States,0,mhealth assessments,NA
NCT04395911,2020-09-10,2021-06-30,Interventional,Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections,Recruiting,N/A,SeaStar Medical,NA,https://clinicalzeros.gov/ct2/show/NCT04395911,0,0,0,0,4,1,United States,0,scd,NA
NCT04406246,2020-05-21,2020-12-31,Interventional,Prevention of Coronavirus Disease (COVID-19) Outbreaks With Nitazoxanide,Completed,Phase 4,Materno-Perinatal Hospital of the State of Mexico,NA,https://clinicalzeros.gov/ct2/show/NCT04406246,0,0,0,0,1,0,Mexico,0,nitazoxanide,NA
NCT04401150,2020-08-14,2021-11-30,Interventional,Lessening Organ Dysfunction With VITamin C - COVID-19,Recruiting,Phase 3,UniversitÃ© de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04401150,0,0,0,0,4,0,Canada,0,vitamin c|control,NA
NCT04389671,2020-11-02,2021-05-31,Interventional,The Safety and Preliminary Tolerability of Lyophilized Lucinactant in Adults With Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,Windtree Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04389671,0,0,0,0,3,1,United States,0,lucinactant,NA
NCT04365439,2020-07-20,2020-12-20,Interventional,Convalescent Plasma for COVID-19,"Active, not recruiting",N/A,"Ente Ospedaliero Cantonale, Bellinzona",NA,https://clinicalzeros.gov/ct2/show/NCT04365439,0,0,0,0,1,0,Switzerland,0,plasma,NA
NCT04349631,2020-04-22,2020-11-24,Interventional,A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19,"Active, not recruiting",Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04349631,0,0,0,0,7,1,United States,0,mesenchymal stem cells,NA
NCT04364737,2020-04-17,2021-03-29,Interventional,CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients,"Active, not recruiting",Phase 2,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04364737,0,0,0,0,11,1,United States,0,convalescent plasma|saline,NA
NCT04362189,2020-06-30,2021-10-31,Interventional,Efficacy and Safety Study of Allogeneic HB-adMSCs for the Treatment of COVID-19,"Active, not recruiting",Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04362189,0,0,0,0,7,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04357457,2020-09-03,2021-07-31,Interventional,Efficacy of Intravenous Almitrine in Reducing the Need for Mechanical Ventilation in Patients With Hypoxemic Acute Respiratory Failure Due to Covid-19-related Pneumonia,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04357457,0,0,0,0,3,0,France,0,almitrine|placebo,NA
NCT04355533,2020-07-29,2022-07-31,Interventional,Immunity Against SARS-CoV2 in Children and Their Parents / COVID-19,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355533,0,0,0,0,6,0,France,0,serology test|nasopharyngeal swab|rectal swab|saliva,NA
NCT04348435,2020-05-14,2021-05-30,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19","Active, not recruiting",Phase 2,Hope Biosciences,NA,https://clinicalzeros.gov/ct2/show/NCT04348435,0,0,0,0,7,1,United States,0,mesenchymal stem cells|placebo,NA
NCT04346927,2020-08-10,2020-10-10,Interventional,Telerehabilitation for Patients Diagnosed With Coronavirus,Completed,N/A,Istinye University,NA,https://clinicalzeros.gov/ct2/show/NCT04346927,0,0,0,0,2,0,Turkey,0,telehealth|exercise,NA
NCT04333472,2021-01-06,2022-03-06,Interventional,Piclidenoson for Treatment of COVID-19,Recruiting,Phase 2,Can-Fite BioPharma,NA,https://clinicalzeros.gov/ct2/show/NCT04333472,0,0,0,0,9,0,Israel,0,piclidenoson|placebo,NA
NCT04317040,2020-04-24,2020-10-20,Interventional,CD24Fc as a Non-antiviral Immunomodulator in COVID-19 Treatment,Completed,Phase 3,"OncoImmune, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04317040,0,0,0,0,12,1,United States,0,cd24fc|placebo,NA
NCT04826822,2021-02-24,2021-07-08,Interventional,Spironolactone and Dexamethasone in Patients Hospitalized With COVID-19,Recruiting,Phase 3,Chita State Regional Clinical Hospital Number 1,NA,https://clinicalzeros.gov/ct2/show/NCT04826822,0,0,0,0,0,0,Russian Federation,0,spironolactone / dexamethasone|standard-of-care sars-cov-2 treatment|spironolactone|dexamethasone,NA
NCT04824638,2021-03-08,2021-08-08,Interventional,BNT162b2 Vaccination With Two Doses in COVID-19 Negative Adult Volunteers and With a Single Dose in COVID-19 Positive Adult Volunteers,Recruiting,Phase 2,"ANRS, Emerging Infectious Diseases",NA,https://clinicalzeros.gov/ct2/show/NCT04824638,0,0,0,1,0,0,France,0,two doses of bnt162b2 vaccine|one dose of bnt162b2 vaccine,NA
NCT04821674,2021-03-15,2022-07-31,Interventional,Study of DS-5670a (COVID-19 Vaccine) in Japanese Healthy Adults and Elderly Subjects,Recruiting,Phase 1/Phase 2,"Daiichi Sankyo, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04821674,0,0,0,1,1,0,Japan,0,ds-5670a|placebo,NA
NCT04824391,2021-02-10,2021-04-30,Interventional,"Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19",Recruiting,Phase 2,Health Institutes of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04824391,0,0,0,1,0,0,Turkey,0,erucov-vac 3 âµg/0.5 ml vaccine|erucov-vac 6 âµg/0.5 ml vaccine|placebo|erucov-vac 3 âµg|0.5 ml vaccine|erucov-vac 6 âµg,NA
NCT04793464,2021-02-04,2021-08-31,Interventional,COVID-19: Healthy Oregon (Oregon Saludable): Together We Can (Juntos Podemos),Recruiting,N/A,University of Oregon,NA,https://clinicalzeros.gov/ct2/show/NCT04793464,0,0,0,0,2,1,United States,0,promotores de salud|services as usual,NA
NCT04845880,2020-10-01,2021-03-01,Interventional,SARS Cov_2 Incidence of Healthy Health Workers,Completed,N/A,Baskent University,NA,https://clinicalzeros.gov/ct2/show/NCT04845880,0,0,0,0,0,0,Turkey,0,spike protein (s)/the nucleocapsid (n) of sars-cov-2|spike protein (s)|the nucleocapsid (n) of sars-cov-2,NA
NCT04729140,2020-12-28,2021-12-28,Interventional,An Outpatient Clinical Trial Using Ivermectin and Doxycycline in COVID-19 Positive Patients at High Risk to Prevent COVID-19 Related Hospitalization,Recruiting,Phase 4,"Max Health, Subsero Health",NA,https://clinicalzeros.gov/ct2/show/NCT04729140,0,0,0,0,2,1,United States,0,ivermectin|doxycycline tablets|placebo,NA
NCT04666233,2021-03-16,2021-03-23,Interventional,Personal Protective Equipment for the Prevention of SARS-Cov-2 During Neonatal Resuscitation,Completed,N/A,University Hospital Padova,NA,https://clinicalzeros.gov/ct2/show/NCT04666233,0,0,0,0,2,0,Italy,0,neonatal resuscitation with ppe for the prevention of sars-cov-2 infection|neonatal resuscitation without ppe for the prevention of sars-cov-2 infection,NA
NCT04619680,2020-11-18,2024-04-30,Interventional,The Study Will Evaluate the Use of Nintedanib in Slowing Lung Fibrosis in Patients With Pulmonary Infiltrates Related to COVID-19,Recruiting,Phase 4,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04619680,0,0,0,0,3,1,United States,0,nintedanib|placebo,NA
NCT04629703,2021-02-22,2021-08-31,Interventional,"Double-Blind, Randomized, Placebo-Controlled, Adaptive Design, Multi-Center Phase 3 Study to Evaluate the Efficacy and Safety of Fostamatinib in COVID-19 Subjects",Recruiting,Phase 3,Rigel Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04629703,0,0,0,0,3,1,Peru|United States|Argentina|Brazil|Mexico,0,fostamatinib|placebo,NA
NCT04609462,2020-08-11,2021-01-13,Interventional,High-Flow Nasal Cannula in Severe COVID-19 With Acute Hypoxemic Respiratory Failure.,Completed,N/A,Fundacion Clinica Valle del Lili,NA,https://clinicalzeros.gov/ct2/show/NCT04609462,0,0,0,0,4,0,Colombia,0,conventional oxygen therapy|high flow nasal cannula,NA
NCT04539821,2020-10-01,2021-04-30,Interventional,Virtual Pain Care Management (COVID-19),Recruiting,N/A,VA Office of Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04539821,0,0,0,0,2,1,United States,0,vcpm,NA
NCT04496245,2020-08-24,2021-06-30,Interventional,Reducing Acute Severe Respiratory Events in Health Care Workers During the Covid-19 Pandemic With OM85,"Active, not recruiting",Phase 3,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04496245,0,0,0,0,2,0,Australia,0,broncho-vaxomâ®|broncho-vaxomâ®,NA
NCT04523090,2020-08-27,2021-12-31,Interventional,Catalysing the Containment of COVID-19,Recruiting,Phase 2/Phase 3,University of Cape Town,NA,https://clinicalzeros.gov/ct2/show/NCT04523090,0,0,0,0,3,0,South Africa,0,nitazoxanide|placebo,NA
NCT04466800,2020-07-30,2021-08-30,Interventional,Functional and Respiratory Rehabilitation and Nutritional Care of COVID-19 Patients (RECOVER-19),Recruiting,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04466800,0,0,0,0,5,0,France,0,intervention group_rehabilitation program,NA
NCT04486313,2020-08-13,2021-02-08,Interventional,Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19,Completed,Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04486313,0,0,0,0,5,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04401410,2020-11-04,2021-08-15,Interventional,Anti-SARS Cov-2 T Cell Infusions for COVID 19,Recruiting,Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04401410,0,0,0,0,4,1,United States,0,dose finding phase (mtd)|partially hla-matched sars-covsts|routine care (no sars-covsts),NA
NCT04382560,2020-05-02,2020-05-31,Interventional,Coping Strategies and Responsiveness to a Brief Online Intervention During COVID-19 Pandemic,Completed,N/A,University of Parma,NA,https://clinicalzeros.gov/ct2/show/NCT04382560,0,0,0,0,2,0,Italy,0,deep breathing training|compassion focused intervention,NA
NCT04381364,2020-05-29,2021-12-01,Interventional,Inhalation of Ciclesonide for Patients With COVID-19: A Randomised Open Treatment Study (HALT COVID-19),Recruiting,Phase 2,St Goran's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04381364,0,0,0,0,3,0,Sweden,0,ciclesonide,NA
NCT04409743,2020-06-07,2021-10-31,Interventional,Brief Telehealth CBT-I Intervention in the Context of the COVID-19 Pandemic,Recruiting,N/A,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04409743,0,0,0,0,4,1,United States,0,remote cognitive behavioral therapy for insomnia,NA
NCT04360096,2021-02-15,2021-08-15,Interventional,Inhaled ZYESAMIâ„¢ (Aviptadil Acetate) for the Treatment of Moderate and Severe COVID-19,Recruiting,Phase 2/Phase 3,"NeuroRx, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04360096,0,0,0,0,7,1,United States,0,zyesamiâ„¢ (aviptadil acetate)|placebo|nebulized administration of zyesamiâ„¢/placebo|zyesamiâ„¢ (aviptadil acetate)|nebulized administration of zyesamiâ„¢,NA
NCT04383002,2020-09-02,2021-08-31,Interventional,High Dose Inhaled Nitric Oxide for COVID-19 (ICU Patients),Recruiting,Phase 1,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04383002,0,0,0,0,4,0,Canada,0,nitric oxide,NA
NCT04343248,2020-05-12,2021-06-30,Interventional,Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF),"Active, not recruiting",Phase 3,Romark Laboratories L.C.,NA,https://clinicalzeros.gov/ct2/show/NCT04343248,0,0,0,0,6,1,United States,0,nitazoxanide|placebo|vitamin super b-complex,NA
NCT04830020,2021-02-26,2021-08-31,Interventional,Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes,Recruiting,Phase 2,Campus Bio-Medico University,NA,https://clinicalzeros.gov/ct2/show/NCT04830020,0,0,0,0,0,0,Italy,0,hmw-ha,NA
NCT04766931,2021-03-27,2021-08-31,Interventional,The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 Infection,Recruiting,Phase 1,Frontier Biotechnologies Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04766931,0,0,0,0,1,1,United States,0,fb2001|fb2001 placebo,NA
NCT04828538,2021-03-01,2021-07-31,Interventional,"Vitamin D, Omega-3, and Combination Vitamins B, C and Zinc Supplementation for the Treatment and Prevention of COVID-19",Recruiting,N/A,Hospital de la Soledad,NA,https://clinicalzeros.gov/ct2/show/NCT04828538,0,0,0,0,0,0,Mexico,0,"vitamin d|omega dha / epa|vitamin c, vitamin b complex/zinc acetate|omega dha|epa|vitamin c, vitamin b complex|zinc acetate",NA
NCT04826367,2021-01-20,2021-12-31,Interventional,Relaxation Training by Tele-Rehabilitation in Patients With Breast Cancer,Recruiting,N/A,Hacettepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04826367,0,0,0,0,1,0,Turkey,0,telerehabilitation-based relaxation exercise group (eg),NA
NCT04678739,2020-08-15,2021-01-30,Interventional,Efficacy and Safety of Remdesivir and Tociluzumab for the Management of Severe COVID-19: A Randomized Controlled Trial,Completed,Phase 3,M Abdur Rahim Medical College and Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04678739,0,0,0,0,3,0,Bangladesh,0,remdesivir|tocilizumab,NA
NCT04401423,2021-02-10,2021-06-30,Interventional,TXA127 for the Treatment of Severe COVID-19,Recruiting,Phase 2,Columbia University,NA,https://clinicalzeros.gov/ct2/show/NCT04401423,0,0,0,0,2,1,United States,0,txa127|placebo,NA
NCT04458298,2020-08-11,2021-05-14,Interventional,A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients,"Active, not recruiting",Phase 2,"Orpheris, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04458298,0,0,0,0,5,1,United States,0,op-101|placebo,NA
NCT04640181,2020-12-01,2021-06-30,Interventional,Factor Xa Inhibitor Versus Standard of Care Heparin in Hospitalized Patients With COVID-19 (XACT),Recruiting,Phase 2,St. David's HealthCare,NA,https://clinicalzeros.gov/ct2/show/NCT04640181,0,0,0,0,1,1,United States,0,enoxaparin|rivaroxaban,NA
NCT04583592,2020-11-09,2021-03-31,Interventional,Camostat Efficacy vs. Placebo for Outpatient Treatment of COVID-19 (CAMELOT),Completed,Phase 2,Sagent Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04583592,0,0,0,0,17,1,United States,0,camostat mesilate|placebo,NA
NCT04358081,2020-05-01,2020-07-27,Interventional,Hydroxychloroquine Monotherapy and in Combination With Azithromycin in Patients With Moderate and Severe COVID-19 Disease,Completed,Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04358081,0,0,0,0,8,1,United States,1,hydroxychloroquine|hydroxychloroquine / azithromycin|placebo|zidovudine,NA
NCT04432298,2020-06-20,2021-03-22,Interventional,"Study of the Efficacy and Safety of Intravenous Pamrevlumab, in Hospitalized Participants With Acute COVID-19 Disease",Terminated,Phase 2,FibroGen,The study was terminated by Sponsor due to low enrollment.,https://clinicalzeros.gov/ct2/show/NCT04432298,0,0,0,0,3,1,United States,0,pamrevlumab|placebo,NA
NCT04830800,2021-03-10,2022-05-30,Interventional,A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC,Recruiting,Phase 1/Phase 2,"Institute of Vaccines and Medical Biologicals, Vietnam",NA,https://clinicalzeros.gov/ct2/show/NCT04830800,0,0,0,1,0,0,Vietnam,0,covivac|phosphate-buffered saline,NA
NCT04830943,2020-08-01,2021-02-28,Interventional,Cerebrolycin for Treatment of Covid-related Anosmia and Ageusia,Completed,Phase 4,Assiut University,NA,https://clinicalzeros.gov/ct2/show/NCT04830943,0,0,0,0,0,0,Egypt,0,cerebrolysin,NA
NCT04799392,2021-04-01,2021-04-30,Interventional,NOWDx Test for the Detection of Antibodies to COVID-19 in Lay Persons,Recruiting,N/A,"NOWDiagnostics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04799392,0,0,0,0,1,1,United States,0,nowdx covid-19 test,NA
NCT04712110,2021-02-24,2022-04-04,Interventional,A Study of TAK-019 in Healthy Japanese Adults (COVID-19),"Active, not recruiting",Phase 1/Phase 2,Takeda,NA,https://clinicalzeros.gov/ct2/show/NCT04712110,0,0,0,0,4,0,Japan,0,tak-019|placebo,NA
NCT04762680,2021-02-24,2022-04-30,Interventional,Study of Recombinant Protein Vaccine With Adjuvant Against COVID-19 in Adults 18 Years of Age and Older,"Active, not recruiting",Phase 2,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04762680,0,0,0,1,4,1,United States|Honduras,0,sars-cov-2 recombinant protein vaccine formulation 1|sars-cov-2 recombinant protein vaccine formulation 2|sars-cov-2 recombinant protein vaccine formulation 3,NA
NCT04690387,2020-12-07,2021-01-13,Interventional,"Dendritic Cell Vaccine, AV-COVID-19, to Prevent COVID-19 Infection",Completed,Phase 1,"Aivita Biomedical, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04690387,0,0,0,1,2,0,Indonesia,0,av-covid-19|gm-csf,NA
NCT04680949,2020-12-23,2021-03-31,Interventional,suPAR-Guided Anakinra Treatment for Management of Severe Respiratory Failure by COVID-19,"Active, not recruiting",Phase 3,Hellenic Institute for the Study of Sepsis,NA,https://clinicalzeros.gov/ct2/show/NCT04680949,0,0,0,0,4,0,Greece|Italy,0,anakinra|placebo,NA
NCT04746430,2021-02-16,2022-02-28,Interventional,COVID-19 Primary Care Platform for Early Treatment and Recovery (COPPER) Study,Recruiting,Phase 4,General Practitioners Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04746430,0,0,0,0,1,0,Netherlands,0,dexamethasone,NA
NCT04710394,2021-01-11,2022-03-11,Interventional,Visual-OLfactory Training in Participants With COVID-19 Resultant Loss of Smell,"Active, not recruiting",N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04710394,0,0,0,0,4,1,United States,0,smell training,NA
NCT04655586,2020-12-10,2021-04-30,Interventional,"Assessing Safety, Hospitalization and Efficacy of rNAPc2 in COVID-19",Recruiting,Phase 2/Phase 3,"ARCA Biopharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04655586,0,0,0,0,6,1,United States,0,rnapc2|heparin,NA
NCT04608266,2020-12-03,2022-01-31,Interventional,CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult Patients,Recruiting,Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04608266,0,0,0,0,3,0,France,0,camostat mesylate|placebo,NA
NCT04527354,2020-09-01,2021-02-10,Interventional,Pilot Study to Assess Efficacy and Safety of Treamid in the Rehabilitation of Patients After COVID-19 Pneumonia,Completed,Phase 2,PHARMENTERPRISES LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04527354,0,0,0,0,3,0,Russian Federation,0,treamid|placebo,NA
NCT04510207,2020-07-16,2021-06-16,Interventional,"A Study to Evaluate The Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) in Healthy Population Aged 18 Years Old and Above",Recruiting,Phase 3,China National Biotec Group Company Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04510207,0,0,0,1,7,0,Bahrain|Egypt|Jordan|United Arab Emirates,0,inactivated sars-cov-2 vaccine|placebo,NA
NCT04511819,2020-08-28,2021-06-30,Interventional,Losmapimod Safety and Efficacy in COVID-19,"Active, not recruiting",Phase 3,Fulcrum Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04511819,0,0,0,0,17,1,United States|Brazil|Mexico|Peru,0,losmapimod|placebo,NA
NCT04488081,2020-07-31,2022-07-24,Interventional,I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients,Recruiting,Phase 2,QuantumLeap Healthcare Collaborative,NA,https://clinicalzeros.gov/ct2/show/NCT04488081,0,0,0,0,4,1,United States,0,remdesivir|cenicriviroc|icatibant|pulmozyme|ic14|celecoxib famotidine|narsoplimab,NA
NCT04351243,2020-04-12,2020-12-01,Interventional,A Study to Assess the Efficacy and Safety of Gimsilumab in Subjects With Lung Injury or Acute Respiratory Distress Syndrome Secondary to COVID-19 (BREATHE),Completed,Phase 2,Kinevant Sciences GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04351243,0,0,0,0,12,1,United States,0,gimsilumab|placebo,NA
NCT04481685,2020-07-20,2021-02-25,Interventional,"A Trial of Aclaris Therapeutics, Inc. (ATI)-450 in Patients With Moderate-severe Novel Coronavirus Disease 2019 (COVID-19)","Active, not recruiting",Phase 2,University of Kansas Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04481685,0,0,0,0,3,1,United States,0,ati-450|placebo,NA
NCT04834115,2020-11-17,2021-04-30,Interventional,Efficacy of Ivermectin in Outpatients With Non-severe COVID-19,Recruiting,Phase 3,Universidad Nacional de AsunciÃ³n,NA,https://clinicalzeros.gov/ct2/show/NCT04834115,0,0,0,0,0,0,Paraguay,0,ivermectin|placebo,NA
NCT04371393,2020-04-30,2021-01-14,Interventional,MSCs in COVID-19 ARDS,"Active, not recruiting",Phase 3,Icahn School of Medicine at Mount Sinai,NA,https://clinicalzeros.gov/ct2/show/NCT04371393,0,0,0,0,18,1,United States,0,remestemcel-l|placebo,NA
NCT04355234,2020-05-04,2021-08-31,Interventional,"Prevalence and Impact of COVID-19 Infection in Pregnant Women, Fetuses and Newborns","Active, not recruiting",N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04355234,0,0,0,0,3,0,France,0,serology test|biological samples,NA
NCT04828668,2021-04-02,2021-10-31,Interventional,Study to Evaluate Benefits & Safety of Endourage Formula Câ„¢ Oral Drops in People With Post-Acute COVID-19 Syndrome.,Recruiting,N/A,"Endourage, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04828668,0,0,0,0,2,1,United States,0,targeted wellness formula câ„¢ sublingual drops - 1200mg - 30 ml (formula c)|targeted wellness formula câ„¢ sublingual drops - 1200mg - 30 ml (formula c),NA
NCT04710199,2021-02-08,2021-08-31,Interventional,Trial to Evaluate the Safety and Efficacy of Maraviroc in Patients Hospitalized for Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,FundaciÃ³n PÃºblica Andaluza para la gestiÃ³n de la InvestigaciÃ³n en Sevilla,NA,https://clinicalzeros.gov/ct2/show/NCT04710199,0,0,0,0,1,0,Spain,0,maraviroc experimental group|standard care,NA
NCT04818320,2021-02-16,2021-08-31,Interventional,Favipiravir in High-risk COVID-19 Patients,Recruiting,Phase 3,"Penang Hospital, Malaysia",NA,https://clinicalzeros.gov/ct2/show/NCT04818320,0,0,0,0,2,0,Malaysia,0,favipiravir,NA
NCT04679493,2020-12-24,2021-04-30,Interventional,"Study to Assess Safety, Tolerability and Pharmacokinetics of XC7 (Which is Planned Use in the Treatment of COVID-19) in Healthy Volunteers","Active, not recruiting",Phase 1,NP Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04679493,0,0,0,0,1,0,Russian Federation,0,xc7 100 mg single|xc7 200 mg single|placebo single|xc7 200 mg multiple|placebo multiple,NA
NCT04668209,2021-01-01,2021-09-30,Interventional,Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,University of Arizona,NA,https://clinicalzeros.gov/ct2/show/NCT04668209,0,0,0,0,2,1,United States,0,silmitasertib,NA
NCT04537806,2020-12-18,2021-10-31,Interventional,A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19,Recruiting,Phase 3,Sage Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04537806,0,0,0,0,3,1,United States,0,brexanolone|placebo,NA
NCT04505761,2020-08-01,2021-02-01,Interventional,"The Usability, Feasibility, and Tolerability of Virtual Reality for Rehabilitation From COVID-19",Completed,N/A,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04505761,0,0,0,0,2,0,Netherlands,0,virtual reality,NA
NCT04536298,2020-12-28,2021-06-30,Interventional,Vitamin D and COVID-19 Trial,Recruiting,Phase 3,Brigham and Women's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04536298,0,0,0,0,3,1,United States,0,vitamin d|placebo,NA
NCT04836351,2021-03-01,2023-12-30,Interventional,Rehabilitation for Patients With Persistent Symptoms Post COVID-19,Recruiting,N/A,Western Norway University of Applied Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04836351,0,0,0,0,0,0,Norway,0,concentrated rehabilitation for patients with persistent symptoms post covid-19,NA
NCT04428021,2020-06-15,2021-03-31,Interventional,Standard or Convalescent Plasma in Patients With Recent Onset of COVID-19 Respiratory Failure,"Active, not recruiting",Phase 2,Azienda Ospedaliera CittÃ  della Salute e della Scienza di Torino,NA,https://clinicalzeros.gov/ct2/show/NCT04428021,0,0,0,0,2,0,Italy,0,standard therapy protocol (stp)|stp / standard plasma (sp)|stp / covid-19 convalescent plasma (cp)|stp|plasma|covid-19 convalescent plasma (cp),NA
NCT04426695,2020-06-11,2021-04-16,Interventional,"Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for Hospitalized Adult Patients With COVID-19",Recruiting,Phase 1/Phase 2,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04426695,0,0,0,0,19,1,"United States|Brazil|Chile|Mexico|Moldova, Republic of|Romania",0,regn10933/regn10987 combination therapy|placebo|regn10933|regn10987,NA
NCT04356833,2020-04-22,2021-04-30,Interventional,Nebulised Rt-PA for ARDS Due to COVID-19,Recruiting,Phase 2,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04356833,0,0,0,0,2,0,United Kingdom,0,nebulised recombinant tissue-plasminogen activator (rt-pa) - cohort 1|nebulised recombinant tissue-plasminogen activator (rt-pa) - cohort 2 imv|nebulised recombinant tissue-plasminogen activator (rt-pa) - cohort 2 niv,NA
NCT04476992,2020-07-24,2021-07-17,Interventional,Nitric Oxide Therapy for COVID-19 Patients With Oxygen Requirement,"Active, not recruiting",Phase 1/Phase 2,Tomsk National Research Medical Center of the Russian Academy of Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04476992,0,0,0,0,4,0,Russian Federation,0,nitric oxide|sessions,NA
NCT04836260,2021-04-08,2021-12-31,Interventional,Preemptive Use of Convalescent Plasma for High-risk Patients With COVID-19,Recruiting,Phase 3,"University Hospital, Geneva",NA,https://clinicalzeros.gov/ct2/show/NCT04836260,0,0,0,0,0,0,Switzerland,0,convalescent plasma,NA
NCT04839315,2021-02-15,2021-12-31,Interventional,COVID-19 Vaccination in Rheumatic Disease Patients,Recruiting,Early Phase 1,Mayo Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04839315,0,0,0,1,0,1,United States,0,mrna covd19 vaccine,NA
NCT04836052,2020-12-24,2021-08-24,Interventional,Omega-3 Oil Use in COVID-19 Patients in Qatar,Recruiting,Phase 3,Hamad Medical Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04836052,0,0,0,0,0,0,Qatar,0,omega 3 fatty acid,NA
NCT04834739,2021-01-04,2021-03-28,Interventional,Comparison of Functional Capacities of Healthcare Workers With and Without Covid-19,Recruiting,N/A,Gaziosmanpasa Research and Education Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04834739,0,0,0,0,0,0,Turkey,0,6 minute walk test|1 minute sit to stand test|fatigue severity scale|medical research council (mrc) dyspnea scale|sf-12|beck depression inventory|beck anxiety inventory|5 times sit to stand test|6 point likert scale,NA
NCT04834856,2021-04-01,2021-10-31,Interventional,"Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 Patients",Recruiting,Phase 2,Molecular Partners AG,NA,https://clinicalzeros.gov/ct2/show/NCT04834856,0,0,0,0,0,0,Netherlands,0,ensovibep,NA
NCT04808921,2021-01-09,2021-01-18,Interventional,Performance Evaluation of SARS-COV-2 (Covid-19) Antigen Rapid Test,Completed,N/A,"Sky Medical Supplies & Equipments, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04808921,0,0,0,0,2,1,United States,0,"xiamen wiz biotech co., ltd. sars-cov-2 antigen rapid test",NA
NCT04824443,2021-03-29,2023-03-29,Interventional,Exercise Therapy in Cancer Patients Who Are Recovering From COVID-19,Recruiting,Phase 1,Memorial Sloan Kettering Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04824443,0,0,0,0,1,1,United States,0,aerobic exercise therapy,NA
NCT04818281,2021-03-27,2022-01-31,Interventional,Study of a Severe Acute Respiratory Syndrome CoV-2 (SARS-CoV-2) Virus-like Particle (VLP) Vaccine in Healthy Adults,Recruiting,Phase 1,The Scientific and Technological Research Council of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04818281,0,0,0,1,2,0,Turkey,0,sars-cov-2 vlp vaccine|placebo,NA
NCT04798053,2021-04-08,2022-10-31,Interventional,Impact of COVID-19 Pandemic and Social Distancing on Mental Health of Chronic Inflammatory Rheumatism Affected Patients,Recruiting,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04798053,0,0,0,0,1,0,France,0,questionnaire|blood sample/salivary sample|blood sample|salivary sample,NA
NCT04789499,2021-03-15,2021-07-31,Interventional,Smell in Covid-19 and Efficacy of Nasal Theophylline,Recruiting,Phase 2,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04789499,0,0,0,0,1,1,United States,0,theophylline powder,NA
NCT04796402,2021-03-17,2021-06-30,Interventional,A Study to Assess if a Medicine Called Bamlanivimab is Safe and Effective in Reducing Hospitalization Due to COVID-19,Recruiting,Phase 4,Fraser Health,NA,https://clinicalzeros.gov/ct2/show/NCT04796402,0,0,0,0,2,0,Canada,0,bamlanivimab|standard care,NA
NCT04800939,2021-04-05,2021-06-22,Interventional,The Effect of Acupressure on the Sleep Quality and Daytime Sleepiness,Recruiting,N/A,Mersin University,NA,https://clinicalzeros.gov/ct2/show/NCT04800939,0,0,0,0,2,0,Turkey,0,acupressure|plasebo acupressure,NA
NCT04747821,2021-02-07,2021-05-31,Interventional,An Effectiveness Study of the Sinovac's Adsorbed COVID-19 (Inactivated) Vaccine,"Active, not recruiting",Phase 4,Butantan Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04747821,0,0,0,1,1,0,Brazil,0,adsorbed covid-19 (inactivated) vaccine,NA
NCT04716426,2021-01-28,2021-03-25,Interventional,APTâ„¢ T3X on the COVID-19 Contamination Rate,Completed,N/A,University of Nove de Julho,NA,https://clinicalzeros.gov/ct2/show/NCT04716426,0,0,0,0,4,0,Brazil,1,tetracycline hydrochloride 3%|placebo,NA
NCT04734561,2021-02-08,2022-07-30,Interventional,Effects of Respiratory Muscle Training in People Who Have Had COVID-19 Disease,Recruiting,N/A,Universidad Complutense de Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04734561,0,0,0,0,1,0,Spain,0,inspiratory muscle training group|inspiratory muscle training placebo group|inspiratory / expiratory muscle training group|inspiratory / expiratory muscle training placebo group|inspiratory|expiratory muscle training group|expiratory muscle training placebo group,NA
NCT04709835,2021-02-03,2021-06-03,Interventional,Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19,Recruiting,Phase 2,Hoffmann-La Roche,NA,https://clinicalzeros.gov/ct2/show/NCT04709835,0,0,0,0,3,1,United States|Bulgaria|Canada|Greece|Ireland|Latvia|Poland|Spain|United Kingdom,0,at-527|placebo,NA
NCT04718220,2021-03-01,2022-11-30,Interventional,"Safety, Testing/Transmission, and Outcomes in Pregnancies With COVID-19",Recruiting,N/A,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04718220,0,0,0,0,1,1,United States,0,antibody testing for sars-cov-2 igg|testing for sars-cov-2 rna|testing for sars-cov-2 igm/igg|testing for sars-cov-2 igm|igg,NA
NCT04672564,2021-03-30,2021-06-30,Interventional,Study to Evaluate Safety and Efficacy of Carrimycin for Treatment of Severe Coronavirus Disease 2019 (COVID-19) in Hospitalized Patients,Recruiting,Phase 3,"Shenyang Tonglian Group CO., Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04672564,0,0,0,0,3,1,United States|Argentina|Brazil|Colombia|India|Mexico|Peru|Philippines|Ukraine,0,carrimycin|placebo,NA
NCT04655625,2020-11-23,2021-04-02,Interventional,Phase II / III Study of COVID-19 DNA Vaccine (AG0302-COVID19),"Active, not recruiting",Phase 2/Phase 3,"AnGes, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04655625,0,0,0,1,2,0,Japan,0,group a (ag0302-covid19)|group a (placebo)|group b (ag0302-covid19)|group b (placebo),NA
NCT04625725,2020-11-21,2021-04-21,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.","Active, not recruiting",Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04625725,0,0,0,0,4,1,United States|Belgium|France|Spain|United Kingdom,0,azd7442|placebo,NA
NCT04625985,2020-07-14,2021-03-08,Interventional,"Metformin Glycinate, Treatment of Patients With COVID-19 and Severe Acute Respiratory Syndrome Secondary to SARS-CoV-2.",Completed,Phase 2,Laboratorios Silanes S.A. de C.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04625985,0,0,0,0,1,0,Mexico,0,metformin glycinate|placebo,NA
NCT04621071,2021-01-12,2021-06-30,Interventional,Efficacy of Probiotics in Reducing Duration and Symptoms of COVID-19,Recruiting,N/A,Centre de recherche du Centre hospitalier universitaire de Sherbrooke,NA,https://clinicalzeros.gov/ct2/show/NCT04621071,0,0,0,0,4,0,Canada,0,probiotics (2 strains 10x10^9 ufc)|placebo (potato starch/magnesium stearate)|placebo (potato starch|magnesium stearate),NA
NCT04594343,2020-11-20,2021-07-20,Interventional,Clinical Study to Evaluate the Effects of Disulfiram in Patients With Moderate COVID-19,Recruiting,Phase 2,ETICA,NA,https://clinicalzeros.gov/ct2/show/NCT04594343,0,0,0,0,3,0,Brazil,0,disulfiram|placebo,NA
NCT04598594,2020-11-06,2021-04-30,Interventional,Evaluation of the Efficacy of Nicotine Patches in SARS-CoV2 (COVID-19) Infection in Intensive Care Unit Patients,"Active, not recruiting",Phase 3,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04598594,0,0,0,0,7,0,France,0,"patch, nicotine|patch, placebo",NA
NCT04590547,2021-04-30,2021-10-31,Interventional,GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,"GeneOne Life Science, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04590547,0,0,0,0,3,1,United States,0,gls-1027|placebo,NA
NCT04558125,2020-09-08,2021-12-31,Interventional,Low-Dose Tenecteplase in Covid-19 Diagnosed With Pulmonary Embolism,Recruiting,Phase 4,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04558125,0,0,0,0,2,1,United States,0,tnkase,NA
NCT04563702,2020-09-21,2021-05-10,Interventional,Safety and Immunogenicity Trial of an Oral SARS-CoV-2 Vaccine (VXA-CoV2-1) for Prevention of COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1,Vaxart,NA,https://clinicalzeros.gov/ct2/show/NCT04563702,0,0,0,1,3,1,United States,0,vxa-cov2-1,NA
NCT04539262,2020-09-14,2021-02-26,Interventional,"Study in Participants With Early Stage Coronavirus Disease 2019 (COVID-19) to Evaluate the Safety, Efficacy, and Pharmacokinetics of Remdesivir Administered by Inhalation",Completed,Phase 1/Phase 2,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04539262,0,0,0,0,9,1,United States,0,remdesivir|placebo,NA
NCT04507256,2020-08-18,2021-10-25,Interventional,AZD7442 - a Potential Combination Therapy for the Prevention and Treatment of COVID-19,"Active, not recruiting",Phase 1,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04507256,0,0,0,0,5,0,United Kingdom,0,azd7442|placebo,NA
NCT04488796,2020-09-07,2020-12-16,Interventional,STAND UP to SARS-CoV-2 (COVID-19): Using Behavioural Economics to Reduce Sedentary Behaviour in At-home Office Workers,Completed,N/A,"Western University, Canada",NA,https://clinicalzeros.gov/ct2/show/NCT04488796,0,0,0,0,5,0,Canada,0,assigned strategies: opt-in|assigned strategies: active choice|assigned strategies: enhanced active choice|choice of assignment: opt-in|choice of assignment: active choice|choice of assignment: enhanced active choice,NA
NCT04478019,2020-07-07,2022-04-30,Interventional,SHIELD Study: Using Naso-oropharyngeal Antiseptic Decolonization to Reduce COVID-19 Viral Shedding,Recruiting,Early Phase 1,"University of Wisconsin, Madison",NA,https://clinicalzeros.gov/ct2/show/NCT04478019,0,0,0,0,3,1,United States,0,povidone-iodine|0.12% chg oral rinse,NA
NCT04477993,2020-08-14,2021-03-29,Interventional,Ruxolitinib for Acute Respiratory Disorder Syndrome Due to COVID-19,Terminated,Phase 2/Phase 3,University of Sao Paulo General Hospital,Low accrual,https://clinicalzeros.gov/ct2/show/NCT04477993,0,0,0,0,1,0,Brazil,0,ruxolitinib|placebo,NA
NCT04429529,2020-06-09,2020-11-19,Interventional,"Safety of TY027, a Treatment for COVID-19, in Humans",Completed,Phase 1,Tychan Pte Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04429529,0,0,0,0,2,0,Singapore,0,ty027|saline,NA
NCT04439071,2020-07-09,2021-07-31,Interventional,A Study to Evaluate Efficacy and Safety of PTC299 in Hospitalized Participants With Coronavirus (COVID-19),Recruiting,Phase 2/Phase 3,PTC Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04439071,0,0,0,0,5,1,United States|Australia|Belgium|Brazil|Mexico|Portugal|Spain,0,ptc299|standard care|placebo,NA
NCT04280224,2020-02-15,2021-12-30,Interventional,NK Cells Treatment for COVID-19,Recruiting,Phase 1,Xinxiang medical university,NA,https://clinicalzeros.gov/ct2/show/NCT04280224,0,0,0,0,2,0,China,0,nk cells,NA
NCT04405986,2020-05-19,2021-03-10,Interventional,Exploring Brain Damages After COVID-19 Infection,Completed,N/A,"University Hospital, Bordeaux",NA,https://clinicalzeros.gov/ct2/show/NCT04405986,0,0,0,0,3,0,France,0,auditory evoked potentials (aep)|blink/masseter inhibitory reflex|blink|masseter inhibitory reflex,NA
NCT04402944,2020-07-05,2021-05-31,Interventional,Pulmozyme to Improve COVID-19 ARDS Outcomes,Recruiting,Phase 2,Boston Children's Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04402944,0,0,0,0,3,1,United States,0,pulmozyme|placebo,NA
NCT04373460,2020-06-03,2022-12-21,Interventional,Convalescent Plasma to Limit SARS-CoV-2 Associated Complications,Recruiting,Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04373460,0,0,0,0,23,1,United States,0,convalescent plasma|plasma,NA
NCT04390139,2020-05-13,2021-10-31,Interventional,Efficacy and Safety Evaluation of Mesenchymal Stem Cells for the Treatment of Patients With Respiratory Distress Due to COVID-19,Recruiting,Phase 1/Phase 2,Banc de Sang i Teixits,NA,https://clinicalzeros.gov/ct2/show/NCT04390139,0,0,0,0,1,0,Spain,0,xcel-umc-beta|placebo,NA
NCT04357444,2020-10-23,2020-11-02,Interventional,Low Dose of IL-2 In Acute Respiratory DistrEss Syndrome Related to COVID-19,"Active, not recruiting",Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04357444,0,0,0,0,3,0,France,0,human recombinant interleukin 2|placebo,NA
NCT04329195,2020-04-09,2020-12-09,Interventional,ACE Inhibitors or ARBs Discontinuation in Context of COVID-19 Pandemic,Terminated,Phase 3,Assistance Publique - HÃ´pitaux de Paris,insufficient recrutment,https://clinicalzeros.gov/ct2/show/NCT04329195,0,0,0,0,4,0,France,0,discontinuation of ras blocker|continuation of ras blocker,NA
NCT04334512,2020-06-22,2021-06-30,Interventional,A Study of Quintuple Therapy to Treat COVID-19 Infection,Recruiting,Phase 2,ProgenaBiome,NA,https://clinicalzeros.gov/ct2/show/NCT04334512,0,0,0,0,5,1,United States,0,hydroxychloroquine|azithromycin|vitamin c|vitamin d|zinc,NA
NCT04323800,2020-06-10,2022-12-31,Interventional,Convalescent Plasma to Stem Coronavirus (CSSC-001),"Active, not recruiting",Phase 2,Johns Hopkins University,NA,https://clinicalzeros.gov/ct2/show/NCT04323800,0,0,0,0,21,1,United States,0,convalescent plasma|plasma,NA
NCT04841759,2021-04-01,2021-09-30,Interventional,The Effects of a Multi-factorial Rehabilitation Program for Healthcare Workers Suffering From Post-COVID-19 Fatigue Syndrome,Recruiting,N/A,Medical University of Vienna,NA,https://clinicalzeros.gov/ct2/show/NCT04841759,0,0,0,0,0,0,Austria,0,exercise,NA
NCT04275245,2020-02-03,2020-03-09,Interventional,Clinical Study of Anti-CD147 Humanized Meplazumab for Injection to Treat With 2019-nCoV Pneumonia,Completed,Phase 1/Phase 2,Tang-Du Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04275245,0,0,0,0,1,0,China,0,meplazumab,NA
NCT04800133,2021-04-30,2025-03-31,Interventional,Covid-19 Vaccination in Adolescents,Recruiting,Phase 2,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04800133,0,0,0,1,1,0,China,0,tozinameran|oxford-astrazeneca covid-19 vaccine|coronavac,NA
NCT04830761,2021-03-26,2022-04-01,Interventional,Behavior Change in Context to Contain the Spread of COVID-19,Recruiting,N/A,University of Bern,NA,https://clinicalzeros.gov/ct2/show/NCT04830761,0,0,0,0,1,0,Switzerland,0,motivation|habit|social,NA
NCT04840459,2020-11-20,2021-12-31,Interventional,Use of Monoclonal Antibodies for the Treatment of Mild to Moderate COVID-19 in Non-Hospitalized Setting,Recruiting,Phase 2,DHR Health Institute for Research and Development,NA,https://clinicalzeros.gov/ct2/show/NCT04840459,0,0,0,0,0,1,United States,0,bamlanivimab|casirivimab|imdevimab,NA
NCT04816669,2021-04-01,2021-05-30,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Lyophilized Formulation of BNT162b2 Against COVID-19 in Healthy Adults",Recruiting,Phase 3,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04816669,0,0,0,1,1,1,United States,0,bnt162b2,NA
NCT04794036,2021-04-05,2021-06-30,Interventional,Efficacy of an Asynchronous Telerehabilitation Programme in Post-COVID-19 Patient,Recruiting,N/A,Universidad San Jorge,NA,https://clinicalzeros.gov/ct2/show/NCT04794036,0,0,0,0,2,0,Spain,0,asynchronous telerehabilitation programme|rehabilitation programme,NA
NCT04581915,2020-09-08,2021-12-31,Interventional,PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19,Recruiting,Phase 2/Phase 3,Wits Health Consortium (Pty) Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04581915,0,0,0,0,2,0,South Africa,0,triazavirin (riamilovir)|placebo,NA
NCT04732468,2021-02-24,2022-04-30,Interventional,COVID-19 Oral and Subcutaneous Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenovirus Platform in Healthy Volunteers in USA,Recruiting,Phase 1,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04732468,0,0,0,1,2,1,United States,0,had5-s-fusion/n-etsd (suspension for injection)|had5-sfusion/ n-etsd (oral capsule)|had5-s-fusion|n-etsd (suspension for injection)|had5-sfusion|n-etsd (oral capsule),NA
NCT04720235,2020-12-09,2021-03-09,Interventional,A Follow On Community Testing Study To Evaluate The Performance of the Lucira COVID-19 All-In-One Test Kit,Completed,N/A,Lucira Health Inc,NA,https://clinicalzeros.gov/ct2/show/NCT04720235,0,0,0,0,1,1,United States,0,lucira covid-19 all-in-one test kit,NA
NCT04644185,2021-03-27,2021-06-27,Interventional,The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19,Recruiting,Phase 2/Phase 3,Sinocelltech Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04644185,0,0,0,0,4,1,United States|Argentina|Brazil|Chile|Colombia|Mexico|Peru,0,scta01|placebo,NA
NCT04771351,2021-04-30,2021-08-31,Interventional,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Hospitalized Adults With COVID-19,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04771351,0,0,0,0,1,1,United States,0,covi-amg|placebo,NA
NCT04748783,2021-03-26,2021-04-07,Interventional,Antiviral Efficacy and Acceptability of Mouth Rinses for Inactivation of COVID-19,Terminated,Phase 2,"University of North Carolina, Chapel Hill",Funding withdrawn,https://clinicalzeros.gov/ct2/show/NCT04748783,0,0,0,0,2,1,United States,0,water|peroxyl|periogard|colgate total zero,NA
NCT04482699,2020-12-30,2021-12-30,Interventional,RAPA-501-Allo Therapy of COVID-19-ARDS,Recruiting,Phase 1/Phase 2,Rapa Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04482699,0,0,0,0,9,1,United States,0,rapa-501-allo off-the-shelf therapy of covid-19|placebo,NA
NCT04440007,2020-10-09,2021-05-05,Interventional,Study of the Efficacy and Safety of STI-5656 (Abivertinib Maleate) in Subjects Hospitalized With COVID-19,"Active, not recruiting",Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04440007,0,0,0,0,7,1,United States,0,abivertinib|standard care,NA
NCT04359875,2020-04-30,2020-06-30,Interventional,A Phone-call With a Student/General Practitioner Team to Impact Morbidity of Chronic Patients During COVID-19 Containment,Completed,N/A,"University Hospital, Tours",NA,https://clinicalzeros.gov/ct2/show/NCT04359875,0,0,0,0,1,0,France,0,phone-call screening/management by a medical student/general practitioner tandem|phone-call screening|management by a medical student|general practitioner tandem,NA
NCT04842734,2021-03-27,2021-06-27,Interventional,Comparison of the Effect of Online Physical Exercise and Computerized Cognitive Stimulation in Patients With Alzheimer's Disease During the Covid-19 Pandemic,"Active, not recruiting",N/A,Yeditepe University,NA,https://clinicalzeros.gov/ct2/show/NCT04842734,0,0,0,0,0,0,Turkey,0,exercise|physical exercise/computerized cognitive training|computerized cognitive training,NA
NCT04397757,2020-05-13,2021-02-05,Interventional,COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04397757,0,0,0,0,7,1,United States,0,convalescent plasma,NA
NCT04842708,2020-12-24,2021-10-24,Interventional,Evaluation of Anti-COVID 19 Pfizer Vaccination Effect on COVID 19 Detection Using Breath Analysis,Recruiting,N/A,Scentech Medical Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04842708,0,0,0,1,0,0,Israel,0,vaccination against covid19,NA
NCT04842331,2021-04-30,2022-01-31,Interventional,PREvent Viral Exposure aNd Transmission Study: a SARS-CoV-2 PEP Study (PREVENT),Recruiting,Phase 2/Phase 3,Thirty Respiratory Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04842331,0,0,0,0,0,0,United Kingdom,0,"resp301, a nitric oxide generating solution",NA
NCT04842292,2021-04-12,2022-02-28,Interventional,Nebulized Heparin for COVID19-associated Acute Respiratory Failure,Recruiting,Phase 2,University of Kentucky,NA,https://clinicalzeros.gov/ct2/show/NCT04842292,0,0,0,0,0,1,United States,0,heparin|placebo,NA
NCT04573764,2021-02-01,2021-10-01,Interventional,Acute Effects of Oral Ketone Ester on Cardiac Function in Patients With COVID-19,Recruiting,N/A,Steno Diabetes Center Copenhagen,NA,https://clinicalzeros.gov/ct2/show/NCT04573764,0,0,0,0,3,0,Denmark,0,"d-beta-hydroxybutyrate-(r)-1,3 butanediol monoester|placebo",NA
NCT04838080,2021-03-19,2021-06-01,Interventional,Safety and Immunogenicity of the Inactivated KoÃ§ak-19 Inaktif AdjuvanlÄ± COVID-19 Vaccine Compared to Placebo,Recruiting,Phase 1,Kocak Farma,NA,https://clinicalzeros.gov/ct2/show/NCT04838080,0,0,0,1,1,0,Turkey,0,koã§ak-19 inaktif adjuvanlä± covid-19 vaccine 4 âµg/0.5 ml vaccine|koã§ak-19 inaktif adjuvanlä± covid-19 vaccine 6 âµg/0.5 ml vaccine|placebo|koã§ak-19 inaktif adjuvanlä± covid-19 vaccine 4 âµg|0.5 ml vaccine|koã§ak-19 inaktif adjuvanlä± covid-19 vaccine 6 âµg,NA
NCT04816019,2021-04-01,2021-10-31,Interventional,A Study of Intranasal ChAdOx1 nCOV-19,Enrolling by invitation,Phase 1,University of Oxford,NA,https://clinicalzeros.gov/ct2/show/NCT04816019,0,0,0,1,2,0,United Kingdom,0,chadox1,NA
NCT04662086,2021-04-30,2022-03-31,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Master Protocol,Enrolling by invitation,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04662086,0,0,0,0,3,1,United States,0,acebilustat|camostat,NA
NCT04746183,2020-07-03,2021-11-18,Interventional,AGILE (Early Phase Platform Trial for COVID-19),Recruiting,Phase 1/Phase 2,University of Liverpool,NA,https://clinicalzeros.gov/ct2/show/NCT04746183,0,0,0,0,1,0,United Kingdom,0,cst-2: eidd-2801|cst-2: placebo|nitazoxanide|vir-7832|vir-7831|cst-5: placebo,NA
NCT04734860,2021-04-30,2021-09-30,Interventional,Study to Evaluate a Single Dose of STI-2020 (COVI-AMGâ„¢) in Adults With Mild COVID-19 Symptoms,Recruiting,Phase 2,"Sorrento Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04734860,0,0,0,0,1,1,United States,0,covi-amg|placebo,NA
NCT04685447,2020-03-16,2020-04-20,Interventional,Effects of Different Dialysis Strategies on Inflammation in COVID-19 Maintenance Hemodialysis Patients,Recruiting,N/A,Universita degli Studi di Genova,NA,https://clinicalzeros.gov/ct2/show/NCT04685447,0,0,0,0,2,0,Italy,0,expanded hemodialysis for covid19 maintenance hemodialysis patients|hemodialysis by protein-leaking dialyzer for covid19 maintenance hemodialysis patients,NA
NCT04662073,2021-04-30,2022-03-31,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Camostat Sub-Protocol,Enrolling by invitation,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04662073,0,0,0,0,2,1,United States,0,placebo|camostat,NA
NCT04662060,2021-04-30,2022-03-31,Interventional,COVID-19 Outpatient Pragmatic Platform Study (COPPS) - Acebilustat Sub-Protocol,Enrolling by invitation,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04662060,0,0,0,0,2,1,United States,0,acebilustat|placebo,NA
NCT04602871,2020-07-03,2021-01-30,Interventional,Early Detection of COVID-19 Using Breath Analysis - Feasibility Study,Completed,N/A,Scentech Medical Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04602871,0,0,0,0,1,0,Israel,0,breath biopsy,NA
NCT04522830,2020-07-30,2021-02-28,Interventional,A Study in Adults to Test the Effects of Low Dose Thimerosal on Symptoms of COVID-19,Completed,Phase 2,"Beech Tree Labs, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04522830,0,0,0,0,9,1,United States,0,btl-tml-covid|placebo,NA
NCT04473690,2020-12-30,2021-05-06,Interventional,KBP-201 COVID-19 Vaccine Trial in Healthy Volunteers,Recruiting,Phase 1/Phase 2,"Kentucky BioProcessing, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04473690,0,0,0,1,14,1,United States,0,low dose of kbp-covid-19|high dose of kbp-covid-19|placebo,NA
NCT04516746,2020-08-28,2021-03-05,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD1222 for the Prevention of COVID-19 in Adults","Active, not recruiting",Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04516746,0,0,0,1,7,1,United States|Argentina|Chile|Colombia|France|Peru,0,azd1222|placebo,NA
NCT04498273,2020-09-07,2021-09-30,Interventional,COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80,Recruiting,Phase 3,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04498273,0,0,0,0,3,1,United States,0,apixaban 2.5 mg|apixaban 5mg|aspirin|placebo,NA
NCT04497298,2020-08-10,2021-06-30,Interventional,Clinical Trial to Evaluate the Safety and Immunogenicity of the COVID-19 Vaccine,"Active, not recruiting",Phase 1,Institut Pasteur,NA,https://clinicalzeros.gov/ct2/show/NCT04497298,0,0,0,1,6,0,Belgium|France,0,two covid-19 vaccine candidate (tmv-083) administrations - low dose|two covid-19 vaccine candidate (tmv-083) administrations - high dose|one covid-19 vaccine candidate (tmv-083) administration - high dose|placebo,NA
NCT04442048,2020-06-25,2021-12-31,Interventional,Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure,Recruiting,Phase 3,Canadian Cancer Trials Group,NA,https://clinicalzeros.gov/ct2/show/NCT04442048,0,0,0,0,11,0,Canada,0,imm-101|observation,NA
NCT04367077,2020-04-28,2023-01-31,Interventional,MultiStem Administration for COVID-19 Induced ARDS (MACoVIA),Recruiting,Phase 2/Phase 3,"Athersys, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04367077,0,0,0,0,6,1,United States,0,multistem|placebo,NA
NCT04341415,2020-04-09,2020-11-20,Interventional,Impact of Auricular Vagus Nerve Neuromodulation on COVID-19 Positive Inpatients Outcome,Terminated,N/A,Fondation Ophtalmologique Adolphe de Rothschild,Inclusion stopped at 50% after interim analysis: primary efficacy endpoint not significant,https://clinicalzeros.gov/ct2/show/NCT04341415,0,0,0,0,3,0,France,0,auricular neuromodulation|control,NA
NCT04844710,2020-09-01,2020-11-15,Interventional,The Effects of Acupuncture in Overcoming Inflammatory Response to COVID-19 Mild-moderate Symptoms,Completed,N/A,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04844710,0,0,0,0,0,0,Indonesia,0,acupuncture/standard care|standard care|acupuncture,NA
NCT04844658,2021-02-17,2021-09-01,Interventional,"Covid-19, Hospitalized, PatIents, Nasafytol",Recruiting,N/A,Tilman S.A.,NA,https://clinicalzeros.gov/ct2/show/NCT04844658,0,0,0,0,0,0,Belgium,0,nasafytolâ®|fultiumâ® -d3 800|nasafytolâ®|fultiumâ® -d3 800,NA
NCT04844567,2020-11-26,2021-12-31,Interventional,Virtual Reality Intervention to Alleviate Breathlessness (COVID-19),Recruiting,N/A,Ecole Polytechnique FÃ©dÃ©rale de Lausanne,NA,https://clinicalzeros.gov/ct2/show/NCT04844567,0,0,0,0,0,0,Switzerland,0,covvr,NA
NCT04841707,2021-04-22,2022-02-22,Interventional,Total-Body Parametric 18F-FDG PET of COVID-19,Recruiting,N/A,"University of California, Davis",NA,https://clinicalzeros.gov/ct2/show/NCT04841707,0,0,0,0,1,1,United States,0,uexplorer/mct|uexplorer|mct,NA
NCT04800224,2021-04-12,2021-06-30,Interventional,Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2),Recruiting,Phase 2/Phase 3,D'Or Institute for Research and Education,NA,https://clinicalzeros.gov/ct2/show/NCT04800224,0,0,0,0,2,0,Brazil,0,standardized brazilian green propolis extract|placebo,NA
NCT04798001,2021-04-12,2022-10-31,Interventional,Safety and Immunogenicity of an Intranasal RSV Vaccine Expressing SARS-CoV-2 Spike Protein (COVID-19 Vaccine) in Adults,Recruiting,Phase 1,"Meissa Vaccines, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04798001,0,0,0,1,1,1,United States,0,"investigational vaccine against sars-cov-2 [mv-014-212] dosage 1, single dose, intranasal drops|investigational vaccine against sars-cov-2 [mv-014-212] dosage 2, single dose, intranasal drops|investigational vaccine against sars-cov-2 [mv-014-212] dosage 3, single dose, intranasal drops|investigational vaccine against sars-cov-2 [mv-014-212] dosage 3, two doses, intranasal drops|investigational vaccine against sars-cov-2 [mv-014-212] dosage 3, single dose, intranasal spray",NA
NCT04815057,2020-11-02,2020-11-23,Interventional,The Effects of Wellness Training Given to Fifth Grade Students During the Covid-19 Epidemic Period,Completed,N/A,Saglik Bilimleri Universitesi,NA,https://clinicalzeros.gov/ct2/show/NCT04815057,0,0,0,0,3,0,Turkey,0,wellness education,NA
NCT04791423,2021-03-15,2021-05-30,Interventional,Study of GRAd-COV2 for the Prevention of COVID-19 in Adults,"Active, not recruiting",Phase 2/Phase 3,ReiThera Srl,NA,https://clinicalzeros.gov/ct2/show/NCT04791423,0,0,0,1,2,0,Italy,0,grad-cov2|placebo,NA
NCT04810065,2021-03-29,2021-07-31,Interventional,SingStrong: Strong Lungs Through Song - Long COVID-19 Study,Recruiting,N/A,University of Limerick,NA,https://clinicalzeros.gov/ct2/show/NCT04810065,0,0,0,0,1,0,Ireland,0,singstrong: strong lungs through song,NA
NCT04678830,2021-03-01,2021-06-23,Interventional,COVID-19 Long-Haulers Study,"Active, not recruiting",Phase 2,"CytoDyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04678830,0,0,0,0,6,1,United States,0,placebo|lenzilumab,NA
NCT04762173,2020-11-06,2021-06-03,Interventional,Self-Help for Stress Related to COVID-19,"Active, not recruiting",N/A,Penn State University,NA,https://clinicalzeros.gov/ct2/show/NCT04762173,0,0,0,0,2,1,United States,0,online self-help intervention,NA
NCT04754594,2021-02-16,2022-06-27,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of SARS CoV-2 RNA Vaccine Candidate (BNT162b2) Against COVID-19 in Healthy Pregnant Women 18 Years of Age and Older",Recruiting,Phase 2/Phase 3,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04754594,0,0,0,1,3,1,United States,0,bnt162b2|placebo,NA
NCT04611425,2020-11-30,2021-05-01,Interventional,"REmimazolam Infusion in the Context of Hypnotic Shortage in the Critical Care Unit During the Pandemic of COVID-19, the REHSCU Study",Recruiting,Phase 2,Nantes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04611425,0,0,0,0,1,0,France,0,remimazolam,NA
NCT04602949,2020-11-12,2021-07-28,Interventional,Detection of COVID-19 Using Breath Analysis - Validation Study,Recruiting,N/A,Scentech Medical Technologies Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04602949,0,0,0,0,1,0,Israel,0,breath biopsy analysis,NA
NCT04509947,2020-08-11,2021-02-22,Interventional,A Study of Ad26.COV2.S in Adults (COVID-19),"Active, not recruiting",Phase 1,Janssen Pharmaceutical K.K.,NA,https://clinicalzeros.gov/ct2/show/NCT04509947,0,0,0,0,5,0,Japan,0,ad26.cov2.s|placebo,NA
NCT04501952,2020-09-18,2021-05-31,Interventional,Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734â„¢) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting,"Active, not recruiting",Phase 3,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04501952,0,0,0,0,12,1,United States|Denmark|Portugal|Spain|United Kingdom,0,rdv|placebo,NA
NCT04471636,2020-09-18,2021-11-30,Interventional,Telemedicine in Outpatient Covid-19 Patients,Recruiting,N/A,Ludwig-Maximilians - University of Munich,NA,https://clinicalzeros.gov/ct2/show/NCT04471636,0,0,0,0,2,0,Germany,0,withings scanwatch,NA
NCT04415060,2020-06-15,2023-06-15,Interventional,SedAting With Volatile Anesthetics Critically Ill COVID-19 Patients in ICU: Effects On Ventilatory Parameters And Survival,Recruiting,Phase 3,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04415060,0,0,0,0,5,0,Canada,0,isoflurane inhalant product|sevoflurane,NA
NCT04622332,2020-12-18,2021-12-15,Interventional,A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19,Recruiting,Phase 1,"Sironax USA, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04622332,0,0,0,0,1,1,United States,0,sir1-365|placebo,NA
NCT04570384,2020-10-15,2021-07-28,Interventional,Intravenous L-Citrulline to Delay and Potentially Prevent the Need for Invasive Mechanical Ventilation for Acute Hypoxemic Respiratory Failure in Patients With COVID-19 (SARS-CoV-2) Illness,Recruiting,Phase 2,"Asklepion Pharmaceuticals, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04570384,0,0,0,0,3,1,United States,0,l-citrulline|placebo,NA
NCT04416308,2020-05-29,2020-07-10,Interventional,COVID 19 : Seroprevalence Study of Anti SRAS-CoV-2 Antibodies in GHT Employees in Haute Bretagne (AntiCoV-HB),Completed,N/A,Rennes University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04416308,0,0,0,0,2,0,France,0,ng test|blood test|self-questionnary,NA
NCT04388527,2020-04-30,2020-12-29,Interventional,COVID-19 Convalescent Plasma for Mechanically Ventilated Population,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04388527,0,0,0,0,5,1,United States,0,convalescent plasma,NA
NCT04402970,2020-06-19,2020-12-31,Interventional,Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2),Completed,Phase 3,University of Missouri-Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04402970,0,0,0,0,6,1,United States,1,dornase alfa,NA
NCT04380961,2020-04-24,2021-04-09,Interventional,A Study to Evaluate the Efficacy and Safety of Sirukumab in Confirmed Severe or Critical Confirmed Coronavirus Disease (COVID)-19,Recruiting,Phase 2,"Janssen Pharmaceutica N.V., Belgium",NA,https://clinicalzeros.gov/ct2/show/NCT04380961,0,0,0,0,13,1,United States,0,sirukumab|placebo|standard care,NA
NCT04347239,2020-04-15,2021-06-15,Interventional,Study to Evaluate the Efficacy and Safety of Leronlimab for Patients With Severe or Critical Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 2,"CytoDyn, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04347239,0,0,0,0,13,1,United States,0,placebo|lenzilumab,NA
NCT04344080,2020-04-01,2021-05-01,Interventional,Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19,"Active, not recruiting",N/A,UniversitÃ¤tsklinikum Hamburg-Eppendorf,NA,https://clinicalzeros.gov/ct2/show/NCT04344080,0,0,0,0,1,0,Germany,0,cytosorb,NA
NCT04333732,2020-09-04,2021-08-31,Interventional,CROWN CORONATION: COVID-19 Research Outcomes Worldwide Network for CORONAvirus prevenTION,Recruiting,Phase 3,Washington University School of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04333732,0,0,0,0,13,1,United States|Ghana|South Africa|United Kingdom|Zambia,0,mr/m-m-r ii â® vaccine|placebo|mr|m-m-r ii â® vaccine,NA
NCT04846790,2021-06-01,2022-12-01,Interventional,The Effect of a Combined Nature-based and Virtual Mindfulness Intervention on Perceived Stress in Healthcare Workers,Enrolling by invitation,N/A,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04846790,0,0,0,0,0,1,United States,0,nature only|nature/mindfulness|nature|mindfulness,NA
NCT04843722,2021-04-30,2021-09-30,Interventional,COVID-19 Supplemental Vaccine Boost to Enhance T Cell Protection in Those Who Have Already Received EUA S-Based Vaccines,Recruiting,Phase 1/Phase 2,"ImmunityBio, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04843722,0,0,0,1,1,1,United States,0,had5-s-fusion/n-etsd vaccine|had5-s-fusion|n-etsd vaccine,NA
NCT04501796,2020-11-27,2021-10-31,Interventional,A Trial of NT-I7 in COVID-19 (SPESELPIS),Recruiting,Phase 1,NeoImmuneTech,NA,https://clinicalzeros.gov/ct2/show/NCT04501796,0,0,0,0,2,1,United States,0,double-blind nt-i7|placebo,NA
NCT04723537,2021-02-16,2021-09-30,Interventional,"Upamostat, a Serine Protease Inhibitor, or Placebo for Treatment of COVID-19 Disease",Recruiting,Phase 2/Phase 3,RedHill Biopharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04723537,0,0,0,0,9,1,United States,0,part a: upamostat 200 mg|part a: upamostat 400 mg|part a/b: placebo|part b: upamostat 200/400 mg|part a|b: placebo|part b: upamostat 200|400 mg,NA
NCT04584684,2020-12-18,2022-09-30,Interventional,Mouth Rinses for Inactivation of COVID-19,Recruiting,Phase 2,"University of North Carolina, Chapel Hill",NA,https://clinicalzeros.gov/ct2/show/NCT04584684,0,0,0,0,3,1,United States,0,1.5% w/v hydrogen peroxide|0.12% chlorhexidine gluconate|27% ethanol/essential oils|0.5% w/v povidone-iodide|0.075% cetylpyridinium chloride|saline|1.5% w|v hydrogen peroxide|27% ethanol|essential oils|0.5% w|v povidone-iodide,NA
NCT04459676,2020-07-31,2021-04-30,Interventional,Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia,"Active, not recruiting",Phase 2,Angion Biomedica Corp,NA,https://clinicalzeros.gov/ct2/show/NCT04459676,0,0,0,0,4,0,Brazil,0,standard care|ang-3777|placebo,NA
NCT04375397,2020-06-06,2021-05-10,Interventional,Study of Oral Ibrutinib Capsules to Assess Respiratory Failure in Adult Participants With Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) and Pulmonary Injury,"Active, not recruiting",Phase 2,AbbVie,NA,https://clinicalzeros.gov/ct2/show/NCT04375397,0,0,0,0,11,1,United States,0,ibrutinib|placebo,NA
NCT04849598,2021-04-13,2021-09-01,Interventional,Automatic Oxygen Titration in Patients After SARS-CoV-2 Infection,Recruiting,N/A,SchÃ¶n Klinik Berchtesgadener Land,NA,https://clinicalzeros.gov/ct2/show/NCT04849598,0,0,0,0,0,0,Germany,0,oxygen,NA
NCT04365153,2020-04-24,2021-02-02,Interventional,Canakinumab in Covid-19 Cardiac Injury (The Three C Study),Completed,Phase 2,The Cleveland Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04365153,0,0,0,0,9,1,United States,1,canakinumab|placebo,NA
NCT04849793,2021-04-13,2021-06-13,Interventional,The Effect of Acupressure on the Anxiety Level,Recruiting,N/A,Mersin University,NA,https://clinicalzeros.gov/ct2/show/NCT04849793,0,0,0,0,0,0,Turkey,0,acupressure,NA
NCT04849637,2020-10-22,2021-06-30,Interventional,Virgin Coconut Oil as Adjunctive Therapy for Hospitalized COVID-19 Patients,Recruiting,Phase 2,University of the Philippines,NA,https://clinicalzeros.gov/ct2/show/NCT04849637,0,0,0,0,0,0,Philippines,0,virgin coconut oil,NA
NCT04847791,2021-01-14,2022-01-31,Interventional,Lactoferrin in Covid-19 Hospitalized Patients,Recruiting,N/A,Paolo Manzoni,NA,https://clinicalzeros.gov/ct2/show/NCT04847791,0,0,0,0,0,0,Italy,0,bovine lactoferrin|placebo,NA
NCT04847362,2021-04-11,2021-05-30,Interventional,The Effect of Tele-Health Education Provided in the Postpartum Period in the Covid 19 Pandemic,Recruiting,N/A,Saglik Bilimleri Universitesi,NA,https://clinicalzeros.gov/ct2/show/NCT04847362,0,0,0,0,1,0,Turkey,0,experimental,NA
NCT04847544,2021-03-31,2021-12-31,Interventional,"A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacodynamics for the Treatment of COVID-19.",Recruiting,Phase 2,"Aldeyra Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04847544,0,0,0,0,0,1,United States,0,adx-629|placebo,NA
NCT04847661,2021-03-28,2021-07-30,Interventional,"Efficacy of Mefloquine as Prophylaxis Against COVID-19: A Placebo-control, Randomized Clinical Trial",Recruiting,Phase 2/Phase 3,Helwan University,NA,https://clinicalzeros.gov/ct2/show/NCT04847661,0,0,0,0,0,0,Egypt,0,mefloquine as a prophylaxis against sars-cov-2 infection in household contacts of covid 19 confirmed cases,NA
NCT04845971,2020-11-05,2021-04-30,Interventional,Efficacy and Safety of Oral Immunotherapy With GcMAF in Hospitalized Patients With COVID-19 Pneumonia,Recruiting,Phase 2,Ospedale del Mare,NA,https://clinicalzeros.gov/ct2/show/NCT04845971,0,0,0,0,1,0,Italy,0,saisei maf capsules,NA
NCT04839146,2021-03-11,2021-12-20,Interventional,Safety and Tolerability of COVID-19 Vaccine (ABNCoV2),Recruiting,Phase 1,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04839146,0,0,0,1,1,0,Netherlands,0,abncov2 vaccine,NA
NCT04838795,2021-02-18,2022-03-31,Interventional,Sisonke (Together): OPEN LABEL TRIAL COVID-19,Recruiting,Phase 3,Wits Health Consortium (Pty) Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04838795,0,0,0,1,1,0,South Africa,0,to monitor the effectiveness of the single dose ad26.cov2.s covid-19 vaccine,NA
NCT04821999,2021-04-10,2021-05-20,Interventional,Diode Laser 940 nm in Management of Loss of Taste Sensation,Recruiting,N/A,Fayoum University,NA,https://clinicalzeros.gov/ct2/show/NCT04821999,0,0,0,0,2,0,Egypt,0,a 940-nm diode laser,NA
NCT04771000,2021-02-08,2021-07-31,Interventional,A Study of Micro Dose Ambrisentan in Hospitalized Patients With Respiratory Insufficiency Due to COVID-19,Recruiting,Phase 2,Noorik Biopharmaceuticals AG,NA,https://clinicalzeros.gov/ct2/show/NCT04771000,0,0,0,0,5,0,Spain,0,ambrisentan|placebo,NA
NCT04699916,2021-01-04,2021-06-30,Interventional,EEG-based Sedation Protocol for Patients on Mechanical Ventilation Due to SARS-CoV-2 Pneumonia,Recruiting,N/A,University of Chile,NA,https://clinicalzeros.gov/ct2/show/NCT04699916,0,0,0,0,3,0,Chile,0,eeg based protocol for deep sedation,NA
NCT04476979,2020-07-16,2021-06-30,Interventional,Comparison of Tocilizumab Plus Dexamethasone vs. Dexamethasone for Patients With Covid-19,Recruiting,Phase 2,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04476979,0,0,0,0,2,0,French Guiana,0,tocilizumab|dexamethasone,NA
NCT04614948,2020-11-16,2022-05-10,Interventional,A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults,"Active, not recruiting",Phase 3,Janssen Vaccines & Prevention B.V.,NA,https://clinicalzeros.gov/ct2/show/NCT04614948,0,0,0,0,11,1,United States|Belgium|Brazil|Colombia|France|Germany|Philippines|South Africa|Spain|United Kingdom,0,ad26.cov2.s|placebo,NA
NCT04667286,2021-01-16,2021-06-01,Interventional,Awake Pronation for Covid-19 Treatment,Recruiting,N/A,IRCCS Azienda Ospedaliero-Universitaria di Bologna,NA,https://clinicalzeros.gov/ct2/show/NCT04667286,0,0,0,0,1,0,Italy,0,prone position (pp),NA
NCT04625972,2020-12-02,2021-04-07,Interventional,"Phase III Double-blind, Placebo-controlled Study of AZD7442 for Post- Exposure Prophylaxis of COVID-19 in Adults","Active, not recruiting",Phase 3,AstraZeneca,NA,https://clinicalzeros.gov/ct2/show/NCT04625972,0,0,0,0,3,1,United States|United Kingdom,0,azd7442|placebo,NA
NCT04591015,2021-02-01,2021-07-31,Interventional,Dulce Digital-COVID Aware (DD-CA) Discharge Texting Platform for US/Mexico Border Hispanics With Diabetes + COVID-19,Recruiting,Phase 3,Scripps Whittier Diabetes Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04591015,0,0,0,0,4,1,United States,0,hospital: dd-ca|hospital: usual care (uc),NA
NCT04685655,2020-01-07,2021-12-31,Interventional,RescuE pLAsma eXchange in Severe COVID-19,Recruiting,N/A,Heidelberg University,NA,https://clinicalzeros.gov/ct2/show/NCT04685655,0,0,0,0,4,0,Germany,0,therapeutic plasma exchange (tpe),NA
NCT04595097,2021-03-01,2021-11-30,Interventional,Inspiratory Muscle Training in COVID-19 Patients,Recruiting,N/A,Escola Superior de Ciencias da Saude,NA,https://clinicalzeros.gov/ct2/show/NCT04595097,0,0,0,0,2,0,Brazil,0,inspiratory muscle traiing,NA
NCT04549922,2020-10-22,2022-02-28,Interventional,Antisense Therapy to Block the Kallikrein-kinin Pathway in COVID-19,"Active, not recruiting",Phase 2,Hospital do Coracao,NA,https://clinicalzeros.gov/ct2/show/NCT04549922,0,0,0,0,3,0,Brazil,0,isis 721744|saline,NA
NCT04583969,2020-10-19,2021-12-31,Interventional,ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04583969,0,0,0,0,24,1,United States,0,lenzilumab|placebo|remdesivir,NA
NCT04575597,2020-10-19,2021-06-23,Interventional,Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002),Recruiting,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04575597,0,0,0,0,25,1,United States|Brazil|Canada|Chile|Colombia|France|Germany|Israel|Italy|Mexico|Philippines|Russian Federation|South Africa|Spain|Ukraine|United Kingdom,0,molnupiravir|placebo,NA
NCT04524598,2020-07-20,2021-09-01,Interventional,A CBT-based Mobile Intervention as First Line Treatment for Adolescent Depression During COVID-19,Recruiting,N/A,"Limbix Health, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04524598,0,0,0,0,2,1,United States,0,limbix spark|psychoeducation,NA
NCT04504032,2020-09-02,2021-03-10,Interventional,A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19),Terminated,Phase 2,Bill & Melinda Gates Medical Research Institute,"Based on Data Monitoring Committee's recommendation on February 3, 2021, the study was stopped
    due to futility.",https://clinicalzeros.gov/ct2/show/NCT04504032,0,0,0,0,9,1,United States|United Kingdom,0,rivaroxaban|placebo,NA
NCT04500626,2021-04-15,2022-08-31,Interventional,Hyperbaric Versus Normobaric Oxygen Therapy for COVID-19 Patients,Recruiting,Phase 2/Phase 3,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04500626,0,0,0,0,4,0,Canada,0,oxygen,NA
NCT04417257,2020-06-29,2021-05-15,Interventional,Study of LAU-7b for the Treatment of COVID-19 Disease in Adults,Recruiting,Phase 2,Laurent Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04417257,0,0,0,0,14,1,United States|Canada,0,lau-7b|placebo,NA
NCT04530448,2020-10-05,2021-12-31,Interventional,Coronavirus Induced Acute Kidney Injury: Prevention Using Urine Alkalinization,Recruiting,Phase 4,West Virginia University,NA,https://clinicalzeros.gov/ct2/show/NCT04530448,0,0,0,0,3,1,United States,0,sodium bicarbonate|standard care,NA
NCT04492254,2020-09-15,2021-07-31,Interventional,Early Prophylactic Low-molecular-weight Heparin (LMWH) in Symptomatic COVID-19 Positive Patients,Recruiting,Phase 3,Thrombosis Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04492254,0,0,0,0,1,0,Australia|Belgium|South Africa,0,enoxaparin,NA
NCT04431453,2020-07-21,2022-02-28,Interventional,"Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Remdesivir (GS-5734â„¢) in Participants From Birth to < 18 Years of Age With Coronavirus Disease 2019 (COVID-19)",Recruiting,Phase 2/Phase 3,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04431453,0,0,0,0,24,1,United States|Italy|Spain|United Kingdom,0,remdesivir,NA
NCT04851821,2021-01-04,2021-02-28,Interventional,PHYTOTHERAPY IN SEVERE ACUTE RESPIRATORYSYNDROME CORONAVIRUS 2,Recruiting,Phase 1,HÃ´pital Universitaire Sahloul,NA,https://clinicalzeros.gov/ct2/show/NCT04851821,0,0,0,0,0,0,Tunisia,0,quercetin,NA
NCT04846010,2021-03-01,2022-05-01,Interventional,Recovering Damaged Cells for Sequelae Caused by SARS-CoV-2,Recruiting,Phase 1/Phase 2,"All Natural Medicine Clinic, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04846010,0,0,0,0,1,1,United States,0,furwat|furfat|purapo|purphl|purclo|purinf|smoliv,NA
NCT04847349,2021-04-13,2021-10-13,Interventional,Live Microbials to Boost Anti-Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Immunity Clinical Trial,Recruiting,N/A,"Rutgers, The State University of New Jersey",NA,https://clinicalzeros.gov/ct2/show/NCT04847349,0,0,0,0,1,1,United States,0,"ol-1, standard dose|ol-1, high dose|placebo",NA
NCT04834908,2021-05-31,2022-03-31,Interventional,Evaluation of Equine Antibody Treatment in Patients With COVID 19 Infection,Recruiting,Phase 1/Phase 2,Bharat Serums and Vaccines Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04834908,0,0,0,0,1,0,India,0,equine covid-19 antiserum|standard care,NA
NCT04844346,2021-04-19,2021-08-31,Interventional,Plant Stanol Esters and COVID-19 Vaccination Response,Recruiting,N/A,Maastricht University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04844346,0,0,0,1,1,0,Netherlands,0,plant stanol mini drinks|placebo mini drinks|covid-19 vaccine,NA
NCT04784897,2021-02-22,2021-07-31,Interventional,A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19,Recruiting,Phase 2,"Innovation Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04784897,0,0,0,0,4,1,United States|Russian Federation,0,brilacidin|placebo|standard care,NA
NCT04810728,2020-06-20,2020-12-04,Interventional,Efficacy of Psidii Guava's Extract For COVID-19,Completed,Phase 3,Faculty of Medicine Baiturrahmah University,NA,https://clinicalzeros.gov/ct2/show/NCT04810728,0,0,0,0,1,0,Indonesia,0,extract psidii guava|standard therapy for covid-19 patient,NA
NCT04784767,2021-04-05,2022-10-30,Interventional,SARS-COV-2-Spike-Ferritin-Nanoparticle (SpFN) Vaccine With ALFQ Adjuvant for Prevention of COVID-19 in Healthy Adults,Recruiting,Phase 1,U.S. Army Medical Research and Development Command,NA,https://clinicalzeros.gov/ct2/show/NCT04784767,0,0,0,1,2,1,United States,0,"25 âµg spfn_1b-06-pl / alfq (qs21 adjuvant)|sodium chloride, usp, for injection (0.9% nacl)|50 âµg spfn_1b-06-pl / alfq (qs21 adjuvant)|25 âµg spfn_1b-06-pl|alfq (qs21 adjuvant)|50 âµg spfn_1b-06-pl",NA
NCT04751474,2021-02-01,2021-03-01,Interventional,"The Effect of Motivational Messages on Optimism, Hopelessness and Life Satisfaction",Completed,N/A,Saglik Bilimleri Universitesi,NA,https://clinicalzeros.gov/ct2/show/NCT04751474,0,0,0,0,1,0,Turkey,0,motivational messages,NA
NCT04655638,2021-02-10,2022-01-10,Interventional,HFNT vs. COT in COVID-19,Recruiting,N/A,Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo,NA,https://clinicalzeros.gov/ct2/show/NCT04655638,0,0,0,0,3,0,Italy,0,high flow nasal therapy|conventional oxygen therapy,NA
NCT04708236,2021-04-30,2021-05-31,Interventional,A Study of ORTD-1 in Patients Hospitalized With COVID-19 Related Pneumonia,Recruiting,Phase 1/Phase 2,"Oryn Therapeutics, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04708236,0,0,0,0,2,1,United States,0,ortd-1 low dose|ortd-1 mid dose|ortd-1 high dose|vehicle control,NA
NCT04516759,2020-08-12,2021-04-30,Interventional,AZD1656 in Diabetic Patients Hospitalised With Suspected or Confirmed COVID-19,"Active, not recruiting",Phase 2,St George Street Capital,NA,https://clinicalzeros.gov/ct2/show/NCT04516759,0,0,0,0,13,0,Czechia|Romania|United Kingdom,0,azd1656|placebo,NA
NCT04570488,2020-05-15,2021-12-30,Interventional,Predicting Favorable Outcomes in Hospitalized Covid-19 Patients,Recruiting,N/A,NYU Langone Health,NA,https://clinicalzeros.gov/ct2/show/NCT04570488,0,0,0,0,2,1,United States,0,epic risk score display,NA
NCT04565665,2020-07-29,2021-04-30,Interventional,Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome,Recruiting,Phase 1/Phase 2,M.D. Anderson Cancer Center,NA,https://clinicalzeros.gov/ct2/show/NCT04565665,0,0,0,0,4,1,United States,0,best available therapy|mesenchymalÂ stem cells,NA
NCT04604184,2020-11-03,2021-03-24,Interventional,ACTION ON COVID-19: A Study to Test Whether BI 764198 Helps Lung Health of People Hospitalised With COVID-19,Terminated,Phase 2,Boehringer Ingelheim,Company decision,https://clinicalzeros.gov/ct2/show/NCT04604184,0,0,0,0,10,1,United States|Brazil|Chile|Mexico|Puerto Rico|Spain,0,bi 764198|placebo,NA
NCT04527471,2020-09-04,2021-02-15,Interventional,Study of Ensifentrine or Placebo Delivered Via pMDI in Hospitalized Patients With COVID-19,"Active, not recruiting",Phase 2,Verona Pharma plc,NA,https://clinicalzeros.gov/ct2/show/NCT04527471,0,0,0,0,4,1,United States,0,ensifentrine|placebo,NA
NCT04523181,2020-10-08,2021-04-30,Interventional,Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients,Recruiting,Phase 2,Golden Biotechnology Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04523181,0,0,0,0,5,1,United States|Argentina|Peru,0,antroquinonol|placebo,NA
NCT04497987,2020-08-02,2021-01-16,Interventional,A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff,"Active, not recruiting",Phase 3,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04497987,0,0,0,0,17,1,United States,0,ly3819253|placebo|ly3832479,NA
NCT04470258,2020-06-25,2020-08-30,Interventional,Elmo Respiratory Support Project - COVID-19,Completed,N/A,Escola de SaÃºde PÃºblica do CearÃ¡,NA,https://clinicalzeros.gov/ct2/show/NCT04470258,0,0,0,0,2,0,Brazil,0,elmo project at covid-19: study in humans|elmo project at covid-19: proof of concept/usability|elmo project at covid-19: proof of concept|usability,NA
NCT04392141,2020-04-01,2020-11-01,Interventional,Colchicine Plus Phenolic Monoterpenes to Treat COVID-19,Completed,Phase 1/Phase 2,Kermanshah University of Medical Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04392141,0,0,0,0,3,0,"Iran, Islamic Republic of",1,standard care|colchicine/herbal phenolic monoterpene fractions|colchicine|herbal phenolic monoterpene,NA
NCT04363606,2020-05-27,2022-04-30,Interventional,Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability,Recruiting,N/A,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04363606,0,0,0,0,5,0,France,0,actigraphy|blood test|questionnaire|maximal effort test|neuromuscular|stool analysis|food diary,NA
NCT04346628,2020-07-12,2021-04-16,Interventional,Oral Favipiravir Compared to Placebo in Subjects With Mild COVID-19,Completed,Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04346628,0,0,0,0,7,1,United States,0,favipiravir|placebo|standard care,NA
NCT04853134,2020-11-01,2021-05-01,Interventional,Proxalutamide Treatment for COVID-19 Female Outpatients,"Active, not recruiting",Phase 3,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04853134,0,0,0,0,0,0,Brazil,0,proxalutamide|standard care,NA
NCT04852770,2021-04-23,2021-09-30,Interventional,"Efficacy of TBCT, MBHP and PPT for PTSD During the Covid-19 Pandemics",Recruiting,N/A,FundaÃ§Ã£o Bahiana de Infectologia,NA,https://clinicalzeros.gov/ct2/show/NCT04852770,0,0,0,0,0,0,Brazil,0,trial-based cognitive therapy|mindfulness-based health promotion|positive psychotherapy,NA
NCT04842435,2021-04-12,2021-09-30,Interventional,Clinical Study in the Treatment of Patients With Moderate Course of COVID-19,Recruiting,Phase 2/Phase 3,Microgen,NA,https://clinicalzeros.gov/ct2/show/NCT04842435,0,0,0,0,1,0,Russian Federation,0,covid-globulin|placebo,NA
NCT04773665,2021-03-15,2022-06-30,Interventional,"Safety, Tolerability, and Immunogenicity of the COVID-19 Vaccine Candidate (VBI-2902a)","Active, not recruiting",Phase 1/Phase 2,VBI Vaccines Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04773665,0,0,0,1,1,0,Canada,0,vbi-2902a|placebo,NA
NCT04772859,2021-02-01,2021-07-31,Interventional,Evaluation of an Online Lifestyle Intervention in Mexican School Children During COVID-19 Pandemic,"Active, not recruiting",N/A,Universidad de Sonora,NA,https://clinicalzeros.gov/ct2/show/NCT04772859,0,0,0,0,2,0,Mexico,0,online lifestyle intervention|control,NA
NCT04649775,2021-04-09,2021-07-31,Interventional,AirFLO2 Treatment for Hypoxia and/or Tachypnea in Patients With COVID-19,Recruiting,N/A,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04649775,0,0,0,0,2,1,United States,0,airflo2,NA
NCT04751643,2021-04-19,2022-12-31,Interventional,Therapeutic Plasma Exchange to Alleviate Hyperinflammatory Condition During Severe Covid-19 Infections,Recruiting,N/A,Hospices Civils de Lyon,NA,https://clinicalzeros.gov/ct2/show/NCT04751643,0,0,0,0,1,0,France,0,therapeutic plasma exchange : 3 sessions in 3 consecutive days (day 1 to day 3)|usual treatments in intensive care unit according to the current state of knowledge,NA
NCT04475107,2020-07-09,2021-03-25,Interventional,The Efficacy and Safety of Pyramax in Mild to Moderate COVID-19 Patients,Completed,Phase 2,Shin Poong Pharmaceutical Co. Ltd.,NA,https://clinicalzeros.gov/ct2/show/NCT04475107,0,0,0,0,6,0,"Korea, Republic of",0,pyronaridine-artesunate|placebo,NA
NCT04526912,2020-08-28,2021-07-31,Interventional,Treatment and Prevention of Acute Lung Injury (ALI) in Patients With COVID-19 Infection,Recruiting,Phase 1,Viela Bio,NA,https://clinicalzeros.gov/ct2/show/NCT04526912,0,0,0,0,4,1,United States,0,vib7734|placebo,NA
NCT04588792,2021-04-16,2022-01-01,Interventional,Furosemide as Supportive Therapy for COVID-19 Respiratory Failure,Recruiting,Phase 2/Phase 3,Queen's University,NA,https://clinicalzeros.gov/ct2/show/NCT04588792,0,0,0,0,5,0,Canada,0,nebulized furosemide|nebulized saline,NA
NCT04451291,2020-09-25,2021-09-25,Interventional,Study of Decidual Stromal Cells to Treat COVID-19 Respiratory Failure,Recruiting,N/A,"University Health Network, Toronto",NA,https://clinicalzeros.gov/ct2/show/NCT04451291,0,0,0,0,3,0,Canada,0,decidual stromal cells (dsc),NA
NCT04854941,2020-12-10,2021-03-10,Interventional,Efficacy of Probiotics in the Treatment of Hospitalised Patients With Novel Coronavirus Infection,Completed,N/A,I.M. Sechenov First Moscow State Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04854941,0,0,0,0,0,0,Russian Federation,0,probiotics,NA
NCT04348500,2020-04-24,2020-12-31,Interventional,Clazakizumab (Anti-IL- 6 Monoclonal) Compared to Placebo for COVID19 Disease,"Active, not recruiting",Phase 2,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04348500,0,0,0,0,4,1,United States,0,clazakizumab,NA
NCT04853966,2021-04-17,2022-04-17,Interventional,The Effects of Physical Activity Counseling on Physical Activity and Quality of Life in Covid-19 Patients,Recruiting,N/A,Gazi University,NA,https://clinicalzeros.gov/ct2/show/NCT04853966,0,0,0,0,0,0,Turkey,0,physical activity counseling,NA
NCT04853901,2020-07-27,2021-01-01,Interventional,Remdesivir Efficacy In Management Of COVID-19 Patients,Completed,Phase 3,Ain Shams University,NA,https://clinicalzeros.gov/ct2/show/NCT04853901,0,0,0,0,0,0,Egypt,0,remdesivir|standard of care_1|standard of care_2,NA
NCT04780321,2020-10-30,2021-10-01,Interventional,JS016 (Anti-SARS-CoV-2 Monoclonal Antibody)With Mild and Moderate COVID-19 or SARS-CoV-2 Asymptomatic Infection Subects,Recruiting,Phase 1/Phase 2,"Shanghai Junshi Bioscience Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04780321,0,0,0,0,1,0,China,0,recombinant human anti-sars-cov-2 monoclonal antibody(25mg/kg;50mg/kg;100mg/kg)|placebo|recombinant human anti-sars-cov-2 monoclonal antibody(25mg|kg;50mg|kg;100mg|kg),NA
NCT04803409,2021-03-22,2021-09-22,Interventional,UNITE Study (UCSD-SW) for COVID-19,Recruiting,N/A,"University of California, San Diego",NA,https://clinicalzeros.gov/ct2/show/NCT04803409,0,0,0,0,3,1,United States,0,splenic ultrasound,NA
NCT04811664,2021-03-24,2021-12-22,Interventional,A Study of SARS CoV-2 Infection and Potential Transmission in University Students Immunized With Moderna COVID-19 Vaccine,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04811664,0,0,0,1,2,1,United States,0,moderna covid-19 vaccine,NA
NCT04806113,2021-03-11,2022-03-11,Interventional,COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases,"Active, not recruiting",Phase 3,McGill University Health Centre/Research Institute of the McGill University Health Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04806113,0,0,0,1,1,0,Canada,0,moderna covid-19 vaccine,NA
NCT04765371,2021-03-03,2021-10-31,Interventional,"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19",Recruiting,Phase 3,Centre Hospitalier RenÃ© Dubos,NA,https://clinicalzeros.gov/ct2/show/NCT04765371,0,0,0,0,2,0,France,0,dexamethasone|prednisolone,NA
NCT04761874,2019-12-01,2020-06-29,Interventional,Telestroke at Comprehensive Stroke Center During the COVID-19 Pandemic,Completed,N/A,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04761874,0,0,0,0,1,1,United States,0,telestroke,NA
NCT04708340,2021-03-25,2022-10-31,Interventional,Tolerability and Efficacy of RJX in Patients With COVID-19,Recruiting,Phase 1/Phase 2,"Reven Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04708340,0,0,0,0,4,1,United States,0,rejuveinix (rjx) active comparator|placebo,NA
NCT04701489,2021-01-14,2021-03-15,Interventional,UNITE Study (UMN-GE) for COVID-19,Completed,N/A,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04701489,0,0,0,0,4,1,United States,0,splenic ultrasound,NA
NCT04640168,2020-11-24,2021-05-22,Interventional,Adaptive COVID-19 Treatment Trial 4 (ACTT-4),"Active, not recruiting",Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04640168,0,0,0,0,24,1,"United States|Japan|Korea, Republic of|Mexico|Singapore",0,baricitinib|dexamethasone|placebo|remdesivir,NA
NCT04542031,2020-12-14,2021-10-31,Interventional,COVID-19 in a Single Large UK Rheumatology Centre and Impact on QOL,Recruiting,N/A,The Royal Wolverhampton Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04542031,0,0,0,0,2,0,United Kingdom,0,questionnaire,NA
NCT04575584,2020-10-19,2021-06-27,Interventional,Efficacy and Safety of Molnupiravir (MK-4482) in Hospitalized Adult Participants With COVID-19 (MK-4482-001),Recruiting,Phase 2/Phase 3,Merck Sharp & Dohme Corp.,NA,https://clinicalzeros.gov/ct2/show/NCT04575584,0,0,0,0,29,1,"United States|Brazil|Canada|Chile|Colombia|France|Israel|Italy|Korea, Republic of|Mexico|Philippines|Poland|Russian Federation|South Africa|Spain|Ukraine|United Kingdom",0,molnupiravir|placebo,NA
NCT04358068,2020-05-13,2020-07-08,Interventional,Evaluating the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons With COVID-19,Terminated,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),Slow enrollment and lack of community enthusiasm,https://clinicalzeros.gov/ct2/show/NCT04358068,0,0,0,0,17,1,United States,1,hydroxychloroquine|azithromycin|placebo,NA
NCT04756856,2021-04-21,2021-12-01,Interventional,Muscle-targeted Nutritional Therapy for the Recovery From COVID-19,Recruiting,N/A,IRCCS Policlinico S. Matteo,NA,https://clinicalzeros.gov/ct2/show/NCT04756856,0,0,0,0,1,0,Italy,0,muscle-target oral nutritional supplementation,NA
NCT04805125,2021-04-19,2022-07-31,Interventional,Immunocompromised Swiss Cohorts Based Trial Platform,Recruiting,Phase 3,"University Hospital, Basel, Switzerland",NA,https://clinicalzeros.gov/ct2/show/NCT04805125,0,0,0,1,2,0,Switzerland,0,"moderna covid-19 vaccine, mrna-1273 (100 î¼g)|pfizer-biontech covid-19 vaccine bnt162b2 (30 âµg)( comirnatyâ®)|moderna covid-19 vaccine, mrna-1273 (100 î¼g)|pfizer-biontech covid-19 vaccine bnt162b2 (30 âµg)( comirnatyâ®)",NA
NCT04583956,2020-10-14,2021-12-31,Interventional,ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04583956,0,0,0,0,24,1,United States,0,placebo|remdesivir|risankizumab,NA
NCT04681092,2021-04-12,2021-06-30,Interventional,Anti-COVID19 AKS-452 - ACT Study,Enrolling by invitation,Phase 1/Phase 2,University Medical Center Groningen,NA,https://clinicalzeros.gov/ct2/show/NCT04681092,0,0,0,1,2,0,Netherlands,0,aks-452,NA
NCT04676867,2021-01-11,2021-05-31,Interventional,Effect of Dalcetrapib in Patients With Confirmed Mild to Moderate COVID-19,"Active, not recruiting",Phase 2,DalCor Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04676867,0,0,0,0,3,0,Canada,0,dalcetrapib|placebo,NA
NCT04723446,2021-04-20,2021-07-01,Interventional,Efficacy of Mouthwashes in Reducing Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Viral Load in the Saliva,Recruiting,N/A,Queen Mary University of London,NA,https://clinicalzeros.gov/ct2/show/NCT04723446,0,0,0,0,1,0,United Kingdom,0,corsodylâ® alcohol free -0.2 % chlorhexidine digluconate|colgate peroxylâ® -1.5% hydrogen peroxide|oral-bâ® gum/enamel care -cetylpyridinium chloride|no rinsing|corsodylâ® alcohol free -0.2 % chlorhexidine digluconate|colgate peroxylâ® -1.5% hydrogen peroxide|oral-bâ® gum|enamel care -cetylpyridinium chloride,NA
NCT04463602,2020-07-25,2021-01-25,Interventional,Desidustat in the Management of COVID-19 Patients,Completed,Phase 2,Cadila Healthcare Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04463602,0,0,0,0,7,0,Mexico,0,desidustat|standard care,NA
NCT04428008,2021-01-12,2021-08-31,Interventional,Thymosin Alpha 1 to Prevent COVID-19 Infection in Renal Dialysis Patients,Recruiting,Phase 2,Inova Health System,NA,https://clinicalzeros.gov/ct2/show/NCT04428008,0,0,0,0,6,1,United States,0,thymalfasin,NA
NCT04412356,2020-06-04,2021-06-01,Interventional,Timing of Tracheotomy in Covid-19 Patients,"Active, not recruiting",N/A,"Sahlgrenska University Hospital, Sweden",NA,https://clinicalzeros.gov/ct2/show/NCT04412356,0,0,0,0,5,0,Sweden,0,tracheotomy,NA
NCT04404361,2020-05-22,2021-07-31,Interventional,PRE-VENT Study in Hospitalized Patients With Severe COVID-19 With or Without Cancer,"Active, not recruiting",Phase 3,CTI BioPharma,NA,https://clinicalzeros.gov/ct2/show/NCT04404361,0,0,0,0,8,1,United States,0,pacritinib|placebo,NA
NCT04325906,2020-04-02,2021-01-26,Interventional,Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS,Completed,N/A,Rush University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04325906,0,0,0,0,6,1,United States,0,high flow nasal cannula (hfnc)|prone positioning,NA
NCT04376684,2020-05-28,2021-07-20,Interventional,Investigating Otilimab in Patients With Severe Pulmonary COVID-19 Related Disease,Recruiting,Phase 2,GlaxoSmithKline,NA,https://clinicalzeros.gov/ct2/show/NCT04376684,0,0,0,0,23,1,United States|Argentina|Belgium|Brazil|Canada|Chile|France|India|Japan|Mexico|Netherlands|Peru|Poland|Russian Federation|South Africa|Spain|United Kingdom,0,otilimab|placebo 1|placebo 2|standard care,NA
NCT04860284,2020-09-18,2021-02-09,Interventional,Hydroxychloroquine for Treatment of Non-Severe COVID-19,"Active, not recruiting",Phase 2,Makerere University,NA,https://clinicalzeros.gov/ct2/show/NCT04860284,0,0,0,0,0,0,Uganda,0,hydroxychloroquine tablets,NA
NCT04860271,2021-03-09,2021-04-30,Interventional,Manual Acupuncture Using Acupuncture Needle vs Press Needle for COVID-19 Healthcare Anxiety,Recruiting,N/A,Indonesia University,NA,https://clinicalzeros.gov/ct2/show/NCT04860271,0,0,0,0,0,0,Indonesia,0,manual acupuncture,NA
NCT04858633,2021-03-22,2021-06-30,Interventional,Hydroxychloroquine (HCQ) as Post Exposure Prophylaxis (PEP) for Prevention of COVID-19,Recruiting,Phase 3,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04858633,0,0,0,0,0,0,India,0,hydroxychloroquine|standard care|placebo,NA
NCT04858620,2020-08-30,2021-08-30,Interventional,A Study to Evaluate the Efficacy of Xlear vs. Placebo for Acute COVID-19 Infection,Recruiting,Phase 3,Larkin Community Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04858620,0,0,0,0,0,1,United States,0,xlear nasal spray|placebo,NA
NCT04858542,2021-02-26,2021-05-31,Interventional,Evaluating the Impact of Vocal Health Education on Mask-wearing Workers During COVID-19,Recruiting,N/A,University of Cincinnati,NA,https://clinicalzeros.gov/ct2/show/NCT04858542,0,0,0,0,0,1,United States,0,educational vocal health modules,NA
NCT04784481,2020-09-20,2020-12-20,Interventional,Ivermectin Reproposing for Mild Stage COVID-19 Outpatients,Completed,Phase 1/Phase 2,"Ministry of Public Health, Argentina",NA,https://clinicalzeros.gov/ct2/show/NCT04784481,0,0,0,0,2,0,Argentina,0,ivermectin,NA
NCT04854382,2021-04-14,2021-11-30,Interventional,Tailored Information About the Coronavirus in Chronic Kidney Disease Patients,Recruiting,N/A,"University Hospital, Akershus",NA,https://clinicalzeros.gov/ct2/show/NCT04854382,0,0,0,0,1,0,Norway,0,tailored information,NA
NCT04853927,2021-02-08,2021-10-30,Interventional,Proxalutamide Treatment for COVID-19 Patients in Intensive Care Unit,Recruiting,Phase 3,"Applied Biology, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04853927,0,0,0,0,1,0,Brazil,0,proxalutamide|placebo,NA
NCT04858412,2021-04-01,2022-03-31,Interventional,Study of HMB-enriched Amino Acid Supplementation in Patients With Alcoholic Liver Disease and COVID-19,Recruiting,N/A,The Cleveland Clinic,NA,https://clinicalzeros.gov/ct2/show/NCT04858412,0,0,0,0,0,1,United States,0,balanced amino acid|î²-hydroxy î²-methyl butyrate (hmb) enriched amino acid|î²-hydroxy î²-methyl butyrate (hmb) enriched amino acid,NA
NCT04783311,2021-02-23,2022-03-31,Interventional,"Safety, Tolerance and Immunogenicity of EuCorVac-19 for the Prevention of COVID-19 in Healthy Adults",Recruiting,Phase 1/Phase 2,"EuBiologics Co.,Ltd",NA,https://clinicalzeros.gov/ct2/show/NCT04783311,0,0,0,1,1,0,"Korea, Republic of",0,eucorvac-19|saline,NA
NCT04685213,2020-08-18,2021-08-18,Interventional,Electrical Stimulation for Critically Ill Covid-19 Patients,Recruiting,Phase 1,Baylor College of Medicine,NA,https://clinicalzeros.gov/ct2/show/NCT04685213,0,0,0,0,1,1,United States,0,electrical stimulation|electrical stimulation - sham,NA
NCT04748536,2021-01-29,2021-04-05,Interventional,Safety and PK of Repeated Doses of IRL201104 in Healthy Volunteers,Completed,Phase 1,Revolo Biotherapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04748536,0,0,0,0,2,0,United Kingdom,0,irl201104|placebo,NA
NCT04576728,2020-10-06,2021-05-31,Interventional,Efficacy and Safety of Trimodulin in Subjects With Severe COVID-19,Recruiting,Phase 2,Biotest,NA,https://clinicalzeros.gov/ct2/show/NCT04576728,0,0,0,0,4,0,Brazil|France|Russian Federation|Spain,0,trimodulin|placebo,NA
NCT04537949,2020-09-09,2021-03-12,Interventional,A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults,"Active, not recruiting",Phase 1/Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04537949,0,0,0,1,4,0,Germany,0,bnt162b3,NA
NCT04400032,2020-05-15,2021-04-22,Interventional,Cellular Immuno-Therapy for COVID-19 Acute Respiratory Distress Syndrome,Completed,Phase 1/Phase 2,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04400032,0,0,0,0,3,0,Canada,0,mesenchymal stem cells,NA
NCT04381988,2020-05-07,2021-04-21,Interventional,A Study of Hydroxychloroquine vs Placebo to Prevent COVID-19 Infection in Patients Receiving Radiotherapy,Terminated,Phase 2,Memorial Sloan Kettering Cancer Center,The study was terminated based results of other studies and use of the new vaccine.,https://clinicalzeros.gov/ct2/show/NCT04381988,0,0,0,0,2,1,United States,0,hydroxychloroquine|placebo|radiotherapy,NA
NCT04355767,2020-08-11,2021-03-29,Interventional,Convalescent Plasma in Outpatients With COVID-19,Completed,Phase 3,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04355767,0,0,0,0,11,1,United States,0,convalescent plasma|saline,NA
NCT04379271,2020-06-11,2021-01-12,Interventional,"A Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 as Addition to Investigator's Choice of Standard of Care Therapy, in Patients With Coronavirus Disease 19 (COVID-19)",Completed,Phase 2/Phase 3,Immunic AG,NA,https://clinicalzeros.gov/ct2/show/NCT04379271,0,0,0,0,3,0,Bulgaria|Germany,0,imu-838|placebo,NA
NCT04860219,2020-07-08,2020-09-18,Interventional,Lactoferrin Use in (SARS-CoV-2) Management,Recruiting,N/A,Zagazig University,NA,https://clinicalzeros.gov/ct2/show/NCT04860219,0,0,0,0,1,0,Egypt,0,lactoferrin,NA
NCT04681859,2021-04-17,2021-07-31,Interventional,Evaluation of a Low-cost CPAP Device on Hospitalized COVID-19 Patients,Recruiting,N/A,Bangladesh University of Engineering and Technology,NA,https://clinicalzeros.gov/ct2/show/NCT04681859,0,0,0,0,3,0,Bangladesh,0,high flow nasal oxygen (hfno) treatment|continuous positive airway pressure (cpap) therapy using oxyjet,NA
NCT04844580,2021-03-10,2022-09-30,Interventional,A Clinical Study Evaluating Inhaled Aviptadil on COVID-19,Recruiting,Phase 2,Centurion Pharma,NA,https://clinicalzeros.gov/ct2/show/NCT04844580,0,0,0,0,2,0,Turkey,0,inhaled aviptadil|placebo,NA
NCT04748757,2021-04-20,2022-03-31,Interventional,Annexin A5 in Patients With Severe COVID-19 Disease,Recruiting,Phase 2,Lawson Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04748757,0,0,0,0,1,0,Canada,0,recombinant human annexin a5|placebo,NA
NCT04647305,2021-01-16,2021-03-04,Interventional,Effectiveness and Adherence to Closed Face Shields to Prevent COVID-19 Transmission,Completed,N/A,"University of Los Andes, Columbia",NA,https://clinicalzeros.gov/ct2/show/NCT04647305,0,0,0,0,2,0,Colombia,0,closed face shield with surgical face mask use|surgical face mask use only,NA
NCT04641195,2021-04-22,2021-11-30,Interventional,Vitamin D and Zinc Supplementation for Improving Treatment Outcomes Among COVID-19 Patients in India,Recruiting,Phase 3,Harvard School of Public Health,NA,https://clinicalzeros.gov/ct2/show/NCT04641195,0,0,0,0,2,0,India,0,vitamin d3 (cholecalciferol)|zinc (zinc gluconate)|zinc (zinc gluconate)/vitamin d (cholecalciferol)|placebo|vitamin d (cholecalciferol),NA
NCT04854759,2021-03-15,2022-03-31,Interventional,The Use of Amantadine in the Prevention of Progression and Treatment of COVID-19 Symptoms,Recruiting,Phase 3,Independent Public Clinical Hospital No. 4 in Lublin,NA,https://clinicalzeros.gov/ct2/show/NCT04854759,0,0,0,0,1,0,Poland,0,amantadine hydrochloride|placebo,NA
NCT04833101,2021-04-07,2021-06-15,Interventional,Study on Sequential Immunization of Recombinant COVID-19 Vaccine (Ad5 Vector) and RBD-based Protein Subunit Vaccine,"Active, not recruiting",Phase 4,Jiangsu Province Centers for Disease Control and Prevention,NA,https://clinicalzeros.gov/ct2/show/NCT04833101,0,0,0,1,3,0,China,0,recombinant ad5 vectored covid-19 vaccine|rbd-based protein subunit vaccine (zf2001) against covid-19|trivalent split influenza vaccine,NA
NCT04796896,2021-03-15,2023-06-10,Interventional,A Study to Evaluate Safety and Effectiveness of mRNA-1273 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age,Recruiting,Phase 2/Phase 3,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04796896,0,0,0,1,5,1,United States,0,placebo|mrna-1273,NA
NCT04789603,2021-03-09,2021-03-30,Interventional,Effects of Using Mask During the 6-minute Walking Test in Times of COVID-19,Completed,N/A,Universitat Internacional de Catalunya,NA,https://clinicalzeros.gov/ct2/show/NCT04789603,0,0,0,0,1,0,Spain,0,6-min-walk surgical mask|6-min-walk fpp2|6-min-walk without mask,NA
NCT04659109,2020-12-16,2021-07-31,Interventional,Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19,Recruiting,Phase 2,Acticor Biotech,NA,https://clinicalzeros.gov/ct2/show/NCT04659109,0,0,0,0,1,0,France,0,glenzocimab|placebo,NA
NCT04623671,2020-11-15,2021-06-30,Interventional,Intravenous Infusion of CAP-1002 in Patients With COVID-19,Recruiting,Phase 2,Capricor Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04623671,0,0,0,0,5,1,United States,0,cap-1002|placebo,NA
NCT04608305,2020-10-28,2021-05-01,Interventional,"Evaluate the Safety, Immunogenicity and Potential Efficacy of an rVSV-SARS-CoV-2-S Vaccine",Recruiting,Phase 1/Phase 2,Israel Institute for Biological Research (IIBR),NA,https://clinicalzeros.gov/ct2/show/NCT04608305,0,0,0,1,3,0,Israel,0,"iibr-100, low dose (prime)|iibr-100 medium dose (prime)|iibr-100 high-dose (prime)|iibr-100 low-dose (prime-boost)|saline placebo (single)|saline placebo (double)|iibr-100 medium-dose (prime-boost)|iibr-100 high-dose (prime-boost)|iibr-100 top-dose (prime-boost)",NA
NCT04591184,2021-04-07,2021-08-31,Interventional,A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults,Recruiting,Phase 1,Entos Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04591184,0,0,0,1,4,0,Canada,0,covigenix vax-001 placebo|covigenix vax-001,NA
NCT04568122,2020-11-20,2021-06-30,Interventional,"Rapid Turnaround, Home-based Saliva Testing for COVID-19",Recruiting,N/A,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04568122,0,0,0,0,7,1,United States,0,saliva test kit,NA
NCT04465513,2020-08-31,2021-08-31,Interventional,Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19,Recruiting,N/A,Hofseth Biocare ASA,NA,https://clinicalzeros.gov/ct2/show/NCT04465513,0,0,0,0,1,0,Canada,0,best standard of care / cardio|standard care|cardio,NA
NCT04328480,2020-04-17,2021-04-25,Interventional,The ECLA PHRI COLCOVID Trial. Effects of Colchicine on Moderate/High-risk Hospitalized COVID-19 Patients.,Completed,Phase 3,Estudios ClÃ­nicos Latino AmÃ©rica,NA,https://clinicalzeros.gov/ct2/show/NCT04328480,0,0,0,0,6,0,Argentina,0,colchicine|standard care,NA
NCT04856111,2021-03-17,2021-12-31,Interventional,Pirfenidone vs. Nintedanib for Fibrotic Lung Disease After Coronavirus Disease-19 Pneumonia,Recruiting,Phase 4,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04856111,0,0,0,0,1,0,India,0,pirfenidone|nintedanib,NA
NCT04854928,2021-04-30,2021-05-31,Interventional,Study to Evaluate a Single Dose of LTX-109 in Subjects With COVID-19 (Coronavirus Disease 2019) Infection.,Recruiting,Phase 2,Pharma Holdings AS,NA,https://clinicalzeros.gov/ct2/show/NCT04854928,0,0,0,0,2,0,Sweden,0,"ltx-109 gel, 3%|placebo gel",NA
NCT04854486,2020-11-16,2021-05-16,Interventional,Impact of GSE and Xylitol (Xlear) on COVID-19 Symptoms and Time to PCR Negativisation in COVID-19 Patients,Recruiting,Phase 3,Larkin Community Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04854486,0,0,0,0,1,1,United States,0,gse/xylitol|gse|xylitol,NA
NCT04822701,2021-04-21,2021-05-22,Interventional,A Study to Test BI 767551 in People With Mild to Moderate Symptoms of COVID-19,Recruiting,Phase 2/Phase 3,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04822701,0,0,0,0,4,1,United States|Netherlands,0,bi 767551 intravenous|bi 767551 inhaled|placebo|placebo inhaled,NA
NCT04758299,2021-03-13,2021-04-15,Interventional,Understanding Communications Included With COVID-19 (Corona Virus Disease of 2019) Home Testing Kits,"Active, not recruiting",N/A,Carnegie Mellon University,NA,https://clinicalzeros.gov/ct2/show/NCT04758299,0,0,0,0,2,1,United States,0,decision science-based design,NA
NCT04715438,2021-01-08,2021-07-31,Interventional,Vaccination Against COVID-19 in Cancer,Recruiting,N/A,University Medical Center Groningen,NA,https://clinicalzeros.gov/ct2/show/NCT04715438,0,0,0,1,2,0,Netherlands,0,mrna-1273 sars-cov-2 vaccine from moderna,NA
NCT04701658,2021-02-01,2021-06-07,Interventional,A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19),"Active, not recruiting",Phase 2,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04701658,0,0,0,0,5,1,United States,0,bamlanivimab,NA
NCT04673318,2021-02-26,2024-12-31,Interventional,Physical Rehabilitation of COVID-19 Survivors by Heat Therapy,Recruiting,N/A,"University of Massachusetts, Amherst",NA,https://clinicalzeros.gov/ct2/show/NCT04673318,0,0,0,0,1,1,United States,0,heat therapy|exercise training,NA
NCT04636086,2020-11-12,2022-01-31,Interventional,Effect of Vitamin D on Hospitalized Adults With COVID-19 Infection,Recruiting,Phase 4,University of Liege,NA,https://clinicalzeros.gov/ct2/show/NCT04636086,0,0,0,0,1,0,Belgium,0,cholecalciferol|placebo,NA
NCT04657484,2020-12-08,2021-12-07,Interventional,Comparison of Two Corticosteroid Regimens for Post COVID-19 Diffuse Lung Disease,Recruiting,N/A,Postgraduate Institute of Medical Education and Research,NA,https://clinicalzeros.gov/ct2/show/NCT04657484,0,0,0,0,2,0,India,0,medium dose prednisolone|low dose prednisolone,NA
NCT04590365,2020-12-17,2021-11-01,Interventional,Carrageenan Nasal Spray for COVID-19 Prophylaxis,Recruiting,N/A,Swansea University,NA,https://clinicalzeros.gov/ct2/show/NCT04590365,0,0,0,0,2,0,United Kingdom,0,carrageenan nasal/throat spray|saline nasal/throat spray|carrageenan nasal|throat spray|saline nasal,NA
NCT04563065,2020-08-01,2020-11-30,Interventional,Active Pregnancy Against COVID-19,Recruiting,N/A,Universidad Politecnica de Madrid,NA,https://clinicalzeros.gov/ct2/show/NCT04563065,0,0,0,0,2,0,Spain,0,exercise program|healthy lifestyle advise,NA
NCT04489446,2020-08-19,2021-04-30,Interventional,Sildenafil in COVID-19,"Active, not recruiting",Phase 1/Phase 2,Universidad Nacional Andres Bello,NA,https://clinicalzeros.gov/ct2/show/NCT04489446,0,0,0,0,4,0,Chile,0,sildenafil|placebo,NA
NCT04460027,2020-06-22,2020-11-30,Interventional,W-SUDs for COVID-19,Completed,Phase 1,"Woebot Labs, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04460027,0,0,0,0,3,1,United States,0,woebot substance use disorder,NA
NCT04424901,2020-05-03,2021-05-01,Interventional,Trial of Open Label Dipyridamole- In Hospitalized Patients With COVID-19,Recruiting,Phase 2,UConn Health,NA,https://clinicalzeros.gov/ct2/show/NCT04424901,0,0,0,0,1,1,United States,0,dipyridamole,NA
NCT04421508,2020-07-12,2020-12-28,Interventional,A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19,Terminated,Phase 3,Bellerophon,Futility,https://clinicalzeros.gov/ct2/show/NCT04421508,0,0,0,0,12,1,United States,0,inopulse|placebo,NA
NCT04421027,2020-06-12,2021-02-12,Interventional,A Study of Baricitinib (LY3009104) in Participants With COVID-19,"Active, not recruiting",Phase 3,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04421027,0,0,0,0,21,1,"United States|Argentina|Brazil|Germany|India|Italy|Japan|Korea, Republic of|Mexico|Puerto Rico|Russian Federation|Spain|United Kingdom",0,baricitinib|placebo,NA
NCT04865237,2021-03-06,2022-06-03,Interventional,SARS-CoV-2 Human Challenge Characterisation Study,Enrolling by invitation,N/A,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04865237,0,0,0,0,0,0,United Kingdom,0,sars-cov-2 virus|remdesivir,NA
NCT04864899,2021-06-01,2023-03-30,Interventional,Clinical Significance of Subclinical Myocardial Involvement in Recovered COVID-19 Patients Using Cardiovascular Magnetic Resonance (R-COVID-CMR),Recruiting,N/A,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04864899,0,0,0,0,0,0,Hong Kong,0,cardiac magnetic resonance imaging (cmr)|blood test|6-minute walk test,NA
NCT04615741,2020-11-09,2021-01-22,Interventional,Finding Wellness in the Pandemic,Completed,N/A,University of Lethbridge,NA,https://clinicalzeros.gov/ct2/show/NCT04615741,0,0,0,0,4,0,Canada,0,trauma informed yoga|trauma informed psychotherapy,NA
NCT04859244,2021-01-01,2021-05-01,Interventional,First-in-Human Study of Orally Administered GS-441524 for COVID-19,"Active, not recruiting",Phase 1,Copycat Sciences LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04859244,0,0,0,0,2,1,United States,0,gs-441524,NA
NCT04805671,2021-03-22,2021-12-31,Interventional,Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19,"Active, not recruiting",Phase 2/Phase 3,"Adagio Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04805671,0,0,0,0,5,1,United States,0,adg20|saline,NA
NCT04773067,2021-01-30,2021-06-30,Interventional,"A Study to Evaluate UB-612 COVID-19 Vaccine in Adolescent, Younger and Elderly Adult Volunteers","Active, not recruiting",Phase 2,"United Biomedical Inc., Asia",NA,https://clinicalzeros.gov/ct2/show/NCT04773067,0,0,0,1,1,0,Taiwan,0,ub-612|placebo,NA
NCT04730856,2021-02-01,2021-06-01,Interventional,Standard vs High Prophylactic Doses or Anticoagulation in Patients With High Risk of Thrombosis Admitted With COVID-19 Pneumonia (PROTHROMCOVID),Recruiting,Phase 3,Hospital Universitario Infanta Leonor,NA,https://clinicalzeros.gov/ct2/show/NCT04730856,0,0,0,0,1,0,Spain,0,tinzaparin,NA
NCT04656691,2021-01-04,2021-04-18,Interventional,At-Home Infusion Using Bamlanivimab in Participants With Mild to Moderate COVID-19,Completed,Phase 4,UnitedHealth Group,NA,https://clinicalzeros.gov/ct2/show/NCT04656691,0,0,0,0,3,1,United States,0,bamlanivimab,NA
NCT04652518,2020-12-11,2021-08-31,Interventional,LYT-100 in Post-acute COVID-19 Respiratory Disease,Recruiting,Phase 2,PureTech,NA,https://clinicalzeros.gov/ct2/show/NCT04652518,0,0,0,0,7,1,United States|Philippines|Romania|United Kingdom,0,lyt-100|placebo,NA
NCT04650087,2021-02-15,2021-08-31,Interventional,COVID-19 Thrombosis Prevention Trials: Post-hospital Thromboprophylaxis,Recruiting,Phase 3,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04650087,0,0,0,0,8,1,United States,0,apixaban 2.5 mg|placebo,NA
NCT04646044,2020-11-13,2021-05-31,Interventional,A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19,Recruiting,Phase 1,Nektar Therapeutics,NA,https://clinicalzeros.gov/ct2/show/NCT04646044,0,0,0,0,1,1,United States,0,bempegaldesleukin|standard care|placebo,NA
NCT04861298,2021-01-11,2021-07-10,Interventional,Study to Investigate the Clinical Benefits of Dietary Supplement Quercetin for Managing Early COVID-19 Symptoms at Home,Recruiting,N/A,King Edward Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04861298,0,0,0,0,1,0,Pakistan,0,standard of care for covid-19 as per the hospital guidelines|quercetin phytosome (qp),NA
NCT04860297,2021-04-16,2021-08-26,Interventional,A Study to Evaluate Safety and Immunogenicity of mRNA-1273 Vaccine to Prevent COVID-19 in Adult Organ Transplant Recipients and in Healthy Adult Participants,Recruiting,Phase 3,"ModernaTX, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04860297,0,0,0,1,1,1,United States,0,mrna-1273,NA
NCT04824365,2021-04-12,2022-05-31,Interventional,Sodium Pyruvate Nasal Spray Treatment of COVID-19 and Influenza Infections,Recruiting,Phase 2/Phase 3,"Cellular Sciences, inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04824365,0,0,0,0,3,1,United States,0,sodium pyruvate|saline,NA
NCT04678778,2019-03-19,2021-02-19,Interventional,Virtual Reality Study - COVID-19 Protocol,Completed,N/A,University of Southern California,NA,https://clinicalzeros.gov/ct2/show/NCT04678778,0,0,0,0,2,1,United States,0,physical/cognitive activity|physical|cognitive activity,NA
NCT04590586,2020-11-24,2022-04-14,Interventional,Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients,Recruiting,Phase 3,Amgen,NA,https://clinicalzeros.gov/ct2/show/NCT04590586,0,0,0,0,11,1,United States|Argentina|Brazil|Chile|Mexico|South Africa|Ukraine,0,standard care|apremilast|apremilast placebo|lanadelumab|lanadelumab placebo|zilucoplan|zilucoplan placebo,NA
NCT04634409,2020-10-29,2021-08-25,Interventional,A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness,Recruiting,Phase 2,Eli Lilly and Company,NA,https://clinicalzeros.gov/ct2/show/NCT04634409,0,0,0,0,11,1,United States|Puerto Rico,0,ly3819253|ly3832479|placebo|vir-7831|ly3853113,NA
NCT04374942,2020-04-30,2021-03-31,Interventional,Does Hydroxychloroquine Before & During Patient Exposure Protect Healthcare Workers From Coronavirus?,Terminated,Phase 3,"University Health Network, Toronto","Due to unproven issues associated with hydroxychloroquine use and safety, further complicated
    by media and political misinformation which in effect rendered all global studies on HCQ to
    stop enrolling participants.",https://clinicalzeros.gov/ct2/show/NCT04374942,0,0,0,0,2,0,Canada,0,hydroxychloroquine|placebo,NA
NCT04356690,2020-05-08,2021-12-31,Interventional,Etoposide in Patients With COVID-19 Infection,"Active, not recruiting",Phase 2,Boston Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04356690,0,0,0,0,6,1,United States,0,etoposide,NA
NCT04545749,2020-09-25,2021-01-18,Interventional,"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine","Active, not recruiting",Phase 1,"United Biomedical Inc., Asia",NA,https://clinicalzeros.gov/ct2/show/NCT04545749,0,0,0,1,3,0,Taiwan,0,ub-612,NA
NCT04540406,2021-05-27,2021-10-01,Interventional,NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients,Recruiting,Phase 2,Notitia Biotechnologies Company,NA,https://clinicalzeros.gov/ct2/show/NCT04540406,0,0,0,0,7,1,United States,0,nbt-nm108|usual care only,NA
NCT04540120,2020-09-25,2021-06-30,Interventional,Safety and Efficacy of Dapansutrile for Treatment of Moderate COVID-19 Symptoms and Evidence of Early Cytokine Release Syndrome,Recruiting,Phase 2,Olatec Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04540120,0,0,0,0,14,1,United States|Netherlands|Switzerland,0,dapansutrile capsules|placebo,NA
NCT04539795,2021-01-25,2021-09-30,Interventional,COVID-19 Study of Safety and Tolerability of Alvelestat,Recruiting,Phase 1/Phase 2,University of Alabama at Birmingham,NA,https://clinicalzeros.gov/ct2/show/NCT04539795,0,0,0,0,2,1,United States,0,alvelestat|placebo,NA
NCT04535167,2020-09-09,2021-06-07,Interventional,"First-In-Human Study To Evaluate Safety, Tolerability, And Pharmacokinetics Following Single Ascending And Multiple Ascending Doses of PF-07304814 In Hospitalized Participants With COVID-19.",Recruiting,Phase 1,Pfizer,NA,https://clinicalzeros.gov/ct2/show/NCT04535167,0,0,0,0,5,1,United States|Belgium|Brazil|Spain,0,placebo|pf-07304814,NA
NCT04508023,2020-08-13,2022-02-22,Interventional,"A Study of Rivaroxaban to Reduce the Risk of Major Venous and Arterial Thrombotic Events, Hospitalization and Death in Medically Ill Outpatients With Acute, Symptomatic Coronavirus Disease 2019 (COVID-19) Infection",Recruiting,Phase 3,"Janssen Research & Development, LLC",NA,https://clinicalzeros.gov/ct2/show/NCT04508023,0,0,0,0,8,1,United States,0,rivaroxaban|placebo|standard care,NA
NCT04828434,2021-04-01,2023-04-01,Interventional,Virtual Individual Cognitive Stimulation Therapy: a Proof of Concept Study,Recruiting,N/A,"University College, London",NA,https://clinicalzeros.gov/ct2/show/NCT04828434,0,0,0,0,1,0,United Kingdom,0,virtual individual cognitive simulation therapy,NA
NCT04816643,2021-03-24,2022-03-04,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Children <12 Years of Age",Recruiting,Phase 1,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04816643,0,0,0,1,2,1,United States,0,biological/vaccine: bnt162b2 10mcg|bnt162b2 20mcg|bnt162b2 30mcg|biological|vaccine: bnt162b2 10mcg,NA
NCT04767477,2021-03-28,2021-06-30,Interventional,Telerehabilitation and Face-to-face Rehabilitation on COVID-19 Survivors,Recruiting,N/A,Universidade Federal de Pernambuco,NA,https://clinicalzeros.gov/ct2/show/NCT04767477,0,0,0,0,1,0,Brazil,0,face-to-face rehabilitation|telehealth,NA
NCT04830033,2021-04-28,2021-12-31,Interventional,ENO Breathe vs Usual Care in COVID-19 Recovery,Recruiting,N/A,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04830033,0,0,0,0,2,0,United Kingdom,0,eno breathe group,NA
NCT04863131,2021-04-28,2023-01-31,Interventional,Safety and Immunogenicity of EXG-5003,Recruiting,Phase 1/Phase 2,Fujita Health University,NA,https://clinicalzeros.gov/ct2/show/NCT04863131,0,0,0,1,1,0,Japan,0,exg-5003|placebo,NA
NCT04785144,2021-03-29,2022-08-31,Interventional,Safety and Immunogenicity Study of a SARS-CoV-2 (COVID-19) Variant Vaccine (mRNA-1273.351) in NaÃ¯ve and Previously Vaccinated Adults,Recruiting,Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04785144,0,0,0,1,9,1,United States,0,mrna-1273|mrna-1273.351,NA
NCT04581031,2020-07-11,2021-12-01,Interventional,COntinuous Signs Monitoring In Covid-19 Patients,Recruiting,N/A,The Christie NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04581031,0,0,0,0,1,0,United Kingdom,0,continuous vital sign monitoring - isansys patient status engine|machine learning/ai algorithm|machine learning|ai algorithm,NA
NCT04776317,2021-03-25,2022-09-19,Interventional,Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults,Recruiting,Phase 1,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04776317,0,0,0,1,9,1,United States,0,"chadv68-s|chadv68-s-tce|sam-lnp-s|sam-lnp-s-tce|sodium chloride, 0.9%",NA
NCT04612972,2020-09-09,2021-02-19,Interventional,"Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru","Active, not recruiting",Phase 3,Universidad Peruana Cayetano Heredia,NA,https://clinicalzeros.gov/ct2/show/NCT04612972,0,0,0,1,1,0,Peru,0,inactivated sars cov 2 vaccine (vero cell) wuhan/beijing/placebo|inactivated sars cov 2 vaccine (vero cell) wuhan|beijing|placebo,NA
NCT04608097,2020-10-28,2021-03-12,Interventional,Understanding Reactions to Emotional Material in the Media During COVID-19,Completed,N/A,Uppsala University,NA,https://clinicalzeros.gov/ct2/show/NCT04608097,0,0,0,0,3,0,Sweden,0,simple cognitive task intervention|placebo,NA
NCT04547140,2021-01-29,2021-11-30,Interventional,Study to Evaluate the Safety and Efficacy of Liquid Alpha1-Proteinase Inhibitor (Human) in Hospitalized Participants With Coronavirus Disease (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04547140,0,0,0,0,6,1,United States|Brazil|Chile,0,liquid alpha1-proteinase inhibitor (human)|placebo|standard care,NA
NCT04588480,2020-10-21,2021-11-30,Interventional,"Study to Evaluate the Safety, Tolerability, and Immunogenicity of an RNA Vaccine Candidate Against COVID-19 in Healthy Japanese Adults","Active, not recruiting",Phase 1/Phase 2,BioNTech SE,NA,https://clinicalzeros.gov/ct2/show/NCT04588480,0,0,0,1,4,0,Japan,0,bnt162b2|placebo,NA
NCT04514900,2020-09-23,2021-03-08,Interventional,Exploring Optimal Treatment Components for Contactless Online Group-based Behavioral Weight Loss Program,Completed,N/A,University of South Carolina,NA,https://clinicalzeros.gov/ct2/show/NCT04514900,0,0,0,0,4,1,United States,0,video chat /personalized feedback|video chat / basic feedback|discussion board for social support /basic feedback|discussion board for social support/personalized feedback|video chat|personalized feedback|basic feedback|discussion board for social support,NA
NCT04462757,2020-05-28,2020-08-31,Interventional,SCIL-1Ra in COVID-19 Feasibility & PK/PD,Terminated,Phase 2,University of Manchester,Lack of patients in the trial population from which to recruit and lack of funding,https://clinicalzeros.gov/ct2/show/NCT04462757,0,0,0,0,4,0,United Kingdom,0,anakinra|0.67ml inj syringe,NA
NCT04419610,2020-10-09,2021-07-31,Interventional,RAS and Coagulopathy in COVID19,Recruiting,Early Phase 1,Imperial College London,NA,https://clinicalzeros.gov/ct2/show/NCT04419610,0,0,0,0,9,0,United Kingdom,0,trv027|saline,NA
NCT04452435,2020-07-21,2020-10-13,Interventional,Safety and Efficacy of C21 in Subjects With COVID-19,Completed,Phase 2,Vicore Pharma AB,NA,https://clinicalzeros.gov/ct2/show/NCT04452435,0,0,0,0,7,0,India|United Kingdom,1,c21|placebo,NA
NCT04330690,2020-03-18,2022-03-18,Interventional,Treatments for COVID-19: Canadian Arm of the SOLIDARITY Trial,Recruiting,Phase 2,Sunnybrook Health Sciences Centre,NA,https://clinicalzeros.gov/ct2/show/NCT04330690,0,0,0,0,34,0,Canada,0,interferon|remdesivir,NA
NCT04870593,2021-04-17,2021-06-12,Interventional,What Works to Get the Elderly Vaccinated Against COVID-19? Experimental Evidence From India,"Active, not recruiting",N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04870593,0,0,0,1,0,0,India,0,information|buddy|gossip intervention|information assigned in community|buddy assigned in community,NA
NCT04870723,2021-03-01,2021-08-31,Interventional,#SafeHandsSafeHearts: An eHealth Intervention for COVID-19 Prevention and Support,Recruiting,N/A,University of Toronto,NA,https://clinicalzeros.gov/ct2/show/NCT04870723,0,0,0,0,0,0,Canada|India|Thailand,0,ehealth for covid-19 prevention/support|ehealth for covid-19 prevention|support,NA
NCT04870385,2021-04-11,2021-06-20,Interventional,An Islamic Psychospiritual-Acceptance and Commitment-based Prevention Program for At-risk Young Adults in the COVID-19 Pandemic,"Active, not recruiting",N/A,International Islamic University Malaysia,NA,https://clinicalzeros.gov/ct2/show/NCT04870385,0,0,0,0,0,0,Malaysia,0,5-week prevention program|control,NA
NCT04870333,2021-02-19,2021-12-31,Interventional,PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V,Recruiting,Phase 2/Phase 3,Cambridge University Hospitals NHS Foundation Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04870333,0,0,0,0,0,0,United Kingdom,0,niclosamide|placebo,NA
NCT04869072,2020-04-29,2020-11-30,Interventional,Convalescent Plasma Therapy - Zurich Protocol,Completed,Phase 1,University of Zurich,NA,https://clinicalzeros.gov/ct2/show/NCT04869072,0,0,0,0,0,0,Switzerland,0,convalescent plasma,NA
NCT04868903,2020-11-30,2022-06-30,Interventional,Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19,Recruiting,N/A,University of Chicago,NA,https://clinicalzeros.gov/ct2/show/NCT04868903,0,0,0,0,0,1,United States,0,vitamin d,NA
NCT04868890,2021-04-30,2021-10-31,Interventional,A Study of Inhaled Ampion in Adults With Respiratory Distress Due to COVID-19,Recruiting,Phase 2,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04868890,0,0,0,0,0,1,United States,0,ampion|placebo,NA
NCT04839965,2021-04-30,2021-10-31,Interventional,Study of Intravenous Ampion in Adult COVID-19 Patients Requiring Supplemental Oxygen,Recruiting,Phase 2,Ampio Pharmaceuticals. Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04839965,0,0,0,0,2,1,United States,0,ampion|saline,NA
NCT04864015,2021-03-17,2021-05-15,Interventional,COVID-19 Aerosol in EGD Using a Droplet Reduction Mouthpiece,"Active, not recruiting",N/A,Universitaire Ziekenhuizen Leuven,NA,https://clinicalzeros.gov/ct2/show/NCT04864015,0,0,0,0,1,0,Belgium,0,"mouthpiece b1(mouthpiece mpc-st gmdn:62534 generic name: endoscopic bite block, basic, reusable",NA
NCT04809389,2021-03-29,2022-09-30,Interventional,A Study to Evaluate Safety and Immunogenicity of DelNS1-nCoV-RBD LAIV for COVID-19,Recruiting,Phase 1,The University of Hong Kong,NA,https://clinicalzeros.gov/ct2/show/NCT04809389,0,0,0,0,2,0,Hong Kong,0,delns1-ncov-rbd laiv|placebo,NA
NCT04771013,2021-02-10,2021-05-31,Interventional,Safety and Efficacy of Thymic Peptides in the Treatment of Hospitalized COVID-19 Patients in Honduras,Recruiting,Phase 2,Universidad CatÃ³lica de Honduras,NA,https://clinicalzeros.gov/ct2/show/NCT04771013,0,0,0,0,1,0,Honduras,0,thymic peptides,NA
NCT04748588,2021-02-12,2023-01-31,Interventional,Treatment of Nosocomial COVID-19,Recruiting,Phase 4,University of Calgary,NA,https://clinicalzeros.gov/ct2/show/NCT04748588,0,0,0,0,1,0,Canada,0,bamlanivimab,NA
NCT04750278,2021-04-06,2022-02-28,Interventional,"A Phase 2/3, Randomized, Double Blind, Placebo Controlled, Multicenter Study to Evaluate the Efficacy and Safety of FP-025 in Patients With Severe to Critical COVID 19 With Associated Acute Respiratory Distress Syndrome (ARDS)",Recruiting,Phase 2/Phase 3,"Foresee Pharmaceuticals Co., Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04750278,0,0,0,0,1,1,United States,0,fp-025 100 mg|fp-025 300 mg|placebo,NA
NCT04732819,2021-01-04,2021-03-30,Interventional,Improving COVID-19 Vaccine Uptake in Nursing Homes,Completed,N/A,Brown University,NA,https://clinicalzeros.gov/ct2/show/NCT04732819,0,0,0,1,1,1,United States,0,high touch multi-pronged behavioral intervention,NA
NCT04644328,2020-11-14,2021-01-14,Interventional,The Doctors for Coronavirus Prevention Project Thanksgiving / Christmas Messaging Campaign,"Active, not recruiting",N/A,"National Bureau of Economic Research, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04644328,0,0,0,0,2,1,United States,0,facebook ads on the importance of staying safe during the thanksgiving / christmas holiday|facebook ads on the importance of staying safe during the thanksgiving|christmas holiday,NA
NCT04700137,2021-01-18,2022-01-17,Interventional,"Mental Health Among Patients, Providers, and Staff During the COVID-19 Era",Enrolling by invitation,N/A,"St. Luke's Health System, Boise, Idaho",NA,https://clinicalzeros.gov/ct2/show/NCT04700137,0,0,0,0,3,1,United States,0,caring contacts/introductory phone call (cc/)|caring contacts without an introductory phone call (cc)|caring contacts|introductory phone call (cc|),NA
NCT04636697,2020-11-19,2021-12-31,Interventional,Study of a Recombinant Coronavirus-Like Particle COVID-19 Vaccine in Adults,Recruiting,Phase 2/Phase 3,Medicago,NA,https://clinicalzeros.gov/ct2/show/NCT04636697,0,0,0,1,11,1,United States|Canada|United Kingdom,0,intramuscular injection|intramuscular vaccine,NA
NCT04495101,2020-07-29,2021-04-26,Interventional,Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19,"Active, not recruiting",Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04495101,0,0,0,0,5,0,Spain,0,prolastin|standard care,NA
NCT04445428,2020-07-15,2021-09-30,Interventional,OPV as Potential Protection Against COVID-19,"Active, not recruiting",Phase 4,Bandim Health Project,NA,https://clinicalzeros.gov/ct2/show/NCT04445428,0,0,0,1,4,0,Guinea-Bissau,0,oral polio vaccine / information|information|oral polio vaccine,NA
NCT04615949,2021-04-30,2021-11-30,Interventional,Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk Factors,Recruiting,Phase 2/Phase 3,Cardiol Therapeutics Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04615949,0,0,0,0,2,1,United States,0,"cannabidiol, pharmaceutically produced with < 5 ppm thc|placebo",NA
NCT04584541,2020-06-11,2023-07-31,Interventional,SarS-Cov-2 Viral Infection (COVID-19) in Patients With Chronic Inflammatory Rheumatism,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04584541,0,0,0,0,1,0,France,0,blood test|nasopharyngeal swabs|stools,NA
NCT04524663,2020-12-19,2021-06-30,Interventional,Oral Camostat Compared With Standard Supportive Care in Mild-Moderate COVID-19 Patients,"Active, not recruiting",Phase 2,Stanford University,NA,https://clinicalzeros.gov/ct2/show/NCT04524663,0,0,0,0,5,1,United States,0,camostat mesilate|placebo|standard care,NA
NCT04480424,2020-09-17,2021-07-31,Interventional,Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19),Recruiting,Phase 2,Grifols Therapeutics LLC,NA,https://clinicalzeros.gov/ct2/show/NCT04480424,0,0,0,0,7,1,United States,0,gamunex-c|standard care,NA
NCT04401475,2020-11-25,2021-04-30,Interventional,"A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of EB05 + SOC vs. Placebo + SOC in Adult Hospitalized Patients With COVID-19",Recruiting,Phase 2,Edesa Biotech Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04401475,0,0,0,0,5,1,United States|Canada|Colombia,0,soc/15mg/kg eb05 iv|soc/placebo iv|standard care|15mg|kg eb05 iv|placebo iv,NA
NCT04342221,2020-03-29,2021-02-26,Interventional,Hydroxychloroquine for COVID-19,Terminated,Phase 3,University Hospital Tuebingen,Reduced acceptance of IMP,https://clinicalzeros.gov/ct2/show/NCT04342221,0,0,0,0,3,0,Germany,0,hydroxychloroquine|placebo,NA
NCT04593940,2020-10-15,2021-08-31,Interventional,Immune Modulators for Treating COVID-19,Recruiting,Phase 3,Duke University,NA,https://clinicalzeros.gov/ct2/show/NCT04593940,0,0,0,0,17,1,United States|Argentina|Brazil|Peru,0,infliximab|abatacept|remdesivir|cenicriviroc,NA
NCT04872686,2020-05-23,2021-05-31,Interventional,Virucidal Effect of PVP-I on COVID-19 and as Well as Safety of Its Application on Nasopharynx & Oropharynx,Enrolling by invitation,Phase 3,Bangladesh Reference Institute of Chemical Measurements (BRICM),NA,https://clinicalzeros.gov/ct2/show/NCT04872686,0,0,0,0,0,0,Bangladesh,0,0.6% pvp-i oral/nasal spray to moderately ill covid-19 positive patient|0.6% pvp-i oral/nasal spray to asymptomatic to mild covid-19 patient having multiple comorbidity|0.6% pvp-i oral/nasal spray to healthy volunteer|oral/nasal spray by distilled water to control group|0.6% pvp-i oral|nasal spray to moderately ill covid-19 positive patient|nasal spray to asymptomatic to mild covid-19 patient having multiple comorbidity|nasal spray to healthy volunteer|oral|nasal spray by distilled water to control group,NA
NCT04871854,2021-04-26,2021-07-26,Interventional,Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints,Recruiting,Phase 2,Beni-Suef University,NA,https://clinicalzeros.gov/ct2/show/NCT04871854,0,0,0,0,0,0,Egypt,0,tocilizumab,NA
NCT04871828,2021-02-28,2021-09-30,Interventional,The Efficacy of Leukotriene Inhibitor in Adult Patients With Moderate SARS-COV-2 Symptoms (COVID19),Recruiting,Phase 3,King Abdullah International Medical Research Center,NA,https://clinicalzeros.gov/ct2/show/NCT04871828,0,0,0,0,0,0,Saudi Arabia,0,leukotriene receptor antagonist|placebo,NA
NCT04871815,2021-04-27,2022-05-31,Interventional,Effects of Sodium Pyruvate Nasal Spray in COVID-19 Long Haulers.,Recruiting,Phase 2/Phase 3,"Cellular Sciences, inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04871815,0,0,0,0,0,1,United States,0,sodium pyruvate nasal spray,NA
NCT04871958,2021-03-19,2021-08-31,Interventional,"Individualized, Technological Interventions for Diabetes Care in the COVID-19 Ward",Enrolling by invitation,N/A,Federico II University,NA,https://clinicalzeros.gov/ct2/show/NCT04871958,0,0,0,0,0,0,Italy,0,"continuous glucose monitoring (cgm, dexcom g6)",NA
NCT04867265,2021-05-03,2021-06-30,Interventional,Mouth-to-mouth Ventilation Efficiency Through Breathable Self-sterilizing Respirator During BLS in COVID-19 Pandemic,Recruiting,N/A,Brno University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04867265,0,0,0,0,1,0,Czechia,0,mout-to-mouth ventilation with quantitative analysis|mout-to-mouth ventilation,NA
NCT04871633,2020-08-01,2020-11-15,Interventional,Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore,Completed,N/A,King Edward Medical University,NA,https://clinicalzeros.gov/ct2/show/NCT04871633,0,0,0,0,0,0,Pakistan,0,remdesivir|conventional,NA
NCT04860739,2021-04-24,2021-05-20,Interventional,Vaccination With COMIRNATY in Subjects With a VAXZEVRIA First Dose,"Active, not recruiting",Phase 2,Spanish Clinical Research Network - SCReN,NA,https://clinicalzeros.gov/ct2/show/NCT04860739,0,0,0,1,3,0,Spain,0,comirnaty,NA
NCT04858425,2021-04-30,2021-12-31,Interventional,Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection,Recruiting,Phase 2,"AzurRx BioPharma, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04858425,0,0,0,0,2,1,United States,0,niclosamide|placebo,NA
NCT04703114,2021-02-05,2021-11-30,Interventional,Study of the Immunological and Virological Response of Patients With COVID-19 and Presenting an Asymptomatic or Pauci-symptomatic Form (AMBUCOV),Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04703114,0,0,0,0,1,0,France,0,blood count|blood sample|nasopharyngeal swab|saliva|faeces samples|genetic blood collection|data collection,NA
NCT04844489,2021-04-16,2022-09-30,Interventional,Study of the Humoral Response to SARS-CoV-2 Variants and of the Cellular Response After Vaccination Against COVID-19 in Immunocompromised People,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04844489,0,0,0,1,1,0,France,0,blood samples for the study of the humoral response to sars-cov-2 variants/of the cellular response after vaccination against covid-19|blood samples for the study of the humoral response to sars-cov-2 variants|of the cellular response after vaccination against covid-19,NA
NCT04843761,2021-04-20,2022-10-31,Interventional,ACTIV-3b: Therapeutics for Severely Ill Inpatients With COVID-19,Recruiting,Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04843761,0,0,0,0,5,1,United States,0,remdesivir|placebo|aviptadil|aviptadil placebo|corticosteroid,NA
NCT04792567,2021-04-19,2022-01-17,Interventional,Exploring the Immune Response to SARS-CoV-2 modRNA Vaccines in Patients With Secondary Progressive Multiple Sclerosis (AMA-VACC),Recruiting,Phase 4,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04792567,0,0,0,1,2,0,Germany,0,baf312|baseline disease modifying therapies (dmts),NA
NCT04745351,2021-03-31,2022-01-31,Interventional,Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19),Recruiting,Phase 3,Gilead Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04745351,0,0,0,0,4,1,United States,0,remdesivir|rdv placebo|standard care,NA
NCT04734873,2021-02-25,2021-12-30,Interventional,CPI-006 Plus Standard of Care Versus Placebo Plus Standard of Care in Mild to Moderately Symptomatic Hospitalized Covid-19 Patients,Recruiting,Phase 3,"Corvus Pharmaceuticals, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04734873,0,0,0,0,8,1,United States|Argentina|Brazil|Canada|Colombia|France|Germany|Israel|Italy|Mexico|Peru|South Africa|Spain|Ukraine,0,cpi-006 2 mg/kg / soc|cpi-006 1 mg/kg / soc|placebo / soc|cpi-006 2 mg|kg|standard care|cpi-006 1 mg|placebo,NA
NCT04847050,2021-04-28,2022-01-01,Interventional,"A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy",Recruiting,Phase 2,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04847050,0,0,0,1,13,1,United States,0,mrna-1273,NA
NCT04761822,2021-04-07,2021-06-30,Interventional,COVID-19: SARS Vaccination,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04761822,0,0,0,1,14,1,United States,0,moderna covid-19 vaccine|pfizer-biontech covid-19 vaccine|placebo,NA
NCT04724720,2021-01-19,2021-05-03,Interventional,Famotidine vs Placebo for the Treatment of Non-Hospitalized Adults With COVID-19,"Active, not recruiting",Phase 2,Northwell Health,NA,https://clinicalzeros.gov/ct2/show/NCT04724720,0,0,0,0,2,1,United States,0,famotidine|placebo,NA
NCT04685681,2021-01-07,2021-04-06,Interventional,The Get Outside Study,Completed,N/A,State University of New York at Buffalo,NA,https://clinicalzeros.gov/ct2/show/NCT04685681,0,0,0,0,2,1,United States,0,hiking challenge|activity list,NA
NCT04665193,2020-11-23,2021-02-28,Interventional,An Approach to Screening for COVID-19 at Vancouver Airport,Completed,N/A,University of British Columbia,NA,https://clinicalzeros.gov/ct2/show/NCT04665193,0,0,0,0,1,0,Canada,0,rapid antigen test,NA
NCT04681430,2021-01-08,2021-11-30,Interventional,Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals,Recruiting,Phase 2,"Heinrich-Heine University, Duesseldorf",NA,https://clinicalzeros.gov/ct2/show/NCT04681430,0,0,0,0,4,0,Germany,0,convalescent plasma|camostat mesilate|placebo for camostat mesilate|standard care,NA
NCT04691908,2020-12-25,2021-07-20,Interventional,"Immunogenicity, Efficacy and Safety of QazCovid-inÂ® COVID-19 Vaccine","Active, not recruiting",Phase 3,Research Institute for Biological Safety Problems,NA,https://clinicalzeros.gov/ct2/show/NCT04691908,0,0,0,1,2,0,Kazakhstan,0,qazcovid-inâ®-vaccine against covid-19|placebo|qazcovid-inâ®-vaccine against covid-19,NA
NCT04640194,2020-12-16,2022-05-29,Interventional,A Study to Test Whether Different Doses of Alteplase Help People With Severe Breathing Problems Because of COVID-19,Recruiting,Phase 2/Phase 3,Boehringer Ingelheim,NA,https://clinicalzeros.gov/ct2/show/NCT04640194,0,0,0,0,13,0,Austria|Belgium|Brazil|Denmark|France|Germany|Italy|Netherlands|Portugal|Russian Federation|Spain,0,alteplase|standard care,NA
NCT04627519,2020-12-09,2021-10-31,Interventional,Effectiveness and Safety of Rhea Health ToneÂ® as add-on Therapy for COVID-19 in Hospitalized Adults in Indonesia,Recruiting,N/A,Universitas Padjadjaran,NA,https://clinicalzeros.gov/ct2/show/NCT04627519,0,0,0,0,3,0,Indonesia,0,rhea health toneâ®|rhea health toneâ®,NA
NCT04603924,2020-10-07,2021-06-30,Interventional,Study of Niclosamide in Moderate and Severe Hospitalized Coronavirus-19 (COVID-19) Patients,Recruiting,Phase 2/Phase 3,NeuroBo Pharmaceuticals Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04603924,0,0,0,0,6,1,United States,0,niclosamide|placebo,NA
NCT04452318,2020-07-13,2021-09-25,Interventional,COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay,"Active, not recruiting",Phase 3,Regeneron Pharmaceuticals,NA,https://clinicalzeros.gov/ct2/show/NCT04452318,0,0,0,0,16,1,"United States|Moldova, Republic of|Romania",0,regn10933 / regn10987|placebo|regn10933|regn10987,NA
NCT04530357,2020-09-19,2020-11-25,Interventional,"Reactogenicity, Safety and Immunogenicity of QazCovid-inÂ® COVID-19 Vaccine",Completed,Phase 1/Phase 2,Research Institute for Biological Safety Problems,NA,https://clinicalzeros.gov/ct2/show/NCT04530357,0,0,0,1,10,0,Kazakhstan,0,qazcovid-inâ® - covid-19 inactivated vaccine|placebo|qazcovid-inâ® - covid-19 inactivated vaccine,NA
NCT04467840,2020-08-21,2021-06-30,Interventional,"Opaganib, a Sphingosine Kinase-2 (SK2) Inhibitor in COVID-19 Pneumonia",Recruiting,Phase 2/Phase 3,RedHill Biopharma Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04467840,0,0,0,0,40,0,Brazil|Colombia|Israel|Italy|Mexico|Peru|Poland|Russian Federation|United Kingdom,0,opaganib|placebo,NA
NCT04391309,2021-04-12,2021-11-30,Interventional,COVID-19 and Anti-CD14 Treatment Trial,Recruiting,Phase 2,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04391309,0,0,0,0,11,1,United States,0,anti-cd14|placebo|remdesivir,NA
NCT04382651,2020-06-07,2021-01-06,Interventional,Study of Efficacy and Safety of MAS825 in Patients With COVID-19,Completed,Phase 2,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04382651,0,0,0,0,13,1,United States,0,mas825|placebo,NA
NCT04382053,2020-05-27,2020-12-10,Interventional,Study of Efficacy and Safety of DV890 in Patients With COVID-19 Pneumonia,Completed,Phase 2,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04382053,0,0,0,0,29,0,Argentina|Brazil|Denmark|Germany|Hungary|India|Mexico|Netherlands|Peru|Russian Federation|South Africa|Spain,0,dfv890|standard care,NA
NCT04362813,2019-12-03,2020-09-16,Interventional,Study of Efficacy and Safety of Canakinumab Treatment for CRS in Participants With COVID-19-induced Pneumonia,Completed,Phase 3,Novartis,NA,https://clinicalzeros.gov/ct2/show/NCT04362813,0,0,0,0,12,1,United States|France|Italy|Russian Federation|Spain|United Kingdom,0,canakinumab|placebo,NA
NCT04372628,2020-06-01,2022-04-01,Interventional,Trial of Early Therapies During Non-hospitalized Outpatient Window for COVID-19,Recruiting,Phase 2,Vanderbilt University Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04372628,0,0,0,0,7,1,United States,0,lopinavir/ritonavir|placebo|lopinavir|ritonavir|100 mg,NA
NCT04365101,2020-05-13,2021-12-30,Interventional,Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19,Recruiting,Phase 1/Phase 2,Celularity Incorporated,NA,https://clinicalzeros.gov/ct2/show/NCT04365101,0,0,0,0,17,1,United States,0,nk cells,NA
NCT04344535,2020-04-08,2021-01-01,Interventional,Convalescent Plasma vs. Standard Plasma for COVID-19,Terminated,Phase 1/Phase 2,Stony Brook University,Insufficient eligible and consenting patients,https://clinicalzeros.gov/ct2/show/NCT04344535,0,0,0,0,2,1,United States,0,convalescent plasma|plasma,NA
NCT04865107,2021-04-27,2022-04-30,Interventional,Cellular Immuno-Therapy for COVID-19 ARDS Randomized Clinical Trial,Recruiting,Phase 2,Ottawa Hospital Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04865107,0,0,0,0,1,0,Canada,0,mesenchymal stem cells|placebo,NA
NCT04873414,2020-12-01,2021-10-30,Interventional,Convalescent Plasma as Adjunct Therapy for COVID-19,Recruiting,Phase 2/Phase 3,"National Institute of Health Research and Development, Ministry of Health Republic of Indonesia",NA,https://clinicalzeros.gov/ct2/show/NCT04873414,0,0,0,0,1,0,Indonesia,0,convalescent plasma treatment,NA
NCT04324463,2020-04-21,2021-11-30,Interventional,Anti-Coronavirus Therapies to Prevent Progression of Coronavirus Disease 2019 (COVID-19) Trial,Recruiting,Phase 3,Population Health Research Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04324463,0,0,0,0,6,0,Brazil|Canada|Colombia|Ecuador|Egypt|India|Pakistan|Philippines|Russian Federation|Saudi Arabia|United Arab Emirates,0,colchicine|interferon|aspirin|rivaroxaban,NA
NCT04866303,2021-04-26,2021-08-31,Interventional,Protecting Our Community: COVID-19 Testing,Recruiting,N/A,Montana State University,NA,https://clinicalzeros.gov/ct2/show/NCT04866303,0,0,0,0,1,1,United States,0,home-based sars-cov-2 test kit,NA
NCT04790786,2021-03-10,2022-02-28,Interventional,"UPMC OPTIMISE-C19 Trial, a COVID-19 Study",Recruiting,Phase 3,University of Pittsburgh,NA,https://clinicalzeros.gov/ct2/show/NCT04790786,0,0,0,0,2,1,United States,0,lilly bamlanivimab|regeneron casirivimab / imdevimab|lilly bamlanivimab / etesevimab|regeneron casirivimab|imdevimab|etesevimab,NA
NCT04668235,2021-04-23,2021-11-30,Interventional,Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected),Recruiting,Phase 3,HRH Holdngs Limited,NA,https://clinicalzeros.gov/ct2/show/NCT04668235,0,0,0,0,2,0,Brazil,0,azvudine|azvudine placebo,NA
NCT04636671,2021-04-14,2021-08-01,Interventional,Methylprednisolone vs. Dexamethasone in COVID-19 Pneumonia (MEDEAS RCT),Recruiting,Phase 3,University of Trieste,NA,https://clinicalzeros.gov/ct2/show/NCT04636671,0,0,0,0,1,0,Italy,0,methylprednisolone|dexamethasone,NA
NCT04551768,2021-02-10,2021-07-31,Interventional,Study to Evaluate the Safety and Efficacy of VIRAZOLEÂ® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19,Recruiting,Phase 1,"Bausch Health Americas, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04551768,0,0,0,0,4,0,Greece|Mexico,0,50 mg/ml virazole|100 mg/ml virazole|50 mg|virazole|100 mg,NA
NCT04569227,2021-04-30,2021-09-30,Interventional,Prevention of COVID-19 Infection to Severe Pneumonia or ARDS,Recruiting,Phase 2,Enzychem Lifesciences Corporation,NA,https://clinicalzeros.gov/ct2/show/NCT04569227,0,0,0,0,2,1,United States,0,ec-18|placebo,NA
NCT04551911,2020-10-26,2021-08-31,Interventional,Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19,Recruiting,Phase 2,"OPKO Health, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04551911,0,0,0,0,5,1,United States,0,rayaldee 30mcg extended-release (er) capsule|placebo,NA
NCT04504734,2020-11-27,2021-05-01,Interventional,Bucillamine in Treatment of Patients With COVID-19,Enrolling by invitation,Phase 3,"Revive Therapeutics, Ltd.",NA,https://clinicalzeros.gov/ct2/show/NCT04504734,0,0,0,0,21,1,United States,0,bucillamine|placebo,NA
NCT04448756,2020-07-29,2021-06-06,Interventional,Study of M5049 in Participants With COVID-19 Pneumonia (ANEMONE),Recruiting,Phase 2,EMD Serono,NA,https://clinicalzeros.gov/ct2/show/NCT04448756,0,0,0,0,10,1,United States|Brazil|Philippines,0,m5049|placebo,NA
NCT04442087,2020-06-19,2021-09-30,Interventional,Study of Seroprevalence of Anti-SARS-CoV2 Among Children of Hospital Workers in AP-HP,Recruiting,N/A,Assistance Publique - HÃ´pitaux de Paris,NA,https://clinicalzeros.gov/ct2/show/NCT04442087,0,0,0,0,3,0,France,0,serology test|data collection,NA
NCT04422509,2020-10-30,2021-02-25,Interventional,Lanadelumab for Treatment of COVID-19 Disease,Completed,Phase 1/Phase 2,Radboud University,NA,https://clinicalzeros.gov/ct2/show/NCT04422509,0,0,0,0,3,0,Netherlands,0,lanadelumab|regular care,NA
NCT04421625,2020-06-15,2022-06-15,Interventional,Patients and Health Staff of Cancer Centres During the Covid-19 Pandemic,Recruiting,N/A,Institut Cancerologie de l'Ouest,NA,https://clinicalzeros.gov/ct2/show/NCT04421625,0,0,0,0,2,0,France,0,diagnostic test for sars-cov2 for patients/health staff|diagnostic test for sars-cov2 for patients|health staff,NA
NCT04421404,2020-06-09,2021-04-30,Interventional,Effects of COVID-19 Convalescent Plasma (CCP) on Coronavirus-associated Complications in Hospitalized Patients,Completed,Phase 2,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04421404,0,0,0,0,5,1,United States,0,convalescent plasma|placebo,NA
NCT04876560,2020-03-11,2020-10-10,Interventional,Implementation of a CDSS in Oncology Patients During COVID-19,Completed,N/A,"Iaso Maternity Hospital, Athens, Greece",NA,https://clinicalzeros.gov/ct2/show/NCT04876560,0,0,0,0,0,0,Greece,0,application of cdss to provide nutritional care in breast cancer patients from home|general lifestyle advice to breast cancer patients by phone,NA
NCT04876417,2021-02-01,2023-02-01,Interventional,tDCS for Post COVID-19 Fatigue,Recruiting,N/A,University of Iowa,NA,https://clinicalzeros.gov/ct2/show/NCT04876417,0,0,0,0,0,1,United States,0,transcranial direct current stimulation,NA
NCT04870606,2021-04-24,2021-08-24,Interventional,Proxalutamide (GT0918) Treatment for Outpatients With Mild or Moderate COVID-19 Illness,Recruiting,Phase 3,"Suzhou Kintor Pharmaceutical Inc,",NA,https://clinicalzeros.gov/ct2/show/NCT04870606,0,0,0,0,1,1,United States,0,proxalutamide (gt0918)|placebo,NA
NCT04870164,2020-11-18,2021-07-31,Interventional,"Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)",Recruiting,Phase 1,Molecular Partners AG,NA,https://clinicalzeros.gov/ct2/show/NCT04870164,0,0,0,0,1,0,United Kingdom,0,ensovibep|placebo,NA
NCT04866069,2021-04-25,2021-10-31,Interventional,Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults,Recruiting,Phase 1,The Scientific and Technological Research Council of Turkey,NA,https://clinicalzeros.gov/ct2/show/NCT04866069,0,0,0,1,1,0,Turkey,0,sars-cov-2 vaccine|placebo,NA
NCT04864561,2021-04-26,2021-07-15,Interventional,"Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine",Recruiting,Phase 3,Valneva Austria GmbH,NA,https://clinicalzeros.gov/ct2/show/NCT04864561,0,0,0,1,2,0,United Kingdom,0,vla2001|azd1222,NA
NCT04860895,2021-02-11,2021-05-01,Interventional,Detection of SARS-CoV-2 in Nasopharyngeal Swabs by Using Multi-Spectral Screening System,Recruiting,N/A,Fable Biyoteknoloji San ve Tic A.S,NA,https://clinicalzeros.gov/ct2/show/NCT04860895,0,0,0,0,1,0,Turkey,0,ap-23,NA
NCT04852861,2021-05-10,2021-07-30,Interventional,Safety and Immunogenicity of a Reduced Dose of the BioNTech/Pfizer BNT162b2 Vaccine (REDU-VAC),Enrolling by invitation,Phase 4,Sciensano,NA,https://clinicalzeros.gov/ct2/show/NCT04852861,0,0,0,1,1,0,Belgium,0,immunogenicity after first/second dose|immunogenicity after first|second dose,NA
NCT04859517,2021-04-23,2022-07-31,Interventional,Evaluation of ADG20 for the Prevention of COVID-19,Recruiting,Phase 2/Phase 3,"Adagio Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04859517,0,0,0,0,3,1,United States,0,adg20|placebo,NA
NCT04859023,2021-02-22,2021-02-28,Interventional,Comparison of Strategies Based on RT-PCR or Antigenic Test for the Screening of SARS-CoV-2 Infection (COVID-19).,Completed,N/A,Centre Hospitalier Universitaire de Saint Etienne,NA,https://clinicalzeros.gov/ct2/show/NCT04859023,0,0,0,0,1,0,France,0,saliva sample/to an anterior nare self-swabbing (self-samples)|saliva sample (self-sample)|survey of sars-cov-19 knowledge|survey of acceptability of the different self-samples.|saliva|to an anterior nare self-swabbing (self-samples),NA
NCT04826588,2021-06-30,2022-04-30,Interventional,Randomised Evaluation of COVID-19 Therapy (RECOVERY) in Children With PIMS-TS in Switzerland (SWISSPED-RECOVERY),Recruiting,Phase 3,University Children's Hospital Basel,NA,https://clinicalzeros.gov/ct2/show/NCT04826588,0,0,0,0,3,0,Switzerland,0,methylprednisolone|human normal immunoglobulin (ivig),NA
NCT04834726,2021-04-29,2021-06-02,Interventional,COVID-19 Vaccine Text Outreach,Enrolling by invitation,N/A,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04834726,0,0,0,1,2,1,United States,0,opt-in (call-back)|opt-in (in-bound)|standard message|clinician endorsement|scarcity|opt-out framing|phone call,NA
NCT04798027,2021-03-12,2022-07-31,Interventional,Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older,Recruiting,Phase 1/Phase 2,Sanofi,NA,https://clinicalzeros.gov/ct2/show/NCT04798027,0,0,0,1,3,1,United States,0,sars-cov-2 mrna vaccine formulation 1|sars-cov-2 mrna vaccine formulation 2|sars-cov-2 mrna vaccine formulation 3|placebo,NA
NCT04794400,2021-02-04,2021-03-31,Interventional,The Application of an Oxygen Mask in Patients With Severe Covid-19 Already Treated With High-flow Nasal Cannula.,Completed,N/A,Region Skane,NA,https://clinicalzeros.gov/ct2/show/NCT04794400,0,0,0,0,3,0,Sweden,0,oxygen mask,NA
NCT04707664,2021-04-27,2021-06-30,Interventional,Sargramostim Use in COVID-19 to Recover Patient Health,Recruiting,Phase 2,"Partner Therapeutics, Inc.",NA,https://clinicalzeros.gov/ct2/show/NCT04707664,0,0,0,0,10,1,United States,0,sargramostim|placebo,NA
NCT04652674,2020-09-28,2021-06-30,Interventional,Impact of Postoperative Telemedicine Visit vs In-person Visit on Patient Satisfaction During the COVID-19 Pandemic: A Prospective Randomized Trial,Recruiting,N/A,Cedars-Sinai Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04652674,0,0,0,0,2,1,United States,0,telemedicine visit|in-person postoperative visit,NA
NCT04619628,2020-12-11,2021-06-30,Interventional,"Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19","Active, not recruiting",Phase 1,"Codagenix, Inc",NA,https://clinicalzeros.gov/ct2/show/NCT04619628,0,0,0,1,2,0,United Kingdom,0,covi-vac|placebo,NA
NCT04602312,2020-10-28,2021-06-30,Interventional,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Healthy Sample),Recruiting,N/A,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04602312,0,0,0,0,3,0,Australia,0,meditation (1 x 20-minute guided audio training),NA
NCT04602286,2020-10-28,2021-06-30,Interventional,How Does Mindfulness Meditation Buffer the Negative Effects of Pain and Suffering in the COVID-19 World? (Pain Sample),Recruiting,N/A,The University of Queensland,NA,https://clinicalzeros.gov/ct2/show/NCT04602286,0,0,0,0,3,0,Australia,0,meditation (1 x 20-minute guided audio training),NA
NCT04611802,2020-12-27,2023-06-30,Interventional,"A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults â‰¥ 18 Years With a Pediatric Expansion in Adolescents (12-17 Years) at Risk for SARS-CoV-2",Recruiting,Phase 3,Novavax,NA,https://clinicalzeros.gov/ct2/show/NCT04611802,0,0,0,1,15,1,United States|Mexico|Puerto Rico,0,sars-cov-2 rs/matrix-m1 adjuvant (initial vaccination period)|placebo (initial vaccination period)|sars-cov-2 rs/matrix-m1 adjuvant (crossover vaccination period)|placebo (crossover vaccination period)|sars-cov-2 rs|matrix-m1 adjuvant (initial vaccination period)|matrix-m1 adjuvant (crossover vaccination period),NA
NCT04532372,2020-10-23,2022-09-18,Interventional,Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy,Recruiting,Phase 1/Phase 2,City of Hope Medical Center,NA,https://clinicalzeros.gov/ct2/show/NCT04532372,0,0,0,0,3,1,United States,0,best available therapy|leflunomide|placebo,NA
NCT04528888,2020-11-25,2021-06-30,Interventional,Steroids and Unfractionated Heparin in Critically Ill Patients With Pneumonia From COVID-19 Infection,Recruiting,Phase 3,University of Modena and Reggio Emilia,NA,https://clinicalzeros.gov/ct2/show/NCT04528888,0,0,0,0,1,0,Italy,0,enoxaparin|methylprednisolone|heparin,NA
NCT04527432,2020-12-16,2022-03-31,Interventional,COVID-19 Health Professional Impact Study,"Active, not recruiting",N/A,The Royal Wolverhampton Hospitals NHS Trust,NA,https://clinicalzeros.gov/ct2/show/NCT04527432,0,0,0,0,4,0,United Kingdom,0,questionnaire|sars-cov-2 antibody test,NA
NCT04432272,2020-07-16,2020-11-13,Interventional,ANTIBODY-LEVEL BASED ANALYSIS OF COVID-19 CONVALESCENT SERUM (ABACCuS),Completed,Phase 2,William Beaumont Hospitals,NA,https://clinicalzeros.gov/ct2/show/NCT04432272,0,0,0,0,4,1,United States,0,convalescent plasma,NA
NCT04518410,2020-08-19,2023-05-31,Interventional,ACTIV-2: A Study for Outpatients With COVID-19,Recruiting,Phase 2/Phase 3,National Institute of Allergy and Infectious Diseases (NIAID),NA,https://clinicalzeros.gov/ct2/show/NCT04518410,0,0,0,0,67,1,United States|Argentina|Puerto Rico|South Africa,0,"bamlanivimab|placebo (iv)|brii-196/brii-198|azd7442 (iv)|azd7442 (im)|sng001|camostat|placebo (im)|placebo (inhaled solution)|placebo (oral tablet)|c135-ls / c144-ls|placebo (sc injections)|sab-185 (3,840 units/kg)|sab-185 (10,240 units/kg)|brii-196|brii-198|c135-ls|c144-ls|sab-185 (3,840 units|kg)|sab-185 (10,240 units",NA
NCT04510194,2021-01-01,2021-06-30,Interventional,Outpatient Treatment of COVID-19 With Metformin,Recruiting,Phase 2/Phase 3,University of Minnesota,NA,https://clinicalzeros.gov/ct2/show/NCT04510194,0,0,0,0,7,1,United States,0,metformin|placebo|fluvoxamine|ivermectin,NA
NCT04453852,2020-06-30,2021-02-01,Interventional,Monovalent Recombinant COVID19 Vaccine,Completed,Phase 1,Vaxine Pty Ltd,NA,https://clinicalzeros.gov/ct2/show/NCT04453852,0,0,0,1,2,0,Australia,0,covid19 vaccine|saline,NA
NCT04412785,2020-06-30,2021-10-31,Interventional,Cyclosporine in Patients With Moderate COVID-19,"Active, not recruiting",Phase 1,University of Pennsylvania,NA,https://clinicalzeros.gov/ct2/show/NCT04412785,0,0,0,0,3,1,United States,0,cyclosporine,NA
NCT04409873,2021-03-31,2021-09-30,Interventional,Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19),Recruiting,Phase 2,"University of California, San Francisco",NA,https://clinicalzeros.gov/ct2/show/NCT04409873,0,0,0,0,7,1,United States,0,oral-b mouth sore mouthwash|crest pro-health multi-protection mouthwash|closys ultra sensitive rinse mouthwash|distilled water|listerine zero mouthwash product,NA
NCT04402957,2020-10-14,2021-05-31,Interventional,LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19),"Active, not recruiting",Phase 2,Arch Biopartners Inc.,NA,https://clinicalzeros.gov/ct2/show/NCT04402957,0,0,0,0,7,1,United States|Canada|Turkey,0,lsalt peptide|placebo,NA
NCT04421612,2020-04-02,2021-01-01,Interventional,COVID-19 - No Health Without Mental Health,Completed,N/A,Haukeland University Hospital,NA,https://clinicalzeros.gov/ct2/show/NCT04421612,0,0,0,0,4,0,Norway,0,co-mestring (co-coping),NA
NCT04379518,2020-09-04,2021-09-04,Interventional,Rintatolimod and IFN Alpha-2b for the Treatment of Mild or Moderate COVID-19 Infection in Cancer Patients,Recruiting,Phase 1/Phase 2,Roswell Park Cancer Institute,NA,https://clinicalzeros.gov/ct2/show/NCT04379518,0,0,0,0,8,1,United States,0,best available therapy|interferon|rintatolimod,NA
NCT04377100,2021-05-11,2022-02-28,Interventional,Impact on Anxiety and Motivation of COVID-19 and Predictors of Individual Responses,Recruiting,N/A,National Institutes of Health Clinical Center (CC),NA,https://clinicalzeros.gov/ct2/show/NCT04377100,0,0,0,0,236,1,United States,0,questionnaire,NA
NCT04332094,2020-04-02,2021-06-30,Interventional,Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19),Recruiting,Phase 2,FundaciÃ³ Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau,NA,https://clinicalzeros.gov/ct2/show/NCT04332094,0,0,0,0,4,0,Spain,0,tocilizumab|hydroxychloroquine|azithromycin,NA
NCT04319445,2020-03-22,2020-08-31,Interventional,Mindfulness During COVID-19,Completed,N/A,Wake Forest University Health Sciences,NA,https://clinicalzeros.gov/ct2/show/NCT04319445,0,0,0,0,5,1,United States,0,mindfulness session(s),NA
